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Abstract 
 
Among the gynecologic malignancies, epithelial ovarian tumors are the leading cause 
of death. For the past few decades, the only treatment has involved surgical resection of the 
tumor and/or general chemotherapies. In an attempt to improve treatment options, we have 
shown that several oncogenes that are overexpressed in ovarian cancer, PI3K, PKCiota, and 
cyclin E, all of which have been shown to lead to a poor prognosis and decreased survival, 
converge into a single pathway that could potentially be targeted therapeutically. 
  
Because of the ability of either PKCiota or cyclin E overexpression to independently 
induce anchorage-independent growth, a hallmark of cancer, we hypothesized that targeting 
PKCiota expression in ovarian cancer cells could induce a reversion of the transformed 
phenotype through down regulation of cyclin E. To test this hypothesis, we first 
established a correlation between PKCiota and cyclin E in a panel of 20 ovarian cancer cell 
lines. To show that PKCiota is upstream of cyclin E, PKCiota was stably knocked down using 
RNAi in IGROV cells (epithelial ovarian cancer cell line of serous histology). The silencing of 
PKCiota resulted in decreased expression of cell cycle drivers, such as cyclin D1/E and 
CDK2/4, and an increase in p27. These alteration in the regulators of the cell cycle resulted in 
a decrease in both proliferation and anchorage-independent growth, which was specifically 
through cyclin E, as determined by a rescue experiment. We also found that the mechanism of 
cyclin E regulation by PKCiota was at the level of degradation rather than transcription. Using 
two inhibitors to PI3K, we found that both the active form of PKCiota and total cyclin E levels 
decreased, implying that the PKCiota/cyclin E pathway is downstream from PI3K. In 
conclusion, we have identified a novel pathway in epithelial ovarian tumorigenesis (PI3K Æ 
PKCiota Æ Cyclin E Æ anchorage-independent growth), which could potentially be targeted 
therapeutically.  
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CHAPTER 1 
 
Introduction: The Role of Cyclin E in PKCiota-Driven Early Ovarian Tumorigenesis 
 
 
 
 
 
DISSERTATION OVERVIEW 
 
Briefly, this dissertation will start by focusing on the significance of studying ovarian 
cancer. Because strides have been made in identifying cancer pathways, more targeted 
therapeutics have been designed. While ovarian cancer has very few targeted therapies, this 
dissertation identifies a potential cancer pathway in ovarian cancer that can be targeted 
therapeutically.  
PKCiota and cyclin E both have oncogenic characteristics. This dissertation will go into 
great detail about these oncogenic characteristics. Both PKCiota and cyclin E tend to be 
amplified at the genomic level, thus upstream targets could potentially be inconsequential. 
This dissertation focuses on PKCiota’s regulation of cyclin E. I have found that regulation of 
cyclin E by PKCiota is at the level of protein stability. Inhibiting PKCiota expression leads to a 
decrease in cyclin E levels, both full length and low molecular weight (LMW-E) cyclin E. 
Importantly, knockdown of PKCiota not only leads to a decrease in endogenous cyclin E 
levels, but also exogenous levels of cyclin E. This is very important because even if cyclin E is 
amplified at the genetic level, inhibition of PKCiota will still cause decreases in the levels of 
amplified cyclin E. 
This dissertation also focuses on the ability of PKCiota and cyclin E to be involved in 
anchorage-independent growth. In this dissertation, I have demonstrated that the role of 
PKCiota in transformation, but not in migration, is through cyclin E.  
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CANCER OVERVIEW 
CANCER 
The Centers for Disease Control and Prevention (CDC) states that the leading cause of 
death in the United States of America is heart disease at 616,067 deaths in 2009. Immediately 
following heart disease, the second leading cause of death in the US is cancer with 562,875 
deaths (CDC, 2010). In 2010, according to the American Cancer Society (ACS), 569,490 
people are expected to die from cancer (that is 1500 per day). This number is nearly 
unchanged from five years ago-570,280. These statistics mean that nearly 1 out of 4 
Americans will die from cancer (CF&F, 2005; CF&F, 2010).    
The American Cancer Society defines cancer as “a group of diseases characterized by 
uncontrolled growth and spread of abnormal cells.” Cancer can be due to both intrinsic 
and extrinsic factors, such as: age, weight, lifestyle, smoking, viral infections, chemical or 
radiation exposure, and genetic mutations to name a few (CF&F, 2010).  
 
OVARIAN CANCER 
Ovarian cancer is the leading cause of death among the gynecologic malignancies. 
Due to a lack of obvious symptoms and no sufficiently accurate method of screening, early 
detection is rare, making the prognosis quite poor. Symptoms include pelvic pain and swelling 
of the abdomen (due to an accumulation of fluid). Other symptoms include a feeling of 
fullness, abdominal pain or bloating (CF&F, 2010).  
Risk factors for ovarian cancer include weight, age, use of post-menopausal hormone 
supplements (estrogen alone), inherent characteristics such as a family history of breast or 
ovarian cancer, and genetic mutations such as BRCA1/2 or Lynch syndrome (hereditary 
nonpolyposis colon cancer). Certain factors can actually decrease ones risk of ovarian cancer, 
these factors include pregnancy and long-term use oral contraceptives (due to the lack of 
ovulation). Surgical removal of one’s reproductive organs, such as a hysterectomy can also 
decrease the risk of ovarian cancer. Woman with a high risk of ovarian cancer can have their 
ovaries removed as a means of prevention (CF&F, 2010).   
Treatment of ovarian cancer involves the use of chemotherapy and surgery. Surgery 
includes the removal of one or both ovaries (one in the case of younger women who still desire 
to have children), the uterus (hysterectomy), and the fallopian tubes (salpingo-ophorectomy). 
Chemotherapy can be administered either systemically or localized to the intraperitoneal 
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cavity.  Better prognosis has been observed in patients who have had their surgeries 
performed by a gynecologic oncologist.  
Treatment of ovarian cancer through the use of first-line chemotherapeutics differs 
between institutions, but likely involves cisplatin, carboplatin, gemcitabine, doxorubicin, or 
paclitaxel or combinations of these agents (Campos, 2010). As for therapeutics that target 
specific cancer pathways in ovarian cancer, many clinical trials exist. Some of the more 
promising clinical trials include targeting VEGF. Because the treatment of ovarian cancer 
results in chemoresistance, VEGF inhibitors are promising reagents due to cancers’ need for 
angiogenesis in order to promote metastases and tumor growth (Campos, 2010). Currently, 
Avastin (Bevacizumab) a VEGF (vascular endothelial growth factor) humanized monoclonal 
antibody that inhibits its activity (through inhibition of angiogenesis) is being tested in clinical 
trials for the treatment of ovarian cancer (CF&F, 2010; Los, 2007). Bevacizumab was the first 
VEGF inhibitor. The initial clinical trial testing Bevacizumab was published in 2004 and was 
performed in colon cancer in combination with irinotecan, fluorouracil, and leucovorin. These 
combinations between Bevacizumab and first-line metastatic colon cancer chemotherapeutics 
resulted in an increase in overall survival and progression-free survival (Hurwitz, 2004). 
Currently, at least twelve clinical trials exist for the Bevacizumab in several cancer types, 
including ovarian cancer (Campos, 2010).  Another targeted therapy in clinical trials for the 
treatment of ovarian cancer is Recentin (Cediranib or AZD2171) by AstraZeneca which is also 
a VEGF inhibitor, by inhibiting the kinase activity of vascular endothelial growth factor 
receptor-2 tyrosine kinase (Wedge, 2005). Several clinical trials involving AZD2171 have been 
performed in ovarian cancer with a positive response. Matulonis et al published a phase II 
clinical trial that, although no patients exhibited a complete response, 17% exhibited a partial 
response and 13% exhibited stable disease (Matulonis, 2009). Also, Garcia et al in a phase II 
clinical trial, which dichotomized patients according to platinum sensitivity, demonstrated that 
AZD 2171 treatment led to 41% response rate in patients that were sensitive to platinum 
therapy while only a 29% response rate was observed in patients who exhibited platinum 
resistance (Garcia, 2008). Currently, this drug is in phase III clinical trials for the treatment of 
ovarian cancer (Campos, 2010). Because Avastin and Recentin are potent VEGF 
(angiogenesis) inhibitors, they were believed to be potentially useful for preventing recurrence 
and extending survival (Wedge, 2005). However, thus far, these two drugs only extended 
overall survival by less than six months. Thus, the need for more targeted treatments of 
ovarian cancer pathways exist. At this time, the 5 year survival rate is only 46%, thus more 
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research needs to be done to investigate the important pathways to target in ovarian 
tumorigenesis. 
The ovaries are composed of three tissue types: epithelial, germ, and stromal cells. 
Ovarian cancer can arise from abnormalities in any of these three tissue types and are termed 
ovarian epithelial tumors, germ cell tumors, and stromal tumors accordingly. In normal ovaries, 
the epithelial cells form a polarized monolayer and make up the covering of the ovaries. 
Ovarian cancer that arises from epithelial cells is the predominant form of ovarian cancer and 
will be the focus of this dissertation. The germ cells make up the eggs, and the stromal cells 
(or stroma) are the remainder of the ovaries which are composed of hormones and hold the 
ovaries together (ACS, 2010).  
According to the American Cancer Society (ACS), epithelial ovarian tumors can be 
further divided into three types: benign epithelial tumors, LMP tumors (tumors of low malignant 
potential- or borderline epithelial ovarian cancer), and malignant epithelial ovarian tumors. 
Both benign epithelial tumors and LMP tumors are rarely life-threatening. However, the 
malignant epithelial ovarian tumors, which account for 90% of all ovarian cancers, have a 
worse prognosis than the other two epithelial tumors, but the survival depends on the stage. 
Invasive epithelial ovarian cancer diagnosed at stage I has 89% 5-year survival, while stage II 
has 66%, stage III has 34%, and stage IV has only 18% 5-year survival. LMP tumors have 
99% 5-year survival at stage I, 98% at stage II, 96% at stage III, and 77% at stage IV (ACS, 
2010). Thus, invasive epithelial ovarian tumors exhibit the need for more targeted therapies.  
Based on the histology of epithelial ovarian tumors, these tumors can be further 
classified into subtypes: serous, mucinous, endometrioid, or clear-cell tumors. While the latter 
three tumor types are likely low-stage lesions, serous tumors are usually high-stage lesions. 
Serous epithelial ovarian tumors are the predominant subtype of ovarian epithelial tumors 
comprising 40% of this type of ovarian cancer and will be the focus of this dissertation. 
Endometrioid tumors compose 20% of ovarian epithelial tumors, mucinous are only 1%, and 
clear-cell tumors are 6% (Health-Communities, 2010). 
Both germ cell and stromal cell tumors are rarer than epithelial tumors but exhibit a 
better prognosis. Germ cell tumors, which account for approximately 3% of ovarian cancers, 
exhibit more than 90% 5-year survival. While stromal tumors, which account for approximately 
5% of ovarian cancers, are found in older women (over the age of 50); they can also be found 
in women of younger age (young girls). Stromal tumors tend to produce hormones and can be 
either benign or malignant. Malignant stromal tumors still have an overall good prognosis with 
greater than 70% overall survival (ACS, 2010).  
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Like most cancer types, ovarian cancer contains hotspots of mutations that occur 
leading to the onset of ovarian cancer. These mutations include gene amplification or 
deletions, activating or inactivating mutations, promoter and hypo-methylation, as well as loss 
of heterozygosity (LOH). Table 1 contains a complete list of the genetic abnormalities that 
occur in ovarian cancer along with the genes affected by these abnormalities (Bast, 2009). 
Included in the list of genes with genomic amplification, which result in overexpression of their 
transcripts, are PKCiota and cyclin E. Several known oncogenes exist specifically in the 
epithelial type of ovarian cancer (Table 2). Both PKCiota, which is amplified in 44% and 
overexpressed in 78% of epithelial ovarian cancers, and cyclin E, which is amplified in 12-36% 
and overexpressed in 42-63% of epithelial ovarian cancers, are oncogenes in this ovarian 
cancer subtype and will be discussed below in great detail (Bast, 2009). The discrepancy 
between the percent of ovarian cancers with genomic amplification and the percent containing 
overexpression could be due to the ability of several other aberrant genes on these lists to 
regulate PKCiota and cyclin E. 
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Table 1: Genetic abnormalities in epithelial ovarian cancer 
Adapted from (Bast, 2009) 
 
Event Effect Chromosome Gene 
Gene 
amplification 
Activation 1q22 
3q26 
5q31 
8q24 
19q 
20p 
20q13.2 
RAB25 
PRKCI, EVI1 and PIK3CA 
FGF1 
MYC 
PIK3R1, CCNE1, and AKT2 
ND 
AURKA 
Gene deletion Inactivation 4q, 5q, 16q, 17p, 17q, Xp and Xq ND 
Mutation Activation NA KRAS (15%), BRAF (12%), 
CTNNB1 (12%), CDKN2A (10%), 
APC (9%), PIK3CA (8%), KIT (7%) 
and SMAD4 (7%) 
Hypomethylation Activation NA IGF2 and SAT2 
Loss of 
heterozygosity 
Inactivation 17p13 and 17q21 (in 50% of cases 
or more) 
1p, 3p, 5q, 5q, 6q, 7q and 8q (in 
fewer than 30% of cases) 
ARHI, PEG3, PLAGL1, RPS6KA2, 
TP53, BRCA1, BRCA2, 
PTEN, OPCML and WWOX 
Mutation Inactivation NA TP53 (62%), BRCA1 (5%), BRCA2 
(<5%) and PTEN (3–8%) 
Promoter 
methylation 
Inactivation NA ARHI, DAPK1, CDH13, MLH1, 
ICAM1, PLAGL1, DNAJC15, 
MUC2, OPCML, PCSK6, PEF3, 
CDKN2A, CDKN1A, 
RASSF1, SOCS1, SOCS2, 
PYCARD and SFN 
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Table 2: Oncogenes associated with epithelial ovarian cancer 
Adapted from (Bast, 2009) 
 
Gene Chromosome Percentage of 
cancers in 
which amplified
Percentage of 
cancers in which 
overexpressed 
Percentage of 
cancers in 
which mutated 
Function 
RAB25 1q22 54% 80–89% ND Cytoplasmic 
GTPase and 
apical vessel 
trafficking 
EVI1 3q26 ND ND ND Transcription 
factor 
EIF5A2 3q26 ND ND ND Elongation factor 
PRKCI 3q26 44% 78% ND Cytoplasmic 
serine-threonine 
protein kinase 
PIK3CA 3q26 9–11% 32% 8–12% Cytoplasmic lipid 
kinase 
FGF1 5q31 ND 51% ND Growth factor for 
cancer and 
angiogenesis 
MYC 8q24 20% 41–66% ND Transcription 
factor 
ECFR 7q12 11–20% 9–28% <1% Protein tyrosine 
kinase growth 
factor receptor 
NOTCH3 9p13 20–21% 62% ND Cell surface 
growth factor 
receptor 
KRAS 12P11–12 5% 30–52% 2–24% Cytoplasmic 
GTPase 
ERBB2 17q12–21 6–11% 4–12% ND Protein tyrosine 
kinase growth 
factor receptor 
PIK3R1 19q ND ND ND Cytoplasmic lipid 
kinase 
CCNE1 19q12 12–36% 42–63% ND Cyclin 
AKT2 19q13.2 12–27% 12% ND Cytoplasmic 
serine–threonine 
protein kinase 
AURKA 20q13 10–15% 48% ND Nuclear serine–
threonine protein 
kinase 
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CYCLIN E 
EUKARYOTIC CELL CYCLE 
As mentioned, the American Cancer Society defines cancer as “a group of diseases 
characterized by uncontrolled growth and spread of abnormal cells” (ACS, 2010). Proliferation 
of a eukaryotic cell is controlled by the cell cycle, which is defined as the sequence of events 
between two cell divisions and is highly regulated. The cell cycle begins with a single cell with 
one copy of its DNA (N), the cell replicates its DNA (2N), and ends with two genetically 
identical daughter cells, each with one copy of the DNA (Heichman, 1994). A cell about to 
divide must exit Go (the dormant, quiescent stage) by exposure to a mitogenic stimulus and 
enter into the first phase of the cell cycle, Gap1 or G1 phase (Pardee, 1989). The G1 phase is 
important for normal cell division because in the G1 phase, the cell prepares for DNA 
replication (Synthesis or S phase).  
The pause between G1 and S phase is known as the G1/S transition or checkpoint. 
The G1/S checkpoint is where cells, which have the proper protein expression pattern are able 
to make the transition into the S phase (Reed, 1997)-review. In S phase, DNA from the mother 
cell is replicated and chromosomes are duplicated.  As with all processes within the cell cycle, 
DNA replication and chromosome duplication are also highly regulated processes to ensure 
that the DNA is only replicated once (Heichman, 1994). Also in S phase, the centrosomes, 
which are involved in the division of the DNA between the two daughter cells, are duplicated 
(Lacey, 1999). Upon completion of proper chromosome and centrosome duplication, the 
cycling cell enters the second gap phase, G2.  
Like G1 phase, G2 phase is time that the cell spends examining its ability to enter the 
next phase of the cell cycle without error (Johnson, 1999).  In the case of G2, the next phase 
of the cell cycle is mitosis or M phase. Mitosis is the phase of the cell cycle in which the cells 
physically divides into two genetically identical daughter cells. See Table 3 for a detailed view 
of the phases of the cell cycle.  
 
 
 
 
 
 
 
 
 
 
Table 3: Regulators of the different stages of the eukaryotic cell cycle 
 
Phase Function Predominant 
CDK
Predominant 
Cyclin
CDK
Inhibitor
In
te
rp
ha
se
M
ito
si
s
G1
Gap1
G2
Gap2
S
Synthesis
M
Mitosis
Receive Mitogenic Stimuli
Cell Growth
Protein Sythesis
Preparation for S Phase
DNA  Replication
Chromosome Duplication
Centrosome Duplication
Preparation  for M Phase
Centrosome Maturation
Chromosome Condensation
Chromosome Separation 
Cell Division
CDK4
CDK6
CDK2
CDK2
CDK2
CDK1
CDK1
Cyclin 
D1/ D2/ D3
Cyclin 
E1/ E2
Cyclin 
A1/ A2
Cyclin 
A1/ A2
Cyclin 
B1/ B2/ B3
Cyclin F
p16 INK4A
p15 INK4B
p18 INK4C
p19 INK4D
(cyclin E)
p21 CIP1
p27 KIP1
p57 KIP2
-
-
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Mitosis can be further divided into stages: prophase, prometaphase, metaphase, 
anaphase, and telophase. In prophase, the nuclear envelope is broken down and the 
condensed chromosomes start to align for cell division. In prometaphase, the spindle begins to 
form. In metaphase, the chromosomes align at the metaphase plate. Then, during anaphase, 
the sister chromatids migrate to the poles, and the cleavage furrow begins to form, marking 
the beginning of cytokinesis.  At telophase, the final phase of mitosis, the spindles 
disassemble, the nuclear envelopes of each new daughter cell form, and the chromosomes 
decondense. At that point, one round of the cell cycle has completed, resulting in two 
genetically identical daughter cells that are equivalent to the initial mother cell. See Table 4 for 
detailed view of the phases of mitosis. 
 
 
 
 
 
 
 
 
Table 4: Functions of the different stages of mitosis 
 
Phase Function
M
ito
si
s
Prophase
Metaphase
Prometaphase
Anaphase
Telophase
Nuclear  Envelope  Break  Down
Chromosome  Alignment
Spindle  Formation
Sister chromatids migrate to the poles
Chromosomes  align  on  metaphase  plate 
Cytokinesis
Spindle  Disassembly
Chromosome  Decondensation
Nuclear  Envelope  Reformation 
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Each of these cell cycle phases contains protein regulators (See Table 3). These 
regulators are the accelerators and breaks for the cell cycle. The accelerators of the cell cycle 
are complexes made of two subunits, a catalytic subunit (CDK) and a regulatory subunit 
(cyclin). The catalytic subunit of the cell cycle is a kinase, whose activity drives the cycle 
forward and is ubiquitously expressed throughout the cell cycle. The catalytic subunits are 
known as cyclin dependent kinases (or CDKs) because the CDKs depend on binding of the 
regulatory subunits (cyclins) for enzymatic activation. The expression patterns of cyclins are 
temporal throughout the cell cycle (see Table 3). The cyclins are up-regulated by transcription 
and down-regulated by ubiquitin-mediated proteasomal degradation in a highly organized 
fashion. When a cyclin is transcriptionally up-regulated and binds to a CDK, this cyclin-CDK 
complex is then active and drives the cell cycle forward. Activation occurs through a series of 
phosphorylation events, both activating and inactivating (see Figure 1). An inhibitory kinase is 
able to phosphorylate the CDK-subunit until the cell is adequately prepared to go into the next 
phase. At which point, the cyclin/ CDK complex is de-phosphorylated by the phosphatase, 
CDC25. Another phosphorylation event necessary to progress the cell cycle is the 
phosphorylation of the E2F inhibitor, RB. Phosphorylation of Rb results in release of the 
transcription factor, E2F and transcriptional activation of cell cycle genes (see Figure 1). In the 
case of the G1 and S cyclin-CDK complexes, CDK-inhibitors are able to bind the cyclin-CDK 
complexes and render these complexes inactive, thereby halting the cell cycle. These CDK-
inhibitors are specific to cyclin-CDK complexes (see Table 3). The G1/S CDK/cyclin 
complexes are activated by phosphorylation of the CDK subunit by CAK, CDK-activating 
complex, which is composed of cyclin H and CDK7 (Fisher, 1994). The cyclin that this 
dissertation will focus on will be cyclin E, the cyclin involved in the G1-S phase transition by 
binding CDK2 due to the importance of cyclin E in driving tumorigenesis. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Schematic of the Phosphorylation Events that Lead to Cell Cycle Progression 
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CYCLIN E 
The cyclin E family consists of two genes, CCNE1 (cyclin E1) and CCNE2 (cyclin E2). 
Cyclin E1 was originally identified in two separate labs using a yeast complementation assay. 
Both laboratories, using budding yeast (Saccharomyces cerevisiae), performed this assay to 
rescue the deficiency of the G1 cyclin function using a human cDNA library prepared from the 
human glioblastoma cell line, U118 (Koff, 1991; Lew, 1991). However, the cyclin E1 mRNA 
that was originally identified was not the full length form, but a spliced form, which is 15 aa 
shorter than the endogenous cyclin E and not translated under physiological conditions in 
human cell lines. Both the long and short forms of cyclin E1 that were identified in this study 
bound CDK2 and led to its activation, as determined by rapid G1 progression and increased 
cyclin E-associated kinase activity. Additionally, the short form of cyclin E1 used in its original 
discovery was an artifact of NotI restriction enzyme digestion, and does not exist in vivo  
(Ohtsubo, 1995). Both mouse and human cyclin E2 were identified using a yeast two-hybrid 
assay with p27 (Lauper, 1998) and Cdk2 (Zariwala, 1998) as bait. Cyclin E2 was found to bind 
CDK2, phosphorylate histone H1, and isolate (increase in G1 phase and get degraded in S) 
throughout the cell cycle like cyclin E1 (Lauper, 1998). However, the cyclin E2 protein 
appeared to be regulated similar to cyclin E1 in regards to Rb but not p53, as determined by 
response to the viral E6 and E7 proteins (Zariwala, 1998). Essentially, both cyclin E1 and 
cyclin E2 were upregulated in response to the E7 oncoprotein (which suppresses Rb), but only 
cyclin E2 was upregulated by the suppression of p53 via viral E6. 
Cyclin E1 and cyclin E2 have overall sequence homology at 48 percent (Lauper, 1998; 
Zariwala, 1998; Gudas, 1999). However, some regions of cyclin E1 and cyclin E2 are more 
conserved than others. For example, the cyclin box domain of cyclin E1 and E2 shares over 
75 percent homology (Lauper, 1998; Zariwala, 1998; Gudas, 1999). The centrosome 
localization sequence (CLS) is also conserved in both cyclin E1 and E2 (Matsumoto, 2004). 
The NLS of cyclin E1 appears to be dispensable for nuclear localization (Porter, 2001; Geisen, 
2002; Kelly, 1998). Most likely, cyclin E1 and E2 are able to translocate into the nucleus 
through interactions with other proteins containing NLSs. Although cyclins E1 and E2 are 
similar but not conserved in their substrate binding motifs (MRAIL and VDCLE), cyclins 
E1/CDK2 and E2/CDK2 are both able to bind the substrates, p21, p27, pRb, and histone H1 
(Lauper, 1998; Zariwala, 1998; Gudas, 1999).  See Table 5 for a complete list of CDK2 
substrates and the sites phosphorylated by CDK2.  
Figure 2: Cyclin E Protein Domains 
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 NLS = nuclear localization sequence 
 CLS = centrosome localization sequence 
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Table 5: CDK2 Substrates  
 
Substrate Residue (Site) 
Cyclin E1 T (380), S (399) 
Myogenic differentiation antigen 1 S (200) 
Nucleophosmin 1 T (199) 
Parathyroid hormone related 
protein T (108) 
Retinoblastoma 1 
S (230), S (567), S (608), S (612), S (807), S (811),  
T (821)  
Nuclear transcription factor Y, 
alpha S (320), S (326) 
p53 S (315), S(392) 
Ubiquitin conjugating enzyme 
E2A S (120) 
HIRA T (555), S (687) 
Coilin S (184) 
Inhibitor of DNA binding 3 S (5) 
Inhibitor of DNA binding 2 S (5) 
Upstream binding factor S (389), S (484) 
Cyclin dependent kinase inhibitor 
1B T (187) 
B Myb 
T (266), S (393), T (405), T (440), T (444),  S (452),  
T (487), T (494), T (515), T (518), T (520), S (577) 
ORC1 S (258), S (273), T (375) 
p73 T (86) 
Forkhead box protein M1 T (649) 
CDC6 S (106), S (54), S (74) 
Cell division autoantigen 1 S (20), T (340) 
Protein tyrosine phosphatase, non 
receptor type 2 S (304) 
Cell division cycle 7 T (376) 
CP110 protein 
S (170), T (194), S (366), S (372), S (400), S (45),  
S (516), T (566) 
Cyclin dependent kinase 7 S (164), T (170) 
Protein regulator of cytokinesis 1 T (470), T(481) 
CDX2 S (283), S (287), S (291), S (295) 
SMAD3 T (179), S (204), S (208), S (213), T (8) 
Protein kinase, cAMP dependent, 
regulatory, type I, alpha T (209), S (83) 
DNA replication licensing factor 
MCM4 T (110), T (19), S (3), S (32), S (54), T (7) 
 
* Adapted from the Human Protein Research Database- CDK2
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Cyclins E1 and E2 also likely have similar methods of degradation as they both contain 
a PEST motif, which is involved in the E3 ubiquitin ligase, FBW7, binding (Moroy, 2004)-
review, (Koepp, 2001; Gudas, 1999; Won, 1996; Strohmaier, 2001). Both the phosphorylation 
sites that target cyclin E for degradation and the prolyl bonds that allow PIN1 to aid in their 
isomerization, which also targets cyclin E for degradation, are highly conserved.  The studies 
that have been performed to date comparing the two cyclin Es, suggest that cyclin E1 is the 
dominant one and also the cyclin that is most likely to be the driver of oncogenesis. Thus, from 
this point forward, all references to cyclin E are for cyclin E1.  
Cyclin E is important in cell cycle regulation, as cyclin E is involved in the checkpoint at 
the G1 to S phase transition (Johnson, 1999)-review. In G1, upon phosphorylation of the Rb-
E2F complex, E2F is released to transcriptionally upregulate G1 to S phase transition genes, 
including cyclin E (Cobrinik, 2005)-review. The cyclin E promoter is transcriptionally activated 
by E2F, as discovered using a cyclin E reporter gene with mutations at two potential E2F 
binding sites (Botz, 1996; Ohtani, 1995). Cyclin E, when bound to CDK2, leads to hyper-
phosphorylation of Rb, creating a positive feedback loop (Moroy, 2004). When Rb is 
phosphorylated by cyclin E-CDK2, Rb undergoes a conformational change releasing E2F, a 
transcription factor which drives the cell cycle forward by transcriptionally regulating genes 
involved in S phase (Sherr, 1996)- review. 
  As cells move through S phase, cyclin E gets down-regulated by ubiquitin-mediated 
proteasomal degradation (Singer, 1999; Nishitani, 2006). Cyclin E, which is unbound to CDK2, 
gets degraded by the E3 ubiquitin ligases, Cul3 (shown using Cul3-/- mice) and Cul4 (shown 
using RNAi) (Singer, 1999) and (Nishitani, 2006), respectively. The E3 ubiquitin ligase 
responsible for the degradation of CDK2-bound cyclin E is the SCF complex (Skp/Cullin/F-box, 
with the F-box protein that binds cyclin E being FBW7) (Nishitani, 2006; Koepp, 2001; 
Strohmaier, 2001; Moberg, 2001). Using FBW7 knockout mice and FBW7 RNAi in HeLa cells, 
Fbw7 loss was shown to lead to cyclin E protein accumulation (Tetzlaff, 2004; Yada, 2004). 
Similarly, mutations in FBW7 can lead to tumorigenesis, most likely through elevated cyclin E 
protein levels (Calhoun, 2003; Ekholm-Reed, 2004; Gu, 2007).  
FBW7 (4q32) is located at a frequently deleted region of the genome (Spruck, 2002; 
Knuutila, 1999). Overall, mutations in FBW7 exist in 6% of all tumors. However, some tumor 
types have higher levels of FBW7 mutations than others. The highest level of FBW7 mutations 
exist in T‑cell acute lymphoblastic leukemias (T-ALL) and cholangiocarcinomas (nearly 30%) 
followed by pancreatic, gastric, colon, prostate, and endometrial cancers (approximately 10%) 
 
 
18
(Maser, 2007; Lee, 2006; Kemp, 2005; Hubalek, 2004; Calhoun, 2003; Akhoondi, 2007). 
However, some tumor types rarely exhibit mutations in FBW7, these include bladder, bone, 
breast, leukemia, liver, lung, and ovarian (Nowak, 2006; Lee, 2006; Kwak, 2005; Sgambato, 
2007; Yan, 2006). The majority of FBW7 mutations are point mutations (approximately 75%), 
which can result in the inability of FBW7 to either form homodimers or bind its substrate (such 
as cyclin E). Other mutations that can occur in FBW7 are nonsense mutations (result in a 
truncated form of the FBW7 protein by insertion of a premature stop codon), these truncated 
forms of FBW7 can either be rendered inactive or dominant-negative depending on the 
location of the mutation (Welcker, 2008). Because inactivating mutations in FBW7 can result in 
chromosomal instability (Rajagopalan, 2004), a known effect of cyclin E overexpression (see 
below), one could infer that the effect of inactivation of FBW7 on tumorigenesis is through the 
inability to degrade cyclin E, resulting in increased cyclin E/ CDK2 activity, increased 
proliferation and chromosomal instability, thus increased tumorigenesis. 
During the cell cycle, cyclin E is not only required for Go exit and the G1 to S transition, 
but it is also involved in DNA replication and centrosome duplication (Hwang, 2005). 
Centrosome duplication occurs at the G1/S transition (Lacey, 1999). In Xenopus oocytes, 
inhibition of Cyclin E-CDK2 activity followed by phenotypic reversion with cyclin E-CDK2 
showed that cyclin E-CDK2 is required for centrosome duplication (Hinchcliffe, 1999). Also, 
using confocal microscopy, Hinchcliffe et al was able to show that cyclin E localized to the 
centrosome (Hinchcliffe, 1999).  In 1999, Hinchcliffe et al stated, “The abnormally high number 
of centrosomes found in many human tumor cells can lead directly to aneuploidy and genomic 
instability through the formation of multipolar mitotic spindles.” Under normal circumstances, 
the cyclin E/CDK2 complex is able to phosphorylate CDC25C, resulting in its activation. 
However, in a study by Bagheri-Yarmand et al in which I was involved, in a breast cancer 
model, we found that when bound to CDK2, tumor-specific LMW-E (but not full length cyclin E) 
could lead to an increase in chromosomal instability through the premature inactivation of 
CDC25C. This LMW-E-induced aberrant inactivation of CDC25C in turn resulted in an early 
exit from mitosis, complete with centrosome amplification, chromosome missegregation, and 
anaphase bridges as determined by time-lapsed confocal microscopy. In a rescue experiment, 
by silencing CDC25C in the presence of LMW-E, we found that CDC25C was necessary for 
this effect of LMW-E on chromosomal instability (Bagheri-Yarmand, 2010; Bagheri-Yarmand, 
2010). Thus, cyclin E is very important in its role in centrosome duplication and if altered can 
lead to genomic instability.  
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Some of the functions of cyclin E require CDK2 enzymatic activity; however some 
functions are CDK2-independent. For example, cyclin E, independent of CDK2, was 
determined to be necessary for endoreduplication (DNA replication in the absence of cell 
division) in drosophila (Sauer, 1995; Knoblich, 1994). This same group found that cyclin E 
(through activation of CDK2) was necessary for drosophila embryogenesis. Specifically, 
Knoblich et al found that mutant drosophila cyclin E (DmcycE) embryos lacked the ability to 
exit the sixteenth round of cell division in early embryogenesis, which was through drosophila 
CDK2 (Dmcdc2c) activity (Knoblich, 1994). Another function of cyclin E, which is dependent on 
CDK2 activity to induce Cdc7 accumulation (which phosphorylates Mcm2), is MCM loading 
onto chromatin at the pre-RC (pre-replication complex) during DNA replication, as determined 
by overexpression of Ad-cyclin E (Ekholm-Reed, 2004; Chuang, 2009). Another event, which 
is necessary for S-phase entry, that is controlled by cyclin E, through CDK2, is histone 
biosynthesis. Specifically, the cyclin E/CDK2 complex can phosphorylate NPAT, resulting in 
increased gene expression of histones, as determined by Histone H4 expression (Zhao, 
2000). As mentioned above, cyclin E through CDK2 activation is also involved in cell growth 
through phosphorylation of Rb resulting in release of the transcription factor, E2F (Cobrinik, 
2005)-review. Defects in these processes due to aberrant cyclin E expression and/or activity 
can result in cancer. 
 
CYCLIN E AND CANCER 
Many proteins are involved in cell cycle control; defects in these regulators can result in 
tumorigenesis (Sherr, 1996; Pardee, 1989). Using a breast cancer model system (both tissue 
samples and breast cancer cell lines), cyclins A, B, E, and D1/D3 and CDKs 1 and 2 were 
shown to be overexpressed compared to control (either normal adjacent tissue or non-
tumorigenic cell lines) as determined by Northern and Western blot analysis, indicating their 
important role in driving tumorigenesis (Keyomarsi, 1993). Specifically, cyclin E was found to 
be overexpressed in all 10 breast cancer cell lines, compared to the 3 control cell lines, 
indicating cyclin E is of particular relevance in cancer (Keyomarsi, 1993). Improper regulation 
of cyclin E can result in increased proliferation and genomic instability, which can lead to 
cancer (Ohtsubo, 1993; Ohtsubo, 1995; Resnitzky, 1994). Specifically, cyclin E deregulation 
through overexpression or increased activity can result in breast, ovarian, prostate, and colon 
cancers (Bedrosian, 2004; Keyomarsi, 2002; Wingate, 2005; Sherr, 1996; Keyomarsi, 1994; 
Keyomarsi, 1995; Keyomarsi, 1993). Cyclin E1, cyclin E2, and the cyclin E catalytic subunit 
CDK2 knockout mice are all viable. However, double knockout of cyclin E1/E2 resulted in an 
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embryonic lethal phenotype at day 11.5 with defects in extra embryonic tissues most likely due 
to defects in endoreduplication (see above) (Geng, 2003; Parisi, 2003). In fact, cyclin E1-/-E2-/- 
MEFs (mouse embryo fibroblasts) derived from these knockouts were able to proliferate 
normally in culture (Mendez, 2003). Cyclin E1 knockout mice are viable and fertile with no 
observed abnormalities, possibly due to compensation by cyclin E2 (Parisi, 2003). Similarly, 
cyclin E2 knockout mice are viable with no observed abnormalities. However, unlike cyclin E1 
knockout mice, cyclin E2 knockout mice exhibit reduced male fertility (Geng, 2003). Similarly, 
the CDK2 knockout mice were also viable exhibiting a reduced body size and sterility (Berthet, 
2003; Ortega, 2003). Perhaps the explanation of why the cyclin E and CDK2 knockout mice 
are viable with very little observed defects results from functional redundancies between 
cyclins and CDKs, allowing for other cyclins or CDKs to compensate for loss of these essential 
drivers of the cell cycle. Which is why individual knockout of either cyclin E1 or E2 have no 
phenotypic abnormalities, but double knockouts of cyclin E1 and E2 are embryonic lethal. 
While individual cyclin E knockout mice were viable and exhibited no observed phenotypic 
abnormalities, knockout of both cyclin E1 and cyclin E2 (E1-/-E2-/-) in MEFs (mouse embryo 
fibroblasts) showed resistance to oncogenic transformation. More specifically, in response to 
v-HA-Ras (plus either DNp53, myc, or E1A) or myc alone, cyclin E1-/-E2-/- MEF exhibit 
significant reduced foci formation when compared to the cyclin E1+/+E2+/+ MEFs (Geng, 2003), 
thus implying the role of cyclin E in tumorigenesis is more likely due to transformation than 
changes in proliferation. Aberrant cyclin E, or down-regulation of cyclin E inhibitors, such as 
p21, p27, or FBW7, can result in alterations in the G1 to S transition, endoreduplication, 
centrosomal amplification, and even mitotic catastrophe: all of which could lead to genomic 
instability and thus cancer (see above). 
Cyclin E is involved in several stages of tumorigenesis from initial transformation to 
metastasis. For example, Geng et al had shown that cyclin E1-/-E2-/- MEFs were resistant to 
Ras or myc-induced transformation (Geng, 2003). Also, Geisen et al found that cyclin E-
binding to CDK2 was not necessary for Ras-induced transformation, indicating this function of 
cyclin E is CDK2-independent (Geisen, 2002). Similarly, through a mutation on cyclin E 
resulting in decreased degradation (increased stability- T393A), stabilized cyclin E led to 
increased Ras-induced transformation in vitro and lung cancer in vivo (Loeb, 2005). In 
testicular germ cell tumors, Datta et al found that a significant correlation existed between 
cyclin E and clinical stage and metastasis (Datta, 2000). In a similar correlative study but in 
non- small cell lung cancer (NSCLC), cyclin E was found to correlate with survival in early 
stage NSCLC and metastasis formation (Muller-Tidow, 2001). Through examination of 
 
 
21
colorectal cancer patient samples, Li et al found that cyclin E significantly with metastasis 
formation (Li, 2001). Also, in breast cancer, cyclin E correlates with tumor stage and a poor 
prognosis, implicating the role of cyclin E as a biomarker in tumorigenesis (Keyomarsi, 1994; 
Datta, 2000; Keyomarsi, 2002). Post-translational cleavage of cyclin E (LMW-E) is also 
implicated in the tumorigenic phenotype. Cyclin E in the steps of tumorigenesis will be covered 
in detail below.  
 
 LOW MOLECULAR WEIGHT CYCLIN E (LMW-E) 
In a PNAS paper published in 1993, Keyomarsi and Pardee reported the existence of 
low molecular weight isoforms of cyclin E in breast cancer, which were tumor specific and 
generated post-translationally as indicated by lack of multiple mRNA transcripts in a Northern 
blot assay (Keyomarsi, 1993). These LMW-E isoforms, which are also present in several 
cancer types including ovarian cancer (Bedrosian, 2004; Davidson, 2007), are cleaved post-
translationally by the serine protease, elastase (Porter, 2001). Use of elastase in vitro with 
both endogenous and exogenous cyclin E revealed that incubation with elastase was able to 
cleave cyclin E into low molecular weight isoforms that mimic those observed in vivo. Elastase 
has an endogenous inhibitor, Elafin (Yokota, 2007), which if overexpressed can lead to growth 
arrest as well as apoptosis of breast cancer cells in an Rb-dependent fashion (Caruso, 2010). 
LMW-E is generated by elastase cleavage of full length cyclin E (E1) at two sites, between 
N40/N45 (E3) and between A69/D70 (E6) (Porter, 2001) (see figure 2b and c). LMW-EL2 and 
LMW-EL5 are phosphorylated forms of EL3 and EL6 respectively (Mull, 2009), while EL4 is 
expressed due to an alternate M46 start site (Porter, 2001). The EL2/EL3 doublet has been 
termed cyclin E-T1, LMW-E-T1, or cyclin E-truncation 1, while the EL5/EL6 doublet has been 
termed cyclin E-T2, LMW-E-T2, or cyclin E-truncation 2. Another group showed that cyclin E 
could be cleaved by calpains in response to exogenous Ca2+ and that inhibition of calpain by 
calpeptin could result in a decrease in the cleavage of cyclin E (Wang, 2003). However, while 
calpain activity was increased in breast cancer cells (HTB-126, HTB-123, HTB-124, and ZR75) 
compared to the control HMECs, the LMW forms of cyclin E generated in response to calpain 
differed from the elastase cleavage pattern, which more closely resembles the pattern of cyclin 
E cleavage observed in cancer.  
LMW-E is predominantly expressed in the cytoplasm, as compared with full length 
cyclin E, which is predominantly nuclear. In immortalized breast (MCF10A and 76NE6), breast 
cancer (MCF7-Her18 and MDA-MB-157), and ovarian cancer (IGROV, FUOV1, and OVCAR-
3) cell lines, fractionation experiments revealed that LMW-E expression was predominantly 
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cytoplasmic, while full length cyclin EL was found in both the nucleus and the cytoplasm (Delk, 
2009). Using a protein complementation assay, cytoplasmic LMW-E was determined to bind 
CDK2 in the cytoplasm. This cytoplasmic LMW-E/CDK2 complex was also determined to 
display kinase activity, as determined by an in vitro kinase assay. Because FBW7, the E3 
ubiquitin ligase for cyclin E, is nuclear, this can account for the increased stability of LMW-E 
compared with cyclin EL (Delk, 2009). The unique localization of LMW-E to the cytoplasm as 
compared to the nuclear localization of cyclin EL potentially allows for the screening of cancer 
patients expressing LMW-E via IHC in order to provide a more efficient regiment of treatment 
for this category of breast and ovarian cancer patients.    
The LMW-E isoforms are not merely the effect of tumorigenesis, but are contributors to 
the process. Studies have been performed on LMW-E using normal breast epithelial cells, as 
well as breast, ovarian, melanoma, and colorectal cancer cells (Porter, 2001; Bedrosian, 2004; 
Bales, 2005; Corin, 2006). In these different model systems, our lab and others have found 
LMW-E to be involved in an accelerated G1/S transition (most likely due to increased cyclin E-
associated kinase activity- presumably through CDK2), lengthened period of S phase, 
shortened M phase and increased genomic instability. LMW-E was demonstrated to be 
hyperactive as indicated by increased phosphorylation of both histone H1 and GST-Rb, using 
an in vitro kinase assay (Porter, 2001). Specifically, in mortal (70N and 81N), immortalized 
(MCF10A and 76NE6), and tumor (MDA-MB-436 and MDA-MB-157) breast cell lines, 
overexpression of exogenous, flag-tagged LMW-E exhibited increased cyclin E-associated 
kinase activity compared to the full length form of cyclin E. This increase in cyclin E-associated 
kinase activity translated into an increase in the capability of normal cells (81N) as well as 
immortalized cells (76NE6) to enter S and subsequently G2/M phases of the cell cycle, 
indicating LMW-E is hyperactive in its ability to activate CDK2 in a breast model system 
(Porter, 2001; Wingate, 2003). In spite of the increased cyclin E-associated kinase activity 
observed with LMW-E overexpressing cells, the LMW-E/CDK2 complex binds p21 and p27 
more efficiently than the cyclin EL/CDK2 complex, as determined by a series of 
immunoprecipitation (IP): Western blot analyses in MCF7 breast cancer cells (Akli, 2004). 
However, the LMW-E/CDK2 complex is more resistant to these CKIs, as determined by an IP 
(with p21 or p27) followed by an H1 kinase assay. These results were validated using an in 
vitro kinase assay with purified p21 from SF9 insect cells using GST-Rb as the substrate (Akli, 
2004). Thus, even in the presence of increased binding to the CKIs, p21 and p27, LMW-
E/CDK2 has increased kinase activity compared to cyclin EL/CDK2.  
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LMW-E also causes an increase in chromosomal instability as compared to full length 
cyclin E. Akli et al determined that in MCF7 cells with stably expressed exogenous cyclin E, 
LMW-E caused an increase in the percentage of metaphases with aberrations as compared to 
the parental, vector control, of cyclin EL overexpressing MCF7 clones (Akli, 2004). This 
change in the percentage of aberrations was due to an increase in the number of chromosome 
breaks, which resulted in an increase in the percent polyploidy in the MCF7-LMW-E clones 
(Akli, 2004). Using an MCF7-Tet-on cyclin E inducible model system, we found that in addition 
to chromosome breaks, fragments and dicentric chromosomes were observed in the LMW-E 
inducible clones compared to the cyclin EL induced MCF7-Tet-on cells (Nanos-Webb in 
revision). Exploring the mechanism of chromosomal instability induced by LMW-E, we found 
that LMW-E (but not cyclin EL), through its binding CDK2, led to increased chromosomal 
instability through its premature inactivation of CDC25C, leading to centrosome amplification, 
an early exit from mitosis, chromosome missegregation, and anaphase bridges, resulting in 
chromosomal instability (Bagheri-Yarmand, 2010; Bagheri-Yarmand, 2010). Thus, at least one 
of the roles of LMW-E in tumorigenesis is through induction of chromosomal instability. 
 
CYCLIN E AND TRANSFORMATION 
Several steps are necessary to transform a normal cell into a malignant cell (Hanahan, 
2000). These steps include: (1) evading apoptosis, (2) self-sufficiency in growth signals, (3) 
insensitivity to anti-growth signals, (4) sustained angiogenesis, (5) limitless replicative 
potential, as well as (6) tissue invasion and metastasis.  
(1) Evading Apoptosis: Surprisingly, cyclin E overexpression has been shown to 
sensitize cells to the induction of apoptosis, which is the opposite effect needed for 
transformation. This phenomenon could be an evolutionarily adaptive mechanism cells have 
acquired to counteract a deregulation in the expression of cyclin E. In a breast cancer model 
system (MCF7 and T47D cell lines), exogenous cyclin E overexpression resulted in an anti-
apoptotic protein (Bcl-2) and an increase in two pro-apoptotic proteins (Bad and Bax), as 
determined by Western blot analysis (Dhillon, 2003). This change in mediators of apoptosis 
observed upon over expression of cyclin E translated to an increase in cytokine-induced (Fas, 
TNFalpha, and TRAIL) apoptosis, as determined by TUNEL analysis (Dhillon, 2003). Overall, 
most studies of cyclin E in apoptosis have been performed in the presence of ionizing radiation 
(IR). For example, in hematopoietic cell lines (Multiple-myeloma IM-9, U-266, and lymphoma 
Molt-4) exposed to IR (4-20 Gy), cyclin E is cleaved into a non-CDK2 binding truncation, 
referred to as p18 (due to its size), as observed by Western blot analysis (Mazumder, 2002). 
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Exogenous Bcl-2 expression can prevent this truncation and p18 expression is caspase 3-
dependent, indicating p18-cyclin E could be involved in apoptosis. In fact, exogenous 
overexpression of the truncated p18-cyclin E induced apoptosis, as determined by annexin V-
FITC analysis (Mazumder, 2002). Thus, contrary to the first hallmark of cancer, evasion of 
apoptosis, cyclin E seems to exhibit a pro-apoptotic function. However, because cyclin E is 
oncogenic, this role of cyclin E is likely suppressed by the tumorigenic characteristics of cyclin 
E.  
(2) Self-Sufficiency in Growth Signals: This particular hallmark of cancer has not been 
extensively studied in regards to cyclin E. However, transformed cells that, by another 
mechanism unrelated to cyclin E, have induced an autocrine response (self-sufficiency in 
growth signals) require cyclin E activity to perform proliferation. An example of this being in 
endometrial carcinoma cells, where estrogen-induction caused an autocrine response via 
upregulation of IGR1 (insulin growth factor 1), resulting in an increase in cyclin E expression 
followed by increased proliferation (Kashima, 2009). Thus, although cyclin E may not be 
responsible for the induction of the autocrine response, cyclin E is still necessary to 
accomplish the effect of this response. 
(3) Insensitivity to Anti-Growth Signals: The majority of studies of cyclin E in the 
transformation process have been on this particular hallmark of cancer. Previously, I have 
mentioned that in breast cancer, LMW-E is able to bind the CKIs p21 and p27. However, 
LMW-E is resistant to their inhibitory effects (Akli, 2004). Other studies have also shown that 
cyclin E is able to evade growth arrest signals. For example, in MCF7 (ER+) breast cancer 
cells, addition of the antiestrogen (tamoxifen) causes growth arrest. However, exogenous 
expression of cyclin E is able to delay this growth arrest (Dhillon, 2002). Similarly, in a breast 
cancer model system, MCF7 cells expressing ectopic LMW-E show a reduction in growth 
arrest in response to the antiestrogen, ICI 182,780 (fulvestrant), when compared to the MCF7 
vector control and cyclin EL overexpressing cells, as determined by flow cytometry cell cycle 
analysis (Akli, 2004). Along the same lines, also in a breast cancer model (MCF-7/Ac1- MCF7 
cells which have been transfected with aromatase, the enzyme that converts androgens to 
estrogens), MCF7/Ac1 cells infected with LMW-E (but not the LacZ control of cyclin EL) exhibit 
resistance to the G1-growth arrest induced by addition of the aromatase inhibitor (AI), letrozole 
(Akli, 2010). This bypass of growth arrest was due to an increase in cyclin E-associated CDK2 
kinase activity, and could therefore be blocked by addition of the CDK-inhibitor, Roscovitine. 
Thus, several studies have indicated that cyclin E and LMW-E can exhibit insensitivity to anti-
growth signals, the third hallmark of cancer.      
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(4) Sustained Angiogenesis: Minimal research has been performed regarding cyclin E’s 
role in angiogenesis. However, in a melanoma model system, LMW-E was demonstrated to 
cause an increase in human melanoma cell xenograft tumors with sustained angiogenesis, the 
fourth hallmark of cancer, compared to vector control or cyclin EL overexpressing melanoma 
cells (Bales, 2005). This model system was used due to the differential expression of LMW-E 
in melanoma cells and metastatic melanoma as compared to normal melanocytes, which only 
express cyclin EL (Bales, 2005). Thus, although the mechanism of LMW-E induced 
angiogenesis has not been resolved, LMW-E can lead to an increase in angiogenesis. 
(5) Limitless Replicative Potential: By examining IMR-90 cells (human fetal lung 
fibroblasts) that lack limitless replicative potential (senescent cells), Dulic et al found that cyclin 
E protein (as determined by Western blot analysis) and mRNA (as determined by Northern 
blot analysis) levels were 10 to 15 fold higher in quiescent cells (high confluency) versus 
senescent cells (high passage), indicating cyclin E could be down regulated in senescence, 
which could account for their inability to enter S-phase (Dulic, 1993). Similarly, upon induction 
of both senescent and quiescent cells with growth factors, cyclin E protein levels (as measured 
by Western blot analysis) and cyclin E-associated kinase activity (as measured by an H1 
kinase assay) only increased in the quiescent cells, while the senescent cells remained 
unaffected. Also, upon treatment of these cells under these two conditions with CDC25, cyclin 
E-associated kinase activity only increased in the quiescent cells, while the senescent cells 
exhibited no change in cyclin E activity (Dulic, 1993). While this mechanism of downregulation 
of cyclin E levels and activity in this study of senescence was not addressed, this implies that 
downregulation of cyclin E can result in a decrease in limitless replicative potential, the fifth 
hallmark of cancer, indicating the necessity of cyclin E for limitless replicative potential. In an 
effort to devise the mechanism of cyclin E regulation in senescent versus proliferating 
melanocytes, Bandyopadhyay et al found that p300/CBP (a histone acetyltransferase- HAT) 
was recruited to the cyclin E promoter during proliferation of melanocytes versus in senescent 
cells that recruit histone deacetylases (HDACs), as determined by ChIP analysis 
(Bandyopadhyay, 2002). Thus, cyclin E through its transcriptional regulation, at least in part, 
can control the ability of cells to senesce versus undergo limitless replicative proliferation.   
(6) Tissue Invasion and Metastasis: Very little research on invasion has been 
performed in regards to cyclin E expression. The only study, to my knowledge, involved a 
negative correlation (increased cyclin E correlated with a decrease in invasion) between cyclin 
E overexpression and an infiltrative phenotype as determined by IHC (immuno-histochemistry) 
in 985 breast cancer patient primary tumor samples (Berglund, 2006). However, no direct link 
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or mechanism was established between cyclin E overexpression and invasion, nor were any 
invasion assays performed. Cyclin E has however been studied more extensively in its effect 
on metastasis.   
Cyclin E expression has been shown to be correlated with metastasis in several model 
systems. For example, in gastric carcinoma, by examination of cyclin E levels in tissue 
samples by IHC, Sakaguchi et al was able to show that cyclin E levels correlated with 
metastasis: 39% lymph node metastasis positive with strong cyclin E staining versus only 12% 
with low cyclin E staining (p < 0.05) (Sakaguchi, 1998). However, no direct studies of the effect 
of cyclin E expression on metastasis were investigated in this study. Another group showed 
the correlation between cyclin E and metastasis in colorectal carcinoma. Using tissue samples 
stained for cyclin E expression using IHC, Li et al found that cyclin E levels significantly 
correlated with both lymph nodal metastasis and peritoneal metastasis in a colorectal 
carcinoma model (Li, 2001). However, like the Sakaguchi study, no direct investigation of the 
effect of cyclin E expression on metastasis was reported. However, in these two studies, cyclin 
E expression, either cyclin EL or LMW-E was not differentiated. 
Several studies have been performed which directly link LMW-E expression with 
metastasis. In a transgenic mouse model system, Akli et al found that LMW-E could contribute 
to metastatic mammary carcinomas and that this effect is through the interruption of the ARF-
p53 pathway (Akli, 2007). More specifically, generation of transgenic mouse models 
exogenously expressing cyclin E (either full length alone, cyclin EL- M46A, which is unable to 
generated the alternatively translated LMW form of cyclin E, EL4, or LMW-E-T1) under control 
of the MMTV promoter, showed an increase in the number of lung metastases formed. 
Transgenic mice expressing LMW-E-T1 exhibited 25% (with wt p53) and 35.2% (with p53-/+) 
metastatic tumors (n = 53 and 26, respectively) as compared to cyclin EL-M46A transgenic 
mice which exhibited 14.3% (with wt p53) and 0% (with p53-/+) metastatic tumors (n = 67 and 
17, respectively) (Akli, 2007). Thus, LMW-E was demonstrated to be a direct initiator of lung 
tumor metastases in the breast cancer model system.  Also, melanoma xenograft models 
demonstrated that LMW-E led to increasing lung metastasis (Bales, 2005). More specifically, 
in a mouse xenograft model, SB-2 melanoma cells expressing exogenous cyclin E (either 
vector alone, cyclin EL, LMW-E-T1 or LMW-E-T2) were injected into mice. The vector alone 
group did not form lung metastases, the cyclin EL group formed metastases in 40% of the 
mice, while both the LMW-E-T1 and LMW-E-T2 groups formed metastases in 100% of the 
mice (n = 10 for each group) (Bales, 2005). Thus, LMW-E, more so than cyclin EL, is able to 
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lead to an increase in metastasis in both the breast cancer and melanoma model systems. 
However, this dissertation will be focusing on the role of cyclin E in the initial stages of 
tumorigenesis: transformation and anchorage-independent growth. 
 
CYCLIN E AND ANCHORAGE-INDEPENDENT GROWTH  
One of the factors that sets apart a transformed cell from a non-transformed cell is 
anchorage-independent growth (Kang, 1996). The loss of anchorage-dependence correlates 
with the tumorigenic phenotype in vivo (Shin, 1975). Adherent cells that have undergone 
transformation are able to grow in suspension (anchorage-independent growth).  
Cells that lack substrate adhesion (adherent cells cultured in suspension) tend to arrest 
in late G1 (Otsuka, 1975; Campisi, 1983; Guadagno, 1991; Han, 1993). Three G1 events 
occur in adherent cells which have been cultured in suspension that cause these cells to arrest 
in G1 (fail to grow in suspension): (1) decrease in cyclin E-CDK2 kinase activity, (2) decrease 
in Rb phosphorylation, and (3) a decrease in cyclin A expression (Fang, 1996; Kang, 1996). 
(1) Predictably, changes in cyclin E expression would alter the activity of the cyclin E/CDK2 
complex. (2) Similarly, because cyclin E, when bound to CDK2, leads to hyper-
phosphorylation of Rb, creating a positive feedback loop (Moroy, 2004), alterations in cyclin E 
could affect the phosphorylation of Rb, which could in turn affect anchorage-independent 
growth. (3) Likewise, cyclin E-CDK2 is upstream in the cell cycle, thus a decrease in cyclin A 
expression is likely a result of loss of cyclin E-CDK2 kinase activity (Fang, 1996). Therefore, 
according to these three necessary steps for non-transformed cells to be able to grow in 
suspension independently of anchorage, cyclin E can be linked to all three steps.    
Cyclin E exhibits a role in Ras-induced transformation. Kang et al, in ER-1-2 (somatic 
cell mutant rat fibroblasts, which are defective in oncogene-mediated, anchorage-independent 
growth), PKC3-F4 (non-transformed fibroblasts that only grow in suspension upon oncogene-
induction, i.e. RasV12), and NIH3T3 (mouse embryonic fibroblasts) all non-transformed 
fibroblasts, showed that Ras induced-transformation induced cyclin E kinase activity. When 
ER-1-2, PKC3-F4, and NIH3T3 cells where grown in suspension, these cells arrested in G1 
phase, had undetectable phospho-Rb levels, and showed no cyclin E-CDK2 kinase activity as 
demonstrated using a kinase assay with histone H1 as the substrate. However, upon 
exogenous Ras expression, PKC3-F4 and NIH3T3 cells not only grew in the suspended state 
but induced cyclin E-CDK2 kinase activity and Rb phosphorylation (Kang, 1996). Similarly, 
Haas et al found that exogenous expression of the CDK-inhibitors, p21 and p27, abrogated 
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cyclin E/HA-Ras-induced transformation as determined by loss of foci formation (Haas, 1997). 
Also, cyclin E1-/-E2-/- MEFs showed resistance to oncogenic transformation (as mentioned 
above) (Geng, 2003). Thus, an adherent characteristic, such as cyclin E-CDK2 kinase activity 
is implicated in transformation.  
Both CDK2- dependent and CDK2-independent cyclin E-associated activity has been 
implicated in transformation. In a Science paper, Fang et al showed that the decreased cyclin 
E-CDK2 activity that was observed in cells that were arrested by being grown in suspension 
was due to increases in the CDK-inhibitors, p21 and p27. In KD untransformed human diploid 
fibroblasts, Fang et al synchronized these cells in Go by serum starvation and placed the cells 
in suspension culture. Upon re-addition of growth factors, the arrested, suspended KD cells 
failed to undergo DNA synthesis, implying that arrest of suspended cells occurs in G1 phase. 
In both KD and IMR90 untransformed human diploid fibroblasts, the protein levels of cyclin E 
and CDK2 were unchanged between the adherent and suspended cells. However, the cyclin 
E/CDK2 kinase activities were lower in the suspended cells than the attached cells. Similarly, 
HUT12 cells, an anchorage-independent variant of KD cells, showed similar levels of cyclin E 
and CDK2 kinase activity when attached or adherent. Although CAK is responsible for 
phosphorylation and activation of cyclin E-CDK2, no changes in CAK levels or activity were 
observed. The suspended KD and IMR90 cells did however reveal a four-fold increase in the 
CDK-inhibitors p21 and p27, but not p57 (Fang, 1996), indicating the inhibition of cyclin 
E/CDK2 activity was responsible for the arrest observed in the G1 phase of the cell cycle. This 
goes along with the finding by Haas et al that p21 and p27 expression abrogated cyclin E/HA-
Ras-induced transformation (Haas, 1997). Thus, the decrease in cyclin E-CDK2 activity was 
most likely due to this increase in p21 and p27. However, the transformed HUT12 cells 
exhibited similar elevated levels of p21 and p27, but the higher levels of cyclin E and CDK2 
were able to overcome this inhibition (Fang, 1996).  
Since the inhibitory roles of p21 and p27 are highly implicated in cyclin E’s role in 
transformation, it seems likely that LMW-E would exhibit increased anchorage-independent 
growth. As previously stated, research in our laboratory has shown that LMW-E binds p21 and 
p27 but is resistant to the inhibitory effects of these CDK inhibitors. In fact, the IC50 value of 
p21 necessary to decrease the cyclin E-associated kinase activity, as determined by a GST-
Rb kinase assay, for the full length form of cyclin E was 25 nM, while the IC50 values for LMW-
E-T1 and LMW-E-T2 were 125 nM and 105 nM, respectively. While similar results were 
observed with p27, the exact IC50 values for p27 were not published. Thus, 5-fold more p21 
and p27 is necessary to inhibit CDK2/LMW-E activity as compared to CDK2/cyclin EL (Akli, 
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2004; Wingate, 2005). As discussed previously, Akli et al in our lab has shown that LMW-E 
transgenic mice exhibit increased incidence of breast cancer development as compared to the 
full length cyclin E transgenic mice (Akli, 2007). Thus LMW-E could potentially lead to 
transformation and anchorage-independent growth by evading the inhibitory effects of p21 and 
p27 up-regulation. While up to this point, active CDK2 has been shown to be necessary for 
induction of anchorage-independent growth, cyclin E is able to play a role in transformation 
that is not dependent on CDK2. 
Cyclin E could also have a role in transformation that is CDK2-independent. Cyclin E is 
necessary for Ras-induced transformation. However, kinase-dead cyclin E expressing REFs 
(rat embryo fibroblasts) still exhibited Ras-induced transformation (Geisen, 2002), thus 
implying that Ras induction of transformation is dependent on cyclin E, but independent of 
cyclin E’s binding to CDK2. In fact, using a series of truncated forms of cyclin E, Geisen et al 
showed that mutant cyclin E (which was unable to bind CDK2) was (in cooperation with HA-
Ras) able to induce transformation of rat embryo fibroblasts, as measured by foci formation 
(Geisen, 2002). Thus, in REFs, cyclin E (independently of CDK2 binding) was able to lead to 
foci formation, an indication of cyclin E’s potential to induce transformation. However, in the 
Geisen study, no in vivo analysis of transformation was investigated. Thus, it is highly probable 
that cyclin E can be involved in transformation and anchorage-independent growth 
independently of CDK2 binding and activity. 
Thus cyclin E plays a critical role in oncogenic transformation, and the effect of cyclin E 
on anchorage-independent growth could be CDK2-dependent or CDK2-independent. Also, 
Ras mediated transformation seems to be at least partially through an increase in cyclin E-
CDK2 activity and Rb phosphorylation. 
 
 
 
PKCiota 
NOTE 
Due to the high homology between the two atypical PKC family members, PKCiota and 
PKCzeta, many early papers studying PKCiota and PKCzeta do not differentiate between the 
two isoforms. Thus, when these two isoforms are not distinguished, they will collectively be 
referred to as aPKC. Also, the mouse 
homolog for PKCiota is PKClambda. Thus, 
in mouse studies, PKCiota will be referred 
to as PKCiota/lambda.  
Species Alternative Names
Humans 
PKCiota 
(or aPKC if not differentiated from PKCzeta) 
Mice/Rats PKClambda 
Flies DaPKC 
 
PKC FAMILY OF SERINE/THREONINE KINASES 
 The PKC (protein kinase C) family of serine/threonine kinases is involved in  
various signal transduction cascades and is currently comprised of ten isoforms (Martelli, 
2003). To date, the PKC isoforms reside in the cytosol and upon activation translocate to the 
plasma membrane (Martelli, 2003). These ten isoforms are clustered into three catagories: the 
conventional, novel, and atypical isoforms (see Figure 4). The conventional PKCs (cPKCs) are 
comprised of α, βI, βII, and γ, and are activated by calcium (Ca2+), diacylglycerol (DAG), and 
the membrane lipid phosphatidylserine (PS). The novel PKCs (nPKCs) are comprised of δ, ε, 
η, and θ, and are activated by DAG and PS. The third class of the PKC family, the atypical 
PKCs (aPKCs) will be the focus of this dissertation. The atypical PKCs are comprised of ι/λ 
and ζ (Newton, 1997). 
As the name implies, the atypical PKCs are regulated very differently than the 
conventional or novel PKCs. The atypical PKCs are not directly regulated by Ca2+, DAG, or 
phorbol esters (Nishizuka, 1995). Specifically, because of PKCiota’s (PKC ι/λ) homology to 
PKCzeta (PKC ζ), the PKCiota isoform was found to not be regulated by diacylglycerol (DAG) 
(Selbie, 1993).  While other members of the PKC family bind to phorbol esters (excluding the 
other atypical PKC family member, PKCzeta), PKCiota/ lambda, as determined using a 
phorbol ester binding assay, did not bind to phorbol esters (Akimoto, 1994). Also, both aPKC 
isoforms lacked the N-terminal C2 domain and part of the C1 domain, which accounted for 
aPKC’s lack of activation by DAG and Ca2+ (see Figure 4). Interestingly, in place of the C1/C2 
domains, the aPKCs contain a PB1 domain, allowing these specific isoforms to form 
protein:protein (PB1:PB1) interactions with effector proteins (Hirano, 2004). See “PKCiota- 
Binding Partners” section for great detail.  
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Figure 4: PKC Family of Serine/Threonine Kinases 
 
 
 
Class PKC isoform  Activated By: 
Conventional 
(cPKC) 
 
α(Alpha) 
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Diacylglycerol (DAG) 
The membrane lipid phosphatidylserine (PS) 
 
Novel 
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δ(Delta) 
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DAG 
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 ie p62, PAR-6:PAR-3, MEK5, CDC42 
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INITIAL DISCOVERY OF PKC IOTA/LAMBDA AND CHARACTERISTICS 
PKCiota is a serine/threonine kinase in the PKC family. PKCiota was first identified by 
PCR using loose primers against the highly conserved catalytic domain of other PKC family 
members (Selbie, 1993). Specifically, the PKCiota gene encodes for a 587-amino acid coding 
region which gives rise to a 65-kDa band (western blot analysis) first identified using an 
antibody to the C-terminus of PKCzeta (this region is conserved in PKCiota) (Selbie, 1993). A 
year later, the mouse homolog (PKC lambda) was identified using a mouse P19 embryonal 
carcinoma cells and mouse brain (Akimoto, 1994). The PKCiota/ lambda gene gave rise to a 
74-kDa protein, identified using an antiserum raised against a portion of PKCiota/ lambda 
(Akimoto, 1994). Akimoto et al determined that PKCiota/ lambda was autophosphorylated, 
thus possessing protein kinase activity (Akimoto, 1994). In PKCiota/ lambda kinase assays, 
myelin basic protein (MBP) is used for the substrate due to the ability of PKCiota/ lambda to 
phosphorylate MBP (Kazanietz, 1993). As mentioned, this dissertation will refer to PKCiota as 
such unless the study was conducted in mice, in which case, PKCiota will be referred to as 
PKCiota/lambda. 
The structure of the aPKCs compared to the nPKCs and cPKCs is quite different (see 
Figure 4). Like the nPKCs and cPKCs, the aPKCs contain a catalytic subunit comprised of the 
C3 ATP-binding site and the C4 substrate binding site (Tan, 2003). The crystal structure of the 
catalytic domain of PKCiota revealed that the PKCiota ATP-binding site resembled that of 
PKB/AKT but not PKA (Messerschmidt, 2005). However, unlike the nPKCs and cPKCs, the 
aPKCs contain a distinct PB1 domain and a truncated C1 domain (Hirano, 2004). The PB1 
domain allows the aPKCs to bind effector molecules.   
PKCiota is able to traffic to and from the nucleus. For the most part, PKCiota is 
localized to either the nucleus or cytosol and upon activation is translocated to the plasma 
membrane (in polarized cells). However, PKCiota behaves differently in 2D culture versus 
polarized tissues. In 2D culture, PKCiota is located in the nucleus, but upon activation moves 
to the cytosol. For example, PKCiota/lambda translocates from the nucleus to the cytoplasm 
upon PDGF or EGF stimulation (Akimoto, 1996). PKCiota was found to contain canonical NLS 
(nuclear localization sequence) and NES (nuclear export sequence) sequences allowing the 
trafficking between the two parts of the cell. Specifically, in HeLa and HEK293 cells, 
PKCiota/lambda was shown to traffic to and from the nucleus. Localization was visualized by 
using GFP-fused PKCiota/ lambda constructs (and mutant PKCiota/ lambda constructs). While 
wild-type PKCiota/ lambda localized in the cytoplasm, the kinase-dead and activation loop 
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mutant both localized in the nucleus. A canonical NLS and CRM1-dependent leucine-rich NES 
were identified using truncated forms of PKCiota/ lambda . The NLS was mapped to the N-
terminal portion of the zinc-finger domain, and the NES was mapped to the linker region, 
which is located between the catalytic and the zinc-finger domains. Experiments using 
Leptomycin B, which blocks nuclear export by inhibiting the exportin protein CRM1/exportin1, 
revealed that PKCiota/ lambda possessed the ability to traffic to and from the nucleus 
(Perander, 2001). 
 
THE ATYPICAL PKCS: PKC IOTA/LAMBDA VERSUS PKC ZETA 
PKCiota/ lambda most closely resembled PKC’s lone atypical member, PKCzeta, with 
overall homology of 72% and catalytic domain homology of 84% (Selbie, 1993; Akimoto, 
1994). After PKCzeta, the closest that PKCiota has homology to other PKC family members is 
less that 53% (Selbie, 1993). PKCiota shares similarities with PKCzeta, having a highly 
conserved pseudosubstrate domain and only a single cysteine-rich, zinc finger-like region (C1) 
(Selbie, 1993). Like PKCzeta, PKCiota lacks an apparent Ca(2+)-binding region (C2) (Selbie, 
1993). As expected, PKCiota and PKCzeta, since they are so homologous, can have 
functional redundancies. For example, PKCiota and PKCzeta show functional redundancy 
during vertebrate (zebrafish) retinogenesis in several aspects, including “mitotic division 
location and orientation, cell-type positioning, and retinal pigment epithelial (RPE) and 
photoreceptor cell morphogenesis” (Cui, 2007).  However, PKCiota and PKCzeta also have 
distinct roles, either through PB1 protein-binding or through distinguishing localization.  
 PKCiota and PKCzeta can also have the same role but differential expression patterns 
leading to a loss of functional redundancy. For example, PKCiota/lambda and PKCzeta exhibit 
extremely different gene expression patterns during mouse embryogenesis (Kovac, 2007). 
Additionally, each has alternate cellular localization is demonstrated in the mouse epidermis. 
By examination of the mouse epidermis, which exhibits apical-basal polarity, Helfrich et al 
found that both PKCiota/lambda and PKCzeta are expressed in these cells, but only 
PKCiota/lambda is present at the tight junctions (Helfrich, 2007). Thus, in these particular 
epithelial cells, PKCiota/ lambda and PKCzeta do not exhibit functional redundancy due to 
unique localization.   
PKCiota and PKCzeta can activate the same effector molecule but through different 
pathways. Thus is the case in Ras-induced c-fos expression. Ras through PKCiota is able to 
transcriptionally up-regulate c-fos, a tumor-promoting transcription factor. The PKCiota-
dependent pathway seems to be Ras Æ PKCiota/ lambda Æ c-fos transcriptional activation. 
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However, the Raf/PKCzeta pathway appears to be Ras Æ Raf-1 Æ MEK Æ PKCzeta (but not 
PKCiota/ lambda) Æ c-fos transcriptional activation (Kampfer, 1998). See figure OPP (Overall 
PKCiota Pathway) for a complete overview of the upstream and downstream proteins involved 
in PKCiota signaling. 
 
 
 
 
Figure OPP: Overall PKCiota Pathway 
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PKCiota and PKCzeta can also function in the same pathway but at different locations 
in that pathway. Thus is the case of Ras-induced cyclin D1 transcriptional activation and actin 
remodeling, both of which lead to transformation. Both of these pathways indicate that 
PKCiota is upstream of PKCzeta: Ras ÆPKCiota Æ Rac1 Æ PKCzeta Æ cyclin D1 induction 
(Kampfer, 2001) and Ras ÆPKCiota Æ Rac1 Æ PKCzeta Æ actin remodeling (Uberall, 1999) 
(see OPP figure). 
PKCiota and PKCzeta can also exhibit isoforms-specific functions. For example, in 
order to determine the roles of PKCiota versus PKCzeta in the innate immune response, Soloff 
et al generated a PKCiota/lambda knockout mouse. The PKCiota/ lambda knockout mouse 
was embryonic lethal at day 9, however, they were able to generate a chimera composed of 
the PKCiota/lambda-/- embryonic stem cells and blastocysts. In the PKCiota/lambda-/- chimera, 
Soloff et al found that these cells responded normally to the innate immune response, i.e. 
TNFα serum, EGF, IL-1, or LPS stimulation. Thus, Soloff et al concluded that PKCiota had 
more of a role in embryogenesis and polarity than the innate immune response (Soloff, 2004). 
Unfortunately, the authors never did these studies in a PKCzeta knockout mouse model (or 
PKCiota/lambda-/-PKCzeta-/- mouse), which would better rule out the possibility of redundancy 
among the atypical PKCs. In another study, PKCiota and PKCzeta were found to have 
different characteristics. While caspase-3 cleaved PKCzeta upon UV-irradiation in HeLa cells, 
PKCiota/ lambda was not cleaved in this manner. Mutating the caspase-3 cleavage site in 
PKCzeta resulted in reduce apoptosis (Frutos, 1999).  
An example of PKCiota and PKCzeta having the same role but under different 
conditions is in the case of Na+/K+ATPase activity, where PKCiota and PKCzeta have 
opposing roles. Dominant negative PKCzeta inhibited Na+/K+ATPase activity in serum-
starved MCF7 cells stimulated with AngII. However, using MCF7 cells cultured in 10% serum, 
PKCzeta activity was not changed upon stimulation with AngII; nor did the Na+/K+ATPase 
activity change upon expression of a dominant negative PKCzeta. However, PKCiota 
antisense was able to block AngII-induced Na+/K+ATPase activity in MCF7 cells cultures in 
10% serum. Thus, PKCiota is involved in Na+/K+ATPase activity under high growth factor 
conditions, while PKCzeta is involved in Na+/K+ATPase activity under quiescent conditions 
(Muscella, 2005). 
PKCiota and PKCzeta are not ubiquitously expressed. Thus, the activation of these two 
PKC isoforms can be dependent on their expression. In DU-145 prostate cancer cells, 
PKCiota was able to phosphorylate IKKβ, a protein that upon phosphorylation gets degraded 
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allowing NFκB to translocate to the nucleus. However, in RWPE-1 prostate cancer cells, the 
kinase responsible for IKKβ phosphorylation is PKCzeta (Win, 2008).   
Thus, PKCiota and PKCzeta can show similar effects but their roles may be distinct 
because of unique localization, different conditions of activation or expression, or through 
alternative binding (activating) partners (see Table 7). 
 
PKC IOTA PHOSPHORYLATION/ ACTIVATION 
The analysis of crystal structure of PKCiota revealed that it had two important 
phosphorylation sites. Phosphorylation of Thr403 occurred at the activation loop, while 
phosphorylation of Thr555 (an autophosphorylation site) was in the turn motif (Messerschmidt, 
2005).  
PKCiota is also activated by tyrosine phosphorylation. Src tyrosine phosphorylation of 
PKCiota is necessary for beta-COP recruitment to the pre-golgi intermediates (VTCs) (Tisdale, 
2006) and to the endosome, where it binds p62 (Samuels, 2001). In PC12 cells that have been 
stimulated with NGF, PKCiota is phosphorylated by Src at three sites (tyrosines 256, 271, 325) 
which was inhibited in a dose-dependent manner by the Src inhibitors, PP2 and K252a. In 
response to NGF, Src phosphorylates PKCiota at tyrosines 256, 271, 325.  However, site 
directed mutagenesis revealed that only Y325 phosphorylation by Src was required for 
PKCiota activation and subsequently NFκB activation (Wooten, 2001).  
By liquid chromatography-high accuracy mass spectrometry analysis, Macek et al 
observed several other potentially important phosphorylation sites, S217 and S237/S238 
(possibly linked to improved stability/solubility) and S35/S37 (which is located in the PB1 
domain thus implying the possibility of substrate specificity)  (Macek, 2008). However, to date, 
the exact purpose of the phosphorylation of these sites has not been published. 
Overall, PKCiota regulation occurs at the level of localization, where PKCiota is 
inactive in the cytosol and upon activation translocates to the plasma membrane (Martelli, 
2003). PKCiota degradation is mediated by the E3 ubiquitin ligase, VCB-Cul2, which is a 
complex composed of pVHL (von Hippel-Lindau), a hypoxic induced tumor suppressor gene, 
elongins B and C, Cul-2, and Rbx1. Overexpression of pVHL in HEK293 cells resulted in an 
increase in PKCiota degradation, and an in vitro ubiquitination assay revealed the components 
of the VCB-Cul-2 complex were sufficient for PKCiota ubiquitination (Okuda, 2001).  
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PKC IOTA HAS DIVERSE FUNCTIONS. 
PKCiota/ lambda is a highly conserved polarity protein involved in development of 
multicellular organisms (Suzuki, 2003). PKCiota/ lambda has also been shown to be 
evolutionarily conserved, being expressed in three strains of baker’s yeast extracts, wheat 
germ, c. elegans, goldfish, mice, rats, chickens, rabbits, guinea pigs, and monkeys, just to 
name a few (Kuo, 1995; Izumi, 1998; McCord, 1996). 
PKCiota is involved from initial stages of meiosis and embryogenesis to epithelial cell 
polarity and differentiation. PKCiota is expressed in various tissues throughout the body. In 
chickens, PKCiota was found to be expressed in mesenchymal connective tissue (the 
embryonic tissue that becomes connective tissue, bone, cartilage, the lymphatic system, or 
the circulatory system) of embryonic chick limb buds (Yang, 1998). In the initial discovery
PKCiota/lambda, it was identified by northern blot analysis to be expressed in brain, kidney, 
testis, and ovarian tissues (Akimoto, 1994). The retinas of several different species (rabbit, rat, 
guinea pig and goldfish) exhibited positive immunoreactivity for PKCiota/lambda (McCord, 
1996). Also, PKCiota was expressed in rat testis (gonocytes) (Li, 1997), porcine ASM (airway 
smooth muscle) (Togashi, 1997), and in bovine parathyroid (and is translocated to the cell 
periphery among high Ca2+ levels- but not in low levels) (Onyango, 1999). In humans, 
PKCiota was expressed in kidney, heart, aorta, and vein samples in both the cytosolic (except 
the heart) and membrane fractions. In the latter study, PKCzeta expression patterns were the 
same as PKCiota, except that PKCzeta was only found in the cytosol of the kidney (but not the 
aorta or vein samples) (Erdbrugger, 1997). Oddly, PKCiota/lambda was found in the cytosolic 
fraction of the heart in rats (but not in humans) (Erdbrugger, 1997). Thus, PKCiota is 
expressed in several tissue types. 
 PKCiota is expressed in various cell types as well. However, PKCiota levels are 
highest in epithelial cell lines compared to fibroblasts, lymphoid, or monocytic cells (Bonizzi, 
1999). PKCiota was also expressed in gonocytes (rat testis) (Li, 1997), in dermal papilla cells 
(the cells that make up the ridges of the skin) (Eicheler, 1997), adipocytes (make up adipose 
tissue), (Kotani, 1998), erythrocytes (the “most abundant cells in blood and carry out the vital 
function of oxygen transport”) (Govekar, 2001), and in beta pancreas cells (important in 
glucose-stimulated insulin secretion) (Hashimoto, 2005; Yang, 2005). 
 
Polarity (During Embryogenesis/ Development and Apical-Basal Polarity of Tissues) 
PKCiota through binding to PAR-6 and PAR-3, which together make up the “Par” or 
“aPKC” polarity complex, is involved in asymmetric polarization of cells, at embryogenesis, 
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development, and epithelial sheet formation. This complex is conserved throughout species: 
from xenopus and zebrafish to mice and humans. PKCiota has been shown to localize near 
the polar bodies during oocytes maturation. Atypical PKC also plays a role in animal-vegetal 
polarity of oocytes of Xenopus laevis. Upon maturation of oocytes, either naturally or through 
addition of exogenous hormones, XaPKC (xenopus ortholog to aPKC) localizes to the animal 
region (near the nucleus, where the polar bodies are formed), where XaPKC plays a role in 
maturation, which is dependent on XaPKC kinase function (Nakaya, 2000).  
In zebrafish organogenesis, PKCiota/ lambda is necessary for both the formation and 
the maintenance of tight junctions (zonula adherens) in early vertebrate epithelial development 
(Horne-Badovinac, 2001). Mutations in PKCiota/ lambda in cardiogenic cells results in 
disruption of epithelial cell-cell interactions and cause the heart field to fusion improperly 
(Peterson, 2001).  
PKCiota also plays a role in the polarity of the eye. For example, PKCiota 
overexpression in the drosophila eye can lead to loss of apical-basal polarity (Eder, 2005). 
Also, in a conditional knockout of PKCiota in differentiating photoreceptors in mice, severe 
laminar disorganization was exhibited in both the photoreceptor layer and the entire retina 
(Koike, 2005).  
The intestinal epithelium is also dependent on PKCiota to maintain polarity and 
microvilli formation. In CACO-2 (human intestinal epithelial) cells and in vivo, PKCiota is able 
to directly phosphorylate Ezrin at T567. Ezrin is, like PKCiota, localized to the apical 
membrane upon activation. When PKCiota was silenced by RNAi, levels of Ezrin T567 
phosphorylation decreased, as did the ability to form microvilli structures, a known role of 
active Ezrin. Thus, PKCiota also plays a role in microvilli formation in polarized intestinal 
epithelial cells (Wald, 2008). 
PKCiota is involved in apical-basal polarity of asymmetrically polarized epithelial cells 
through its localization at tight junctions (along with PAR-3/ASIP and PAR-6) and interactions 
with the cytoskeleton. PKCiota levels are the highest in epithelial cell lines compared to 
fibroblasts, lymphoid, or monocytic cells (Bonizzi, 1999). Both PAR-3 (C. elegans) and ASIP 
(rats) contain PDZ domains, which were originally believed to allow these proteins to bind the 
atypical PKC members. However, later PAR-6 was determined to be the linker protein that 
allowed PKCiota and PAR-3 to co-localize (Noda, 2001). When PKCiota/ lambda and ASIP 
are bound in rat intestinal epithelial cells, the complex localizes to the tight junctions, as 
determined by immunoelectron microscopy (Izumi, 1998) (see “PKCiota- Binding Partners: 
PB1 Domain” for details). 
  
 
 
 
Figure 5: Apical-Basal Polarized Epithelial Cells 
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PKCiota is localized to the tight junctions of epithelial cells in several species (see 
Figure 5). For example, PKCiota/ lambda (XaPKC) and PAR-3/ASIP (XASIP) colocalize in 
Xenopus laevis epithelial cells at the Xenopus equivalent of tight junctions (Nakaya, 2000). 
Similarly, in zebrafish organogenesis, PKCiota/ lambda is necessary for both the 
establishment and maintenance of tight junctions (zonula adherens) (Horne-Badovinac, 2001). 
In canine MDCK cells (an excellent model system for apical-basal polarity), mutations in the 
PKCiota/ lambda binding site on PAR-3/ASIP blocked cell-cell contact-induced formation of 
tight junctions (Hirose, 2002). Lastly, in MTD1-A mouse mammary epithelial cells, dominant-
negative PKCiota/ lambda was found to block maturation of spot-like junctions into belt-like 
adheren and tight junctions (Suzuki, 2002). Thus, regardless of species, PKCiota is localized 
to the tight junctions, where it plays a role in the establishment and maintenance of epithelial 
cell polarity. 
Although PKCiota is one of the last proteins to be recruited to the tight junctions, 
PKCiota binding to the PAR-3/ASIP complex is necessary for the establishment of polarity in 
epithelial cells (Suzuki, 2002; Hirose, 2002). PKCiota is localized to the apical edge of tight 
junctions.  In MDCK cells, mutations in the PKCiota/ lambda binding site on PAR-3/ASIP 
blocked cell-cell contact-induced formation of tight junctions. Also, PAR-3/ASIP is 
phosphorylated by PKCiota/ lambda at S827. As expected by PKCiota/ lambda localization, 
phospho-ser827 is localized to the apical edge during the formation of tight junctions (Hirose, 
2002). Similarly, PAR-3/ASIP expression decreases the cytosolic PKCiota levels, recruiting 
PKCiota to tight junctions. Specifically, in 3T3-L1 adipocytes, overexpression of PAR-3/ASIP 
resulted in an increase in the PKCiota/ lambda levels in the LDM and PM fractions, but a 
decrease in the cytosolic fraction. Therefore, PAR-3/ASIP overexpression results in altered 
localization of PKCiota/ lambda (Kotani, 2000). 
PKCiota has also been implicated in the maturation of tight junctions upon polarization. 
In MTD1-A mouse mammary epithelial cells, PKCiota/ lambda was examined upon 
repolarization by immunofluorescence (IF). Repolarization occurred when a monolayer of 
MTD1-A cells was scratched with a sterile needle and allowed to repolarize and wound heal. 
Upon repolarization as determined by IF, the spot-like adheren junctions (AJs) and tight 
junctions (TJs) form. PKCiota/ lambda is one of the last proteins to localize to the tight 
junctions, preceded by E-cadherin and ZO-1 at the adheren junctions and JAM, occludin, and 
claudin-1 at the tight junctions. Exogenous expression of a dominant-negative mutant 
PKCiota/ lambda construct revealed that PKCiota/ lambda was not necessary for the initial 
 
 
42
recruitment of polarity proteins to the tight junction, but rather blocked cortical bundle formation 
which was required for maturation of spot-like junctions into belt-like adheren and tight 
junctions (Suzuki, 2002). Thus, PKCiota/ lambda plays a critical role in the formation of tight 
junctions in epithelial cells.  
One of the roles of PKCiota at the tight junction involves regulation of zonula occludens 
2 (ZO-2 or tight junction protein 2). PKCiota regulates ZO-2 through phosphorylation of ZO-2 
at the tight junctions of polarized cells. ZO-2 is involved with the maintenance of cell polarity in 
epithelial cells through interactions between the plasma membrane and the actin cytoskeleton 
(Avila-Flores, 2001). 
 
Apical-Basal Polarity and transformation- In cancer, amplification or mislocalization of PKCiota 
can occur and result in poor prognosis. Over-expression of oncogenic Ras or oxidants can 
lead to changes in the cytoskeleton. Many of these cytoskeletal alterations occur through 
PKCiota. 
Using intestinal epithelial cells (Caco-2), which inducibly express either wild-type (wt) 
or dominant negative (dn) PKCiota/ lambda, Banan et al was able to show that PKCiota/ 
lambda was the key player in oxidant-induced disruption of the epithelial barrier. While dn 
PKCiota/ lambda expression blocked the effect of H2O2 (an oxidant) on the disruption of the 
epithelial barrier, wt PKCiota/ lambda exacerbated the effect of H2O2 on the epithelial barrier. 
Similarly, wt PKCiota/ lambda expression was independently able to cause effects that 
mimicked H2O2 treatment, i.e. cytoskeletal/ barrier hyperpermeability.  Thus either oxidant 
exposure (through PKCiota/ lambda) or direct activation of PKCiota can lead to disassembly of 
the cytoskeleton through disruption of the integrity of the epithelial barrier, cytoskeletal 
disruption, and discord in the permeability of the monolayer barrier (Banan, 2005). 
Ras, Rac, CDC42, PKCiota/ lambda, and PKCzeta have all individually been 
implicated in stress fiber loss and actin remodeling (Zhao, 1998; Uberall, 1999). Cells, which 
have undergone transformation, have alterations in their actin cytoskeleton, one of these 
alteration is a loss of stress fibers (Mackay, 1998).  While Uberall et al linked Ras with 
PKCiota/lambda and PKCzeta, Coghlan et al linked Ras-CDC42-PKCiota/lambda in stress 
fiber loss. While Rac expression is able to cause stress fiber loss, this phenotype is through a 
different pathway than Ras-CDC42-PKCiota/ lambda pathway (Coghlan, 2000), a study that 
was contradicted by Uberall et al (Uberall, 1999) (see “PKCiota-Signaling: Ras” for details). 
PKCiota is involved in stress fiber loss by its interaction with CDC42. In NIH3T3 cells, 
ectopic expression of constitutively active CDC42 (V12 CDC42) led to a loss in stress fibers 
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(Kozma, 1995). Coghlan et al was able to show that transient exogenous expression of 
PKCiota/ lambda (but not PKCzeta) was able to lead to the same loss of stress fibers 
observed in response to CDC42 overexpression. To show that PKCiota/ lambda was essential 
for CDC42-induced loss of stress fibers, kinase dead mutants of PKCiota/ lambda (KD 
PKCiota/ lambda) and PKCzeta (KD PKCzeta) were used to block CDC42-induced loss of 
stress fibers. The KD PKCiota mutant blocked CDC42- induced loss of stress fibers, but had 
no effect on CDC42- induced membrane ruffling or filopodia formation, indicating that while 
PKCiota/ lambda was essential for CDC42-induced loss of stress fibers, CDC42 induced other 
pathways independently of the PKCiota/ lambda or PKCzeta pathways. Because Rac-1 had 
also been implicated in loss of stress fibers, the KD PKC mutants were used to block loss of 
stress fibers in response to Rac. However, the KD PKC mutants were unable to block Rac-
induced loss of stress fibers. Uberall et al had published that Ras-induced loss of stress fibers, 
was not only dependent on PKCiota/ lambda and PKCzeta, but also dependent on Rac, 
contrary to the finding of Coghlan et al. Coghlan et al was also able to link PKCiota/ lambda 
and PKCzeta to Ras-induced loss of stress fibers by use of the KD PKC mutants. However, 
contrary to the findings of Uberall, upon induction of NIH 3T3 cells with constitutively active 
Ras and either dominant negative CDC42 (N17 CDC42) or dominant negative Rac, only N17 
CDC42, but not dominant negative Rac, was able to block Ras-induced loss of stress fibers.  
Thus, according to Coghlan et al at least two pathways exist for loss of stress fibers in 
transformation, one pathway involving Ras- CDC42- PKCiota/ lambda and one involving Rac 
(independently of Ras or the atypical PKCs). It is important to note that Coghlan et al did not 
directly test the KD PKC mutants on transformation just on indicators of transformation (loss of 
stress fibers). 
Similarly, in NIH3T3 and COS fibroblasts, PKCiota/ lambda is essential for 
transforming RAS-mediated disassembly of actin fibers. PI3K had already been shown to be 
necessary for Ras-induced reorganization of the actin cytoskeleton (Rodriguez-Viciana, 1994). 
Upon addition of transforming Ha-RAS L61, re-organization of the cytoskeleton occurs. RAS 
activates PKCiota/ lambda, which in turn, activates PI3K/Rac-1, leading to disassembly of 
actin fibers. This role of PKCiota was demonstrated using both dominant negative PKCiota/ 
lambda (in the presence of transforming Ha-RAS L61) and constitutively active PKCiota/ 
lambda to mimic the effect of Ha-RAS L61 on cytoskeleton remodeling. Likewise, PKCzeta is 
involved in RAS-mediated cytoskeleton re-modeling, but unlike PKCiota/ lambda, PKCzeta 
acts downstream of PI3K/Rac-1 (Uberall, 1999). Thus, Ras signaling is involved in the 
remodeling of actin in a PKCiota-dependent (Ha-Ras L61 Æ PKCiota/ lambda Æ PI3K/Rac-1 
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Æactin remodeling) and PKCiota-independent (Ha-Ras L61 Æ PI3K/Rac-1 Æ PKC zeta Æ 
actin remodeling) manner. 
Overexpression of PKCiota results in alterations in polarity through cytoskeletal 
changes, from disruption of the integrity of the epithelial barrier to loss of actin stress fibers. 
Many model systems have been used to show these changes, and many other factors are 
involved (Ras, CDC42, Rac-1, and PI3K). Cytoskeletal changes are essential for the 
transformation process, thus demonstrating PKCiota’s vital role in polarity and transformation. 
The role of PKCiota in Ras-induced transformation, which is a large majority of the 
transformation studies, will be discussed in detail in a later section. 
 
Membrane Trafficking- PKCiota is also involved in membrane trafficking and microtubule 
dynamics in the early phase of the secretory pathway (which carries molecules between the 
endoplasmic reticulum (ER) and the Golgi). Upon stimulation with Rab2, a protein involved in 
protein sorting and recycling, PKCiota is recruited to the pre-golgi intermediates (VTCs-
vesicular tubular clusters), where it is involved in recruitment of other secretory proteins, such 
as β-COP. The phosphorylation of GAPDH, in the Src-PKCiota-Rab2-GAPDH complex by 
PKCiota is necessary for the early phase of the secretory pathway. The role of PKCiota in this 
process is also to link these secretory proteins to the cytoskeleton, by recruitment of dynein (a 
microtubule motor protein), to the Rab2-GAPDH-PKCiota complex. However, PKCiota has 
also been implicated in other secretory pathways. For example, PKCiota binds ProF, which 
has WD (tryptophan-aspartic acid dipeptide)-repeats and a propeller-FYVE domain (named for 
its identification in Fab1p, YOTB, Vac1p and EEA1- early endosome antigen 1) (Fritzius, 
2006).  
In NRK (normal rat kidney) cells, in response to stimulation by Rab2, both PKCiota/ 
lambda and β-COP translocate to the membrane of the pre-golgi intermediates or VTCs in a 
dose-dependent manner.  This association of PKCiota/ lambda and β-COP at the VTCs was 
visualized by immunofluorescence. Antibodies against PKCiota/ lambda but not against PKC 
alpha or gamma (the only other PKC isoforms expressed in NRK microsomes) were able to 
reduce β-COP association with the VTCs. Also, VTC-associated β-COP levels are increased 
with PKCiota/ lambda overexpression, indicating PKCiota/ lambda lies upstream of β-COP 
recruitment to the VTCs in response to Rab2 (Tisdale, 2000).  
Using a kinase dead mutant of PKCiota/ lambda (His6-PKCiota/ lambda K275W) in 
HeLa cells, Tisdale was able to show that the kinase activity of PKCiota/ lambda, although not 
activated by Rab2, was necessary for Rab2 induced β-COP VTC association (Tisdale, 2000). 
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Thus Rab2, causes PKCiota/ lambda and β-COP recruitment to the VTCs, which is necessary 
for vesicle budding (Tisdale, 2000).  
Rab2 recruits both PKCiota and GAPDH to the VTCs. Both PKCiota and GAPDH bind 
directly to Rab2 allowing PKCiota to interact with GAPDH. Initially, Tisdale et al found that 
upon stimulation by Rab2, PKCiota phosphorylates GAPDH at the VTCs, which is involved in 
microtubule dynamics in the early phase of the secretory pathway (Tisdale, 2002). A year 
later, Tisdale found that the phosphorylation of GAPDH by PKCiota in endoplasmic reticulum 
to golgi transport, is inhibited by the binding of the small GTPase, Rab2, at the vesicular 
tubular clusters (VTCs) (Tisdale, 2003). 
Src is also involved in this role of PKCiota in VTCs. Tisdale et al found through a 
quantitative membrane binding assay that while PKCiota and GAPDH both interact with Src 
upon Rab2 stimulation, Src does not interact directly with Rab2. More importantly, Src tyrosine 
phosphorylation of PKCiota is necessary for beta-COP recruitment to the pre-golgi 
intermediates (VTCs) (Tisdale, 2006). Thus Rab2, GAPDH, PKCiota, Src form a complex. 
Particularly, Rab2 binds directly to PKCiota and GAPDH, but Src binds only to PKCiota and 
GAPDH (Tisdale, 2006). 
One of the roles of PKCiota in VTCs is recruitment of the microtubule motor protein, 
dynein to the Rab2-GAPDH-PKCiota complex (Tisdale, 2009). Thus, PKCiota is involved with 
protein trafficking through interaction with the VTC components coupling them to the re-
organization of the cytoskeleton.  
 PKCiota recruitment to the endosome can also occur in response to NGF (nerve 
growth factor) stimulation. PKCiota must be phosphorylated by Src before it can be recruited 
to the endosome, where it binds p62 (Samuels, 2001) (Figure 15). 
 
Inflammation- PKCiota plays a role in the inflammatory response through activation of NFκB 
and thus activation of interleukins. For example, PKCiota in prostate cancer can induce IL-6 
through NFκB leading to both survival and growth in an autocrine manner (Ishiguro, 2009). 
While some of the complexes formed with PKCiota induce NFκB activation, others inhibit it. 
The ability of PKCiota to activate NFκB is through its interactions with the PKCiota binding 
partners LIP (lambda interacting protein) (Diaz-Meco, 1996) and p62 (Sanz, 1999). However, 
TNFα-induced NFκB activation is blocked by the binding of PKCiota to PAR-4 (Diaz-Meco, 
1999).  
 PKCiota has been shown to be induced in response to inflammation. In canine colonic 
circular muscle cells, PKCiota was up-regulated in response to inflammation induced by 
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mucosal exposure to both ethanol and acetic acid (Ali, 2002). Similarly, PKCiota was found to 
be in a signalsome with TRAF6, p62, and IKK through a series of immunoprecipitations in 
response to Thymosin alpha 1, a treatment of cancer in clinical trials. This induction of the 
signalsome led to IL-6 expression through the Thymosin alpha 1 (Ta1) Æ 
TRAF6/p62/PKCiota/zeta/ IKK Æ NFκB Æ IL-6 pathway (Zhang, 2005). Also, PKCiota has 
been shown to be upregulated in response to the inflammatory cytokines TNFα and IL-1β 
(Diaz-Meco, 1999; Anthonsen, 2001) and NGF (nerve growth factor) (Wooten, 2000; Wooten, 
2001). 
In Jurkat T-cells, PKCiota binds the cytoplasmic portion of L-selectin. L-selectin, a 
leukocyte adhesion molecule, is involved in the inflammatory response by aiding in the 
leukocyte extravasation step (Vestweber, 1999). A PKCiota pseudosubstrate (dominant 
negative) mutant blocked L-selectin phosphorylation thus implicating PKCiota as an activator 
of L-selectin-mediated signal transduction (Kilian, 2004). Thus, PKCiota interacts with L-
selectin, a leukocyte receptor involved in extravasation, and leads to the phosphorylation of its 
cytoplasmic domain. 
Loss of PKCiota can result in impaired inflammatory response. For example, in 
PKCiota knockout of activated T cells, Yang et al found that cytokine production in Th2 (T-
helper) cells as well as NFκB activation is blocked (Yang, 2009). Additionally, most studies 
used to identify the role of PKCiota in NFκB activation did so by using dominant negative, 
kinase dead, or knockouts of PKCiota, which led to a decreased immune response. 
 
Proliferation- While PKCiota plays an established role in transformed growth, its role in 
proliferation is not as straight forward. It seems that PKCiota can affect growth in a three-
dimensional model, but is not as likely to influence two-dimensional adherent growth.   
While PKCiota is not cell cycle regulated, PKCiota is able to regulate members of the 
cell cycle, including cyclin E, cyclin D1, AP-1 (c-fos and c-jun), and GSK3β. Alteration in the 
cell cycle do not change PKCiota levels. In C6 glioma cells, upon contact inhibition (induction 
of the quiescent state, Go) in the presence of serum, PKCiota protein expression, unlike 
several other PKC family members, remained unchanged (Moreton, 1995).  
PKCiota, in glioma cells, was shown to phosphorylate and co-localize with CAK (or 
least CDK7).  However, these two papers did not show convincing data, in regard to the co-
localization experiments. The co-localization, which was extremely modest, was only upon 
stimulation with DMSO, so these papers lack physiological relevance (Acevedo-Duncan, 2002; 
Bicaku, 2005). 
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There are several studies which conclude that PKCiota is not involved in cell 
proliferation: 1) Zhang et al examined the ability of PKCiota to alter proliferation in three 
ovarian cancer cell lines (Zhang, 2006). In A1847 ovarian cancer cells, CMV-PKCiota was 
transiently overexpressed, and changes in cell number as determined by growth curves were 
documented. No change was observed in proliferation between control and PKCiota-
overexpressing A1847 cells. Similarly, in 2008 and OVCAR10 ovarian cancer cell lines, 
PKCiota was transiently silenced using RNAi, but no changes were observed in doubling time, 
as measured by growth curves (Zhang, 2006). Thus, in three ovarian cancer cell lines, A1847 
and OVCAR10 (PKCiota normal copy number) and 2008 (PKCiota is genomically amplified), 
changes in PKCiota levels alone did not exhibit an effect on cell proliferation in a two-
dimensional model system. 
2)  In another study using a non-small cell lung cancer cells (NSCLC), PKCiota (but not 
PKCzeta) was highly expressed.  By use of wild type (wt) or kinase dead (kd) PKCiota 
exogenous expression in A549 lung cancer cells, PKCiota was determined to be expendable 
in proliferation of adherent cells in culture. However, these PKCiota expressing stable cells 
revealed that PKCiota was necessary for transformed growth, as determined by soft agar 
colony formation, and for tumor growth, as determined by measurement of tumor volume 
(Regala, 2005). Similarly, in H1299 and ChaGo lung cancer cells, expression of kinase dead 
PKCiota resulted in decreased transformed growth, but no change in adherent cell proliferation 
(Regala, 2005). Lastly, both aurothioglucose-ATG (an aPKC-specific inhibitor) and kinase 
dead PKCiota did not affect the rate of proliferation of adherent cells. This decrease in 
transformation of NSCLC cells in the presence of ATG was due to a disruption of the 
PKCiota/PAR-6 complex, resulting in decrease in the level of active Rac1 (GTP versus GDP-
bound) (Stallings-Mann, 2006).Thus, in NSCLC, PKCiota is not likely involved in proliferation 
of adherent cells. 
3) In human chronic myeloid leukemia cells (H562), while PKCiota did not play a role in 
proliferation, PKCiota protected these cells from apoptosis induced by OA (okadaic acid) and 
taxol. Inhibition of PKCiota resulted in a re-sensitization of these cells to the apoptotic stimuli; 
thus indicating PKCiota could play a role in survival rather than proliferation in leukemia 
(Murray, 1997).  
 
Contrary to the studies described above which show lack of involvement of PKCiota in cell 
proliferation, the following studies show that PKCiota does play a role in proliferation. 
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1) In the first ovarian cancer study, by use of IHC in tissue samples of ovarian 
cystadenomas, borderline ovarian tumors, primary tumors, and recurrent invasive ovarian 
cancer that had been formalin-fixed and paraffin-embedded, Weichert et al found that PKCiota 
was expressed in half of the primary and recurrent tumors, but not in the cystadenomas or 
borderline tumors, thus implicating the role of PKCiota in the transformation stage of 
tumorigenesis. PKCiota showed a positive correlation with histopathological grading, FIGO 
stage, and the proliferation index. Specifically, in primary ovarian tumors, the expression of 
PKCiota exhibited a significant correlation with a reduced median survival time (Weichert, 
2003).  
2) In the second ovarian cancer study, PKCiota was genomically amplified leading to 
its over expression in ovarian cancer. In serous ovarian carcinomas, an increase in PKCiota 
DNA copy number correlated with a decreased progression free survival. In a drosophila eye, 
which was used as a model of epithelial cell apical-basal polarity and normal PKCiota 
localization, overexpression of constitutively active PKCiota (DaPKM and rPKCζ) resulted in a 
disruption in polarity, an increase in proliferation, and an increase in cyclin E levels (Eder, 
2005).  
3) In HL-60 (human promyelocytic leukemia) cells, upon stimulation with granulocyte 
colony-stimulating factor (G-CSF), a cytokine and growth factor involved with proliferation, 
differentiation, and survival, PKCiota translocated from the nucleus to the plasma membrane. 
Using PKCiota RNAi, Kanayasu-Toyoda et al was able to block proliferation in response to G-
CSF and thus blocked differentiation (Kanayasu-Toyoda, 2007). Thus, PKCiota plays an 
important role in G-CSF-induced proliferation. 
4) In the brain, PKCiota was differentially expressed in normal versus tumor tissues. 
Using western blot analysis of patient samples, Patel et al found that while PKCiota was not 
expressed in normal brain tissue, it was expressed in a majority of benign meningiomas and 
expressed in all malignant meningiomas and gliomas. Using T98G and U-138MG glioma cells, 
PKCiota RNAi resulted in a decrease in proliferation of these cells in culture (Patel, 2008). 
Thus, PKCiota is involved in the proliferation of malignant meningiomas and gliomas.  
5) PKCiota has also been shown to correlate with the recurrence of hormone refractory 
prostate cancer (HRPC). Inhibition of PKCiota by RNAi resulted in decreased prostate cancer 
cell growth in vitro and decreased tumor volume in vivo. Ishiguro et al found that PKCiota was 
able to induce an autocrine loop of prostate cancer cell proliferation through the increased 
expression of IL-6. In prostate cancer cells, inhibition of PKCiota by RNAi suppressed STAT3 
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phosphorylation and IL-6 expression. Specifically, PKCiota increased IL-6 expression through 
activation of the two transcription factors, AP-1 and NFκB (Ishiguro, 2009). 
While there is no doubt that PKCiota can play an essential role in proliferation, the 
exact mechanism of this effect had not been investigated in two-dimensional versus three-
dimensional culture conditions. All of the studies mentioned above, in which PKCiota had no 
role in proliferation were in vitro studies, examining PKCiota in a two-dimensional model on 
plastic culture dishes (growth curves), while many of the studies indicating PKCiota is vital for 
proliferation were examined either in vivo or on IHC of patient samples examining BrdU 
incorporation or Ki67 staining. PKCiota plays an essential role in three-dimensional polarity, as 
mentioned previously, and the absence of three-dimensional polarity observed in two-
dimensional model systems may cause some of the functions of PKCiota to be hindered, thus 
changes in PKCiota in a two-dimensional model system would not change the rate of 
proliferation. While the polarity predicament may account for some, if not most, of the 
reasoning behind the discrepancies in the proliferation studies with PKCiota, this does not 
account for all the discrepancies. In chapters 2 and 3 of this dissertation, I will show that 
PKCiota causes alterations in proliferation using IGROV ovarian cancer cells in an in vitro two-
dimensional model system, which would not display apical-basal polarity. When PKCiota is 
knocked down in IGROV cells, the result is a decrease in the expression levels of several cell 
cycle regulator proteins, including cyclin E, which translates to a decrease in proliferation, 
even in two-dimensional culture. However, in another ovarian cancer cell line, OVCAR3, 
knockdown of PKCiota does not change cyclin E levels, and inhibition of PKCiota in this cell 
line does not lead to changes in proliferation. Thus, some of the discrepancies in the study of 
PKCiota in proliferation could be due to downstream effector molecules, such as cyclin E, that 
may or may not be downstream of PKCiota in every system investigated.    
 
Another link between PKCiota and cell proliferation has come about from a cell cycle 
regulatory prospective where several studies have found that PKCiota to be upstream of 
modulators and effectors of the cell cycle (see Figure 6). For example, PKCiota is involved in 
the regulation of cyclin E. The link between cyclin E and PKCiota which is the topic of this 
dissertation was originally described by Eder et al as summarized on page (124-126).  
 
 
 
 
Figure 6: Mechanism of PKCiota-Induced Proliferation 
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In another study using a hepatocellular carcinoma model, the expression of PKCiota 
correlated with the expression of cyclin E (Wang, 2009). However, this correlation between 
PKCiota and cyclin E was observed but was no mechanism was determined. 
PKCiota has also been implicated in the Ras-Rac1-cyclin D1 pathway and described 
in the section on Ras-Transfomation.  In HC11 mouse mammary epithelial cells, dominant 
negative mutants of PKCiota/ lambda (or PKCzeta) suppress Ras-induced cyclin D1 
expression, indicating that both PKCiota/ lambda and PKCzeta are essential for cyclin D1 
induction by oncogenic Ras. The induction of cyclin D1 was measured using a cyclin D1 
luciferase reporter assay (Hellbert, 2000).  
In a separate study, in HC11 mouse mammary epithelial cells, through the use of a 
cyclin D1 luciferase reporter gene, Mwanjewe et al was able to show that PLD2 and PKCiota/ 
lambda cooperate in the transcriptional activation of cyclin D1 (Mwanjewe, 2001). 
The transcriptional regulation of cyclin D1 by transforming Ras required two pathways, 
one PKCiota-dependent and one PKCiota-independent. By using constitutively active Ras, 
Raf, MEK, and a cyclin D1 reporter gene, in HC11 mouse mammary epithelial cells, Kampfer 
et al found that PKCiota was not involved in Ras induction of cyclin D1 through the MEK-ERK 
pathway (however PKCzeta was required). By using constitutively active Ras, Rac, and a 
cyclin D1 reporter gene, PKCiota was found to be downstream of Ras but upstream of Rac. 
Interestingly, PKCzeta was found to be involved downstream of Rac (Kampfer, 2001). Thus, 
Ras transcriptionally activates cyclin D1 in a PKCiota-independent (HA-Ras ÆMEK-1 Æ ERKs 
Æ cyclin D1 transcription) pathway and a PKCiota-dependent (HA-Ras Æ PKCiota Æ Rac Æ 
cyclin D1 transcription) pathway.  
PKCiota is also able to activate AP-1, which transcriptionally regulates cyclin D1. While 
PKCzeta induction of cyclin D1 is downstream of Raf-1, as in the case of c-fos induction, 
PKCiota/ lambda does not seem to be in the Raf-Mek pathway for cyclin D1 induction but 
rather in a pathway involving Rac1 (Hellbert, 2000). This is not surprising that the two 
pathways work separately in cyclin D1 induction. The cyclin D1 promoter had already been 
shown to contain an Ets2 binding site (activated by the Raf/MEK/ERK pathway) in addition to 
an AP-1 site.  
In ovarian cancer, GSK3β (glycogen synthase kinase 3 beta) leads to proliferation by 
regulating cyclin D1 (Cao, 2006). PKCiota leads to activation of GSK3β. In 3T3-L1 adipocytes, 
while PKCiota was shown to be phosphorylated and activated by insulin induction via PI3K, 
only TC10 was able to cause PKCiota to associate with the plasma membrane lipid rafts. 
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TC10 is a Ras-like small GTPase that in response to insulin causes PKCiota to associate with 
PAR-3 and PAR-6 at the plasma membrane. Also, the ability of PKCiota to phosphorylate 
GSK3β required TC10 rather than PI3K, which led to GSK3β phosphorylation via AKT 
(Kanzaki, 2004). Thus, AKT through the Insulin Æ PI3K Æ AKT Æ P-GSK3β pathway and 
PKCiota through the Insulin Æ TC10 Æ PAR-6/PKCiota Æ P-GSK3β pathway are able to lead 
to activation of GSK3β (Kanzaki, 2004). Interestingly, Etienne-Manneville found that both 
PKCiota and PAR-6 bind directly to GSK3, leading to reorganization of the cell, while PAR-3 
was not necessary for the activation of GSK3 (Etienne-Manneville, 2001; Etienne-Manneville, 
2003). 
PKCiota is involved in DNA synthesis in fibroblasts (Berra, 1993; Bjorkoy, 1997) and 
in COS and 293 cells (Akimoto, 1998). p70 S6K, a kinase involved in the PI3K pathway, is 
involved in cell cycle progress through DNA synthesis (Lane, 1993; Reinhard, 1994; Pullen, 
1997; Alessi, 1998). p70 S6K binds to PKCiota and PKCzeta via both the regulatory and 
kinase domains, although S6K is not a PKCiota substrate.  PKCiota is required but not on its 
own sufficient to activate serum-induced DNA synthesis via S6K. In both COS and 293 cells, 
two dominant negative mutants (kinase dead and a truncated regulatory domain) of PKCiota/ 
lambda were able to suppress the ability of p70 S6K to lead to DNA synthesis in response to 
serum stimuli, determined by BrdU incorporation. However, a constitutively active form of 
PKCiota was unable to stimulate p70 S6K-induced DNA synthesis, indicating that PKCiota is 
required but not on its own sufficient for the activation of p70 S6K. Specifically, PKCiota’s role 
in DNA synthesis appears to be through the Insulin Æ PI3K Æ PDK1 Æ PKCiota Æ p70 S6K 
Æ g1to s phase progression (DNA synthesis and E2F activation) pathway (Akimoto, 1998). 
While PKCiota plays a role in proliferation, other downstream factors need to be 
examined. As previously stated, we have seen that IGROV cells through the PKCiota/cyclin E 
pathway exhibit decreased proliferation in response to PKCiota inhibition, while OVCAR3 cells, 
which do not display the PKCiota/cyclin E pathway do not exhibit a decrease in proliferation in 
response to PKCiota inhibition. Thus, it is likely that the effect of PKCiota on proliferation is a 
consequence of modifications in the expression pattern of cyclin E, a well documented 
regulator of proliferation. 
 
Differentiation- PKCiota also plays a role in differentiation. The majority of research performed 
on PKCiota in differentiation has been through NGF stimulation, which leads to both survival 
and differentiation through PKCiota.  However, other groups have also examined PKCiota’s 
role in differentiation without NGF stimulation.  
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In HL-60 (human promyelocytic leukemia) cells, upon stimulation with granulocyte 
colony-stimulating factor (G-CSF), a cytokine and growth factor involved with proliferation, 
differentiation, and survival, PKCiota translocated from the nucleus to the plasma membrane. 
At 5 minutes post G-CSF-stimulation, PKCiota translocation occurred, while at 15 minutes post 
G-CSF-stimulation, PKCiota activation occurred. Using PKCiota RNAi, Kanayasu-Toyoda et al 
was able to block proliferation in response to G-CSF and thus blocked differentiation 
(Kanayasu-Toyoda, 2007). Thus, PKCiota plays an important role in G-CSF-induced 
proliferation and differentiation. 
Conversely, a decrease in PKCiota has also been shown to correlate with 
differentiation. In undifferentiated mouse P19 embryonal carcinoma cells, PKCiota/ lambda 
was the most abundantly expressed PKC family member; while the differentiation of these 
cells resulted in a decrease in PKCiota/ lambda expression (Akimoto, 1994). Thus, in P19 
embryonal carcinoma cells, PKCiota has the opposite effect on differentiation than in HL-60 
human promyelocytic leukemia cells. This contradiction between PKCiota’s role in 
differentiation is similar to the variance in the role of PKCiota in proliferation, and is likely due 
to similar reasoning. 
 
Diseases- Diabetes, Alzheimers, Cancer- Alterations in PKCiota levels, localization, or activity 
can also lead to a number of other diseases. Particularly, aberrant PKCiota can lead to 
Alzheimer’s disease, diabetes and insulin-resistance, inflammatory disease, and cancer.  
Diabetes and insulin-resistance are covered in full detail in the “PKCiota- Signaling: Insulin/ 
GLUT4 transport” section. 
PKCiota has a potential role in Alzheimer’s disease. In response to amyloid beta-
peptide (ABP), a peptide linked to neuronal degeneration in Alzheimer’s disease, PC12 neural 
cells undergo apoptosis. However, if PKCiota is overexpressed, PC12 cells display resistance 
to apoptosis. Thus, in Alzheimer’s disease, PKCiota activation could be seen as a potential 
therapy for prevention of this age-related disease (Xie, 2000). 
 PKCiota has also been implicated in inflammatory disease. In human chondrocytes, 
PKCiota contributes to inflammatory joint disease through the pathway: 
IL1 Æ PKCiota Æ ERK/STAT3 phosphorylation Æ c-fos expression  Æ collagenase gene 
induction Æ MMP1 (Litherland, 2010). PKCiota also has other implication in inflammation (see 
“PKCiota- Functions: Inflammation” and “PKCiota-Signaling: NFκB” for details). 
PKCiota has briefly been studied in other diseases. For example, PKCiota is implicated 
in cardiac hypertrophy through the Npr1-PKC-MAPK-GATA1 pathway (Ellmers, 2007). Also, in 
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a PKCiota/lambda mouse model, Sajan et al found that PKCiota/ lambda through activation of 
SREBP-1 (sterol receptor element binding protein-1c) and NFκB is involved in hepatic 
lipogenesis, hyperlipidemia, as well as systemic insulin resistance (Sajan, 2009). 
      
The role of PKCiota in cancer is the one that has been studied the most- PKCiota is 
located on chromosome 3q26, which is an amplicon in several types of cancer and they are 
described in detail in this section: 
 
NSCLC (Non-Small Cell Lung Cancer)- PKCiota is a bona fide oncogene in NSCLC. Regala et 
al found that PKCiota (but not PKCzeta) was overexpressed in lung cancer patient primary 
tumor samples when compared to the normal adjacent lung epithelium. PKCiota DNA copy 
number was amplified in a large majority of squamous cell carcinomas but not in lung 
adenocarcinoma. This increase in PKCiota DNA copy number correlated with PKCiota 
expression levels, which were also amplified in lung cancer patient primary tumor samples 
when compared to the normal adjacent lung epithelium. Importantly, overexpression of 
PKCiota correlated with poor survival, which did not depend on the stage of the tumor. In 
H1299 and ChaGo lung cancer cells, expression of kinase dead PKCiota resulted in 
decreased transformed growth, but no change in adherent cell proliferation. Thus, PKCiota is 
an oncogene in NSCLC (Regala, 2005). 
 
ESCC (Esophageal Squamous Cell Carcinoma)- PKCiota is genomically amplified in several 
types of squamous cell carcinomas (SCCs). Using fluorescence in situ hybridization (FISH), 
Yang et al found that PKCiota was genomically amplified in esophageal squamous cell 
carcinomas (ESCCs)- both patient samples (n =108) and ESCC cells lines (n = 9). In ESCCs 
examined, PKCiota amplification was positively correlated (statistically significant) with tumor 
size, lymph node metastasis, and clinical stage. Also, PKCiota genomic amplification was 
correlated with elevated PKCiota protein expression. Using a tissue array, elevated PKCiota 
protein expression was statistically correlated with lymph node metastasis and clinical stage 
(Yang, 2008). 
 
Hepatic Metastasis of Colorectal Carcinoma- Examination of the expression levels of PKCiota 
in patients with hepatic metastasis of colorectal carcinoma by qRT-PCR revealed that as 
compared to the paratumor mucosa, both the primary foci and hepatic metastatic foci exhibit 
elevated levels of PKCiota. Also, the expression level of PKCiota in the hepatic metastatic foci 
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was higher than in the primary foci (Li, 2004). Thus, PKCiota mRNA expression levels 
correlated with aggressiveness of the tumor in colorectal carcinoma patients. 
 
Malignant Meningioma and Glioma- In the brain, PKCiota was differentially expressed in 
normal versus tumor tissues. Using western blot analysis of patient samples, Patel et al found 
that while PKCiota was not expressed in normal brain tissue, it was expressed in a majority of 
benign meningiomas and expressed in all malignant meningiomas and gliomas. Using T98G 
and U-138MG glioma cells, PKCiota RNAi resulted in a decrease in proliferation of these cells 
in culture (Patel, 2008). 
 
Breast Cancer- Upon examination of 110 breast cancer patient samples by IHC, 80% showed 
elevated levels of PKCiota. Specifically, PKCiota expression was low in non-invasive DCIS 
(ductal carcinoma in situ) but high in invasive ductal carcinomas. In cancer patient samples, 
PKCiota no longer localized to the apical membrane, but was present throughout the 
cytoplasm (Kojima, 2008). Thus, in breast cancer, PKCiota expression correlates with the 
aggressiveness of the disease. 
 
Colon Cancer- Upon induction of colon cancer in rats using azoxymethane, rats had higher 
levels of membrane-bound PKCiota/ lambda and lower cytosolic levels. These levels were 
exacerbated by feeding the rats a high sugar diet and decreased when rats were given fish oil. 
Levels in PKCiota/ lambda mRNA did not change; only the protein localization changed (Jiang, 
1997). 
 
HCC (Hepatocellular Carcinoma)- PKCiota correlated with invasion potential in hepatocellular 
carcinoma. The expression level of PKCiota in hepatocellular carcinoma is significantly higher 
than in the surrounding normal tissue, as determined by both qRT-PCR and IHC. Also, the 
expression levels of PKCiota positively correlated with the invasive potential (Wang, 2009). 
Also, in paraffin-embedded hepatocellular carcinoma tumor tissues, PKCiota was mislocalized 
to the cytoplasm. Cytoplasmic PKCiota in hepatocellular carcinoma correlated with a reduction 
in cell-cell contact, through inhibition of adherens and tight junction formation, as well as a 
reduction in E-cadheren expression and an increase in cytoplasmic beta-catenin. Thus, the 
decrease in cell-cell contacts is likely responsible for the increase in the invasion and 
metastatic potential of HCCs (Du, 2009). 
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Gastric Cancer- PKCiota expression was detected in over 70% of the 177 gastric cancer 
samples examined.  The expression of PKCiota, while it did not correlate with a decrease in E-
cadherin, PKCiota was determined to be a strong prognostic factor for recurrence along with 
presence of nodal metastases (Takagawa, 2010). 
 
PDAC (Pancreatic Ductal Adenocarcinoma)- Ras is mutated in more than 90% of PDACs 
(Pancreatic Ductal Adeno-carcinomas). Predictably, examination of PKCiota status in PDACs 
revealed that PKCiota was also highly expressed, and its expression correlated with poor 
survival. In vitro, using PDAC cells, Scotti et al found that PKCiota inhibition resulted in 
decreased transformation. Similarly, in a mouse model, Scotti found that PKCiota inhibition 
resulted in decreased tumorigenesis (as well as a decrease in both angiogenesis and 
metastasis). The role of PKCiota in pancreatic cancer transformation is also through the Rac-
Pak-Mek-Erk pathway, indicating inhibition of PKCiota-Par-6 binding may be a feasible target 
in pancreatic cancer treatment (Scotti, 2010). 
 
Cholangiocarcinoma (Cancer of the Bile Ducts)- In cholangiocarcinoma (cancer of the bile 
ducts), PKCiota, which was examined by immunohistochemistry, was expressed in tumors but 
absent in benign bile duct tissues. Similarly, PKCiota correlated with the invasion potential of 
cholangiocarcinomas and negatively correlated with the expression of E-cadherin, whose loss 
of function/expression is involved in cancer progression and metastasis (Li, 2007; Li, 2008). 
 
Glioblastoma Multiforme- PKCiota plays a large role in invasion in glioblastoma multiforme, 
which is a primary brain tumor characterized by its highly invasive phenotype. Glioblastomas 
often have overactive PI3K signaling due to mutations in PTEN (tumor suppressor) or in EGFR 
(epidermal growth factor receptor). In U87MG cells, an increase in actin stress fibers as well 
as a decrease in both cell motility and invasion were observed when PKCiota was silenced 
(RNAi). Through a gene expression microarray, RhoB was identified as being down-regulated 
by PKCiota (Baldwin, 2008). Importantly, RhoB is essential for formation of actin stress fibers 
(Nobes, 1995). This inverse relationship between PKCiota and RhoB was validated by both 
depletion and inhibition of PKCiota, which resulted in increased RhoB expression.  
Interestingly, constitutively active RhoB expression repressed PKCiota activation, thereby 
implying a switch between PKCiota overexpression via PI3K (invasive) and RhoB (non-
invasive). Thus, PKCiota activation leads to an invasive phenotype in glioblastoma through 
downregulation of RhoB (Baldwin, 2008). 
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HRPC (Hormone Refractory Prostate Cancer)- PKCiota has also been shown to correlate with 
the recurrence of hormone refractory prostate cancer (HRPC). Inhibition of PKCiota by RNAi 
resulted in decreased prostate cancer cell growth in vitro and decreased tumor volume in vivo. 
In a PNAS paper, Ishiguro et al found that PKCiota was able to induce an autocrine loop of 
prostate cancer cell proliferation through the increased expression of IL-6. In prostate cancer 
cells, inhibition of PKCiota by RNAi suppressed STAT3 phosphorylation and IL-6 expression. 
Specifically, PKCiota increased IL-6 expression through activation of the two transcription 
factors, AP-1 and NFκB (Ishiguro, 2009). Also, fatty acids are involved in prostate cancer, and 
PKCiota is involved in fatty acid induced proliferation in LNCaP prostate cancer cells (Pandian, 
2001). Also in a human prostate cancer cell line, PC3U, PKCiota was found to induce 
apoptosis in response to PKCiota inhibition (ATM-aurothiomalate) in cancer cells, but not in 
human primary epithelial prostate cells, PrEC. ATM-induced apoptosis was determined to be 
through ERK, as determined by a rescue experiment using ERK RNAi with change in 
apoptosis as the readout (Trani, 2009). Therefore, PKCiota plays a significant role in prostate 
cancer growth and provides a potential target to induce apoptosis in a tumor-specific manner. 
 
Melanoma- Out of all eleven PKC isoforms examined, PKCiota was the only isoform that was 
expressed in tumor but not normal lysates. Specifically, PKCiota, while not expressed in 
normal melanocytes, was up-regulated in spontaneously-transformed melanoma cells, 
melanoma cell lines, tumor lysates, melanoma lymph node metastases, and cell lines 
established from these metastases. Thus, PKCiota is implicated in melanocyte transformation 
(Selzer, 2002).  
 
Leukemia (CML)- In K562 leukemia cells (CML), BCR-ABL is involved in chemo-resistance to 
apoptotic drugs, such as taxol. Upon treatment of K562 cells with taxol, PKCiota became 
activated.  Using tyrphostin AG957, which inhibits BCR-ABL, Jamieson et al was able to block 
taxol-induced PKCiota activation and re-sensitize these cells to the apoptotic properties of 
taxol. Also, constitutively active PKCiota was able to revert the chemo-sensitive phenotype of 
K562 cells treated with taxol and tyrphostin AG957 back to the chemo-resistant phenotype. 
Similarly, in a BCR-ABL negative and taxol-sensitive leukemia cell line (HL60), taxol was 
unable to induce PKCiota activation, suggesting that PKCiota would be downstream of BCR-
ABL in response to taxol (Jamieson, 1999). 
 
Table 6: Table of Types of Cancers in which PKCiota was Examined 
Tumor Type Number of Patients Number of Cell Lines Method of Detection of PKCiota Metastasis Outcome References
NSCLC 74 NSCLC (37 LAC & 37 SCC) 4 NSCLC & qRT-PCR (DNA & mRNA) ND PKCiota frequently amplified in SCC not in normal tissue Regala, 2005
1 Non-Transformed Lung Epithelium IHC and Western Blot (protein) PKCiota mRNA/protein increased in tumor samples/ cell lines
PKCiota expression correlates with poor survival
Ectopic PKCiota did not alter proliferation in vitro
ESCC 108 ESCCs 9 ESCC Cell Lines FISH (DNA copy number)
Significant 
Correlation
Significant correlation between PRKCI gene copy number and
tumor size,  lymph node metastasis, and clinical stage Yang, 2008
180 ESCCs
Tissue Microarray and IHC PKCiota expression correlates with lymph node metastasis
and higher stage 
Colorectal Carcinoma
58 colorectal cancer patients 
(25 of them had hepatic metastasis) N/A qRT-PCR (mRNA)
Significant 
Correlation
PKCiota levels were significantly increased in metastasis 
versus primary tumor Li, 2004
Malignant Meningioma
and Glioma
12 normal brain biopsies, 
15 benign meningiomas, 
3 malignant meningiomasand 2 Glioma Cell Lines Western Blot Analysis ND
PKCiota was expressed in malignant meningiomasand 
gliomas but not in normal brain tissue Patel, 2008
3 gliomas PKCiota was involved in proliferation in vitro
Breast Cancer 110 Breast Cancer Patient Samples N/A IHC ND PKCiota was elevated/mislocalized in IDC compared to DCIS Kojima, 2008
HCC 43 N/A qRT-PCR, Western Blot, IHC ND PKCiota correlated with invasive potential Wang, 2009
Both PKCiota and cyclin E significantly correlated with 
increased grade and a lack of differentiation
Significant correlation between PKCiota expression and 
cyclin E expression in HCC
43 N/A PCR, Western Blot, IHC
Significant 
Correlation
PKCiota levels are significantly higher in tumor samples 
compared with normal Du, 2009
PKCiota levels significantly correlated with increased tumor 
size, invasion, metastasis, and stage 
Metastasis: PKCiota was elevated in 93% of lymph node 
metastasis (12 out of 13)
Gastric Cancer 177 N/A IHC No Correlation PKCiota was elevate in 70% of gastric cancer patient samples Takagawa, 2010
PKCiota expression significantly correlated with recurrence, 
a decrease in DSS and RFS
Metastasis: PKCiota expression was NOT correlated with 
metastasis
PDAC 28 Pancreatic Tumor Samples 10 Pancreatic Cancer Cell Lines qRT-PCR, IHC
PKCiota RNAi 
significantly
PKCiota mRNA levels were higher than adjacent normal 
tissue in all 28 samples Scotti, 2010
Xenograft Model
reduced 
metastasis
PKCiota protein levels were elevated in tumor samples and 
significantly correlated with reduced survival
In vitro, PKCiota mRNA/protein was overexpressed in all 
cancer cell lines
In vitro, PKCiota RNAi did not alter rate of proliferation but
did cause decrease in transformed growth
In vivo,PKCiota RNAi blocked pancreatic cancer proliferation
and angiogenesis, but did not affect apoptosis
Metastasis: PKCiota RNAi significantly reduced metastasis
to the kidney, liver, diaphragm, and mesentery
Cholangiocarcinoma 9 Benign Bile Duct Tissues N/A IHC ND
PKCiota expression was significantly higher in 
cholangiocarcinomas than in benign bile duct tissues Li, 2007; Li 2008
35 Cholangiocarcinoma Samples
PKCiota expression was significantly negatively correlated 
with E-cadherin expression
PKCiota was significantly correlated with differentiation and 
invasion potential in cholangiocarcinoma samples
Glioblastoma 
Multiforme N/A 2 Glioblastoma Cell Lines Western Blot Analysis ND
In vitro, PKCiota RNAi decreased cell migration and invasion
via RhoB upregulation Baldwin, 2008 
In vitro, PKCiota's role in migration/invasion is via the PI3K
pathway
Prostate Cancer 29 Prostate Cancer Tissue Samples 3 Prostate Cancer qRT-PCR, IHC ND
Significant increase of PKCiota mRNA levels in prostate 
cancer than adjacent normal tissue Ishiguro, 2009 
1 Normal Prostate Epithelium
PKCiota mRNA levels significantly correlated with PSA failure
time (survival)
Xenograft Model In vitro, PKCiota RNAi led to decreased proliferation
In vitro, PKCiota affected proliferation in an IL-6/STAT3 
autocrine feedback loop
In vivo,PKCiota RNAi led to a significant decrease in
tumor volume
Melanoma 8 (from various sites) 4 Melanoma Cell Lines Western ND
PKCiota protein was overexpressed in all tumor samples
and all cell lines analyzed Selzer, 2002 
Leukemia N/A 1 CML Western Blot Analysis ND
PKCiota activity upregulated in response to Taxol leading to 
chemoresistance Jamieson, 1999
1 PML Kinase Assay Bcr-Abl inhibitor inhibits PKCiota kinase activity
Ovarian Cancer
235 Grade 3 or Stage III or IV- Serous 
Epithelial Ovarian Cancer Specimens
High-Density Array 
Comparative Genomic 
Hybridization (DNA) ND
PRKCI DNA copy number correlated significantly with
poor survival
Eder, 2005
qRT-PCR, IHC, Western Blot PKCiota mRNA was highest in serous histology
PKCiota protein is mislocalized and overexpressed in 
ovarian cancer
PKCiota protein levels correlated with LMW-E expression 
89 Late-stage Primary Ovarian Cancer 
Specimens 18 Ovarian Cancer Cell Lines
Array Comparative Genomic 
Hybridization (DNA) ND
PKCiota DNA copy number was increased in 43.8% of 
ovarian cancer patient samples Zhang, 2006
6 HOSEs qRT-PCR, IHC, Western Blot
PKCiota expression is significantly increased in ovarian 
cancer compared to normal ovary
PKCiota mRNA was significantly higher in the ovarian cancer
cell lines than the HOSEs
PKCiota mRNA was significantly higher in late stage
tumor samples than early stage
PKCiota protein levels were significantly higher in the ovarian
cancer cells than the normal tissue and HOSEs
In vitro, PKCiota RNAi did not affect proliferation in 3 cell lines
In vitro, PKCiota expression resulted in transformation of 
MOSEs
PKCiota levels did not correlate with drug resistance  
N/A Non-Applicable
ND Not Determined
NSCLC Non-Small Cell Lung Cancer
LAC Lung Adenocarcinoma
SCC Squamous Cell Carcinoma
ESCC Esophageal Squamous Cell Carcinoma
IDC Invasive Ductal Carcinoma
DCIS Ductal Carcinoma in situ
HCC Hepatocellular Carcinoma
DSS Disease-Specific Survival
RFS Relapse-Free Survival 
PDAC Pancreatic Ductal Adenocarcinoma
Cholangiocarcinoma Cancer of the Bile Ducts
CML Chronic Myelogenous Leukemia
PML Promyelocytic Leukemia
HOSE Human Ovarian Surface Epithelium
MOSE Mouse Ovarian Surface Epithelium
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Mechanism of PKCiota-induced Transformation- The presence of overexpressed, mutated, 
amplified, or mislocalized PKCiota in the different tumor types underscores the importance of 
this protein in the transformation process. PKCiota was found to be upregulated in many 
spontaneously-transformed cells, and PKCiota is implicated in transformation of several types 
of cells, including melanocytes and lung and ovary epithelium (Selzer, 2002; Regala, 2005; 
Zhang, 2006). Because the details of the transformation experiments were discussed in detail 
for each individual type of cancer above, here I will briefly summarize the mechanism of 
PKCiota-induced transformation.  
The consensus mechanism of PKCiota-induced transformation involves the interaction 
of PKCiota with PAR-6 and Rac1 (see Figure 7). Several studies in various cancer types have 
been performed to identify PKCiota’s role in transformation. (1) In the A549 NSCLC cell line, 
ectopic wt PKCiota but not dn PKCiota (negative control) expression revealed that PKCiota 
was necessary for transformation (soft-agar colony formation) and for tumor growth 
(measurement of tumor volume). Transformation via PKCiota involved Rac1, and kd PKCiota 
decreased P-MEK and P-ERK (western blot analysis). Similarly, the dn PKCiota phenotype 
was rescued by constitutively active Rac1 (RacV12) (Regala, 2005). Thus, the pathway for 
PKCiota-mediated transformed and tumor growth in NSCLC is most likely PKCiota Æ Rac1 Æ 
Pak Æ MEK1/2 Æ ERK1/2. (2) PKCiota is also involved in the transformation process in 
ovarian cancer. In murine ovarian surface epithelium (MOSEs), PKCiota in cooperation with 
mutant Ras was able to induce transformation (soft-agar colony formation). Additionally, 
PKCiota RNAi in ovarian cancer cells caused a reduction in anchorage-independent growth 
(Zhang, 2006). Thus, PKCiota cooperates in Ras-induced transformation. Transformation by 
Ras will be covered in detail in the ‘Ras’ section below. (3) In NSCLC, PKCiota was shown to 
activate Rac1 through its interaction with PAR-6 and Ect2. Ect2, which is commonly amplified, 
overexpressed, and correlated with PKCiota expression in NSCLC, is a guanine NEF 
(nucleotide exchange factor) for Rho GTPases. Inhibition of Ect2 by RNAi (similar to PKCiota 
inhibition) resulted in a decrease in transformation and tumorigenesis. PKCiota or Ect2 
inhibition was reverted upon ectopic expression of Rac1, indicating the role of PKCiota in 
transformation is through the PKCiota/PAR-6/Ect2 Æ Rac1 Æ Pak Æ MEK1/2 Æ ERK1/2 
pathway in NSCLC (Justilien, 2009). (4) In PDAC cells, PKCiota inhibition resulted in 
decreased transformation. Similarly, in a xenograft mouse model, PKCiota inhibition resulted 
in decreased tumorigenesis. The role of PKCiota in pancreatic cancer transformation was 
determined to be through the Rac-Pak-Mek-Erk pathway, indicating the PKCiota-PAR-6 
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binding is also important in pancreatic cancer transformation (Scotti, 2010). Thus, the role of 
PKCiota in transformation is through the PAR-6/Rac1-MEK/ERK pathway (Figure 7).  
Similarly, the PKCiota-PAR-6-Rac1 complex is also involved with transformation 
through activation of MMP-10, a matrix metalloproteinase, which breaks down the extracellular 
matrix (a process necessary for transformation/ cell invasion) (Figure 7). By use of PKCiota 
RNAi in NSCLC cells, Frederick et al was able to block transformation, as measured by soft-
agar colony formation, and downregulate MMP-10 expression. Similar results were observed 
with RNAi to PAR-6 and Rac1 also resulting in downregulation of MMP-10 expression and 
decreased transformation. In PAR-6 deficient cells, overexpression of PAR-6, but not mutant 
PAR-6 that lacks the ability to bind PKCiota, is able to restore MMP-10 expression. Similarly, 
silencing MMP-10 also blocked transformation in these cells, proving that the decrease in 
MMP-10 expression due to downregulation of PKCiota, PAR-6, and Rac1 was not merely an 
artifact but rather the cause of the decrease in transformation. In a reverse experiment, 
constitutively active MMP-10 restored soft-agar colony formation in PKCiota silenced NSCLC 
cells. In vivo, dominant negative (dn) PKCiota blocked both MMP-10 expression and 
tumorigenicity. In NSCLC patient samples, PKCiota and MMP-10 expression is correlated, and 
expression of PKCiota or MMP-10 predicts poor survival. Thus, PKCiota leads to 
transformation via expression of the matrix metalloproteinase, MMP-10 (Frederick, 2008).      
Use of inhibitors of PKCiota PB1:PB1 interactions (aurothiomalate-ATM and 
aurothioglucose-ATG) block transformation and therefore tumorigenesis. PKCiota binds to 
PAR-6 via PB1:PB1 interactions (see “PKCiota- Binding Partners: PB1 Domain” section for 
more details). Use of the PKCiota inhibitor, ATG blocked transformed growth of A549 cells 
(similar to kd PKCiota); mice treated with ATG exhibited decreased tumor volume (similar to 
kd PKCiota). In NSCLC cells, ATG was able to disrupt the PKCiota:PAR-6 complex, resulting 
in decreased active Rac1 (Stallings-Mann, 2006). Also in NSCLC, inhibition of PKCiota by 
ATM blocked Ras-induced tumorigenesis (Regala, 2009). Thus, PKCiota is involved in 
transformation, and PKCiota inhibition may decrease this phenotype by blocking the 
interaction of PKCiota effector molecules.  
 
 
 
 
 
 
 
Figure 7: Mechanism of PKCiota-Induced Transformation 
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In an alternative model, PKCiota was found to lead to transformation through Src-
induced recruitment of PKCiota to the podosome (Figure 7). (Podosome = “invasive adhesions 
on the ventral surface of the cell that are sites of protease secretion”).  In transformed mouse 
fibroblasts (3T3) (by infection with v-Src), PKCiota was identified as a mediator of Src-induced 
transformation. PKCiota inhibition (by RNAi and dn) revealed that PKCiota was necessary for 
Src-induced stress fiber disruption. Specifically, tyrosine phosphorylation of PKCiota by Src 
was necessary for localization of PKCiota to the podosome and in turn transformation 
(Rodriguez, 2009). Thus, PKCiota is essential for Src-induced transformation through its 
localization to the podosomes, leading to degradation of the basement membrane. 
 
Mechanism of PKCiota-Induced Invasion- The mechanism of PKCiota-stimulated invasion 
seems to occur through the MEK/ERK pathway and involves the usual players: Ras, Src, and 
PI3K. Another aspect of invasion is the loss of actin stress fibers; this is addressed in detail in 
the “PKCiota-Functions: Polarity” and “PKCiota- Signaling: Ras” sections (see Figure 8). 
As mentioned, PKCiota activates Rac1 through PAR-6 and Ect2 interactions. In 
NSCLC, like inhibition of PKCiota, inhibition of Ect2 by RNAi resulted in a decrease in 
transformation, invasion, and tumorigenesis, which was reverted upon exogenous expression 
of Rac1. In cancer, Ect2 is mislocalized to the cytoplasm (as is the case with PKCiota), where 
it can then bind to the PKCiota-PAR6 complex. Without mislocalization of PKCiota or PAR-6 to 
the cytoplasm, Ect2 does not become mislocalized, indicating that the PKCiota-PAR-6 
complex recruits Ect2 to the cytoplasm. PKCiota contributes to invasion through the 
PKCiota/PAR-6/Ect2 Æ Rac1 Æ Pak Æ MEK1/2 Æ ERK1/2 pathway in NSCLC (Justilien, 
2009). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8: Mechanism of PKCiota-Induced Invasion 
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Another study found that the interaction of PKCiota and Rac1 is important for invasion.  
Specifically, in RIE (rat intestinal epithelial) cells with stably expressed PKCβII, Zhang et al 
found that RIE-PKCβII cells exhibit increased invasiveness as compared with RIE parental 
cells, which was through the Ras-PKCiota/Rac-MEK/ERK pathway.  By using specific 
inhibitors or RNAi (as was the case for PKCiota/ lambda), PKCβII-induced invasion, as 
measured by matrigel invasion chambers, was blocked. Thus, PKCiota/ lambda was 
necessary for PKCβII-induced invasion in the following order PKCβII ÆRas Æ PKCiota/Rac1 
Æ MEK/ERK Æ invasion through matrigel (Zhang, 2004). Additionally, colon tumor formation 
and progression, seemed to be through cooperation between PKCiota and PKCβII as 
determined by a double knockout mouse model compared to the single knockouts of either 
PKC alone (Murray, 2009). Thus, PKCiota and PKCβII both contribute to tumorigenesis and 
invasion. 
In mouse fibroblasts (3T3 cells) that have undergone transformation due to viral 
infection with v-Src, PKCiota was identified as the driver of Src-mediated transformation and 
invasion. Using three distinct methods to inhibit PKCiota activity (mPS, RNAi, and dn), 
Rodriguez et al found that PKCiota was essential for Src-induced transformation, due to the 
ability of PKCiota to induce stress fiber formation and to polarize at the apical edge. Using a 
Boyden chamber invasion assay and an in situ zymography assay, PKCiota was also found to 
be essential for Src-induced invasion. Specifically, inhibition of PKCiota tyrosine 
phosphorylation resulted in podosome defects. In Src-transformed cells, PKCiota localized to 
the podosomes. Thus, PKCiota is essential for Src-induced transformation and invasion 
through its localization to the podosomes, leading to degradation of the basement membrane 
(Rodriguez, 2009). 
Induction of invasion upon nicotine exposure seems to be through an alternate 
mechanism. Nicotine is one of the key carcinogens in cigarette smoke. Using H1299 or H460 
human lung cancer cells, Xu et al found that PKCiota was able to phosphorylate both mu- and 
m-calpain in an in vitro assay. Specifically, when PKCiota was activated by nicotine, PKCiota 
was able to lead to calpain phosphorylation/ activation. Use of PKCiota RNAi was able to block 
nicotine-induced phosphorylation of the calpains (and thus their activity), migration, and 
invasion of lung cancer cells. Thus PKCiota is a key effector of nicotine-induced 
tumorigenesis.  One of the potential mechanisms of PKCiota RNAi blocking nicotine-induced 
invasion could be through downregulation of mu- and m-calpain secretion, which is known to 
be upregulated upon nicotine exposure in lung cancer cells (Xu, 2006). 
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Pro-Apoptotic PKCiota- Rarely, PKCiota has been shown to have pro-apoptotic effects. In both 
endothelial cells and fibroblasts, PKCiota/ lambda is involved in cPLA2-mediated apoptosis as 
a result of decreased serum levels. cPLA2-mediated apoptosis is due to a lack of ECM 
components, such as fibronectin. cPLA2 leads to PKCiota/ lambda activation, which in turn 
leads to p53-induced apoptosis though a cascade of caspases (SPDC- small prodomain 
caspases). ECM components are able to inhibit cPLA2 Æ PKCiota/ lambda Æ p53-mediated 
cell death through expression of FAK (focal adhesion kinase) according to the pathway FAK 
┤cPLA2 Æ PKCiota/ lambda Æ p53-mediated cell death. This function of PKCiota/ lambda is 
PI3K-independent. This pathway was identified using a DN-FAK (FAT), which, when 
expressed in the absence of serum, would lead to increased apoptosis. A DN-PKCiota was 
able to revert the phenotype to no increase in apoptosis. Thus, PKCiota is involved in the p53-
mediated apoptosis that results from a decrease in FAK function (Ilic, 1998). 
Another circumstance of pro-apoptotic PKCiota involves lipid-induction of PKCiota. 
Upon lipid-induction (addition as fatty acids) in HCAEC (human coronary artery endothelial 
cells), inhibition of PKCiota resulted in a decrease in apoptosis. Similarly, lipid-induction led to 
activation in PKCiota (Staiger, 2009). Thus, PKCiota can also be pro-apoptotic in rare 
occasions.  
 
Anti-Apoptotic PKCiota (Survival)- The majority of the studies on PKCiota in cell death have 
been focused around PKCiota’s role in survival via NFκB activation and inhibition of pro-
apoptotic Bad Kinase. PKCiota is able to phosphorylate IKKβ, leading to the phosphorylation/ 
degradation of IκB, which then causes release of NFκB, allowing this transcription factor to 
translocate to the nucleus where it leads to the expression of anti-apoptotic genes ( see 
“PKCiota- Signaling: NFκB”).  
PKCiota is also able to induce survival through the phosphorylation of Bad Kinase, a pro-
apoptotic enzyme. Upon stimulation with NNK (Nitrosamine 4-(methylnitrosamino)-1-(3-
pyridyl)-1-butanone), a known potent carcinogen in cigarette smoke, PKCiota led to increased 
survival through phosphorylation of pro-apoptotic Bad, which disrupted Bad/Bcl-XL binding. By 
use of immunofluorescent microscopy in A549 cells exposed to NNK, Jin et al was able to find 
that PKCiota and Bad co-localize. Also, in both an in vitro kinase assay and western blot 
analysis using phospho-Bad antibodies, PKCiota was able to phosphorylate Bad at all three 
sites, which are characteristic of NNK exposure (Ser-112, Ser-136, and Ser-155). Upon 
stimulation with NNK in human lung cancer cells, Src becomes activated, which leads to 
PKCiota activation. Both the Src inhibitor, PP2, and a pan-PKC inhibitor, staurosporine, 
blocked NNK-induced Bad phosphorylation. More specifically PKCiota RNAi was used to block 
NNK-induced Bad phosphorylation and subsequently block survival. Thus, PKCiota activation 
in lung cancer cells by the carcinogen NNK can lead to Bad phosphorylation and Bad/Bcl-XL 
disruption, resulting in increased survival and chemoresistance through the pathway: NNK Æ 
Src Æ PKCiota Æ P-Bad Æ survival by Bad not binding Bcl-XL (Jin, 2005).   
In prostate cancer cells, silencing PKCiota by RNAi resulted in apoptosis. However, 
induction of apoptosis occurred through two very distinct mechanisms. In RWPE-1 
(transformed non-malignant prostate) cells, knockdown of PKCiota resulted in apoptosis due 
to a decrease in phosphoBad (Ser-155, Ser-136) and an increase in Bad/Bcl-xL 
heterodimerization. No such effect on Bad was observed in DU-145 (androgen-independent 
malignant prostate) cells. However, RWPE-1 and DU-145 cells both went through apoptosis 
because of mitochondrial dysfunction/ apoptotic cascades, i.e. cytochrome c release, caspase-
7 activation, and PARP cleavage (Win, 2009). Thus, targeting PKCiota in cancer treatment is a 
viable option. Inhibition of PKCiota can result in apoptosis in different pathways, potentially 
due to oncogenic addiction.   
In primary cultures of cerebellar granule cells (CGCs), PKCiota protein levels decrease 
with spontaneous cell death implicating a potential role in survival (Lin, 1997). Also, in LNCaP 
prostate cancer cells, decreased PKCiota membrane abundance correlated with increased 
apoptosis and subsequently antitumor effects (Song, 2004).  
 
Chemoresistance- Survival- Through PKCiota, cells have undergone chemoresistance to pro-
apoptotic drugs, such as: OA (okadaic acid), taxol (several studies), and cisplatin. This 
PKCiota-mediated chemo-resistance is conferred through NFκB activation and inhibition of the 
p38 MAPK pathway. 
In human chronic myeloid leukemia cells (K562), PKCiota protected these cells from 
apoptosis induced by OA (okadaic acid) and taxol.  Inhibition of PKCiota resulted in a re-
sensitization of these cells to the apoptotic stimuli; thus indicating PKCiota could play a role in 
survival in leukemia. PKCzeta did not exhibit the same survival characteristics (Murray, 1997).  
PKCiota is downstream of Bcr-Abl in an NFκB survival pathway. In K562 leukemia cells 
(CML), BCR-ABL is involved in chemo-resistance to apoptotic drugs, such as taxol. Upon 
treatment of K562 cells with taxol, PKCiota became activated. Using tyrphostin AG957, which 
inhibits BCR-ABL, Jamieson et al was able to block taxol-induced PKCiota activation and re-
sensitize these cells to the apoptotic properties of taxol. Also, constitutively active PKCiota 
 
 
66
 
 
67
was able to revert the chemo-sensitive phenotype of K562 cells treated with taxol and 
tyrphostin AG957 back to the chemo-resistant phenotype. Similarly, in a BCR-ABL negative 
and taxol-sensitive leukemia cell line (HL60), taxol was unable to induce PKCiota activation, 
suggesting that PKCiota would be downstream of BCR-ABL in response to taxol according to 
the pathways: In K562, CML cells: TAXOL Æ BCR-ABL Æ PKCiota Æ drug resistance. 
However, if Bcr-Abl is inhibited (by tyrphostin AG957), the pathway would be as follows: 
TAXOL Æ BCR-ABL Æ PKCiota Æ re-sensitization to taxol (Jamieson, 1999). Another study 
found that PKCiota was able to stimulate Bcr-Abl-induced chemoresistance through the 
pathway: Taxol Æ Bcr-Abl Æ PKCi Æ NFκB (due to IκB degradation and RelA transcriptional 
up-regulation) Æ Survival (transcriptional activation of anti-apoptotic genes) (Lu, 2001). Using 
human glioblastoma cells, the expression of PKCiota was demonstrated in causing partial 
resistance to the chemotherapeutic agent, cisplatin. PKCiota RNAi was able to sensitize 
human glioblastoma cells to the cytotoxic effects of cisplatin. Examining the difference 
between parental cells and PKCiota RNAi cells, Baldwin et al found that an enhancer of the 
p38 MAPK pathway, GMFbeta exhibited increased expression in PKCiota silenced cells 
(Baldwin, 2006). Cisplatin is known to induce cytotoxicity partially through the p38 MAP kinase 
pathway (Mansouri, 2003). Basically, Baldwin found that chemoresistance to cisplatin was 
partially through PKCiota’s downregulation of the p38 MAPK pathway through a decrease in 
GMFbeta expression (Baldwin, 2006). 
Thus PKCiota plays an active role in survival and chemoresistance via activation of 
NFκB, phosphorylation of Bad Kinase, and inhibition of the p38 MAPK pathway.  
 
Additional Functions of PKCiota- PKCiota has also been implicated in other processes such as 
hypoxia (Gozal, 1998), ischemia (Albert, 1998) and viral propagation. In the parvovirus minute 
virus of mice (MVM), PKCiota/ lambda phosphorylates the viral protein NS1. Phosphorylation 
of NS1 at T435 and S473 by PKCiota/ lambda, allows for DNA unwinding (NS1 helicase 
activity) and subsequently replication (Dettwiler, 1999; Nuesch, 2003). Additionally, HSV-1 
(Herpes Simplex Virus-1) infection led to IL-15 upregulation, resulting in increased cell 
proliferation and prevents apoptosis by upregulation of anti-apoptotic genes. This HSV-1 
driven increase in IL-15 expression is dependent on PKCiota/ lambda in monocyte cells 
(Ahmad, 2007). 
 PKCiota is an important regulator of several essential biological functions, such as: 
establishment and maintenance of epithelial polarity, microtubule dynamics, membrane 
trafficking, maintenance of tight junctions, inflammation, proliferation, DNA synthesis, survival 
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and invasion, to name a few. While PKCiota is able to influence several of these functions, 
PKCiota is absolutely essential for polarity, as PKCiota is part of a polarity complex being 
localized to the tight junctions of epithelial cells. In fact, PKCiota/lambda knockout mice are 
embryonic lethal due to defects in polarity (Bandyopadhyay, 2004), thus indicating the 
predominant role of PKCiota is in establishment and maintenance of polarity. Similarly, 
overexpression of PKCiota results in aberrant polarity and increased proliferation, which can 
lead to transformation (Eder, 2005; Zhang, 2006). Several diseases such as cancer, along 
with Alzheimer’s disease and diabetes, can be linked to aberrant expression or localization of 
PKCiota, thus indicating the importance of proper regulation of PKCiota. PKCiota is linked to 
many processes involved in the stages of tumorigenesis, such as: polarity, cytoskeletal 
reorganization, proliferation, anchorage-independent growth, survival, chemoresistance, 
invasion, and metastasis. Because PKCiota is involved in so many unique facets of 
tumorigenesis and tumors are heterogeneous, PKCiota is an ideal potential target for cancer 
therapy.     
 
PKC IOTA BINDING PARTNERS 
 The structure of the aPKCs compared to the nPKCs and cPKCs is quite different (see 
Figure 4). Like the nPKCs and cPKCs, the aPKCs contain a catalytic subunit comprised of the 
C3 ATP-binding site and the C4 substrate binding site. However, unlike the nPKCs and 
cPKCs, the aPKCs contain a distinct PB1 domain and a truncated C1 domain (Hirano, 2004). 
The PB1 domain is distinctly located on the atypical PKCs and allows them to bind effector 
molecules, such as p62, PAR-6, and MEK5. These effector molecules can then bind other 
proteins, such as PAR-3 or CDC42, making protein complexes involved in polarity (PKCiota-
PAR-6-PAR-3) or invasion (PKCiota-PAR-6-CDC42) (see Figure 9). However, PKCiota is also 
able to bind proteins through other domains, such as the C1 (zinc-finger) domain or the 
catalytic (kinase) domain. Table 7 provides a complete list of all the PKCiota binding partners. 
Knowledge of the PKCiota binding partners is important because the ability of PKCiota to be 
activated by other proteins via PB1:PB1 interactions is what distinguishes PKCiota (and the 
other member of the atypical PKCs, PKCzeta) from the nPKCs and cPKCs. While Table 7 
provides a comprehensive list of the know functions of PKCiota in binding to its binding 
partners, Figure OPP provides a schematic of the known roles of PKCiota through its 
interaction with the proteins lists below. While most PKCiota-binding partners have a defined 
role, some proteins indentified in PKCiota-binding were not further examined for functional 
relevance (Table 7).  
  
 
 
Figure 9: PKCiota Interactions through PAR-6 Linker Protein 
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PB1 Domain 
PKCiota interactions with several effector molecules, such as p62/ZIP, PAR-6, and 
MEK5, are mediated via the PB1 (Phox and Bem 1) domain on the N-terminus of the peptide. 
The PB1 domain is unique to the atypical PKCs, and allow PKCiota and PKCzeta to be 
activated by protein:protein interactions as opposed to activation by DAG or calcium like the 
other PKC family members. By use of NMR (nuclear magnetic resonance), Hirano et al was 
able to determine that the PB1-PB1 interactions that occur between PKCiota and its effector 
molecule require the PKCiota PB1 domain to take on a ubiquitin-like fold (Hirano, 2004).  
Uniquely, PKCiota contains both a type I and type II PB1 domain. The type I PB1 domain is 
acidic, containing both conserved acidic and hydrophobic residues (Nakamura, 1998). This 
acidic motif in a type I PB1 domain is called a PC motif (from mammalian p40phox and yeast 
Cdc24p). Other names given to the PKCiota PC motif include OPR (octicosapeptide repeat) 
(Ponting, 1996), AID (atypical PKC interaction domain) (Moscat, 2000), or OPCA (OPR, PC, 
and AID) motif (Ponting, 2002). The most common name for the PKCiota PC motif is the 
OPCA motif (Ponting, 2002). The type II PB1 domain is basic and contains a conserved lysine 
residue, which is necessary to bind to the OPCA of other PB1 domain-containing proteins. 
PKCiota contains both the acidic OPCA and the basic lysine residue, indicating that PKCiota is 
able to function as either or a type I or II PB1 domain.  For example, in the case of PKCiota 
binding to p62/ZIP, the PKCiota OPCA motif binds the lysine residue of p62/ZIP (Wilson, 2003; 
Lamark, 2003). However, in the case of MEK5, the MEK5 OPCA motif binds the lysine residue 
on PKCiota’s PB1 domain (Noda, 2003). Thus both the type I and type II domains of PKCiota 
are fully functional.  
The PB1 domain of PKCiota can be targeted therapeutically. Aurothiomalate (ATM) 
and aurothioglucose (ATG) are two gold compounds that can interrupt the PB1:PB1 
interactions of PKCiota with their effector proteins but do not disrupt the PB1:PB1 domains of 
other molecules. This is due to ATM and ATG binding at a conserved cys-residue in the PB1 
domain of PKCiota (and PKCzeta) that is not present in any other PB1 domain-containing 
proteins (Stallings-Mann, 2006). See “PKCiota-PKCiota as a Target for Therapy” section for 
more details.  
 
 
Table 7: PKCiota Binding Partners 
 
PKCiota Binding Partner Binds PKCzeta Region Bound to PKCiota Function Reference
LIP Necessary for PKCiota-induced NFkB activation/
(Lambda Interacting Protein) No Zinc-finger Domain Activates PKCiota Diaz-Meco, 1996
PAR-4 Leads to Growth Inhibition and Cell Death/
Partitioning Defective 4 Yes Zinc-finger Domain Inhibits PKCiota/zeta Activity Diaz-Meco, 1996
Yes, but not as Involved in Lysosomal-Targeted Endosomes/
p62 / ZIP well as PKCiota PB1 Domain Changes PKCiota Localization Sanchez, 1998
ASIP/ PAR-3
Atypical PKC isotype- Yes Binds through PKCiota/lambda to Localize to the Tight Junctions/ Izumi, 1998
Specific Interacting Protein interaction with PAR-6 Also involved in PKCiota Insulin Signaling
p70 S6K The Regulatory and 
p70 S6 Kinase Yes Kinase Domains Involved in DNA Synthesis Akimoto, 1998
FRS2
Fibroblast growth factor Yes Catalytic Domain Upon FGF Stimulation Serves to Localize PKCiota Lim, 1999
Receptor Substrate 2 To the Plasma Membrane
Necessary for CDC42-induces loss of stress fibers
CDC42 Yes Binds through (Required for Ras-Induced Transformation)/ Coghlan, 2000
Cell Division Cycle 42 interaction with PAR-6 Localizes PKCiota to the Plasma Membrane
Seem to Localize PKCiota to the sites of
Adducin Not Determined Not Determined Cell-Cell Contact or Tight Junctions in Adipocytes Laustsen, 2001
PAR-6 Involved in Polarity and Migration/
Partitioning Defective 6 Yes PB1 Domain Links PKCiota to other Effector Molecules Noda, 2001
MEK5 Upon EGF Induction binds PKCiota and Leads
MAP Kinase Kinase Yes PB1 Domain To the Transcriptional Activation of Jun Diaz-Meco, 2001
PSF Polypyrimidine Upon IGF-1 Induction Binds Nuclear PKCiota 
tract-binding protein (PTB)- Not Determined Not Determined Transcriptional Activation of Cytochrome P-450(scc) Urban, 2004
 associated Splicing Factor
L-selectin Not Determined Phosphorylated on the Cytoplasmic
A Leukocyte Receptor Not Determined Most Likely at Catalytic Domain Domain by PKCiota Kilian, 2004
Bad Interaction with PKCiota Leads to Increased
Pro-apoptotic when Not Determined Not Determined Survival and Chemoresistance/ Jin, 2005
Bound to BCL-XL Most Likely at Catalytic Domain Phosphorylated by PKCiota at Three Sites  
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LIP (Lambda Interacting Protein) 
 LIP (Lambda-interacting protein) was initially identified as a binding partner to PKCiota/ 
lambda by a yeast two-hybrid screen. LIP, which binds only to PKCiota/ lambda constructs 
that contain the entire regulatory domain or the zinc-finger domain, is specific to PKCiota/ 
lambda and does not bind to PKC zeta. The interaction between LIP and the zinc-finger lipid-
binding domain of PKCiota/ lambda, which occurs both in vitro and in vivo, is the first reported 
protein binding to a lipid-binding region (Diaz-Meco, 1996). LIP has been shown to activate 
PKCiota. 
Activation of PKCiota by LIP leads to activation of NFκB in a κB-dependent manner. In 
both Cos and NIH3T3 cells, PKCiota/ lambda exogenous expression led to activation of NFκB, 
which was decreased by a dominant negative isoform (pseudosubstrate domain). Exogenous 
LIP, which binds specifically to PKCiota/ lambda, led to κB-dependent promoter activation 
similar to that of TNFα. The activation of κB promoter activity was increased upon co-
transfection with the PKCiota/ lambda expression construct and decreased upon co-
transfection with the dominant negative (kinase dead) PKCiota/ lambda expression construct. 
The decrease in LIP-induced, κB-dependent promoter activity was not observed upon co-
transfection with a dominant negative (kinase dead) form of PKCzeta (Diaz-Meco, 1996). 
Thus, the LIP-induced transcriptional activation of κB leading to the activation of NFκB is 
PKCiota/lambda specific. 
 
PAR-4 
In NIH-3T3 cells, PAR-4, which is induced in apoptotic cells, interacts with both PKCiota 
and PKCzeta via the zinc-finger motifs of the regulatory domains of these atypical PKCs. 
Interaction of PKCiota with PAR-4 results in a decrease in its enzymatic activity and thus 
growth inhibition and cell death. Overexpression of ectopic PKCiota can revert the apoptotic 
phenotype induced by PAR-4 exogenous expression (Diaz-Meco, 1996).  
However, PAR-4 has been deleted in several types of cancers (Cook, 1999). This implies 
that a method for PKCiota activation in some cancers may be through a deletion of the pro-
apoptotic, PKCiota-inhibiting protein, PAR-4.  
 PKCiota is implicated in the TNFα Æ IκB Æ Survival (NFκB) pathway. PAR-4, which 
can also be activated by TNFα, inhibits the TNFα-PKCiota-IκB-NFκB pathway, leading to 
apoptosis (Diaz-Meco, 1999). Specifically, in NIH-3T3 mouse fibroblasts, upon TNFα 
induction, the atypical PKCs function in phosphorylation of IKKβ (Lallena, 1999), which leads 
to IκB phosphorylation and degradation, leading to NFκB nuclear translocation (survival). The 
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TNFα-induced activation of NFкB is in turn inhibited by PAR-4 expression causing onset of 
apoptosis. Pro-apoptotic PAR-4 expression inhibits translocation of NFкB and therefore 
inhibits the transcription of кB in response to TNFα. PAR-4 is able to inhibit TNFα-induced 
survival and cause apoptosis by binding PKCiota/lambda and PKCzeta and inactivating their 
kinase activity. Therefore, addition of constitutively active atypical PKCs revert the effects of 
exogenous PAR-4 expression, causing complete loss of apoptosis in response to TNFα (Diaz-
Meco, 1999).   
Similarly, PKCiota was been shown in several models to be necessary for Ras-
mediated transformation and tumorigenesis. Ectopic Ras expression, which inhibits 
endogenous PAR-4 expression (Berra, 1993), leads to survival. Because Ras inhibits 
expression of PAR-4, addition of exogenous PAR-4 leads to an increase in apoptosis, even in 
the presence of Ras (Diaz-Meco, 1999).  
 Thus, PKCiota binding to PAR-4 is important in tumorigenesis. If PKCiota and PAR-4 
bind, this causes inhibition of PKCiota (and PKCzeta), resulting in growth inhibition and cell 
death. However, if PAR-4 is absent or inactive, PKCiota can lead to survival through the TNFα 
Æ NFκB pathway and to transformation and tumorigenesis through Ras activation. Thus, the 
balance between PKCiota and PAR-4 seems to be important for cell fate.  
 
p62 / ZIP 
 p62 is the human homolog to ZIP-Zeta-Interacting Protein (rat). Both p62 and ZIP were 
identified as aPKC interacting proteins by two separate groups (Sanchez, 1998 and Puls, 
1997, respectively). p62 has several functions: (1) at the endosome (a vesicle formed during 
endocytosis, which is used for trafficking) upon NGF stimulation (2) in a complex with RIP and 
PKCiota in TNFα-induction of NFκB and (3) in a complex with TRAF6/PKCiota in IL-6 
expression. 
Using a yeast two-hybrid system, Sanchez et al was able to identify p62, a 
phosphotyrosine-independent p56(lck) SH2-interacting protein, as a PKCiota binding partner. 
p62, which also binds to a lesser extent to PKCzeta, binds to the V1 domain (Sanchez, 1998). 
The V1 domain of PKCiota is located in the regulatory region of the peptide and is the most 
variable region of the PKC family members (Nishizuka, 1992). Later, the specific region of the 
V1 domain was found to be the PB1 domain (Wilson, 2003; Lamark, 2003). PKCiota binding to 
p62 does not change the activity of PKCiota, indicating that p62 is not a PKCiota substrate. 
Instead, p62 binding to PKCiota serves as a method for localizing PKCiota to the lysosome-
targeted endosomes. p62 leads to EGF endocytic membrane transport; this transport is block 
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by exogenous expression of a dominant negative form of PKCiota (Sanchez, 1998). Therefore, 
PKCiota through binding to p62 likely plays a role in the trafficking of growth factor receptors, 
such as EGF.  
(1) Upon NGF treatment, PKCiota/ lambda localizes with p62 to the endosome (Samuels, 
2001). Some of the purposes of the endosome include carrying either proteins or lipids from 
the plasma membrane to the lysosome, or carrying these molecules to the golgi apparatus for 
processing. The endosome is also used to secrete proteins/lipids out of the cells. Autophagy 
uses many of the same regulators as does the process of the endosome to the lysosome 
(Tooze, 1990). After induction of PC12 cells with NGF, p62 localizes to the endosome, where 
PKCiota/ lambda is recruited upon tyrosine phosphorylation by Src. PKCiota/ lambda co-
localized with p62. This interaction between p62 and PKCiota/ lambda at the endosome had 
been described previously (Sanchez, 1998). However, Samuels et al identified the mechanism 
of this interaction in response to NGF induction (Samuels, 2001).  
Stimulation of PC12 cells with NGF lead to the binding of PKCiota/ lambda and p62, 
this was determined by use of immunoprecipitation analysis. While PKCiota/lambda and p62 
expression levels remained constant upon stimulation by NGF, the binding of p62 to PKCiota/ 
lambda increased 4-times that of non-NGF treated.  Kinetics experiments revealed that 
PKCiota/ lambda peak activation is between 5 to 15 minutes and peak co-localization between 
PKCiota/ lambda and p62 is between 15 to 30 minutes, indicating that PKCiota/ lambda must 
first be activated by phosphorylation before it can bind p62.  
Using an inhibitor of tyrosine kinase activity (genistein), Samuels et al showed that 
tyrosine phosphorylation of PKCiota/ lambda was necessary for the interaction between 
PKCiota/ lambda and p62. However, phosphorylation of PKCiota/ lambda at a tyrosine residue 
is not necessary for p62 to localize to the endosome. Endosomes were visualized using 
immunofluorescence with antibodies to Rab7, a known marker of the endosome. Also, 
fractionation was used to determine the endosomal proteins. Thus, p62 localizes to the 
endosome, and upon tyrosine phosphorylation of PKCiota/ lambda, PKCiota/ lambda gets 
recruited shuttle by p62 to the endosome (Samuels, 2001).  
To determine the tyrosine kinase responsible for PKCiota/ lambda tyrosine 
phosphorylation, Samuels et al added increasing amounts of Src and measured the amount of 
PKCiota/ lambda bound to p62 (Samuels, 2001). Puls et al had already indentified a Src 
phosphorylation site on aPKC at tyrosine 116 (Puls, 1997). Increasing Src expression led to 
increased PKCiota/ lambda bound to p62, indicating that Src is the tyrosine kinase that 
activates PKCiota/ lambda, causing PKCiota/ lambda to be recruited to bind p62 and 
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translocate to the endosome. To determine the specificity of the effect of Src on PKCiota/ 
lambda binding, HEK  293 cells were also given increasing amounts of Src, and as was the 
case with PC12 cells, increasing Src expression resulted in increased PKCiota/ lambda bound 
to p62 (Samuels, 2001).  Because PKCiota had already been established in NGF-induced 
differentiation (Coleman, 1994), antisense p62 was used to determine the role of p62 in NGF-
induced differentiation. They found that antisense p62 blocked NGF-induced neurite 
outgrowth, indicating PKCiota/ lambda binding to p62 is likely necessary for NGF-induced 
neurite outgrowth (Samuels, 2001). Thus, PKCiota plays an important role in the NGF Æ Src 
Æ P-PKCi Æ recruited to bind p62 at the endosome pathway (Samuels, 2001). 
(2) p62 was also determined to be important in NFκB activation. In the TNFα Æ TNFR1Æ 
TRADD Æ RIP/p62/aPKCs (independent of TRAF2)Æ IKKβ Æ degradation of IκB Æ NFκB 
(activation/ nuclear translocation) pathway, p62 links PKCiota/ lambda and PKCzeta to NFκB 
transcriptional activation. Using a dominant negative form of PKCiota/ lambda in 293 cells, 
Sanz et al was able to link both PKCiota/ lambda and PKCzeta to NFκB transcriptional 
activation through the interaction of PKCiota/ lambda or PKCzeta with p62. PKCiota/ lambda 
was not able to bind directly to RIP. Using a series of in vitro and in vivo binding assays, p62 
was shown to bind to RIP, which is a known molecule in the TNFα to NFκB pathway. The 
dominant negative PKCiota/ lambda construct inhibited RIP- induced NFκB activation. 
PKCiota/ lambda, p62, and RIP all must be present in a complex in order for PKCiota/lambda 
to activate IKKβ and therefore activate NFκB. Therefore, while p62 links RIP to PKCiota/ 
lambda, PKCiota/ lambda links p62 to IKKβ (Sanz, 1999). 
(3) PKCiota was found to be in a signalsome with TRAF6, p62, and IKK through a series 
of immunoprecipitations in response to Thymosin alpha 1, a treatment of cancer in clinical 
trials. This induction of the signalsome led to IL-6 expression through the Thymosin alpha 1 
(Ta1) Æ TRAF6/p62/PKCiota/zeta/ IKK Æ NFκB Æ IL-6 pathway (Zhang, 2005). The function 
of p62 in the p62-TRAF6-IKKβ-PKCiota complex, which is formed upon stimulation with NGF 
and leads to NFκB expression, is to lead to the polyubiquitination of TRAF6 (Wooten, 2005). 
 
PAR-3/ ASIP/ Bazooka 
 PAR-3, together with PKCiota and PAR-6, makes up the polarity complex that localizes 
to the tight junctions. See “PKCiota- Functions: Polarity” for a thorough background on polarity 
and tight junctions. PAR-3 is also known as ASIP (atypical PKC isotype-specific interacting 
protein) in rats (Izumi, 1998), Bazooka in drosophila (Muller, 1996), XASIP in xenopus 
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(Nakaya, 2000), and PAR-3 in humans and c. elegans. In addition to the role of PKCiota-PAR-
3 in polarity, this complex also plays a role in glucose transport.   
PAR-3/ ASIP was originally identified as a PKCiota binding protein by Izumi et al. In 
NIH3T3 cells (mouse fibroblasts), COS (monkey kidney cells), epithelial MDCKII cells (Madin 
Darby Canine Kidney), and rat intestinal epithelium, both PKCiota/lambda and PKCzeta bind 
ASIP (atypical PKC isotype-specific interacting protein) (Izumi, 1998). MDCKII cells form a 
tight cell layer and are used to mimic polarized epithelial cells. ASIP is conserved in c. elegans 
(PAR-3) and drosophila (Bazooka), which is where the role of ASIP was found to be in 
establishment and maintenance of asymmetric cell polarity (Izumi, 1998; Tabuse, 1998; 
Schober, 1999; Wodarz, 1999). ASIP is commonly referred to as PAR-3 in humans. Both 
PAR-3 (C. elegans) and ASIP (rats) contain PDZ domains, which were originally believed to 
allow these proteins to bind the atypical PKC members. However, later PAR-6 was determined 
to be the linker protein that allowed PKCiota and PAR-3 to co-localize (Noda, 2001). When 
PKCiota/ lambda and ASIP are bound in rat intestinal epithelial cells, the complex localizes to 
the tight junctions, as determined by immunoelectron microscopy (Izumi, 1998). Similarly, 
exogenous expression of ASIP was able to alter the localization of PKCiota/ lambda (Kotani, 
2000). Also, in Xenopus laevis epithelial cells PKCiota/ lambda (XaPKC) and ASIP (XASIP) 
colocalize at the Xenopus equivalent of tight junctions (Nakaya, 2000). Because 
PKCiota/lambda is localized to the tight junctions, which are found in epithelial cells that have 
apical-basal polarity, PKCiota/lambda was demonstrated to play a role in asymmetric polarity 
of epithelial cells.   
In 3T3-L1 adipocytes, ASIP interacts with PKCiota/ lambda, but not with PKCepsilon or 
AKT, as determined by a series of in vitro immunoprecipitation experiments. While 
endogenous ASIP could only be found in the LDM fraction, overexpression of ASIP resulted in 
an increase in the PKCiota/ lambda levels in the LDM and PM fractions, but a decrease in the 
cytosolic fraction. Therefore, ASIP overexpression results in altered localization of PKCiota/ 
lambda in 3T3-L1 adipocytes (Kotani, 2000). 
Insulin has been shown to induce glucose uptake and GLUT4 translocation in a 
PKCiota/ lambda dependent manner (see “PKCiota- Signaling: Insulin” for more details). 
Kotani et al showed that overexpression of the atypical PKC binding protein, ASIP (PAR-
3/Bazooka), was able to inhibit both insulin-induced and constitutively active PKCiota/ lambda-
induced glucose uptake. Specifically, in 3T3-L1 adipocytes, addition of insulin resulted in an 
increase in glucose uptake as well as an increase in the activity of PKCiota/ lambda, as 
indicated by use of an in vitro kinase assay using MBP as the substrate. The effects of insulin-
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induction on PKCiota/ lambda activation as well as on GLUT4 translocation and therefore on 
glucose uptake were reduced upon addition of exogenous ASIP in a dose-dependent manner, 
indicating that insulin works through PKCiota/ lambda signaling to induce glucose uptake. To 
test the specificity of insulin-induced glucose uptake, Kotani et al used two other methods of 
inducing glucose uptake, growth hormone (GH) and hyperosmolarity (sorbitol). However, ASIP 
did not block GH- or sorbitol- induced glucose uptake, indicating that inhibition of glucose 
uptake by ASIP is insulin and PKCiota/ lambda- specific. Interestingly, ASIP did not block all 
insulin-induced signaling. For example, ASIP did not block the translocation of AKT to the PM 
fraction in response to insulin (Kotani, 2000). Thus, while ASIP blocks PKCiota/ lambda- and 
insulin-induced translocation of GLUT4 and therefore glucose uptake, ASIP does not block all 
insulin signaling.  
 
p70 S6 Kinase 
p70 S6K, a kinase involved in the PI3K pathway, is involved in cell cycle progress 
through DNA synthesis (Lane, 1993; Reinhard, 1994; Pullen, 1997; Alessi, 1998). p70 S6K 
binds to PKCiota and PKCzeta via both the regulatory and kinase domains. PKCiota is 
required, but not on its own sufficient, to activate serum-induced DNA synthesis via S6K, 
which is not a PKCiota substrate. PKCiota/ lambda binds to p70 S6K. In both COS and 293 
cells, two dominant negative mutants (kinase dead and a truncated regulatory domain) of 
PKCiota/ lambda were able to suppress the ability of p70 S6K to lead to DNA synthesis in 
response to serum stimuli, determined by BrdU incorporation. However, a constitutively active 
form of PKCiota was unable to stimulate p70 S6K-induced DNA synthesis, indicating that 
PKCiota is required but not on its own sufficient for the activation of p70 S6K (Akimoto, 1998).  
 
FRS2 
In Swiss 3T3 mouse embryonic fibroblasts, upon stimulation with fibroblast growth factor 
(FGF), FRS2 interacts with both PKCiota/lambda and PKCzeta. This interaction was identified 
using a yeast two hybrid assay and validated using co-immunoprecipitation experiments with 
FGF induction. FRS2 works by binding to FGFR and recruiting proteins to the plasma 
membrane. While FRS2 and a similar isoform, SNT2, bind to PKCiota/lambda, these proteins 
are not a PKCiota/ lambda substrate. However, FGF does increase PKCiota/ lambda kinase 
activity three fold, using hnRNPA1 as a substrate. Using tagged, truncated forms of FRS2 and 
PKCiota/ lambda in 293T cells, Lim et al found that the c-terminus of FRS2 binds to the 
catalytic domain of PKCiota/lambda. FRS2 binds to PKCiota/ lambda two fold more efficiently 
 
 
78
when PKCiota/ lambda is in its “open” constitutively active confirmation as compared to the 
“closed” wild type confirmation. Because PKCiota/ lambda does not phosphorylate or activate 
FRS2, it seems likely that the purpose of FRS2-PKCiota/ lambda interaction is in the 
localization of activated PKCiota/lambda to the plasma membrane (Lim, 1999). 
 
CDC42 
Cell Division Cycle 42 (CDC42) is connected to PKCiota in everything from glucose 
transport, to the cytoskeleton, to transformation and invasion. In rat brain cytosol and NIH 3T3 
mouse fibroblasts, PKCiota/ lambda and PKCzeta were shown to interact with CDC42 by a 
series of immunoprecipitation assays. Truncated constructs of these proteins were used to 
determine the region of interaction between these two proteins. The interaction between 
PKCiota/lambda (regulatory domain) and CDC42 (V12 region) was shown to be both GTP-
dependent (in rat brain cytosol) and indirect, requiring an unknown effector protein (in Cos and 
293 cells) (Coghlan, 2000). Later, the unknown protein that links CDC42 to PKCiota/ lambda 
was found to be PAR-6, which also links PKCiota to PAR-3 (Noda, 2001). In a PKCiota/ 
lambda kinase assay, using myelin basic protein as the substrate, results reveal that CDC42 
was not able to alter the kinase activity of PKCiota/ lambda, thereby implying CDC42s 
interaction with PKCiota/ lambda was to localize PKCiota/ lambda to the plasma membrane. In 
NIH 3T3 cells, PKCiota/ lambda translocates from the nucleus to the cytoplasm upon 
exogenous expression of CDC42. Earlier studies had shown that PKCiota/ lambda was 
translocated from the nucleus to the cytoplasm in response to growth factor stimulation (PDGF 
and EGF), and this translocation was PI3K- dependent (Akimoto, 1996). 
Ras, Rac, CDC42, PKCiota/ lambda, and PKCzeta all individually had been implicated in 
stress fiber loss and actin remodeling (Zhao, 1998; Uberall, 1999). Cells, which have 
undergone transformation, have alterations in their actin cytoskeleton, one of these alteration 
is a loss of stress fibers (Mackay, 1998).  While Uberall et al linked Ras and PKCiota/lambda 
and PKCzeta, Coghlan et al linked Ras-CDC42-PKCiota/lambda in stress fiber loss (RasÆ 
CDC42/PKCiota Æ loss of stress fibers Æ transformation) (Coghlan, 2000). Loss of stress 
fibers is a necessary step in Ras-induced transformation. While Rac expression is able to 
cause stress fiber loss, this phenotype is through a different pathway than the Ras-CDC42-
PKCiota/ lambda pathway (Coghlan, 2000) (see “PKCiota-Signaling: Ras” section for details). 
In NIH3T3 cells, ectopic expression of constitutively active CDC42 (V12 CDC42) led to a 
loss in stress fibers (Kozma, 1995). Coghlan et al was able to show that transient exogenous 
expression of PKCiota/ lambda (but not PKCzeta) was able to lead to the same loss of stress 
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fibers observed in response to CDC42 overexpression. To show that PKCiota/ lambda was 
essential for CDC42-induced loss of stress fibers, kinase dead mutants of PKCiota/ lambda 
(KD PKCiota/ lambda) and PKCzeta (KD PKCzeta) were used to block CDC42-induced loss of 
stress fibers. The KD PKCiota mutant blocked CDC42- induced loss of stress fibers, but had 
no effect on CDC42- induced membrane ruffling or filopodia formation, indicating that while 
PKCiota/ lambda was essential for CDC42-induced loss of stress fibers, CDC42 induced other 
pathways independently of the PKCiota/ lambda or PKCzeta pathways. Because Rac-1 had 
also been implicated in loss of stress fibers, the KD PKCiota mutants were used to block loss 
of stress fibers in response to Rac. However, the KD PKCiota mutants were unable to block 
Rac-induced loss of stress fibers (Coghlan, 2000). Uberall et al had published that Ras-
induced loss of stress fibers, was not only dependent on PKCiota/ lambda and PKCzeta, but 
also dependent on Rac, contrary to the finding of Coghlan et al (Uberall, 1999; Coghlan, 
2000). Coghlan et al was also able to link PKCiota/ lambda and PKCzeta to Ras-induced loss 
of stress fibers by use of the KD aPKC mutants (Coghlan, 2000). However, contrary to the 
findings of Uberall, upon induction of NIH 3T3 cells with constitutively active Ras and either 
dominant negative CDC42 (N17 CDC42) or dominant negative Rac, only N17 CDC42, but not 
dominant negative Rac, was able to block Ras-induced loss of stress fibers.  Thus, according 
to Coghlan et al at least two pathways exist for loss of stress fibers in transformation, one 
pathway involving Ras- CDC42- PKCiota/ lambda and one involving Rac (independently of 
Ras or the atypical PKCs) (Coghlan, 2000). It is important to note that Coghlan et al did not 
directly test the KD aPKC mutants on transformation just on indicators of transformation (loss 
of stress fibers). 
CDC42 is also involved in the insulin-PI3K-PKCiota/ lambda-GLUT-4 transport 
pathway (Insulin Æ PI3K/CDC42 Æ PKCiota/ lambda Æ GLUT4 translocation Æ glucose 
uptake). By use of CDC42 antibody (to block activity) and constitutively active (CA) CDC42 (to 
activate it) in 3T3-L1 adipocytes, CDC42 was examined in response to insulin induction. 
CDC42 is involved in the insulin response through direct interaction with PI3K. However, PI3K 
inhibitors, wortmannin and LY294002, block CA-CDC42 induced GLUT4 translocation to the 
plasma membrane. Also, inhibition of PKCiota/ lambda by microinjection of PKCiota/ lambda 
antibody and a kinase dead mutant resulted in a block of both insulin and CA-CDC42 induced 
GLUT4 transport. Thus, insulin Æ PI3K/CDC42 ÆPKCiota/ lambda are all in the same GLUT4 
translocation pathway that leads to glucose uptake (Usui, 2003). 
Of course, CDC42 also has PKCiota-independent functions. PKCiota was not involved 
in other CDC42-induced steps in transformation, such as membrane ruffling and filapodia 
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formation (Coghlan, 2000). Also, while PKCiota/ lambda was linked to CDC42-induced loss of 
stress fibers, PKCiota/ lambda does not play a role in the previously published CDC42- 
induced JNK activation or Fos expression (Coso, 1995; Minden, 1995; Chang, 1998; Kaneki, 
1999; Coghlan, 2000).  
 
Adducin 
In 3T3-L1 adipocytes, adducin was identified as a PKCiota/ lambda binding protein by 
use of purified PKCiota/ lambda antibody in an immunoprecipitation followed by mass 
spectroscopy to identify the unknown proteins. It is important to note that the antibody used in 
this immunoprecipitation screen was non-specific among the atypical PKCs and could also 
bind PKCzeta. However, because PKCiota/ lambda was the predominant atypical PKC isoform 
in 3T3-L1 cells, the author assumed binding was due to PKCiota/ lambda rather than PKCzeta 
(Laustsen, 2001). Adducin is a cytoskeleton protein involved in the assembly of spectrin–actin 
complexes (Matsuoka, 2000) and is associated at the site of cell-cell contact in epithelial cells 
(Kaiser, 1989). PKCiota lambda forms a polarity complex at the tight junctions with PAR3 and 
PAR6 (Izumi, 1998). PKCiota/ lambda binding to adducin may cause PKCiota to localize to the 
tight junctions (Abdi, 2008). PKCiota/lambda did not seem to phosphorylate adducin in 
response to insulin stimulation (Laustsen, 2001). However, adducin appears to be 
constitutively phosphorylated in 3T3-L1 cells (Abdi, 2008). 
 
PAR-6 
PAR-6 is the linker protein between the PKCiota and the Rho GTPases (Rac and 
CDC42) in migration and invasion and between PKCiota and PAR-3 in polarity. In vitro and in 
vivo, PAR-6 binds the N-terminal regulatory domain of both PKCiota and PKCzeta. The 
binding between PKCiota-PAR-6 is through PB1:PB1 protein:protein interactions. In HeLa and 
COS-7 cells, Noda et al found that PKCiota, PAR-6, and Rac1 co-localize at membrane 
ruffles, which are found in migrating cells at the leading edge (Noda, 2001). However, a year 
prior, Coghan et al found that PKCiota was not involved in other CDC42-induced steps in 
transformation, such as membrane ruffling and filapodia formation (Coghlan, 2000). 
PKCiota and PAR-6 binding requires PAR-3 to bring about polarity in epithelial cells. 
Thus, PKCiota-PAR-6-PAR-3 forms the polarity complex responsible for the development of 
the apical membrane in polarized epithelial cells. Using PAR-3 knockdown in MDCK cells, 
which are polarized and able to form a monolayer in culture, Horikoshi et al found that PKCiota 
and PAR-6 are unable to localize to the apical domain, a phenotype that was rescued upon re-
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addition of PAR-3 (Horikoshi, 2009). However, PKCiota is unable to bind PAR-3 without PAR-
6 (Noda, 2001). Thus, PKCiota, PAR-6, and PAR-3 are all required to make the polarity 
complex. 
The PKCiota-PAR-6 interaction can be targeted therapeutically in cancer. ATG 
(aurothioglucose- a gold compound used in the treatment of rheumatoid arthritis) and ATM 
(aurothiomalate- a similar gold compound) were identified as compounds which disrupt 
PKCiota/PAR-6 binding. Use of ATG blocked transformed growth of A549 cells, to the same 
extent as exogenous overexpression of kinase dead (kd) PKCiota. Also, ATG was able to 
cause a decrease in tumor volume in mice, much to the same extent as kd PKCiota. Similarly, 
both ATG and kd PKCiota did not affect the rate of proliferation of adherent cells. This 
decrease in transformation of NSCLC cells in the presence of ATG was due to a disruption of 
the PKCiota/PAR-6 complex, resulting in a decrease in the level of active Rac1 (GTP versus 
GDP-bound) (Stallings-Mann, 2006).  
Predictably, PKCiota inhibitors (such as ATG or ATM) do not inhibit soft-agar colony 
formation in lung cancer cells that do not overexpress PKCiota. More specifically, ATM 
sensitivity in lung cancer cells is higher in cells overexpressing PKCiota-PAR-6 than in cells 
with PKCiota-p62. In cells with high levels of PKCiota, the IC50 values of ATM are low 
(300nM), while in cells with low levels of PKCiota, the IC50 values of ATM are quite high 
(100μM). Interestingly, ATM sensitivity only correlated with PKCiota levels, it did not correlate 
with overall sensitivity to chemotherapeutics, such as cisplatin, placitaxel, or gemcitabine. The 
trend of ATM being most efficacious in PKCiota overexpressing cells corresponds to the trend 
in vivo, with tumors of high PKCiota levels being the most sensitized to ATM. In vivo, ATM 
manifests its effect through inhibition of the PKCiota-PAR6-Rac-PAK-MEK-ERK pathway, as 
determined by western blot analysis. Thus, ATM treatment both in vitro and in vivo is most 
effective in PKCiota overexpressing tumors, indicating the need for a screening technique for 
lung cancer patients (Regala, 2008). The exact pathway that is targeted by ATM or ATG 
resulting in decreased tumorigenesis in NSCLC is PKCiota/PAR-6/Ect2 Æ Rac1 Æ Pak Æ 
MEK1/2 Æ ERK1/2 (Justilien, 2009). Because the PKCiota-PAR-6 complex recruited Ect2 to 
the cytoplasm leading to transformation, invasion, and tumorigenesis in a NSCLC model, 
inhibition of the binding between PKCiota and PAR-6 by ATM treatment caused a decrease in 
NSCLC incidence through disruption of the PKCiota-PAR-6-Ect2 complex (Justilien, 2009).  
 Thus, PKCiota binding to PAR-6 is essential in apical-basal epithelial cell polarity in 
addition to cellular migration and invasion. Unfortunately, the PKCiota-PAR-6 complex can be 
hijacked, causing cancer cell invasion and eventually metastasis. 
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MEK5 
PKCiota interacts with MEK5 upon stimulation with EGF.  PKCiota/ MEK5 binding is 
required for EGF activation of ERK5; yet MEK5 is not phosphorylated by PKCiota. Activation 
of MEK5 by PKCiota binding leads to downstream transcriptional activation of Jun via the 
MEF2C element. Through a BLAST search, Diaz-Meco found that MEK5 contains a similar 
PB1 domain as the PKCiota-interacting protein p62. In 293T cells, through a series of IP-
western experiments, MEK5 and PKCiota, as well as PKC zeta, were shown to bind via PB1 
domain interactions. By five minutes post EGF treatment, PKCiota (or PKCzeta) and MEK5 
interact. In HeLa cells, exogenous expression of both wild-type and kinase dead aPKC lead to 
increased activation of ERK5 in response to EGF. While ERK5 activation was not dependent 
on the enzymatic activity of aPKC, ERK5 activation did require MEK5 enzymatic activity. 
Mutation of the MEK5 kinase domain resulted in a block of EGF induced ERK5 activation. 
While exogenous expression of PKCiota, both wild type and kinase dead, resulted in an 
increase in Jun promoter activity, as determined by a Jun-luciferase report gene, dominant 
negative forms of aPKC and MEK5 inhibited Jun promoter activity (Diaz-Meco, 2001). Thus, 
EGF stimulation of PKCiota/zeta and MEK5 binding is required for activation of ERK5 and 
subsequently Jun transcription in the EGF Æ PKCiota Æ MEK5/ERK5 Æ Jun (transcriptional 
activation through the MEF2C element) pathway (Diaz-Meco, 2001). 
. 
PSF (polypyrimidine tract-binding protein (PTB)-associated splicing factor) 
Interaction of PSF with nuclear PKCiota led to transcriptional activation of the cytochrome 
P-450(scc) (P-450 side-chain cleavage) through the sequestering of PSF binding to the P-
450(scc) IGFRE (IGF-1 response element).  PSF transcriptionally represses P-450(scc) 
through its interaction with the IGFRE.  In JC-410 (stable porcine granulose) cells, upon IGF-1 
treatment, levels of nuclear PKCiota were increased. Upon IGF-1 treatment or exogenous 
expression of either constitutively active or kinase dead PKCiota, the levels of IGFRE activity 
were increased. Thus, the role of PKCiota in activation of the IGFRE is kinase-independent. 
Examination of nuclear extracts by immunoprecipitation experiments revealed the PKCiota 
bound PSF, leading to a block of PSF repression of P-450(scc) via the IGFRE. Thus, PKCiota 
is able to overcome PSF suppression on the cytochrome P-450(scc) promoter IGFRE by 
interaction with PSF in the nucleus upon IGF-1 treatment (Urban, 2004). 
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L-selectin 
In Jurkat T-cells, PKCiota binds the cytoplasmic portion of L-selectin. L-selectin, a 
leukocyte adhesion molecule, is involved in the inflammatory response by aiding in the 
leukocyte extravasation step (Vestweber, 1999). By use of a GST-fusion to the cytoplasmic 
domain of L-selectin and Jurkat cell lysates, Kilian et al was able to identify PKCiota as an L-
selectin binding partner in an immunoprecipitation experiment. A PKCiota pseudosubstrate 
(dominant negative) mutant blocked L-selectin phosphorylation thus implicating PKCiota as an 
activator of L-selectin-mediated signal transduction. While PKCzeta was not tested for its 
ability to phosphorylate L-selectin, PKCtheta was found to exhibit the same effects as PKCiota 
on L-selectin phosphorylation (Kilian, 2004). Thus, PKCiota and PKCtheta interact with L-
selectin, a leukocyte receptor involved in extravasation, and led to the phosphorylation of its 
cytoplasmic domain. 
 
Bad 
Upon stimulation with NNK (Nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone), 
a known potent carcinogen in cigarette smoke, PKCiota led to increased survival through 
phosphorylation of pro-apoptotic Bad, which disrupted Bad/Bcl-XL binding. PKCzeta was not 
tested. By use of immunofluorescent microscopy in A549 cells exposed to NNK, Jin et al was 
able to find that PKCiota and Bad co-localize. Also, in both an in vitro kinase assay and 
western blot analysis using phospho-Bad antibodies, PKCiota was able to phosphorylate Bad 
at all three sites, which are characteristic of NNK exposure (Ser-112, Ser-136, and Ser-155). 
Upon stimulation with NNK in human lung cancer cells, Src becomes activated, which leads to 
PKCiota activation (Jin, 2005). Src had already been shown to bind PKCzeta by affinity 
chromatography using the regulatory domain of PKCzeta as the bait. This paper also showed 
that Src was able to tyrosine phosphorylate PKCzeta (Seibenhener, 1999). Both the Src 
inhibitor, PP2, and a pan-PKC inhibitor, staurosporine, blocked NNK-induced Bad 
phosphorylation. More specifically PKCiota RNAi was used to block NNK-induced Bad 
phosphorylation and subsequently block survival. Thus, PKCiota activation in lung cancer cells 
by the carcinogen NNK can lead to Bad phosphorylation and Bad/Bcl-XL disruption, resulting 
in increased survival and chemoresistance through the NNK Æ Src Æ PKCiota Æ P-Bad Æ 
survival by Bad not binding Bcl-XL pathway (Jin, 2005).   
In a prostate cancer cell model, silencing PKCiota by RNAi resulted in apoptosis. However, 
induction of apoptosis occurred through two very distinct mechanisms. In RWPE-1 
(transformed non-malignant prostate) cells, knockdown of PKCiota resulted in apoptosis due 
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to a decrease in phosphoBad (Ser-155, Ser-136) and an increase in Bad/Bcl-xL 
heterodimerization. No such effect on Bad was observed in DU-145 (androgen-independent 
malignant prostate) cells. However, RWPE-1 and DU-145 cells both went through apoptosis 
because of mitochondrial dysfunction/ apoptotic cascades, i.e. cytochrome c release, caspase-
7 activation, and PARP cleavage (Win, 2009). Thus, targeting PKCiota in cancer treatment is a 
viable option, and Inhibition of PKCiota can result in apoptosis in different pathways, 
potentially due to oncogenic addiction.   
 
PKCiota, unlike the novel and conventional PKC family members, is regulated by 
protein:protein interactions, many of these interactions are by means of the PB1 domain. This 
unique ability is what allows PKCiota to be involved in so many diverse aspects of the 
biological functions that occur within a eukaryotic cell, from tumor growth and proliferation (p70 
S6K and MEK5) to transformation (CDC42), polarity (ASIP/PAR-3, Adducin, and PAR-6), 
invasion (PAR-6), differentiation (unknown), survival (LIP and BAD), and membrane trafficking 
(p62/ ZIP) (see Table 7 above and Figure OPP below). Some PKCiota binding partners affect 
localization (p62/ ZIP, ASIP/PAR-3, FRS2, CDC42, Adducin, PSF, and L-selectin), while 
others inhibit PKCiota activity (PAR-4).  By determining which binding partners are 
overexpressed in tumor cells, this allows for a better understanding of which pathways are 
predominant in tumorigenesis, in an attempt to discover alternative pathways to be targeted 
therapeutically in cancer patients. Knowledge of which pathways are active in different cancers 
allows for specific regimens to be tailor-fitted to each individual patient. For example, the 
PKCiota inhibitor that I will be discussing in detail works by disrupting PKCiota PB1:PB1 
interactions. However, if the pathway that is active in a particular cancer is not active due to 
PB1:PB1 interactions, but rather interactions of PKCiota at another domain, the PB1-inhibting 
drug would be inadequate and ineffective. Thus, a profound knowledge of the pathways 
involved in tumorigenesis, including protein:protein interactions allows for an improved ability 
to acquire therapies to target these pathways.  
 
 
 
 
 
 
 
 
 
 
Figure OPP: Overall PKCiota Pathway 
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SIGNALING: RAS 
 Ras through PKCiota is able to induce transformation through three main pathways: (1) 
induction of cyclin D1- leading to increased transformed growth, (2) increased transcription of 
tumor-promoting genes- such as MMP-3 (leading to invasion) and c-fos (a tumor-promoting 
transcription factor), and (3) re-arrangement of the cytoskeleton- such as stress fiber loss. As 
always, discrepancies exist in these pathways as indicated by the dashed arrows in the 
diagram below (see Figure 10). These discrepancies could be present for many reasons 
including use of different cells types in these studies.  
 
Ras-PKCiota in Transformation 
Transformation can occur when normal cells assume the ability to survive and grow 
void of anchorage-dependence.  Normal (anchorage-dependent) cells that have detached 
would undergo anoikis- a specific form of programmed cell death (Grossmann, 2002). Ras is a 
well known oncogene recognized for inducing transformation and PKCiota is necessary for 
Ras-induced transformation. PKCzeta (the other atypical PKC family member) had been 
shown to interact with Ras in vitro and in vivo (Diaz-Meco, 1994). 
In NIH 3T3 cells, a dominant negative (kinase-defective) mutant of PKCiota/ lambda 
was able to revert the transformed phenotype resultant of either v-Ras or PC-PLC 
(phosphatidylcholine-hydrolyzing phospholipase C) (Bjorkoy, 1997). Specifically, in v-Ras and 
PC-PLC transformed NIH 3T3 cells, ERK1/2 (extracellular signal-regulated kinase) are 
constitutively activated (even upon growth factor deprivation) and localized to the nucleus. 
Dominant negative PKCiota/ lambda reverts this phenotype. The reversion of the phenotype 
along with transient transfection experiments demonstrate that PKCiota/ lambda is 
downstream of v-Ras but upstream of ERK1/2 in v-Ras and PC-PLC transformed NIH 3T3 
cells (Bjorkoy, 1997). Essentially PKCiota was found to be in the Ras/PLC Æ PKCiota Æ 
MAPK/ERK1/2 Æ ELK Æ transformation pathway. This pathway was then disputed by 
Kampfer et al, stating that the MEK/ERK pathway was involved in oncogenic Ras signaling, 
but this pathway was PKCiota-independent as described below (Kampfer, 2001). Oncogenic 
Ras has been shown to induce transformation through several mechanisms, two of these 
mechanisms are (1) through the G1 phase of the cell cycle by myc (Murray, 1983) and cyclin 
D1 induction (Filmus, 1994; Lovec, 1994) and (2) by phenotypic changes due to alterations in 
cell-cell adhesion molecules, such as the Rho family: CDC42, Rac1, and RhoA, B, and G (Qiu, 
1995; Khosravi-Far, 1995; Prendergast, 1995; Qiu, 1995; Roux, 1997; Lebowitz, 1997) and by 
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actin stress fiber remodeling (Zohn, 1998; Ridley, 1992; Prendergast, 1993; Dartsch, 1994). 
PKCiota/ lambda has been linked to the Rho family members (CDC42 and Rac1), actin 
filament remodeling, and the induction of cyclin D1 (see below). 
 
Ras-PKCiota in Transformation-Cyclin D1 Induction- In HC11 mouse mammary epithelial cells, 
dominant negative mutants of PKCiota/ lambda (or PKCzeta) suppress Ras-induced cyclin D1 
expression, indicating that both PKCiota/ lambda and PKCzeta are essential for cyclin D1 
induction by oncogenic Ras. The induction of cyclin D1 was measured using a cyclin D1 
luciferase reporter assay. While PKCzeta induction of cyclin D1 is downstream of Raf-1, as in 
the case of c-fos induction, PKCiota/ lambda does not seem to be in the Raf-Mek pathway for 
cyclin D1 induction but rather in a pathway involving Rac1 (Hellbert, 2000). This is not 
surprising that the two pathways work separately in cyclin D1 induction. The cyclin D1 
promoter had already been shown to contain an Ets2 binding site (activated by the 
Raf/MEK/ERK pathway) in addition to an AP-1 site. PKCiota has been shown to activate AP-1 
(see “PKCiota-Signaling: NFκB” and “PKCiota-Signaling: AP-1” for details). 
In a separate study, in HC11 mouse mammary epithelial cells, through the use of a 
cyclin D1 luciferase reporter gene, Mwanjewe et al was able to show that PLD2 and PKCiota/ 
lambda cooperate in the transcriptional activation of cyclin D1 (Mwanjewe, 2001). 
 The study that disputed the findings of Bjorkoy et al (mentioned above) found that Ras-
PKCiota-Rac are in a different pathway than Ras-MEK-ERK. Specifically, transcriptional 
regulation of cyclin D1 by transforming Ras required two pathways, one PKCiota- dependent 
and one PKCiota-independent. By using constitutively active Ras, Raf, MEK, and a cyclin D1 
reporter gene, in HC11 mouse mammary epithelial cells, Kampfer et al found that PKCiota 
was not involved in Ras induction of cyclin D1 through the MEK-ERK pathway (however 
PKCzeta was required). By using constitutively active Ras, Rac, and a cyclin D1 reporter 
gene, PKCiota was found to be downstream of Ras but upstream of Rac. Interestingly, 
PKCzeta was found to be involved downstream of Rac (Kampfer, 2001). Thus, Ras 
transcriptionally activates cyclin D1 in a PKCiota-independent (HA-Ras ÆMEK-1 Æ ERKs Æ 
cyclin D1 transcription) pathway and a PKCiota-dependent (HA-Ras Æ PKCiota Æ Rac Æ 
cyclin D1 transcription) pathway. 
 
 
 
 
 
Figure 10: Ras-PKCiota in Transformation 
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Ras-PKCiota in Transformation- Cytoskeletal Reorganization- Ras, Rac, CDC42, PKCiota/ 
lambda, and PKCzeta all individually had been implicated in stress fiber loss and actin 
remodeling (Zhao, 1998; Uberall, 1999). Cells, which have undergone transformation have 
alterations, in their actin cytoskeleton, one of these alteration is a loss of stress fibers (Mackay, 
1998).  While Uberall et al linked Ras with PKCiota/lambda and PKCzeta, Coghlan et al linked 
Ras-CDC42-PKCiota/lambda in stress fiber loss. While Rac expression is able to cause stress 
fiber loss, this phenotype is through a different pathway than Ras-CDC42-PKCiota/ lambda 
pathway (Coghlan, 2000), a study that was contradicted by Uberall et al (Uberall, 1999). 
In NIH3T3 cells, ectopic expression of constitutively active CDC42 (V12 CDC42) led to 
a loss in stress fibers (Kozma, 1995). Coghlan et al was able to show that transient exogenous 
expression of PKCiota/ lambda (but not PKCzeta) was able to lead to the same loss of stress 
fibers observed in response to CDC42 overexpression. To show that PKCiota/ lambda was 
essential for CDC42-induced loss of stress fibers, kinase dead mutants of PKCiota/ lambda 
(KD PKCiota/ lambda) and PKCzeta (KD PKCzeta) were used to block CDC42-induced loss of 
stress fibers. The KD PKCiota mutant blocked CDC42- induced loss of stress fibers, but had 
no effect on CDC42- induced membrane ruffling or filopodia formation, indicating that while 
PKCiota/ lambda was essential for CDC42-induced loss of stress fibers, CDC42 induced other 
pathways independently of the PKCiota/ lambda or PKCzeta pathways. Because Rac-1 had 
also been implicated in loss of stress fibers, the KD PKC mutants were used to block loss of 
stress fibers in response to Rac. However, the KD PKC mutants were unable to block Rac-
induced loss of stress fibers. Uberall et al had published that Ras-induced loss of stress fibers, 
was not only dependent on PKCiota/ lambda and PKCzeta, but also dependent on Rac.  In 
contrast, Coghlan et al reported that, upon induction of NIH 3T3 cells with constitutively active 
Ras and either dominant negative CDC42 (N17 CDC42) or dominant negative Rac, only N17 
CDC42, but not dominant negative Rac, was able to block Ras-induced loss of stress fibers.  
Thus, according to Coghlan et al at least two pathways exist for loss of stress fibers in 
transformation, one pathway involving Ras- CDC42- PKCiota/ lambda and one involving Rac 
(independently of Ras or the atypical PKCs). It is important to note that Coghlan et al did not 
directly test the KD PKC mutants on transformation just on indicators of transformation (loss of 
stress fibers). 
CDC42 also exhibits PKCiota independent functions. While PKCiota/ lambda was 
linked to CDC42-induced loss of stress fibers, PKCiota/ lambda does not play a role in the 
 
 
90
previously published CDC42- induced JNK activation or Fos expression (Coso, 1995; Minden, 
1995; Chang, 1998; Kaneki, 1999; Coghlan, 2000).  
In NIH3T3 and COS fibroblasts, PKCiota/ lambda is essential for transforming RAS-
mediated disassembly of actin fibers. PI3K had already been shown to be necessary for Ras-
induced reorganization of the actin cytoskeleton (Rodriguez-Viciana, 1994). Upon addition of 
transforming Ha-RAS L61, re-organization of the cytoskeleton occurs. RAS activates PKCiota/ 
lambda, which in turn, activates PI3K/Rac-1, leading to disassembly of actin fibers. This role of 
PKCiota was demonstrated using both dominant negative PKCiota/ lambda (in the presence of 
transforming Ha-RAS L61) and constitutively active PKCiota/ lambda to mimic the effect of Ha-
RAS L61 on cytoskeleton remodeling. Likewise, PKCzeta is involved in RAS-mediated 
cytoskeleton re-modeling, but unlike PKCiota/ lambda, PKCzeta acts downstream of 
PI3K/Rac-1 (Uberall, 1999). Thus, Ras signaling is involved in the remodeling of actin in a 
PKCiota-dependent (Ha-Ras L61 Æ PKCiota/ lambda Æ PI3K/Rac-1 Æactin remodeling) and 
PKCiota-independent (Ha-Ras L61 Æ PI3K/Rac-1 Æ PKC zeta Æ actin remodeling) manner. 
 
Ras-PKCiota in Transformation- Transcriptional Activation- Ras through PKCiota is able to 
increase transcription of several tumor promoting genes, such as MMP-3, cyclin D1, and c-
Fos. Transcriptional upregulation of tumor promoting genes, as well as alterations in the 
cytoskeleton are two of the ways Ras induces transformation through PKCiota. 
Ras through PKCiota transcriptionally activates MMP-3 (matrix metalloproteinase 3), 
which is involved in breakdown of the extracellular matrix (leading to invasion into surrounding 
tissue as well as metastasis). In NIH3T3 human fibroblasts, PDGF signaling (as measured by 
induction of the human stromelysin-1 (MMP-3) gene) was affected by PKCiota in a RAF-
independent fashion (Kirstein, 1996). Specifically, MMP-3 transcriptional regulation was 
through two elements on the promoter, a PEA3-AP-1 element and a SPRE-AP-1 element. Raf, 
in a PKCiota-independent manner activated MMP-3 transcription through the PEA3-AP-1 
element according to the pathway: PDGF Æ RAS Æ 1) RAF (PEA3-AP-1 Element) Æ MMP-3 
transcriptional activation, while PKCiota in a Raf-independent manner activated transcription of 
MMP-3 through the SPRE-AP-1 element according to the pathway: PDGF Æ RAS Æ PKCiota 
(SPRE-AP-1 Element) Æ MMP-3 transcriptional activation (Kirstein, 1996). 
 Similar to the transcriptional activation of MMP-3, Ras through PKCiota is able to 
transcriptionally up-regulate c-fos, a tumor-promoting transcription factor. Transforming Ras 
had already been shown to induce c-fos expression (Stacey, 1987). Like MMP-3 
transcriptional up-regulation occurs through two pathways, a PKCiota-dependent pathway and 
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a Raf/PKCzeta-dependent pathway. Using a series of PKCiota/ lambda antisense, dominant 
negative, kinase defective, and constitutively active mutants in HC11 mouse mammary 
epithelial cells, both PKCiota/ lambda and PKCzeta were shown to be necessary for 
transcriptional activation of c-fos by Ha-Ras. The pathway seems to be Ras Æ PKCiota/ 
lambda Æ c-fos transcriptional activation. However, the Raf/PKCzeta pathway appears to be 
Ras Æ Raf-1 Æ MEK Æ PKCzeta (but not PKCiota/ lambda) Æ c-fos transcriptional activation 
(Kampfer, 1998). This implies that PKCiota/ lambda and Raf/PKCzeta are autonomous in their 
roles in c-fos activation.  
Ras leads to co-localization of PKCiota with CDK9/cyclin T1, which is implicated in 
RNA transcription through phosphorylation of RNA polymerase II.  Oncrasin-1 (an inhibitor of 
mutant Ras (Guo, 2008)) works by inhibition of the phosphorylation of RNA polymerase II and 
causes PKCiota to coaggregate with splicing factors into what are known as 
“megaspliceosomes”, which are involved in pre-mRNA processing. Interestingly, PKCiota 
forms a complex with CDK9/cyclin T1, which is the complex involved in the phosphorylation of 
RNA polymerase II. The PKCiota/CDK9/cyclin T1 complex is disrupted by oncrasin-1 in vitro, 
thus resulting in a decrease in RNA polymerase II phosphorylation (Guo, 2009). Therefore, 
PKCiota is likely involved in RNA processing through splicing and transcriptional activation.  
 The role of PKCiota in transcriptional activation has been addressed in several studies. 
For example, using meta-analysis of lung adenocarcinomas (LACs), Erdogan et al found that 
PKCiota expression correlated with COPB2, ELF3, RFC4, and PLS1 expression. By use of 
RNAi to silence either PKCiota or any of these four other genes, Erdogan found that PKCiota 
controlled the expression of these four genes (as determined by qRT-PCR), possibly 
accounting for some of the ability of PKCiota to drive tumorigenesis (Erdogan, 2009). More 
research needs to be done to determine the exact role of these four genes in PKCiota-driven 
tumorigenesis.    
 
Ras-PKCiota in Lipid Signaling- PKCiota/ lambda is involved in lipid signaling. In HC11 mouse 
mammary epithelial cells, through the use of the atypical PKC specific inhibitor, Ro-31-8220, 
PKCiota was identified in Ras-mediated phospholipase D (PLD) signaling. PLD is an important 
enzyme which is necessary for hydrolysis of membrane phospholipids in the generation of 
phosphatidic acid (PA), a signaling lipid and precursor for DAG (diacylglycerol), which is 
involved in the recruitment of cytosolic signaling proteins to the plasma membrane. Through 
transfection experiments, the order Ras Æ PLD1b Æ PKCiota/lambda Æ PLD2 was 
established (Mwanjewe, 2001). Thus, PKCiota plays an active role in lipid signaling. 
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 From the literature analyses done here, one can conclude that PKCiota is necessary 
for Ras –induced transformation by induction of cyclin D1 (resulting in an increase in 
transformed growth), transcriptional activation of genes involved in invasion and tumor-
promotion (such as MMP-3 and c-fos), and cytoskeletal changes (such as loss of stress 
fibers). While these factors taken together could result in transformation, we have found that 
another protein, cyclin E, appears to be a downstream effector molecule in PKCiota-induced 
transformation. Using a rescue of PKCiota knockdown by addition of exogenous cyclin E (EL 
and LMW-E), we found that cyclin E is necessary for PKCiota-induced transformation. The 
next few questions could be: which pathway is PKCiota/cyclin E involved in (expression of 
cyclin D1, MMP-3, or c-fos) or, is cyclin E affecting cytoskeletal organization? Or rather, is 
there another pathway that PKCiota/cyclin E is in that is resulting in the transformed 
phenotype?  Clinically, the question remains if inhibition of Ras, PKCiota, or cyclin E or any 
combination of these oncogenes result in a synergistic decrease in transformed growth in 
vivo? 
 
SIGNALING: NFκB 
NFκB (Nuclear Factor Kappa-light-chain-enhancer of activated B cells) is a 
transcription factor involved in immune response. However, in cancer cells, NFκB is linked to 
survival due to its ability to transcriptionally activate anti-apoptotic genes, thereby suppressing 
apoptosis.  There are of course exceptions. For example, while in epithelial cells NFκB (and 
PAR-6) are involved in survival and chemoresistance, in the stromal compartment, the 
expression of NFκB (and PAR-6) is correlated with a favorable prognosis (Al-Saad, 2008). 
However, overall, NFκB expression leads to survival, an autocrine feedback response, and 
chemoresistance of tumor cells. 
 
Mechanism of PKCiota Activation of NFκB 
Many different laboratories have shown that PKCiota leads to activation of NFκB 
through the pathway (see Figure 11): 
 
 
 
 
Figure 11: Mechanism of PKCiota Activation of NFκB 
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Mechanism of PKCiota Activation of NFκB-TNFα 
Diaz-Meco found that PKCiota (but not PKCzeta) led to the activation of NFκB through 
its interaction with LIP (Lambda Interacting Protein). In both Cos and NIH3T3 cells, 
PKCiota/lambda exogenous expression led to activation of NFκB, which was decreased by a 
dominant negative isoform (pseudosubstrate domain) of PKCiota/lambda. Exogenous LIP, 
which binds specifically to PKCiota/lambda, led to κB- dependent promoter activation similar to 
that of TNFα. The activation of κB promoter, which indicated activation of NFκB, was 
increased upon co-transfection with the PKCiota/ lambda expression construct and decreased 
upon co-transfection with the kinase dead PKCiota/lambda expression construct. The 
decrease in LIP-induced, κB-dependent promoter activity was not observed upon co-
transfection with a kinase dead form of PKCzeta (Diaz-Meco, 1996). However, eventually, 
PKCzeta was shown to phosphorylate and activate IKKβ, which in turn phosphorylated IкB, 
leading to its degradation, causing a release of cytoplasmic NFкB, allowing NFкB to 
translocate to the nucleus, where it is active (Lallena, 1999). Thus, implying both atypical 
PKCs possess the ability to activate NFκB. 
In another study, using a dominant negative form of PKCiota/lambda in 293 cells, Sanz 
et al was able to link both PKCiota/lambda and PKCzeta to NFκB transcriptional activation 
through the interaction of PKCiota/lambda or PKCzeta with RIP and p62. PKCiota/ lambda 
was not able to bind directly to RIP. Using a series of in vitro and in vivo binding assays, p62 
was shown to bind to RIP, which is a known molecule in the TNFα to NFκB pathway. The 
dominant negative PKCiota/lambda construct inhibited RIP- induced NFκB activation. 
PKCiota/lambda, p62, and RIP all must be present in a complex in order for PKCiota/lambda 
to activate IKKβ and therefore activate NFκB. Therefore, while p62 links RIP to PKCiota/ 
lambda, PKCiota/ lambda links p62 to IKKβ. Thus, TNFα Æ TNFR1Æ TRADD Æ 
RIP/p62/aPKCs (independent of TRAF2)Æ IKKβ Æ Degradation of IκB Æ NFκB (activation/ 
nuclear translocation) (Sanz, 1999). 
As mentioned, PKCiota is able to lead to NFκB activation through p62 interaction in 
response to TNFα. Conversely, the TNFα pathway is also able to activate PAR-4, whose 
expression inhibits the TNF Æ PKCiota/p62 Æ NFκB pathway by binding and sequestering 
PKCiota. Thus, TNFα can induce apoptosis (PAR-4) or survival (NFκB) (Diaz-Meco, 1999). 
PAR-4 has been deleted in some cancers (Cook 1999), tipping the balance toward survival. 
Similarly, Ras has been shown to inhibit PAR-4, also leading toward survival (Berra, 1993). In 
NIH-3T3 mouse fibroblasts, upon TNFα induction, pro-apoptotic PAR-4 expression inhibits 
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translocation of NFκB and therefore inhibits the transcription of кB in response to TNFα. PAR-
4 is able to inhibit TNFα-induced survival and cause apoptosis by binding PKCiota/lambda and 
PKCzeta and inactivating their kinase activity. Therefore, addition of constitutively active 
atypical PKCs revert the effects of exogenous PAR-4 expression, causing complete loss of 
apoptosis in response to TNFα (Diaz-Meco, 1999). Thus, a switch is implicated in NFκB 
activation by TNFα between the PKCiota-binding partners, p62 (survival) and PAR-4 
(apoptosis). 
 The TNFα pathway leads to NFκB activation through the pathway: TNFα Æ TNFR1Æ 
TRADD Æ RIP/p62/aPKCs (independent of TRAF2)Æ IKKβ Æ Degradation of IκB Æ NFκB 
(activation/ nuclear translocation) (Sanz, 1999). While this pathway is the consensus, several 
other pathways have been observed in PKCiota activation of NFκB. Anthonsen et al found that 
both inflammatory cytokines TNFα and IL-1β led to NFκB activation through the TNFα/IL-1β Æ 
PI3K Æ PKCi Æ cPLA2 Æ NFκB and TNFα/IL-1β Æ snpPLA2 Æ P-PKCi Æ P-cPLA2 Æ NFκB 
pathways (Anthonsen, 2001). In human keratinocytes, HaCaT cells, Anthonsen et al found that 
by using a pseudo-substrate inhibitor to the atypical PKCs, TNFα/IL-1β induced cPLA2 
phosphorylation, arachidonic acid release, and NFκB activation were all decreased. In NIH3T3 
cells, the role of PKCiota/ lambda in activation of cPLA2 and arachidonic acid release in 
response to TNFα/IL-1β was validated by use of a PKCiota/ lambda kinase-dead mutant to 
block response to TNFα/IL-1β. Interestingly, blocking PI3K activity also blocked PKCiota 
activation and TNFα/IL-1β induced NFκB activation. Thus, PKCiota is involved in TNFα/IL-1β-
induced activation of NFκB via two unique mechanisms (Anthonsen, 2001). 
 
Mechanism of PKCiota Activation of NFκB-NGF- Upon stimulation by NGF (nerve growth 
factor), PKCiota is implicated in several other pathways for NFκB activation, some leading to 
survival and some leading to differentiation (Wooten, 2000). NGF activation of NFκB will be 
covered in detail below in the section on NGF signaling.  
 
Discrepancies in NFκB Regulation by PKCiota- While PKCiota activates NFκB in some cells, 
PKCzeta activates NFκB in other cell lines, yet sometimes NFκB activation is completely 
independent of the atypical PKCs, even upon addition of the same stimulus (TNFα in these 
cases).  
In NIH3T3 (mouse embryonic fibroblasts) and Jurkat (immortalized T-lymphocytes) but 
not MCF7 (epithelial breast cancer) cells, PKCiota/ lambda is involved in NFκB transcriptional 
activation in response to TNFα (in NIH3T3 and Jurkat cells) and IL-1β (in NIH3T3 cells). In the 
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TNFα and IL-1β pathways, PKCiota/lambda is necessary but not sufficient to activate NFκB. In 
MCF7 cells, TNFα was able to activate PKCiota/ lambda and thus AP-1 but not NFκB, 
indicating that the role of PKCiota/ lambda in NFκB activation is cell type specific (Bonizzi, 
1999). In these two cell lines, PKCiota is necessary but not sufficient to activate NFκB 
(exogenous dominant negative (dn) PKCiota blocked NFκB activation but wild type (wt) 
PKCiota did not lead to its activation). Note: The dominant negative used in these experiments 
might also inhibit PKCzeta.  
Similarly, in A549 lung cancer cells, exogenous expression of wild type or kinase dead 
PKCiota did not alter the level of NFκB expression upon TNFα stimulation. Although, TNFα 
expression did still cause an increase in the levels of phospho-IκBα. Thus, in A549 cells, the 
regulation of NFκB by TNFα was independent of PKCiota status (Regala, 2005). 
In activation of NFκB in prostate cancer cells by stimulation with TNFα, the role of 
PKCiota is unclear. In three different prostate cancer cells, three different responses were 
seen in PKCiota activation. For example, in LNCaP cells, PKCiota did not phosphorylate 
IKKαβ, a protein that upon phosphorylation gets degraded allowing NFκB to translocate to the 
nucleus. However, in DU-145 cells, PKCiota was able to phosphorylate IKKαβ. However, in 
RWPE-1 cells, the kinase responsible for IKKαβ phosphorylation is PKCzeta. Thus, the role of 
PKCiota in the activation of NFκB in response to TNFα is not well defined in prostate cancer 
cells (Win, 2008). Because all three of these studies were performed in the same laboratory, it 
is highly unlikely that lab variation (such as different conditions or different reagents) is the 
reason for these discrepancies in PKCiota phosphorylation of IKKαβ in the prostate model. 
PKCiota and PKCzeta exhibit much functional redundancy, as specified earlier in regard to 
their overlapping roles and overlapping binding partners. Thus, there is no surprise that 
PKCzeta is the active kinase in RWPE-1 cells. I speculate that the reason for these 
discrepancies is more likely due to the differences in the levels of PKCiota and PKCzeta in 
these prostate cancer cell lines. For example, I would hypothesize that PKCiota levels are high 
in DU-145 cells, PKCzeta is high in RWPE-1 cells, and another kinase other than atypical PKC 
is high in the LNCaP cells, thus overriding the ability of PKCiota or PKCzeta to phosphorylate 
IKKαβ. Another explanation could be that one or all of the kinases that would usually 
phosphorylate IKKαβ is low in the DU-145 and RWPE-1 cell lines but not in the LNCaP cell 
line.  I believe that PKCiota and PKCzeta are able to phosphorylate IKKαβ, but only under 
altered conditions, such as overexpression of PKCiota or PKCzeta. 
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NFκB and Autocrine Response- PKCiota regulation of NFκB can also stimulate an autocrine 
response, leading to increased tumor cell proliferation and survival. In an early study, PKCiota 
was found to be in a signalsome with TRAF6, p62, and IKK through a series of 
immunoprecipitations in response to Thymosin alpha 1 (Ta1), a treatment of cancer in clinical 
trials which acts on both T-helper and NK-cells and alters hormone regulation in the 
hypothalamus. Ta1 was used in this situation to stimulate an immune response. This induction 
of the signalsome led to IL-6 expression through NFκB according to the pathway: Thymosin 
alpha 1 (Ta1) Æ TRAF6/p62/PKCiota/zeta/ IKK Æ NFκB Æ IL-6 (Zhang, 2005). 
 Similarly, in a prostate cancer model, PKCiota expression led to induction of an 
autocrine response through increased expression of IL-6, resulting in STAT3 phosphorylation/ 
activation and thus proliferation. PKCiota increased the expression of IL-6 through 
upregulation of the two transcription factors, AP-1 and NFκB (Ishiguro, 2009). PKCiota had 
previously been shown to activate AP-1 (see below) (Huang, 1996; Huang, 1997; Bonizzi, 
1999; Huang, 2000). Thus, not only is NFκB activation PKCiota dependent, but it can stimulate 
IL-6 production in an autocrine manner (see Figure 12). 
 
 
 
 
 
 
 
Figure 12: PKCiota-Induced IL-6 Autocrine Signaling 
 
 
 
 
 
 
 
 
98
 
 
99
 
NFκB and Chemoresistance- Chemoresistance, which is the resistance of a tumor to 
chemotherapy, to Taxol in Bcr-Abl positive human erythroleukemia K562 cells is mediated via 
a PKCiota/NFκB-dependent mechanism. In cells that do not contain Bcr-Abl or K562 cells that 
have been treated with the Bcr-Abl inhibitor AG957, Taxol treatment did not lead to 
chemoresistance. Also, treatment with Taxol in the presence of antisense or kinase-dead 
PKCiota did not lead to chemoresistance. Lastly, treatment of Taxol in the presence of NFκB 
inhibition (by blocking IκB degradation) also did not lead to chemoresistance (Lu, 2001). Thus 
PKCiota and NFκB are both necessary for Bcr-Abl induced chemoresistance to Taxol. 
PKCiota regulation of NFκB via phosphorylation of IKKβ has already been established 
(Diaz-Meco, 1996; Sanz, 1999; Diaz-Meco, 1999). Lu et al showed that in addition to the 
regulation of IKKβ by PKCiota, overexpression of a constitutively active PKCiota resulted in an 
increase in the transcription of RelA, a component of the NFκB complex. Thus, NFκB 
regulation in response to Bcr-Abl is through the pathway: Taxol Æ Bcr-Abl Æ PKCiota Æ 
NFκB (due to IκB degradation and RelA transcriptional up-regulation) Æ Survival 
(transcriptional activation of anti-apoptotic genes). Similarly, kinase-dead PKCiota partially 
blocked the transcription of RelA (Lu, 2001). Thus, PKCiota activates NFκB by two 
mechanisms, (1) phosphorylation of IKKβ and (2) transcriptional activation of RelA. Therefore, 
Bcr-Abl is capable of mediating survival in response to Taxol in a PKCiota/ NFκB dependent 
manner. Thus, PKCiota regulation of NFκB due to Bcr-Abl expression induces Taxol-
resistance in CML. 
The study of PKCiota in NFκB has been very extensive. However, as you read, there 
are as many studies indicating PKCiota does influence NFκB as there are studies showing 
PKCiota does not influence NFκB. There are many possible explanations and potential 
reasons for these discrepancies. For example, earlier I mentioned the switch between the two 
PKCiota binding partners, p62 (which leads to survival through PKCiota activation) and PAR-4 
(which leads to cell death through inhibition of PKCiota). Without any fluctuation in PKCiota 
levels, the outcome could be due to the levels of p62 versus PAR-4. Or, if either p62 or PAR-4 
is mutated in that particular cell line, this too could tip the balance of survival versus apoptosis 
in regard to PKCiota activation. Another possible explanation could be through a threshold 
effect of PKCiota activity. If a limiting factor other than PKCiota is limiting PKCiota activity, an 
increase in PKCiota levels would be unable to cause an increase in PKCiota phosphorylation 
and thus unable to cause an increase in NFκB activation. Because a cell contains so many 
regulators of different pathways, other regulators of NFκB would also need to be considered 
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as variables within any given experiment. In closing, I believe that PKCiota does indeed alter 
NFκB activation. However, many other variables need to be considered, including, but not 
limited to, p62 and PAR-4 status.  
 
SIGNALING: AP-1  
 Activation of PKCiota has been show to lead to AP-1 induction. AP-1 is a heterodimeric 
transcription factor composed of c-fos, c-jun, or ATF (activating transcription factor) family 
members. Many studies have been performed using UV (ultraviolet) radiation as a means for 
induction of AP-1. Thus, this dissertation will examine the role of PKCiota in UV-induced AP-1 
activation. 
 As mentioned, AP-1 can be composed of c-fos and c-jun family members. Thus, this 
section will also review the effect of PKCiota on c-fos and c-jun induction. 
 
PKCiota Regulates AP-1 Induction 
 PKCiota is able to activate AP-1 in various model systems through stimuli such as: 
high glucose, PDGF, Ras, or TNFα (Kirstein, 1996; Huang, 1996; Huang, 1997; Bonizzi, 1999; 
Huang, 2000; Hellbert, 2000; Chuang, 2003). Several studies have been performed examining 
the transcriptional upregulation of various genes through AP-1 activation, including: TbetaRII 
(type II transforming-growth-factor-beta receptor), IL-6 (Interleukin-6), cyclin D1, MMP-3 
(matrix metalloproteinase 3), and collagenase gene induction (leading to MMP-1 activation- 
this one will be covered in the c-fos portion of this section) (see Figure 13).  
In the presence of high glucose, in MDCK cells, PKCiota gets translocated into the 
cytosolic fraction, where it becomes activated. Activated PKCiota is able to lead to AP-1 
activation, which leads to AP-1 transcriptional activation of TbetaRII (type II transforming-
growth-factor-beta receptor) (Chuang, 2003).  
PKCiota increased IL-6 expression through activation of the two transcription factors, 
AP-1 and NFκB, which in turn created an autocrine response leading to tumor growth and 
survival (Ishiguro, 2009). 
Oncogenic Ras stimulation led to an increase in cyclin D1 expression through the Ras-
PKCiota-Rac-PKCzeta -AP-1 pathway (Hellbert, 2000). Ras also transcriptionally activates 
MMP-3 (matrix metalloproteinase 3), through the PDGF Æ RAS Æ PKCiota (SPRE-AP-1 
Element) Æ MMP-3 transcriptional activation pathway (Kirstein, 1996) (see “PKCiota- 
Signaling: Ras” section for more details about cyclin D1 and MMP-3 transcriptional 
upregulation through AP-1 and the implications on transformation). 
 
 
 
Figure 13: Mechanism of AP-1 Regulation by PKCiota 
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UV-Induced AP-1- AP-1 is necessary for cellular transformation in JB6 cells. Activation of AP-1 
by TPA was originally shown to be through EGF (Dong, 1994). In JB6 P+ C1 41 mouse 
epidermal cells, dominant negative expression of PKCiota/ lambda resulted in reduced UVB-
induced AP-1 activity (Huang, 1996). In the case of UVB-induced activation of AP-1, activation 
appears to be independent of EGF, but dependent on PKCiota (Huang, 1996). Similarly, in 
JB6 (mouse epidermal) and B82 (mouse fibroblast) cells, dominant negative expression of 
PKCiota/ lambda resulted in reduced UVC-induced AP-1 activity (Huang, 1997).  
 Examining the mechanism of UV-induced AP-1 activation through PKCiota revealed 
that, while AP-1 induction can be through ERK, JNK, or p38 kinase activation, the UV-induced 
activation of AP-1 by PKCiota/ lambda appears to be through ERK in JB6 cells (Huang, 2000). 
 
PKCiota Regulates c-fos Induction- Upon induction with IL-1 (Interleukin-1), PKCiota through 
the ERK/STAT3 pathway has been demonstrated in c-fos activation. This activation of c-fos, 
by IL-1 results in an increase in collagenase expression, leading to activation of MMP-1 
(matrix metalloproteinase 1) according to the pathway: IL1 Æ PKCiota Æ ERK/STAT3 
phosphorylation Æ c-fos expression  Æ collagenase gene induction Æ MMP1 (Litherland, 
2010) (see “PKCiota- Functions: Inflammation” for details). 
Ras through PKCiota is able to transcriptionally up-regulate c-fos, a tumor-promoting 
transcription factor. Transforming Ras had already been shown to induce c-fos expression 
(Stacey, 1987). The PKCiota-dependent pathway seems to be Ras Æ PKCiota/ lambda Æ c-
fos transcriptional activation. However, the PKCiota-independent pathway appears to be Ras 
Æ Raf-1 Æ MEK Æ PKCzeta (but not PKCiota/ lambda) Æ c-fos transcriptional activation 
(Kampfer, 1998). This implies that PKCiota/ lambda and Raf/PKCzeta are autonomous in their 
roles in c-fos activation.  
 
PKCiota Regulates c-jun Induction 
Upon EGF-stimulation, PKCiota through its binding to MEK5 is able to induce c-jun, a 
component of the AP-1 transcription factor. PKCiota/ MEK5 binding is required for EGF 
activation of ERK5; yet MEK5 is not phosphorylated by PKCiota. While exogenous expression 
of PKCiota, both wild type and kinase dead, resulted in an increase in Jun promoter activity, as 
determined by a Jun-luciferase report gene, dominant negative forms of aPKC and MEK5 
inhibited Jun promoter activity. Thus, EGF stimulation of PKCiota/zeta and MEK5 binding is 
required for activation of ERK5 and subsequently Jun transcription in the EGF Æ PKCiota Æ 
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MEK5/ERK5 Æ Jun (transcriptional activation through the MEF2C element) pathway (Diaz-
Meco, 2001). 
PKCiota is able to regulate AP-1 (c-jun and c-fos) in response to several stimuli, 
including: high glucose, PDGF, Ras, TNFα, UVB and UVC, IL1, and EGF. This regulation of 
AP-1 by PKCiota results in transcription activation of many genes involved in tumorigenesis: 
cyclin D1 (transformed growth and proliferation), MMP-3 and collagenase (invasion and 
metastasis), and NFκB (survival and chemoresistance). Because the ability of PKCiota to 
transcriptionally activate so many stages of tumorigenesis, from initial transformation of the 
primary lesion to invasion, metastasis, and survival, this provides sufficient rationale for 
PKCiota to be targeted therapeutically in cancer independently of the other roles of PKCiota in 
tumorigenesis. Because tumors are heterogeneous and often self-sufficient in growth signals, 
blocking PKCiota activation could lead to tumor cell death through sensitization of the tumor 
cells to chemotherapy by blocking growth (cyclin D1) and survival (NFκB). PKCiota inhibition 
could also be used as a means of preventing metastasis (MMP-3 and collagenase). Thus, 
PKCiota, through its activation of AP-1, provides rationale for the use of PKCiota inhibitors in 
clinical trials.   
 
SIGNALING: INSULIN/ GLUT4 TRANSLOCATION 
PKCiota is involved in insulin-induced GLUT4 (a glucose transport molecule) 
translocation and glucose uptake. This particular role of PKCiota is important for reasons 
regarding diabetes and insulin resistance. While PKCiota is amplified in cancer, decreased 
PKCiota can lead to deregulation of the glucose transport pathway that is found in diabetes. 
For example, a muscle-specific knockout in mice of PKCiota/lambda resulted in reduced 
glucose transport (through decreased GLUT4 translocation to the plasma membrane), as well 
as “systemic insulin resistance, impaired glucose tolerance or diabetes, islet beta cell 
hyperplasia, abdominal adiposity, hepatosteatosis, elevated serum triglycerides, FFAs (free 
fatty acids), and LDL-cholesterol, and diminished HDL-cholesterol” (Farese, 2007).  Similarly, 
a decrease in PKCiota in muscle resulted in insulin-resistance in humans (Farese, 2007; 
Beguinot, 2008). Also, insulin-resistant type 2 diabetic patients exhibited reduced PI3K and 
PKCiota activation in response to insulin (Bandyopadhyay, 2005). Thus, PKCiota plays a vital 
role in insulin-induced glucose transport (see Figure 14). 
Reducing the levels of PKCiota expression, which would ideally occur upon treatment 
of cancer patients with PKCiota inhibitors, could then results in an onset of diabetic concerns: 
such as insulin resistance, glucose tolerance, increases in triglycerides, FFAs, and LDL 
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cholesterol, diabetes, or similar issues. Therefore, complications of PKCiota-targeted 
treatment of cancer arise. Thus, treatment of cancer with any type of PKCiota inhibitor should 
be short-term, in order to sensitize the cancer cells to other chemotherapeutics, rather than 
long-term treatment which could result in diabetes-related issues. 
 
Insulin-Stimulated Glucose Transport- Mechanism 
 Several laboratories using different model systems have identified PKCiota-dependent 
and PKCiota-independent mechanisms for insulin-induced GLUT4 (a glucose-transported 
protein) translocation and glucose uptake. GLUT4 translocation refers to the movement of 
GLUT4 from the perinuclear compartment to the plasma membrane (cell surface). Overall, a 
majority of the studies indicate PKCiota is necessary for insulin-induced GLUT4 translocation, 
but several laboratories have found that AKT is the molecule responsible for this translocation.  
Thus, the PKCiota- dependent mechanism and the discrepancies in this mechanism will be 
covered in the Discrepancies in PKCiota’s Role in Insulin-Stimulated Glucose Transport 
section below. For the most part, two pathways have been identified for insulin-stimulated 
glucose transport, which may or may not overlap (one PKCiota-dependent, one AKT-
dependent; but both PI3K-dependent):   
  
 
 
Figure 14: Mechanism of Insulin-PKCiota Stimulated Glucose Transport 
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Two distinct pathways: 
Insulin- stimulated GLUT4 uptake occurs via two pathways, PI3KÆPKCiota and 
PI3KÆAKT. PKCiota as a downstream effector in the PI3K-PDK1 pathway had already been 
studied quite meticulously (Chou, 1998; Akimoto, 1998; Standaert, 1999; Kanoh, 2003). Using 
3T3-L1 adipocytes, insulin was used to stimulate the PI3K pathway. With both exogenous 
dominant negative and constitutively active forms of PKCiota/lambda, PKCiota/lambda was 
demonstrated to be involved in insulin-stimulated glucose uptake as well as the translocation 
of GLUT4 to the plasma membrane. While PI3K also stimulates AKT upon insulin stimulation 
in adipocytes, these two pathways (PI3K Æ AKT and PI3K Æ PKCiota/ lambda) appear to be 
distinct non-overlapping pathways in 3T3-L1 adipocytes (Kotani, 1998). However, contrary to 
Kotani et al, in L6 myotubes, Bandyopadhyay et al showed that PKCiota was necessary for 
AKT-dependent, insulin-induced glucose uptake (Bandyopadhyay, 2000). Thus, PKCiota and 
AKT may or may not be in the same pathway in insulin-stimulated GLUT4 translocation. 
Cbl, which is phosphorylated by the insulin receptor in response to insulin stimulation, 
activates PI3K and subsequently glucose transport. Mutation of Cbl at the pYXXM motif 
prevents glucose transport. Specifically, mutation of Cbl at the pYXXM motif inhibited 3T3-L1 
adipocyte response to insulin by blocking binding of Cbl to PI3K, activation of PI3K, 
activation/translocation of PKCiota/ lambda to the plasma membrane, GLUT4 translocation to 
the plasma membrane, and thus glucose transport. Thus, Cbl binding to PI3K is necessary for 
insulin-induced glucose transport through the PKCiota/ lambda/GLUT4 pathway (Standaert, 
2004). 
The activation of PKCiota/ lambda and PKCzeta in response to insulin requires PIP3 
(phosphatidylinositol-3,4,5-(PO4)(3)) and PDK-1 phosphorylation at the activation loop sites. 
The phosphorylation of PKCiota/ lambda by PDK-1 leads to PKCiota/ lambda activation and 
subsequently autophosphorylation. Activated PKCiota/ lambda in response to insulin can then 
lead to the translocation of GLUT4 to the plasma membrane (Standaert, 1999). Kanoh et al 
also found that PKCiota activation by insulin-stimulated PI3K requires PIP3 in an in vivo rat 
model (Kanoh, 2003). Thus, PDK1 and PIP3 are likely required in the insulin-PI3K-PKCiota-
GLUT4 pathway.  
 CDC42, one of the PKC-iota many binding partners, is also involved in the insulin-
PI3K-PKCiota/ lambda-GLUT-4 transport pathway (Insulin Æ PI3K/CDC42 Æ PKCiota/ 
lambda Æ GLUT4 translocation Æ glucose uptake). By use of CDC42 antibody (to block 
activity) and constitutively active (CA) CDC42 (to activate it) in 3T3-L1 adipocytes, CDC42 was 
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examined in response to insulin induction. CDC42 is involved in the insulin response through 
direct interaction with PI3K. However, PI3K inhibitors, wortmannin and LY294002, block CA-
CDC42 induced GLUT4 translocation to the plasma membrane. Also, inhibition of PKCiota/ 
lambda by microinjection of PKCiota/ lambda antibody and a kinase dead mutant resulted in a 
block of both insulin and CA-CDC42 induced GLUT4 transport. Thus, insulin Æ PI3K/CDC42 
ÆPKCiota/ lambda are all in the same GLUT4 translocation pathway that leads to glucose 
uptake (Usui, 2003). 
Downstream from PKCiota in the insulin-PI3K-PKCiota-GLUT4 pathway, Rab4, a small 
GTPase-binding protein, and KIF3, the motor protein kinesin, are involved in GLUT4 
translocation.  Upon insulin stimulation of 3T3-L1 adipocytes, as visualized by photoaffinity 
labeling, Rab4 becomes activated, and this activated form of Rab4 binds KIF3. Upon binding 
to KIF3, the complex associates with microtubules, as determined by a microtubule capture 
assay. The interaction of Rab4 with KIF3 is necessary for insulin-stimulated GLUT4 
translocation via microtubule reorganization. The role of Rab4/KIF3 is dependent on PI3K/ 
PKCiota/ lambda activation by insulin. Rab4/KIF3 localization to the microtubules and 
subsequently GLUT4 translocation and exocytosis upon insulin stimulation was blocked by 
both a PI3K inhibitor, LY294002, and by ectopic expression of a dominant negative mutant 
PKCiota/ lambda (Imamura, 2003). Thus, Rab4 and KIF3 appear to have a role downstream of 
PI3K and PKCiota/ lambda in GLUT4 translocation and exocytosis.  
Okadaic acid (which inhibits protein phosphatase 1 and 2A) causes insulin-like effects, 
such as glucose transport and GLUT4 translocation. Much like insulin, in both 3T3/L1 and rat 
adipocytes, okadaic acid was used to stimulate the PI3K pathway. With ectopically expressed 
dominant negative PKCiota/ lambda, PKCiota/ lambda was demonstrated to be involved in 
okadaic acid-stimulated glucose uptake as well as the translocation of GLUT4 (Standaert, 
1999).  
GLUT1 translocation has also been examined in response to insulin. Bosch et al found 
that glucose uptake involved two pathways. While PKCiota/ lambda was required for GLUT1 
translocation to the plasma membrane, the MAPK pathway was required for GLUT1 
expression in 3T3-L1 adipocytes upon PMA treatment. Bosch found that PKCiota/ lambda co-
immunoprecipitated with PKCβII. However, PKCiota/ lambda needed to be released from 
PKCβII before it could lead to GLUT1 translocation and glucose uptake (Bosch, 2004).   
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Inhibition of PKCiota Inhibits GLUT4 Translocation 
Insulin has been shown to induce glucose uptake and GLUT4 translocation in a 
PKCiota/ lambda dependent manner. Kotani et al showed that overexpression of the atypical 
PKC binding protein, ASIP (PAR-3/Bazooka), was able to inhibit both insulin-induced and 
constitutively active PKCiota/ lambda-induced glucose uptake. Specifically, in 3T3-L1 
adipocytes, addition of insulin resulted in an increase in glucose uptake as well as an increase 
in the activity of PKCiota/ lambda, as indicated by use of an in vitro kinase assay using MBP 
as the substrate. The effects of insulin-induction on PKCiota/ lambda activation as well as on 
GLUT4 translocation and therefore on glucose uptake were reduced upon addition of 
exogenous PAR-3/ASIP in a dose-dependent manner, indicating that insulin works through 
PKCiota/ lambda signaling to induce glucose uptake. To test the specificity of insulin-induced 
glucose uptake, Kotani et al used two other methods of inducing glucose uptake, growth 
hormone (GH) and hyperosmolarity (sorbitol). However, PAR-3/ASIP did not block GH- or 
sorbitol- induced glucose uptake, indicating that inhibition of glucose uptake by PAR-3/ASIP is 
insulin and PKCiota/ lambda- specific. Interestingly, PAR-3/ASIP did not block all insulin-
induced signaling. For example, PAR-3/ASIP did not block the translocation of AKT to the PM 
fraction in response to insulin (Kotani, 2000). Thus, while PAR-3/ASIP blocks PKCiota/ 
lambda- and insulin-induced translocation of GLUT4 and therefore glucose uptake, PAR-
3/ASIP does not block all insulin signaling.  
 
Glucose Induction of GLUT4 Translocation 
In rat adipocytes and skeletal muscle, PKCiota/ lambda was activated in response to 
glucose induction. The activation of PKCiota/ lambda by glucose was PI3K independent. Upon 
glucose stimulation, the ERK pathway was activated along with phospholipase D, which lead 
to an increase in phosphatidic acid, and thus activation of PKCiota/ lambda (Bandyopadhyay, 
2001). This glucose/phospholipase D/ phosphatidic acid pathway resulted in the translocation 
of GLUT4 to the plasma membrane, similar to the PI3K-dependent insulin-induction of GLUT4 
translocation. Both pathways Insulin/PI3K and glucose/phospholipase D/ phosphatidic acid 
require PKCiota/ lambda for GLUT4 translocation.     
 
Transcriptional Repression 
Insulin stimulation has also been shown to lead to PKCiota-dependent and PKCiota-
independent transcriptional repression. Knockout of PKCiota/ lambda in beta pancreas cells in 
mice reveal that PKCiota/ lambda is important in glucose-stimulated insulin secretion. 
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However, this role of PKCiota seems to be through lack of gene expression of known insulin 
secretion genes. Thus, PKCiota/ lambda is involved in gene repression in response to insulin 
stimulation in pancreatic beta cells (Hashimoto, 2005; Yang, 2005).  
Addition of either metformin, an anti-diabetic drug, or insulin can lead to CREB binding 
protein (CBP) phosphorylation at Ser436 by PKCiota. This phosphorylation of CBP causes 
dissociation of the CREB-CBP-TORC2 complex, which is involved in the transcriptional 
activation of gluconeogenic enzymes. Thus, PKCiota is also able to cause a decrease in 
transcription of several gluconeogenic genes (He, 2009). 
While PKCiota is involved in insulin and PI3K signaling, another molecule besides 
PKCiota is involved in the transcriptional inhibition of PEPCK (phosphoenolpyruvate 
carboxykinase), an enzyme involved in gluconeogenesis, by insulin and PI3K. In HL1C (rat 
hepatoma) and 293 cells, PKCiota/ lambda dominant negative mutants were unable to revert 
the inhibitory effect of insulin on transcription of PEPCK (Kotani, 1999).  
Insulin Stimulated Glucose Transport Varies by Cell Type 
It seems that insulin-stimulated GLUT4 translocation can vary from cell type to cell 
type. In accordance with previous findings, PKCiota/ lambda-/- embryonic stem cells (ES) 
exhibit impaired glucose transport. PKCiota/ lambda-/- ES cells, which were made by 
recombinant DNA techniques, do not exhibit glucose transport in response to insulin unlike 
their PKCiota/ lambda+/+ counterparts. Also, ectopic expression of wild type PKCiota/ lambda 
in PKCiota/ lambda-/- ES cells reverted the insulin resistant phenotype. However, the effect of 
insulin on PKCiota/ lambda dependent glucose transport was not through PI3K, but rather 
dependent on TYK2 (tyrosine protein kinase 2), PLD (phospholipase D), and the ERK 
pathway, as determined by use of the PI3K inhibitor, wortmannin, the MEK1/ERK inhibitor, 
PD98059, and the PLD inhibitor, 1-butanol, on insulin stimulated glucose uptake and PKCiota/ 
lambda activation (Bandyopadhyay, 2004). Thus, PKCiota/lambda was essential for insulin-
stimulated glucose transport in embryonic stem cells. 
Surprisingly, differentiation of the ES PKCiota/ lambda-/- and PKCiota/ lambda+/+ cells 
into adipocytes revealed that PKCiota/ lambda activation in response to insulin was once 
again PI3K-dependent and independent of TYK2, PLD, and ERK. Similar to the PKCiota/ 
lambda-/- ES cells, PKCiota/ lambda-/- adipocytes also exhibited impaired glucose uptake upon 
insulin stimulation when compared to PKCiota/ lambda+/+ adipocytes, which was reverted upon 
ectopic expression of PKCiota/ lambda (Bandyopadhyay, 2004). Thus, PKCiota/ lambda is 
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required for insulin-induced glucose transport whether PI3K signaling is involved or not, as ES 
cells did not but adipocytes did require PI3K. 
As mentioned earlier in this section, in 3T3-L1 adipocytes, two distinct mechanisms 
(PI3K Æ AKT and PI3K Æ PKCiota/ lambda) appear to be non-overlapping pathways in 
insulin-stimulated glucose transport (Kotani, 1998). However, in L6 myotubes, Bandyopadhyay 
et al showed that PKCiota was necessary for AKT-dependent, insulin-induced glucose uptake 
(Bandyopadhyay, 2000). Thus, PKCiota and AKT are likely both involved in insulin-stimulated 
GLUT4 translocation but their roles are cell type specific. 
In a rat model system, Campbell et al found that the liver and muscle tissues exhibited 
different pathways upon IRS- phosphorylation by stimulation with DHEA (5-
Dehydroepiandrosterone), a naturally occurring steroid hormone. In the rat muscle, IRS-1 was 
tyrosine phosphorylated and the PI3K/PKCiota pathway was activated. However, in the rat 
liver, IRS-2 was tyrosyl phosphorylated and the PI3K/AKT pathway was activated. Activation 
of the AKT and PKCiota pathways were determined by western blot analysis with antibodies to 
the phospho (active) forms of these proteins (Campbell, 2004).  
Similarly, Miura et al found that both IRS1 and IRS2 were necessary for Cbl-PI3K 
binding and activation of the PKCiota/ lambda/ GLUT4 pathway. Miura’s study was performed 
in immortalized brown adipocytes (Miura, 2004). 
In both normal and high-fat fed rats, PKCiota/lambda, PKCzeta, and AKT become 
activated in response to insulin stimulation. However, only PKCiota/ lambda and PKCzeta get 
recruited to the plasma membrane upon insulin-induction in rodent skeletal muscle. However, 
this activation of PKCiota/ lambda, PKCzeta, and GLUT4 were all reduced in high fat fed rats 
as compared to the rats on a normal diet (Herr, 2005). Thus, many factors can affect insulin-
stimulated glucose transport. 
 
Discrepancies in PKCiota’s Role in Insulin-Stimulated Glucose Transport  
Besides the discrepancies mentioned in the “PKCiota- Signaling: Insulin/GLUT4- 
Insulin-Stimulated Glucose Transport Varies by Cell Type” section, others have shown that 
PKCiota is dispensable for glucose uptake. AKT was identified as the insulin-stimulated 
regulator of glucose uptake. While PKCiota and AKT are both activated by insulin, they appear 
to be in distinct pathways in 3T3-L1 adipocytes (Kotani, 1998). Also in 3T3-L1 adipocytes, 
PP2A was identified as being an inhibitor of insulin-induced glucose transport. While small t 
antigen, which induces glucose transport by inhibiting PP2A, was not able to activate glucose 
transport in the presence of dominant negative or AKT RNAi, dominant negative and PKCiota 
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RNAi had no effect on glucose transport. Thus, PP2A blocks glucose transport through its 
inhibition of the AKT pathway rather than through PKCiota inhibition (Ugi, 2004). 
Also, in fully differentiated 3T3-L1 adipocytes, using electroporation methods to 
transfect with various siRNAs, Zhou et al found that PKCiota was dispensable in insulin-
induced GLUT4 transport. However, AKT2 (and to a lesser extent AKT1) were necessary for 
insulin-stimulated GLUT4 transport (Zhou, 2004). Thus, PKCiota in these two particular 
studies was found to be dispensable for insulin-induced glucose transport. 
 
PKCiota in Glucose Transport and Uptake-Summary: Tumors exhibit upregulated metabolic 
activity compared to adjacent normal tissue. This principle is the basis of PET (Positron 
Emission Tomography) imaging, which measures glucose metabolism (and uptake), which is 
detectably higher in tumors. As mentioned, PKCiota plays an essential role in glucose 
metabolism, where in response to either insulin or glucose, PKCiota leads to GLUT4 
translocation to the plasma membrane, resulting in glucose uptake, which is necessary to 
generate energy (in the form of ATP- adenosine triphosphate) for cellular function. Because 
PKCiota is vital in this metabolic function and the metabolism is upregulated in tumors, 
inhibition of PKCiota should result in a decrease in tumor cell metabolism and growth, through 
inhibition of tumor cell glucose uptake. This would indicate PKCiota inhibition in tumors should 
result in a decrease in glucose uptake, resulting in the inability of tumor cells to generate ATP 
for cellular functions. In a way, PKCiota inhibition would result in starvation of tumor cells, 
which need high levels of glucose for survival. The role of PKCiota in metabolism is another 
testimony to the statement that PKCiota inhibitors should be considered for clinical trials for 
the treatment of cancer.  
 
SIGNALING: NGF (Nerve Growth Factor) 
PKCiota is involved in NGF signaling, particularly in NGF-induced differentiation, 
survival, and trafficking. In rat pheochromocytoma cells (PC12), which differentiate in response 
to NGF (nerve growth factor), PKCiota/ lambda is involved in both differentiation and survival 
via NFκB activation. More specifically, overexpression of PKCiota/lambda resulted in 
increased differentiation, neurite outgrowth, JNK activation, NFκB activation, and subsequent 
c-Jun phosphorylation in response to NGF stimulation, while antisense PKCiota/ lambda 
blocked NGF-induced NFκB activation (Wooten, 1999). As mentioned, upon NGF-stimulation, 
PKCiota through its binding to p62 is involved in (1) NGF-induced trafficking through its 
localization to the endosome, a vesicle formed for trafficking during endocytosis (Samuels, 
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2001) and (2) leads to survival via NFκB (Samuels, 2001; Wooten, 2005). Thus, redundancy in 
effector molecules occurs in NGF-stimulated PKCiota activation, leading to survival, 
differentiation, and trafficking (see Figure 15). 
 
NGF-PKCiota in Survival 
PKCiota plays a vital role in NGF-induced survival via activation of NFκB. PI3K was 
also required for NGF-induced survival (Yao, 1995). Particularly, induction of survival in PC12 
differentiated cells in response to NGF had been shown to be mediated by the atypical PKCs 
through NFκB (Wooten, 1999). PKCiota/ lambda had already been shown to be downstream 
of PI3K (Akimoto, 1996). Also, Wooten et al showed that while Ras was required for activation 
of Raf1 in response to NGF, both PI3K and PKCiota inhibitors had no effect on the activation 
of Raf1. Using an in vitro kinase assay, Wooten et al was able link PI3K and PKCiota to the 
Ras-Raf-MEK-MAPK cascade by showing that aPKC could directly phosphorylate MEK, and 
this phosphorylation required Src, PI3K, and aPKC. Ras and Src were tested using knockout 
PC12 cells, while PI3K and PKCiota were tested using the specific inhibitors PI3K inhibitors 
(wortmannin and LY294002) and PKCiota inhibitor (chelerythrine chloride). Using these same 
methods, they found that activation of JNK in response to NGF required Ras, Src, PI3K, and 
aPKC. Similarly, activation of NFκB (and therefore survival) required Src, PI3K, PKCiota, and 
JNK, but did not require Ras (Wooten, 2000). Thus the role of Ras in response to NGF is 
predominantly in differentiation, while Src, PI3K and aPKC are required for both NGF-induced 
differentiation and survival. 
While Src is able to lead to NGF-induced activation of PKCiota/NFκB, this function of 
Src is PI3K-independent. The PI3K and PKCiota inhibitors mentioned above had no affect on 
Src activity, indicating that Src regulation of aPKC is independent of PI3K. Using Src knockout 
PC12 cells, Wooten et al was able to find that PKCiota could only activate NFκB if Src was 
found in complex with PKCiota (Wooten, 2000). Similarly, in PC12 cells, PKCiota/ lambda was 
shown to interact with Src, leading to PKCiota/ lambda mediated activation of NFκB and 
consequentially survival. IKK and IκB were also in the Src- PKCiota/ lambda complex. Atypical 
PKC had been shown to associate with IKK and IκB to induce NFκB activation and nuclear 
translocation, and  Src had been found to be necessary to induce PKCiota activation of NFκB 
(Wooten, 2000). PKCiota had also been shown to be phosphorylated by Src. Specifically, in 
the PC12 cell line, upon NGF-treatment, PKCiota was phosphorylated by Src at three sites 
(Tyrosines 256, 271, 325-only 325 was important for the activation of NFκB) (Wooten, 2001). 
 
 
 
 
 
Figure 15: Mechanism of NGF-PKCiota Signaling 
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PKCiota is found to be in a signalsome in response to NGF. Through IP studies, 
PKCiota, along with p62, TRAF6, and IKK, was found to be in a signalsome, which led to IL-6 
expression via NFκB activation (Zhang, 2005). Similarly, NGF-stimulation results in assembly 
of the p62-TRAF6-IKKβ-PKCiota complex leading to NFκB expression. The role of p62 in the 
signalsome is to cause the polyubiquitination of TRAF6 (Wooten, 2005). Thus, PKCiota, 
through a series of interactions, leads to NGF-induced survival through NFκB activation.  
 
NGF-PKCiota in Differentiation 
PKCiota is also involved in NGF-induced differentiation. In PC12 rat 
pheochromocytoma cells, which are a well characterized model system for studying 
differentiation, induction with nerve growth factor (NGF) causes both differentiation and 
survival via Src and Ras (Kremer, 1991). NGF activation leads to the induction of the MAPK 
cascade (Kremer, 1991), p38 (Morooka, 1998), c-Jun N-terminal kinase (JNK) (Heasley, 1996; 
Minden, 1994), PI3K (Kimura, 1994), and the atypical PKCs (Coleman, 1994; Wooten, 1994). 
PKCiota activation in response to NGF had been measured using a kinase assay using MBP 
as the substrate. PKCiota activity due to addition of NGF was blocked using a series of PI3K 
inhibitors (wortmannin and LY294002) and PKCiota inhibitor (chelerythrine chloride) (Wooten, 
2000). Thus PKCiota is downstream of PI3K in NGF signaling. In PC12 cells, differentiation 
due to NGF had been shown to be mediated through Raf-1 (Wood, 1993), the MEK-MAPK 
cascade (Pang, 1995), PI3K signaling (Jackson, 1996; Kimura, 1994; Kobayashi, 1997), and 
through the atypical PKCs (Coleman, 1994). Using co-IP experiments, Wooten et al found that 
both Ras and Src associate with PKCiota. Thus, Ras, Src, and aPKC are required for NGF-
induced differentiation (Wooten, 2000).  
Because PKCiota had already been established in NGF-induced differentiation 
(Coleman, 1994), antisense p62 was used to determine the role of p62 in NGF-induced 
differentiation. Antisense p62 blocked NGF-induced neurite outgrowth, indicating PKCiota/ 
lambda binding to p62 is likely necessary for NGF-induced neurite outgrowth (Samuels, 2001). 
Thus, Ras, Src, p62, and aPKC are required for differentiation in response to NGF, and only 
Src, PI3K, p62, and aPKC are required for survival (via NFκB). 
 
NGF-PKCiota in Trafficking  
As summarized previously, upon NGF treatment, PKCiota/ lambda localizes with p62 
to the endosome, a vesicle formed during endocytosis, which is used for trafficking (Samuels, 
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2001). The endosome functions in (1) carrying either lipids or proteins or to the lysosome (from 
the plasma membrane), (2) carrying lipids/proteins to the golgi apparatus for decomposition, 
and (3) secreting lipids/proteins out of the cells.  
As demonstrated by IP assays in response to NGF in PC12 cells, PKCiota/ lambda 
bound p62 4-times higher than non-NGF stimulated cells, in spite of the fact that 
PKCiota/lambda and p62 levels remained unchanged.  Through kinetics experiments, 
PKCiota/ lambda was determined to first be tyrosine phosphorylated/ activated prior to p62 
binding. However, while tyrosine phosphorylation of PKCiota/ lambda was necessary for 
PKCiota/lambda-p62 binding, this phosphorylation was not necessary for the localization of 
p62 (alone) to the endosome, as determined by IF with antibodies against Rab7 (an 
endosomal marker) and validated by fractionation analysis. Therefore, upon NGF-stimulation, 
p62 localizes at the endosome, followed by tyrosine phosphorylation of PKCiota/ lambda, and 
lastly followed by the recruitment of tyrosine-phosphorylated PKCiota/ lambda by p62 to the 
endosome (Samuels, 2001). Src was identified as the kinase responsible for the tyrosine 
phosphorylation of PKCiota/lambda that resulted in its binding to p62 and subsequently 
translocation to the endosome. This was determined by addition of exogenous Src leading to 
the binding of PKCiota/lambda-p62 in a dose-dependent manner in both PC12 and HEK 293 
cells. Thus, Src activation of PKCiota in response to NGF results in recruitment of PKCiota to 
the endosome by p62.   
 
SIGNALING: EGF  
 EGF, PDGF, and Insulin have all been shown to activate PKCiota. The growth factors, 
EGF and PDGF, activate PKCiota/ lambda through PI3K. Upon stimulation of rat 3Y1 
fibroblasts cells with EGF and PDGF, there was an increase in PKCiota/ lambda in vivo 
phosphorylation. Also, upon addition of EGF and PDGF, PKCiota localization changed from 
nuclear to cytosolic. The activation of PKCiota/ lambda by PDGF was shown to be dependent 
on PI3K in this rat fibroblast model system according to the pathway: PDGF Æ PI3K Æ 
PKCiota/ lambda Æ TRE (TPA Response Element) (Akimoto, 1996). Also, EGF is able to 
induce PKCiota according to the pathway: EGF Æ PKCiota Æ MEK5/ERK5 Æ Jun 
(transcriptional activation through the MEF2C element) (Diaz-Meco, 2001) (see “PKCiota- 
Binding Partners: MEK5” for details). Thus, EGF, PDGF, and insulin can all individually 
activate PKCiota. 
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PKC IOTA AS A TARGET FOR THERAPY 
As described in detail in this chapter, PKCiota is involved in nearly every stage of 
tumorigenesis, from the initial transformation of normal tissue to a malignant state, to 
migration, invasion, and in turn metastasis. PKCiota is involved in several facets of cellular 
functions including cell growth (and tumor growth), proliferation, transformation and 
anchorage-independent growth, invasion, migration, protein/lipid trafficking, survival, 
chemoresistance, and glucose metabolism. This diversity in the functions of PKCiota is due to 
an assortment of PKCiota activators, binding partners, and downstream effector molecules.  
Several of the activators of PKCiota have already been linked to tumorigenesis and quite a 
number of these are considered oncogenes. Activators of PKCiota include: Ras, PI3K, PDK1, 
growth factors (NGF, PDGF, EGF), TNFα, Src, IL1, Bcr-Abl, glucose, and insulin to name a 
few. With this range of oncogenic upstream effector molecules of PKCiota, PKCiota is an 
excellent potential therapeutic target. Due to the participation of PKCiota in so many diverse 
pathways, PKCiota-inhibition provides a means of targeting several cancer pathways 
simultaneously. As you will read, several PKCiota inhibitors are available, but the need for 
more specific inhibitors exists.     
Inhibition of PKCiota has been demonstrated through several mechanisms, including 
specific inhibitors (see below), kinase dead and dominant negative PKCiota constructs, or 
RNAi. For example, because the pro-apoptotic effect of PAR-4 is though the sequestration of 
oncogenic PKCiota/lambda, PKCiota/lambda could be a possible therapeutic target, 
sensitizing cancer cells to apoptosis (Diaz-Meco, 1999).  Also, inhibition of PKCiota by use of 
a kinase dead construct in A549 lung cancer cells decreased soft agar colony formation and 
decreased tumor volume in vivo by four-fold, thus implicating PKCiota as a potential target in 
cancer therapeutics (Regala, 2005). See Table 8 for a complete list of small molecule PKCiota 
inhibitors used. 
To date, the most specific inhibitors of PKCiota work through inhibition of PB1:PB1 
interactions between PKCiota and other PB1-domain containing molecules such as p62/ZIP, 
PAR-6, and MEK5. However, the disruption of the PKCiota:PAR-6 complex seems to be the 
most anti-tumorigenic. Using a FRET-based assay (Fluorescence Resonance Energy 
Transfer), Stallings-Mann et al screened 960 compounds from the GenePlus chemical 
compound library to identify a compound, which disrupted PKCiota/PAR-6 binding. Using this 
screening technique, two gold compounds were identified as disrupting the PKCiota/PAR-6 
complex. ATG (aurothioglucose- a gold compound used in the treatment of rheumatoid 
arthritis) and ATM (aurothiomalate- a similar gold compound) were identified as compounds 
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that disrupt PKCiota/PAR-6 binding. To test the relevance of these two gold compounds, the 
effects of ATM and ATG were examined on adherent cells growth, transformation (soft agar 
colony formation), and tumor growth (volume) (Stallings-Mann, 2006), similar to a previous 
study using (kinase dead PKCiota in non-small cell lung cancer) (Regala, 2005; Regala, 
2005). These experiments revealed that the PKCiota inhibitors, ATM and ATG, were indeed 
able to cause a decrease in transformation and tumor growth while having no effect on 
adherent growth. These results using ATM and ATG were the same as the previous study 
using kd PKCiota (see below for the details of these studies). Thus inhibition of PKCiota 
therapeutically seems like a plausible mechanism for the treatment of NSCLC (Stallings-Mann, 
2006).  
 
 
 
 
 
 
 
 
 
 
 
Figure 16: Structures of PKCiota Inhibitors: ATM and ATG 
Adapted from (Stallings-Mann, 2006) 
 
 
ATG
(Aurothioglucose)
ATM
(Aurothiomalate)
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Table 8: PKCiota Small Molecule Inhibitors 
 
 
PKCiota Inhibitor Type of 
Cancer
Model System Result Effector 
Molecules
Reference
ATG-
Aurothioglucose NSCLC A549 Cells No Change in Proliferation; Rac1 Stallings-Mann, 2006
4-Fold Reduction in Transformed Growth
Xenograft A549 Cells 4-Fold Reduction in Tumor Volume
ATM-
Aurothiomalate NSCLC H1703 Cells Dose-dependent Decrease in Transformed Growth
PKCiota 
via Cys69 Erdogan, 2006
ATM NSCLC
A427 (ATM-Sensitive) and 
H460 (ATM-Insensitive)
Inhibtion of Anchorage-Independent Growth in 
A427 but not H460 Cells ERK Regala, 2008
Xenograft A427 and H460 Cells Decrease in Proliferation in both Cell Lines; 
No Change in Apoptosis or Angiogenesis in either Cell Line
4-Fold Reduction in Tumor Size in A427 Cells Only
ATM Prostate PC3U (Prostate Cancer) Cells & 3-Fold Increase in Apoptosis (only in tumor cells) Caspase3 Trani, 2009
Cancer PrEC (Non-Transformed 
Prostate  Epithelium)
and ERK
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ATM is particularly specific to PKCiota complexes by inhibiting PKCiota-PAR-6 or 
PKCiota-p62 complex formation. While ATM was able to disrupt the PB1:PB1 complexes 
PKCiota-PAR-6 and PKCiota-p62, ATM failed to disrupt other PB1:PB1 complexes, such as 
p62-p62, p62-NBR1, and MEKK3-MEK5. This specificity to PKCiota PB1:PB1 complexes was 
due to the presence of a cysteine residue (cys-69) in the PB1 domain of PKCiota that formed a 
thio-gold adduct when bound to ATM. Disruption of PKCiota-PAR-6 binding by ATM is 
diminished in a PKCiota cys-69 mutant. Thus, ATM is a specific inhibitor of PKCiota complex 
formation via the PKCiota PB1 domain cys-69 residue (Erdogan, 2006).  
Unfortunately, these two particular compounds caused a vast number of side effects in 
the treatment of rheumatoid arthritis and many people withdrew from the study (van Roon, 
2005). Specifically, in a Dutch clinical trial, ATG, which had to be replaced with ATM, was 
withdrawn from the trial due to quality control issues. After the switch to ATM, nearly 25% of 
the patients withdrew from the study due to inefficiency of the drug or side effects (ADR- 
adverse drug reactions), such as pruritus (an itching sensation), dermatitis (skin 
inflammation/rash), stomatitis (skin inflammation/rash in the mouth), and chrysiasis (a change 
in skin pigmentation due to the exposure of gold salts), and hyperpigmentation (darkening of 
skin/nails due to increased melanin). While these patients experienced inefficiency or ADR 
with ATM, many of these patients experienced better results with ATG prior to ATM treatment 
(van Roon, 2005). The van Roon study is the only published study to date looking at ATM and 
ATG in humans. However, phase I clinical trials have begun for the treatment of lung cancer 
with ATM at Mayo Clinic’s Arizona and Minnesota facilities. While the details and results of 
these clinical trials are not yet published, phase II clinical trials are in preparation. Similarly, at 
the Mayo Clinic in Florida, phase I clinical trials are about to begin using ATM in the treatment 
of pancreatic cancer (Mayo_Clinic, 2010). Therefore, while PKCiota would make an excellent 
target for the treatment of some classes of cancer patients, according to the van Roon study, 
less toxic compounds need to be generated. However, the clinical trial reports of the Mayo 
Clinic studies mentioned above when published may indicate otherwise. Generation of more 
specific compound is possible. The structures of the catalytic (crystal structure) and PB1 
(NMR) domains have been determined, making the synthesis of PKCiota-targeted compounds 
a possibility in the near future (Messerschmidt, 2005, and Hirano, 2004, respectively). 
However, use of a myristoylated pseudosubstrate (mPS), a synthetic myristoylated 
peptide inhibitor (such as mPS-PKCzeta), which is cell-permeable, should not be used to 
inhibit PKCiota. In the case of mPS-PKCzeta, addition of mPS-PKCzeta led to eNOS 
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(endothelial nitric oxide synthase) activation in cultured pulmonary artery endothelial cells 
(PAEC). This increased activation of eNOS in response to PKCzeta inhibition was also 
coupled with increased AKT, ERK1/2, and p38 MAPK (Krotova, 2006). This coincides with the 
paper by Baldwin showing that silencing PKCiota by RNAi led to an increase in p38 (Baldwin, 
2006).  However, this result opposes the findings of Ramzy et al that PKCiota expression 
could lead to increased nitric oxide (NO) synthesis (Ramzy, 2006). Thus, the effect of mPS on 
the production of eNOS could be non-specific rather than through the downregulation of 
atypical PKC. Therefore, inhibition of PKCiota activity or binding is likely a better method of 
inhibition than decreasing PKCiota expression levels, which seems to result in increases in 
other tumorigenic pathways. 
Predictably, PKCiota inhibitors (such as ATM) do not inhibit soft-agar colony formation 
in lung cancer cells that do not overexpress PKCiota. More specifically, ATM sensitivity in lung 
cancer cells is higher in cells overexpressing PKCiota-PAR-6 than in cells with PKCiota-p62. 
In cells with high levels of PKCiota, the IC50 values of ATM are low (300nM), while in cells with 
low levels of PKCiota, the IC50 values of ATM are quite high (100μM). Interestingly, ATM 
sensitivity only correlated with PKCiota levels, it did not correlate with overall sensitivity to 
chemotherapeutics, such as cisplatin, placitaxel, or gemcitabine. The sensitivity to ATM and 
not other compounds implies that PKCiota does not predict response to chemotherapeutics, in 
spite of other studies that suggest PKCiota is linked to chemoresistance (as mentioned 
above). The trend of ATM being most efficacious in PKCiota overexpressing cells corresponds 
to the trend in vivo, with tumors of high PKCiota levels being the most sensitized to ATM. In 
vivo, in a mouse xenograft model, two NSCLC cell lines, A427 and H460 were injected 
subcutaneously into nude mice. These two particular cell lines were chosen, as A427 cells 
were very sensitive to ATM treatment in vitro (IC50 = ~0.5 μM), as measured by soft agar 
colony formation, compared with H460 cells which were insensitive (IC50 = ~70 μM). In the 
A427 xenografts, even by 40 days, the average tumor volume of ATM treated mice (ATM was 
as low as 2 mg/kg) were 500 mm3 as compared to the vehicle treated mice, which were 
averaged at 2000 mm3. However, ATM insensitive cells, H460, in the xenograft model were 
not as sensitive to ATM treatment in vivo as the A427 cells, with the average tumor volume of 
ATM-treated mice being 1000 mm3 at 16 days of treatment and 60 mg/kg (and nearly 1500 
mm3 with 20 mg/kg). Thus, response to ATM in vitro predicts response to ATM in vivo. ATM 
manifests its effect through inhibition of the PKCiota-PAR6-Rac-PAK-MEK-ERK pathway, as 
determined by western blot analysis using A427 (ATM sensitive) lung cancer cells compared 
to H460 (ATM insensitive) lung cancer cells (Regala, 2008). Thus, ATM treatment both in vitro 
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and in vivo is most effective in PKCiota overexpressing tumors, indicating the need for a 
screening technique for lung cancer patients. 
PKCiota inhibitors have been studied more extensively in mouse models. Use of the 
PKCiota inhibitor, ATG, blocked transformed growth of A549 cells, to the same extent as 
exogenous overexpression of kinase dead (kd) PKCiota. Also, ATG was able to cause a 
decrease in tumor volume in mice, much to the same extent as kd PKCiota (Stallings-Mann, 
2006). Similarly, both ATG and kd PKCiota did not affect the rate of proliferation of adherent 
cells. This decrease in transformation of NSCLC cells in the presence of ATG was due to a 
disruption of the PKCiota/PAR-6 complex, resulting in a decrease in the level of active Rac1 
(GTP versus GDP-bound) (Stallings-Mann, 2006). Similarly, PKCiota is essential for Ras-
induced tumorigenesis in vivo. Using a transgenic mouse model overexpressing oncogenic 
Ras in the lungs with or without PKCiota expression, Regala et al found that inhibition of 
PKCiota decreased the Ras-induced hyperplasia and tumor formation. Importantly, inhibition 
of PKCiota by the small molecule inhibitor, ATM, blocked Ras-induced tumorigenesis (Regala, 
2009). Thus, PKCiota is essential for tumor initiation in a lung cancer model, and PKCiota 
inhibition is a feasible method of treatment in Ras-induced tumorigenesis.  
Because the PKCiota-PAR-6 complex recruited Ect2 to the cytoplasm leading to 
transformation, invasion, and tumorigenesis in a NSCLC model, inhibition of the binding 
between PKCiota and PAR-6 by ATM treatment would cause a decrease in NSCLC incidence 
through disruption of the PKCiota-PAR-6-Ect2 complex. This pathway is as follows: 
PKCiota/PAR-6/Ect2 Æ Rac1 Æ Pak Æ MEK1/2 Æ ERK1/2 (Justilien, 2009). Thus, 
PKCiota:PAR-6 binding appears to be a practicable target in the treatment of PKCiota-
overexpressing cancers.   
 PKCiota inhibitors were able to sensitize cancer cells to pro-apoptotic drugs, such as 
taxol, cisplatin, and okadaic acid. However, PKCiota inhibitors alone were ineffective. For 
example, in a mouse model, Regala et al found that ATM only influences the proliferation 
index (BrdU positive cells) of the tumor without an effect on apoptosis or vascularization 
(Regala, 2008). Thus, PKCiota inhibition is alone insufficient as a single agent, but needs to be 
used to sensitize tumors to chemotherapeutics. Essentially, the role of PKCiota in 
chemoresistance in tumors in response to apoptotic stimuli is likely through PKCiota’s role in 
survival, through phosphorylation/ inhibition of pro-apoptotic Bad Kinase, activation of anti-
apoptotic NFκB, and inhibition of the pro-apoptotic p38 MAPK pathway. 
 In summary, PKCiota provides a novel therapeutic target for the treatment of cancer 
due to the convergence of so many cancer pathways at PKCiota. These cancer pathways 
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cover a spectrum of stages in tumorigenesis, from transformation to metastasis, and involve a 
plethora of cellular functions, including polarity, cytoskeletal organization, proliferation, cellular 
growth, migration, invasion, induction of anchorage-independent growth, trafficking, survival, 
and metabolism. However, as with most targeted therapies, the need for screening tools for 
cancers that would express those target proteins exists. Luckily, PKCiota overexpression or 
mislocalization, which is detectable by simple IHC, is sufficient to identify subgroups that would 
likely respond to PKCiota inhibition. This principle has been validated in a lung cancer model, 
where PKCiota levels statistically correlated with the sensitivity of these tumor cell lines to a 
PKCiota inhibitor, aurothiomalate, as determined by transformation assays (Regala, 2008). 
While PKCiota provides a potential therapeutic target, the need for more specific, less toxic 
inhibitors exists. For the time being, a gold compound, aurothiomalate (ATM) is in phase I 
clinical trials at the Mayo Clinic for the treatment of both NSCLC and pancreatic cancer. 
However, PKCiota was identified as a bona fide oncogene in several other cancer types, 
including ovarian cancer, which is the focus of this dissertation, and thus the possibility of 
these clinical trials being extended to other cancer types of epithelial origin is highly probable.  
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CYCLIN E AND PKCIOTA IN OVARIAN CANCER 
Cyclin E in Ovarian Cancer 
In 1996, in a screen of ovarian cancer patient samples, Courjal et al identified cyclin E 
as being genetically amplified and overexpressed in many ovarian cancer patients (Courjal, 
1996). Similarly, in 1998, Marone et al showed that cyclin E was amplified in 21% of ovarian 
cancer patients tested, and CDK2 was amplified in 6.4%. Testing the relevance of this study 
on protein expression, Marone et al found this amplification translated to the higher expression 
of cyclin E levels with 29.5% of ovarian cancer samples examined had overexpressed cyclin E 
protein and 6.5% had increased CDK2 protein expression (Marone, 1998). In 2003, Farley et 
al found that cyclin E overexpression correlated with poor survival and that this overexpression 
was due to gene amplification (Farley, 2003). While Courjal found that there was no correlation 
between cyclin E gene amplification and tumor type, stage, or grade, Bedrosian et al found 
there was a correlation between expression of low molecular weight forms of cyclin E (LMW-E) 
and a more advanced stage and grade of ovarian cancer (Courjal, 1996 and Bedrosian, 2004, 
respectively). LMW-E is described in more detail below. Bedrosian et al also found that 
ovarian tumors that overexpress LMW-E demonstrated higher kinase activity, which translated 
to a decrease in doubling time, an increase in S phase fraction, an increase in colony 
formation, and a better response to platinum-based chemotherapies (Bedrosian, 2004; 
Bedrosian, 2007). The increase in cyclin E-associated kinase activity due to the presence of 
LMW-E could also potentially lead to an increase in transformation and metastasis (Fang, 
1996; Kang, 1996; Akli, 2007) (see the “Cyclin E- Cyclin E and Transformation” section). 
Specifically examining serous epithelial ovarian cancer, which is the most lethal and common 
form of ovarian cancer, Nakayama et al found amplification of the cyclin E gene in high grade 
serous epithelial ovarian tumors (Nakayama, 2007). Targeting cyclin E (and LMW-E) in the 
ovarian cancer cell line, OVCAR-3, Todd et al showed that knockdown of cyclin E by RNAi 
resulted in a restored G1-S checkpoint (Todd, 2009). These summarized results insinuate that 
cyclin E could be a potential therapeutic target in the treatment of ovarian cancer. Because 
cyclin E is regulated predominately through the overexpression of the protein product, a 
potential therapy could be to decrease cyclin E protein levels or inhibit its function by inhibiting 
cyclin E-associated kinase activity.  
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PKCiota and Ovarian Cancer:  
Several studies have identified the role of PKCiota in ovarian cancer. The first study 
identified PKCiota as being differentially expressed between ovarian cancer and normal 
epithelial ovarian tissue (Weichert, 2003). The second study found that PKCiota was amplified 
in ovarian cancer, which correlated with elevated PKCiota expression and a poor prognosis 
(Eder, 2005). The third study designated PKCiota as being a bona fide oncogene in ovarian 
cancer (Zhang, 2006). PKCiota has since been labeled an oncogene in several types of 
cancer, see “PKCiota- Functions: Disease- Cancer” for a detailed overview. 
Weichart et al, by use of immuno-histochemistry (IHC) in tissue samples of ovarian 
cystadenomas, borderline ovarian tumors, primary tumors, and recurrent invasive ovarian 
cancer that had been formalin-fixed and paraffin-embedded, found that PKCiota was 
expressed in half of the primary and recurrent malignant ovarian tumors, but not in the normal 
ovarian epithelial tissue, benign cystadenomas, or borderline tumors, thus implicating the role 
of PKCiota in the transformation stage of tumorigenesis. Similarly, PKCiota was not expressed 
in the normal cell line HOSE (human ovarian surface epithelial cells), but PKCiota was 
overexpressed in the tumor cell lines, OVCAR-3, SKOV-3, and OAW-42. Clinically, PKCiota 
showed a positive correlation with histopathological grading, stage, and the proliferation index. 
Specifically, in primary ovarian tumors, the expression of PKCiota exhibited a significant 
correlation with a reduced median survival time (Weichert, 2003).  
In the second study, PKCiota was found to be genomically amplified leading to its over 
expression in ovarian cancer. In serous ovarian carcinomas, an increase in PKCiota DNA copy 
number correlated with a decreased progression free survival. Because the drosophila eye is 
polarized in an apical-basal orientation much like the epithelial tissue that makes up the 
human ovaries, the drosophila eye provides a useful model system for the manipulation of 
proteins involved in asymmetrical cell polarity. Thus, in a drosophila eye, which was used as a 
model of epithelial cell apical-basal polarity and normal PKCiota localization, overexpression of 
two different constitutively active PKCiota mutants (DaPKM-which lacks the PAR-6 binding site 
and the pseudosubstrate domain and rPKCζ- which has a deletion in the pseudosubstrate 
domain) resulted in a disruption in polarity (as determined by mislocalization of the tight 
junction marker, Patj), an increase in proliferation (as determined by BrdU incorporation), and 
an increase in cyclin E levels (as determined by immunofluorescence) (Eder, 2005).  
Eder et al also determined the role of PKCiota localization in ovarian cancer. Using 
IHC, both normal ovarian surface epithelial cells and benign serous or mucinous cysts, 
PKCiota was localized to the apical membrane. However, all serous ovarian patient samples 
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that were evaluated by IHC (322 total) exhibited a loss of PKCiota localization at the apical 
membrane (Eder, 2005).  
In the Zhang study, PKCiota was identified as a bona fide oncogene in ovarian cancer 
(Zhang, 2006). By examining 89 ovarian cancer patient samples, Zhang et al found that 
PKCiota had an increased copy number in 43.9% of the patient samples (Zhang, 2006). Also, 
by examining normal ovarian tissues versus ovarian cancer tissue, Zhang found that PKCiota 
mRNA expression (as determined by a microarray and validated by qRT-PCR) was also 
increased in the tumor samples. The results found in tumor samples were then validated in 18 
ovarian cancer cell lines, versus 6 HOSEs (Human Ovarian Surface Epithelium- normal cells). 
Similarly, protein levels were also elevated in normal versus tumor tissue samples. Protein 
levels of PKCiota were examined using a tissue array and validated with IHC in normal ovarian 
epithelium versus ovarian tumor tissue. Thus, these studies have all identified PKCiota to be 
specifically relevant in ovarian cancer. 
Additionally, these studies also show that overexpression of PKCiota correlated with 
the ovarian tumor stage and grade. Because PKCiota has established roles in proliferation, 
apoptosis, and transformation, Zhang et al examined each of these characteristics in ovarian 
tissues as well. While PKCiota did not play a role in ovarian cancer proliferation or apoptosis, 
PKCiota was involved in transformation (Zhang, 2006). However, in the study by Eder et al, 
the role of PKCiota in ovarian cancer was partly through an increase in proliferation, as 
determined by BrdU incorporation (Eder, 2005). Specifically, in Zhang’s study, the use of 
siRNA to silence PKCiota in ovarian cancer cells exhibited a reduction in anchorage-
independent growth. Additionally, in murine ovarian surface epithelium, PKCiota in cooperation 
with mutant Ras was able to induce transformation. The increase in PKCiota mRNA 
expression that was increased in ovarian cancer patient samples in Zhang’s study was not 
increased in the other types of cancer examined (Zhang, 2006). Eder et al also found PKCiota 
to be amplified at a higher level in ovarian cancer (specifically serous epithelial ovarian cancer) 
than in other epithelial cancers, such as prostate, lung, and colon. However, since these two 
studies, PKCiota has been demonstrated to be amplified in several types and subsets of 
cancer.  
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Link Between PKCiota and Cyclin E in Ovarian Cancer 
The link between PKCiota and cyclin E in ovarian cancer has also been established. 
Using drosophila epithelial tissue as a models system, Eder et al found that expression of 
persistently active PKCiota (DaPKM and rPKCζ) resulted in increases in cyclin E levels, 
increased proliferation, and a disruption of apical-basal polarity. By examining ovarian cancer 
patient tissues, Eder et al also found a correlation between PKCiota protein levels, cyclin E 
levels, and proliferation (Eder, 2005). Because overexpression of the cyclin E/CDK2 inhibitor, 
p21/p27 (Drosophila ortholog is Dacapo) reverted the PKCiota phenotype, cyclin E is 
implicated as the effector molecule responsible for the PKCiota overexpression phenotype. As 
mentioned, this correlation between increased PKCiota and cyclin E expression also occurred 
in ovarian cancer patient samples. Specifically, overexpression of PKCiota in serous epithelial 
tumors correlated with the expression of the tumor-specific isoforms of cyclin E (LMW-E) that 
have been implicated in transformation, genomic instability and metastases (Eder, 2005). 
Similar to findings with cyclin E, increased PKCiota expression correlated with poor survival 
(Farley, 2003; Eder, 2005).    
 
Rationale: 
As you have read, PKCiota is involved in a large number of the steps involved in 
tumorigenesis. The overexpression or mislocalization of PKCiota, observed in various types of 
cancer, results in aberrant epithelial cell polarity, migration/invasion, proliferation, protein/lipid 
trafficking, cellular metabolism, anchorage-independent growth, angiogenesis, survival, and 
metastasis, making PKCiota a prime target for inhibition in epithelial cancers. PKCiota can be 
mislocalized to the cytoplasm, amplified at the genomic level (which correlates with poor 
survival), or PKCiota can be activated by gain of function mutations in several oncogenic 
pathways, such as Ras, PI3K, or Src. Rationally, in numerous model systems, PKCiota 
inhibition via various methods resulted in a reversion of the transformed phenotype, both in 
vitro and in vivo. Because defining cancer pathways is essential for understanding cancer, the 
mechanism of PKCiota-induced oncogenesis, while well published, still needs to be absolved. 
PKCiota regulates several other oncogenic proteins, including ERK, MEK, Rac1, NFκB, ELK, 
IL-6, MMP-3, MMP-10, STAT3, c-fos, cyclin D1, and cyclin E. Because cyclin E is also 
oncogenic, leading to proliferation, transformation and anchorage-independent growth, and 
these two proteins have been correlated in ovarian cancer and hepatocellular carcinoma 
(HCC), we hypothesized that the role of PKCiota in transformation is through cyclin E. In 
Chapter 2 of this dissertation, we examine the regulation of cyclin E by PKCiota and vice 
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versa, and we identified the means of this regulation (transcription versus protein stability). In 
Chapter 3, we examine the functional implications of the regulation of cyclin E by PKCiota in 
terms of proliferation, transformation, and migration. 
In an ovarian cancer model system, we identified the regulation of cyclin E by PKCiota. 
In IGROV and 293T cells, knockdown of PKCiota leads to decreased protein stability of cyclin 
E and LMW-E, while not affecting cyclin E transcription. Conversely, in these two cell lines, 
overexpression of PKCiota results in an increase in full-length cyclin E and LMW-E. However, 
in four ovarian cancer cell lines under both transient and stable ectopic cyclin E expression, 
PKCiota protein levels remain stable, indicating the regulation of cyclin E by PKCiota is uni-
direction.  By examination of the protein expression pattern of PKCiota-overexpression (Wt-
wildtype, CA-constitutively active, and DN-dominant negative) in 293T cells, we found that 
several effector molecules in the PI3K pathway are affected by PKCiota expression, implying 
that the regulation of cyclin E by PKCiota is via the PI3K pathway. In fact, inhibition of PI3K by 
PI-103 and GDC-0941 resulted in decreased phospho-PKCiota (autophosphorylation) and 
decreased cyclin E protein levels without a change in PKCiota expression. Thus, the 
regulation of cyclin E by PKCiota is at the level of protein stability and occurs through the PI3K 
signaling cascade.  
PKCiota and cyclin E are both individually implicated in proliferation, transformation, 
and anchorage-independent growth. These two oncogenic proteins are often overexpressed in 
ovarian cancer, and their expression correlates with poor survival. Using IGROV serous 
ovarian cancer cells, we have found that inhibition of PKCiota by RNAi or small molecule 
inhibitors (aurothiomalate-ATM and aurothioglucose-ATG) results in a decrease in proliferation 
as indicated by a change in growth curves, and that this decrease in proliferation is via down-
regulation of CDK2, CDK4, cyclin D1, and cyclin E and an increase in p27. In IGROV cells, 
PKCiota RNAi resulted in a decrease in transformed cells, a phenotype that was reverted upon 
infection with Ad-cyclin E or Ad-LMW-E. Similarly, inhibition of cyclin E-CDK2 activity (with 
Roscovitine) resulted in a decrease in the number of transformed colonies. However, PKCiota 
knockdown resulting in a decrease in cell motility was not reverted by exogenous cyclin E. 
Thus, PKCiota-induced motility is cyclin E-independent, and cyclin E is implicated as the 
downstream effector molecule responsible for PKCiota-mediated transformation. 
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Regulation of Cyclin E Stability by PI3K/ PKCiota 
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CHAPTER 2: INTRODUCTION 
The leading cause of death among the gynecologic malignancies is ovarian cancer, 
which due to lack of both obvious symptoms or a screening test for early detection, results in a 
poor prognosis (CDC, 2010; CF&F, 2010). An effective target in ovarian cancer is yet to be 
identified. In this chapter, we show that several oncogenes that are overexpressed in ovarian 
cancer, PI3K, PKCiota and cyclin E, all of which have been shown to lead to a poor prognosis 
(Courjal, 1996; Marone, 1998; Farley, 2003; Weichert, 2003; Eder, 2005) converge into a 
single pathway that could potentially be targeted therapeutically. 
PKCiota, an atypical member of the PKC family of serine/ threonine kinases, is an 
oncogene in ovarian cancer (Zhang, 2006). In normal ovarian epithelial cells, as well as in 
benign serous or mucinous cysts, PKCiota is localized to the apical membrane, however, in all 
serous epithelial ovarian cancer patient samples examined (n = 322), PKCiota was either 
mislocalized or overexpressed (Eder, 2005). PKCiota is involved in actin remodeling, apical-
basal polarity, endosomal trafficking, glucose uptake, proliferation, transformation, migration, 
invasion, differentiation, and survival (see Chapter 1). PKCiota has major potential as a 
therapeutic target due to its oncogenic role in ovarian cancer and high potential of being 
overexpressed. PKCiota is the second most overexpressed oncogene in ovarian cancer, by 
being overexpressed in 78% of all epithelial ovarian cancers (Bast, 2009). PKCiota is activated 
by PDK1 downstream of PI3K (Chou, 1998; Akimoto, 1998; Standaert, 1999; Kanoh, 2003). 
The PI3K pathway, either through activation of PI3K, AKT, or inhibition of PTEN, is activated in 
approximately 70% of ovarian cancers (Bast, 2009). Thus, the PI3K/ PDK1/ PKCiota pathway 
is an excellent example of an ovarian cancer pathway to be targeted therapeutically. In this 
chapter, we demonstrate that the PI3K/ PKCiota pathway converges with the cyclin E-CDK2 
pathway in serous ovarian cancer.  
Cyclin E, the regulatory subunit in the cyclin E/CDK2 complex, is also an often 
overexpressed oncogene in ovarian cancer (Bast, 2009). Cyclin E through the activation of 
CDK2 leads to several aspects of tumorigenesis including increased proliferation, anchorage-
independent growth, centrosome amplification, genomic instability, and metastasis (Chapter 
1). In the most lethal and common form of ovarian cancer, serous epithelial ovarian cancer, 
cyclin E is overexpressed in high grade serous epithelial ovarian tumors (Nakayama, 2007). In 
several cancer types, including ovarian cancer, cyclin E is cleaved post-translationally into 
oncogenic, tumor-specific low molecular weight isoforms, termed LMW-E (Keyomarsi, 1993; 
Porter, 2001; Bedrosian, 2004; Davidson, 2007). These LMW-E forms of cyclin E are tumor-
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specific and are characterized by the ability to hyperactivate CDK2, even in the presence of 
CKIs, such as p21 or p27 (Akli, 2004; Wingate, 2005). The overexpression of PKCiota in 
serous epithelial tumors correlates with the presence of LMW-E, which as mentioned in 
Chapter 1 is likely involved in transformation, genomic instability and metastases (Eder, 
2005).Thus, PKCiota is a feasible target for therapy in serous epithelial ovarian cancer, 
potentially through downregulation of other oncogenes, such as cyclin E. 
In this chapter, we demonstrate that cyclin E is downstream of PKCiota and not vice 
versa in serous ovarian cancer cells. We also show that the effect of PKCiota on cyclin E 
expression is at the level of protein stability. Conversely, altered cyclin E expression does not 
alter PKCiota activity or levels. Using an RPPA assay to identify possible downstream effector 
molecules of PKCiota overexpression, we determined that the regulation of cyclin E by 
PKCiota is via the PI3K pathway. The PI3K pathway is activated in approximately 70% of 
epithelial ovarian cancers. Thus, because PKCiota is mislocalized in serous epithelial ovarian 
cancer leading to an increase in cyclin E, inhibition of either PI3K or PKCiota could be a 
possible approach used in the treatment of serous epithelial ovarian cancers. 
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CHAPTER 2: METHODS 
Methods are in the order of appearance in this chapter. 
Cell lines and other reagents. A complete list of cell lines used in this dissertation along with 
their source, histotype, and media used is shown in Table 1. 
 
Table 1: Cell Lines Used in Chapter 2 
Cell 
Lines Availability Organ Source Histotype Media Used 
59M ECACC Ovary Ascites 
Endometriod Carcinoma 
with Clear Cell Areas 
Alpha Complete 
Media 
 293T/17   ATCC Kidney n/a Adherent 
Alpha Complete 
Media 
A2780CP ECACC Ovary Tumor Tissue Ovarian Carcinoma 
Alpha Complete 
Media 
DOV13 
Rauh-
Adelmann, 2000 Ovary Ascites Epithelial Ovarian Cancer 
Alpha Complete 
Media 
EF0-27 DSMZ Ovary 
Solid Omental 
Metastasis 
Mucinous Papillary 
Adenocarcinoma 
Alpha Complete 
Media 
FU-OV-1 DSMZ Ovary 
Post-Hysterectomy 
Tumor Tissue 
Serous Papillary 
Adenocarcinoma 
Alpha Complete 
Media 
HeyA8 Moore, 1997 Ovary Not Specified 
Serous Papillary 
Adenocarcinoma 
Alpha Complete 
Media 
HOC1 Buick, 1985 Ovary Not Specified 
Serous Adenocarcinoma, 
Well Differentiated 
Alpha Complete 
Media 
HOC7 Buick, 1985 Ovary Not Specified 
Serous Adenocarcinoma, 
Well Differentiated 
Alpha Complete 
Media 
IGROV1 MIISB Ovary Primary Tumor 
Serous, Endometriod, 
and clear cell features 
Alpha Complete 
Media 
IOSE29 
Maines-
Bandiera, 1992 Ovary  Not Specified 
Immortalized Ovarian 
Epithelium 
MCDB105:M199 
 
MDAH2774 ATCC Ovary Not Specified Adenocarcinoma 
Alpha Complete 
Media 
OAW42 ECACC Ovary Ascites Cystadenocarcinoma 
Alpha Complete 
Media 
OC316 ICLC Ovary Ascites Adenocarcinoma 
Alpha Complete 
Media 
OVCA 420 Karlan, 1988 Ovary Ascites Serous Carcinoma 
Alpha Complete 
Media 
OVCA 429 Karlan, 1988 Ovary Ascites Serous Carcinoma 
Alpha Complete 
Media 
OV-CA 432 MIISB Ovary Not Specified Serous Carcinoma 
Alpha Complete 
Media 
OVCA 433 Karlan, 1988 Ovary Ascites Serous Carcinoma 
Alpha Complete 
Media 
OVCAR-3 ATCC Ovary Ascites 
Epithelial 
Adenocarcinoma 
Alpha Complete 
Media 
SFHUC Bedrosian, 2004 Ovary Not Specified Not Specified 
Alpha Complete 
Media 
SKOV-3 ATCC Ovary Ascites Adenocarcinoma 
Alpha Complete 
Media 
SW-626 ATCC Ovary Tumor Tissue Ovarian Carcinoma 
Alpha Complete 
Media 
UPN251 
Selvakumaran, 
2001 Ovary Not Specified Serous Carcinoma 
Alpha Complete 
Media 
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Tissue Culture. 
All cell lines (listed in Table 1) were cultured and treated at 37°C in a humidified incubator 
containing 6.5% CO2–93.5% air. 
Alpha Complete Media: HyQ MEM alpha-modification cell culture medium (HyClone) was 
supplemented with 10% fetal bovine serum (FBS) (Atlanta Biologicals), 10 mM HEPES, non-
essential amino acids, 2 mM L-glutamine, sodium pyruvate, hydrocortisone, and 10 μg/mL 
Ciprofloxacin.  
DMEM Complete Media: DMEM (Dulbecco’s Modification of Eagle’s Medium) (Cellgro) was 
supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine, and 10μg/mL 
Ciprofloxacin. 
MCDB105:M199 Media: 1:1 ratio of MCDB 105 (Sigma) and Medium 199 (Sigma) was 
supplemented with 10% FBS, 2mM L-glutamine, and 12.5 μg/mL EGF.  
  
Western Blot Analysis.  
Total cell lysates were prepared/ analyzed using western blot analysis as previously described 
(Keyomarsi, 1995). For each sample 35µg of protein was subjected SDS-PAGE. The protein 
were then transferred at either overnight at 35mV or for 2 hours at 85mV at 4oC to Immobilon 
P (Millipore) membranes. The blots were then blocked for 1 hour at room temperature in 
blocking buffer (5% nonfat dried milk in TBST- 20 mM Tris, 137 mM NaCl, 0.05% Tween, pH 
7.6). After being washed in TBST, the blots were incubated in primary antibodies (see below) 
for 1-2 hours, depending on the antibody.  For the mouse primary antibodies, a secondary 
antibody from eBioscience (called Mouse TrueBlot) was used. For the rabbit primary 
antibodies, a secondary antibody from Thermo-Scientific (Goat anti-rabbit HRP) was used. 
Blots were incubated with either Mouse IgG TrueBlot or anti-Rabbit at a 1:1750 dilution in 
blocking buffer for 45 minutes to 1 hour  at room temperature, then washed 6 times (ten 
minutes each wash), and developed using the Renaissance chemiluminescence system 
according to the manufacturer (Perkin-Elmer Life Sciences, Inc.). 
Primary Antibodies Used:  Primary antibodies used were PKCiota (BD Transduction 
Laboratories- 610176- 1:250 in Blotto), cyclin E (HE-12, Santa Cruz Biotechnology 1:1250 in 
Blotto), p53 (Ab-6, Calbiochem 1:100 in Blotto), Elafin/SKALP (HyCult Biotechnology 1:2000 in 
Blotto), Phospho-PKCiota (Abcam: Phospho T555 + T563 1:1000 in Blotto), p21 (Ab-1, 
Calbiochem 1:200 in Blotto), Cdk2 (Santa Cruz Biotechnology 1:200 in Blotto), actin (C4, 
Chemicon International 1:1000 in Blotto), CDK4 (Santa Cruz Biotechnology 1:200 in Blotto), 
cyclin D1 (Santa Cruz Biotechnology 1:100 in Blotto), p27 (K25020, BD Biosciences-
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Transduction Laboratories 1:250 in Blotto), Phospho-AKT (Ser 473 Cell Signaling 1:750 in 5% 
BSA), AKT (Cell Signaling 1:1000 in Blotto)  
 
Densitometry. 
Densitometric analysis was performed using ImageQuant 5.2 software with freshly scanned 
TIF images of the films obtained from western blot analysis. All quantitative numbers (with 
background subtracted out) were normalized to the control of that particular experiment for 
each antibody. After normalization, each number was divided by the normalized actin numbers 
to control for differences in loading. These values were then plotted using Microsoft Excel in 
bar-graph form for visualization purposes with the y-axis being the normalized, controlled for 
loading values (protein to actin ratio) for each lane.   
 
Statistical Consideration.  
Linear regression curves were plotted on Microsoft Excel using the x-y scatter graph function 
with the y-axis (usually cyclin EL, LMW-E, or total LMW-E) being a function of the x-axis 
(usually PKCiota or phospho-PKCiota). A linear trendline was established for each, and the 
correlation coefficient was determined by Pearson test for the correlation coefficient (r). The p-
value was determined using a significance calculator examining the r-value and the number of 
trials. The student t-test (two-tailed, equal variance) was employed to derive the p-value of the 
experiments with a normal distribution, i.e. all experiments in Chapters 2 and 3 except the 
linear regression.  
 
Stable Clone Selection. 
Stable Clone Selection: MDAH2774 and SFHUC Clones. MDAH2774 and SFHUC, ovarian 
cancer cell lines (see Table 1), were transfected with pcDNA 3.1 plasmids (Invitrogen) with 
cyclin EL or cyclin E constructs Truncation 1 (T1) or Truncation 2 (T2) described elsewhere 
(Porter, 2001) using FuGene Transfection Reagent (Roche Molecular Biochemicals) according 
to the manufacturer’s protocol.  Stable clones were selected for using G418 (Gibco) 48 hours 
post transfection. Positive clones were determined by western blot analysis using the cyclin E 
(HE-12; Santa Cruz Biotechnology) antibody (see western blot analysis).  
Stable Clone Selection: IGROV and OVCAR3 Clones. IGROV and OVCAR3, ovarian cancer 
cell lines, were transfected with pRS-shPKCiota (Origene #TR320472) using GeneJuice 
Transfection Reagent (Novagen) according to the manufacturer’s protocol. PKCiota shRNA 
consisted of 4 individual constructs. However, upon BLAST analysis, only constructs 
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shPKCiota 7 and shPKCiota 8 were determined target only a single ssequence. shControl 
(shRNA 3) contained shGFP. However, these cells did not express GFP, so this made an 
excellent control. Stable clones were selected for using Puromycin (IGROV = 1 μg/mL; 
OVCAR = 0.1 μg/mL) 48 hours post transfection. Positive clones were then determined by 
Western blot analysis using the anti-PKCiota antibody (BD Transduction Laboratories).  
 
Infection with Ad-Cyclin E/ Ad-E2F1. 
Cyclin E (EL, LMW-E-T1, and LMW-E-T2), E2F1, and LacZ adenoviruses were constructed 
using the AdEasy XL adenoviral vector system kit (Strategene). FLAG-tagged cyclin E was 
subcloned into the multiple cloning site (MCS) of the Ad-easy shuttle vector, followed by 
linearization with PmeI. BJ5183-AD-1 bacteria were then transformed with the Ad-Shuttle-
Cyclin E constructs and selected for with kanamycin. In vivo homologous recombination into 
the pAdEasy-1 vector occurred in these cells. The recombinant DNA was then digested with 
PacI. The pAdEasy-1-cyclin E constructs were then transfected into Ad-293 cells, which 
provide the packaging machinery for mature adenovirus. Supernatant was then harvested for 
mature Ad-cyclin E adenovirus. IGROV cells were plated at 1 x 106 cells / 10 cm plate 
overnight before being infected with 1000 MOI of either Ad-Cyclin EL, Ad-LMW-E-T1, or Ad-
LMW-E-T2.  Ad-Cyclin E was kindly provided by Said Akli, as published in (Bagheri-Yarmand, 
2010; Bagheri-Yarmand, 2010). Cells were then harvested at time points indicated for each 
experiment for examined by Western blot analysis with indicated antibodies.  
 
siRNA Transfection. 
siRNA to PKCiota in OVCAR3, IGROV, A2780CP, and SKOV3  was performed using siPORT 
amine reagent (Ambion) using the reverse transfection protocol according to the 
manufacturer’s instructions. 2.3 x 105 cells were used per well of 6 well plates. 2.5 μL of 20 μM 
(20nM total) siRNA was used per well. PKCiota siRNA was purchased from Ambion. Control 
siRNA was Silencer Negative Control Number 1 (cat# 4611) and PKCiota siRNA was Silencer 
Validated PKCiota siRNA (gene code 309 and 311). If only one siRNA was used in this 
experiment, the 309 siPKCiota oligo was used. 311 was used to confirm the results of 309 and 
rule out the possibility of non-specific effects. Sequences would not be released by Ambion 
upon inquiry, but are guaranteed to be unique and specific sequences. 
siRNA to PKCiota in 293T cells was performed using X-tremeGENE siRNA transfection 
Reagent (Roche) according to the manufacturer’s protocol. Cells were plated at 5 x 105 cells 
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per well in 6-well plates. Twenty-four hours later, cells were transfected with the Ambion 
siRNA oligos mentioned above and harvested at the time indicated on each experiment.  
 
Generation of PKCiota Constitutively Active (CA) and Dominant Negative (DN) 
Constructs.  
pCMV6-XL5 PKCiota wildtype (Wt) cDNA was purchased from origene (SC118455) and 
mutated by site-directed mutagenesis using the QuikChange Site-Directed Mutagenesis kit 
(Stratgene). The CA mutation (A129E) and the DN mutation (K122STOP) were performed 
using primers:  
CA Sense: 5’-CCG TAG AGG TGA  ACG CCG CTG GAG AAA GC-3’ 
CA  Antisense: 5’-GCT TTC TCC AGC GGC GTT CAC CTC TAC GG-3’  
DN Sense: 5’-GCC TTG TCC AGG AGA AGA TTA  ATC CAT CTA CCG-3’  
DN Antisense: 5’-CGG TAG ATG GAT TAA TCT TCT CCT GGA CAA GGC-3’  
These mutants have been validated in the literature: (Jamieson, 1999 and Regala, 2005, 
respectively). Confirmation of the targeted mutation was through sequencing using the T7 
primer provided by the DNA core sequencing facility followed by transient transfection into 
293T cells.  
 
Subcloning of pCMV6-XL5-PKCiota Wt, CA, and DN into the pcDNA3.1+ Vector. 
pCMV6-XL5-PKCiota  and pcDNA3.1 constructs were digested with NotI. The vector 
(pcDNA3.1+) and inserts (PKCiota Wt, CA, or DN) were gel purified using the QIAEX II Gel 
Extraction Kit (Qiagen). A 1:3 ratio of vector to insert was ligated (using T4 DNA ligase- 
Roche), and the clones that transduced were subject to sequencing using the T7 primer (as 
above) to determine orientation of insert as well as confirm the mutations within PKCiota. 
 
Cell Sorting using GFP. 
Transient expression of PKCiota. IGROV cells were plated at 1 x 106 cells into 10 cm plates. 
24 hours post-plating, these cells were cotransfected with CMV-GFP and the pcDNA3.1-
PKCiota Wt or CA constructs (or control = pcDNA3.1 alone) using LipoD 293 Transfection 
reagent (Signagen) according to the manufacturer’s protocol. At 24 hours post-transfect, cells 
were trypsinized, washed with PBS, and sorted based on GFP expression. Cell sorting was 
performed using the BD FACSAria. Approximately 1 x 106 cells per condition were added with 
sheath fluid to the nozzle. As individual cells pass through the nozzle, a fluorescent laser is 
passed across the cells and detected by a photomultiplier attached to a readout device thus 
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allowing the GFP positive cells to be deflected into a unique collection tube. The GFP cutoff 
value was determined for each experiment based on transfection with GFP alone. GFP-
negative cells were discarded and GFP-positive cells were examined by Western blot analysis. 
Less than 5% of the original 1 x 106 cells were GFP positive (Vector = 298,000 GFP positive 
cells; Wt = 146,660; and CA = 128,000 for the experiment displayed, which also was an 
indication of other experiments). 
 
 Generation of stable PKCiota expressing IGROV cells. IGROV cells were transfected and 
sorted as above. Following cell sorting, cells were re-plated in alpha complete media 
containing the mammalian selection marker G418. At one week post-selection, single clones 
remained on the tissue culture plate. These clones were picked, grown up, and analyzed by 
Western blot. Of the clones picked, approximately a dozen were designated as ‘potential 
positives’ and were re-examined by Western blot analysis.     
 
Luciferase Assay on Cyclin E-Luciferase. 
The luciferase gene under the control of either the cyclin E promoter (bases -207 to +79 ; 
termed pE) or a mutated cyclin E promoter at two E2F sites (pME) were transfected into 
IGROV shControl or shPKCiota cells using LipoD 293 Transfection Reagent (Signagen) 
according to the manufacturer’s instruction. These two cyclin E reporter constructs, which 
were originally generated as CAT (chloramphenicol acetyltransferase)- reporters (Ohtani, 
1995), were subcloned into luciferase reporter constructs (see Figure M1) (Bresnahan, 1998).  
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Figure M1: Map of pGL3-Basic (pE -207 to +79) 
Vector map of the cyclin E promoter over control of the luciferase reporter gene. The cyclin E 
promoter consists of -207 to +79 as studied in (Ohtani, 1995; Bresnahan, 1998). The cyclin E 
promoter as studied by Ohtani et al was subcloned by Bresnahan et al from the CAT-reporter 
construct into the luciferase reporter construct (pGL3-Basic) through KpnI and SacI restriction 
enzyme digestion. The pME cyclin E reporter construct is similar to the pE with two mutations at 
E2F1 binding sites within the cyclin E promoter region. 
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Lysates were harvested 48 hours post-transfection, and a luciferase assay was performed 
using the “Luciferase Assay System” luciferase kit (Promega). According to the protocol, each 
lysate was resuspended in 100 μL of Luciferase Assay Lysis Buffer. Cells were lysed for 15 
minutes, followed by addition of 20 μL of the cell lysates to a siliconized polypropylene tube. 1 
μL Renilla Luciferase Assay Substrate was added per 100 μL of Luciferase Assay Buffer to a 
separate tube. Immediately before reading, 100 μL of the substrate/ assay buffer was added to 
the cell lysates and read in a luminometer (Monolight 3010- Pharmingen). The controls 
consisted of no cells, no substrate, or mock transfection. Similarly, because pE should be 
activated by E2F1 but pME should be unresponsive, Ad-E2F1 (provided by Dr. Kelly Hunt) at 
1000 MOI was used to validate the findings of the luciferase assay.   
 
qRT-PCR, RNA Isolation, cDNA Synthesis.  
RNA was isolated as previously describe (Chirgwin, 1979). cDNA was synthesized from 
purified RNA using the Transcription First Strand cDNA Synthesis Kit (Roche). This cDNA 
synthesis kit allows for mRNA (with a polyA tail) to be reverse-transcribed with a polyT primer 
into a cDNA transcript. In this kit, 1 μg of mRNA was combined with dT-oligo primer (50 
pmol/μL), Transcriptor Reverse Transcriptase Reaction Buffer (5X), Protector RNase Inhibitor 
(40 U/μL), deoxynucleotide mix (10mM), Transcriptor Reverse Transcriptase (20 U/μL), and 
water. These samples were then run for 60 minutes at 50oC in a thermal cycler (PTC-200, 
Peltier Thermal Cycler- MJ Research) to convert the mRNA to cDNA. Then, the cDNA 
samples were diluted at a 1:50 ratio with autoclaved water and used as a template for qRT-
RPR analysis. Template, SYBR Green, and forward/ reverse primers were added to 96 tube 
plates and subjected to qRT-PCR analysis. Forward/ Reverse primers are as follows: 
Cyclin E Primer 1 (Lin, 2006): 5’- GTC CTG GCT GAA TGT ATA CAT GC -3’ 
Cyclin E Primer 2: 5’- CCC TAT TTT GTT CAG ACA ACA TGG C -3’ 
PKCiota 1 (Self-designed using Pubmed Primer Design Tool): 5’-CGG CAT GTG TAA GGA 
AGG AT-3’ 
PKCiota 2: 5’-CAT CTG GAG TGA GCT GGA CA-3’ 
FBW7 Total 1 (Ekholm-Reed, 2004): 5'-ATGGGCCCTGCTCTTCACTTCATGTCC-3' 
FBW7 Total 2: 5'-CACTGTGCGTTGTATGCATC-3' 
FBW7 Isoform Primers were from (Sangfelt, 2008) 
FBW alpha Primer 1: 5'-GAG CAC ACT GCA AGG AAT GGT GAA GTT-3' 
FBW beta Primer 1: 5’-GTT GCC GGT TCT GCT CCC TAA TCT-3' 
FBW gamma Primer 1: 5'-CCA TGG CTT GGT TCC TGT TGA TCT T-3' 
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FBW alpha, beta, gamma Primer 2: 5'-CCT GTA GGT GGC TGG ACA GAT GT -3' 
p53 Primer 1 (Pattyn, 2003): 5’-TCA ACA AGA TGT TTT GCC AAC TG-3’ 
p53 Primer 2: 5’-ATG TGC TGT GAC TGC TTG TAG ATG-3’ 
 
MG132 Treatment. 
IGROV shPKCiota clones were cultured for 24 hours at which point they were treated with 5 
μM MG132 (Sigma) for 24 hours. 293T cells were plated at low confluency 24 hours prior to 
siRNA transfect (see above). Twenty-four hours post transfection, cells were treated with 5 μM 
MG132. Cells were harvested as above and subjected to western blot analysis with indicated 
antibodies. 
 
RPPA Analysis. 
RPPA (Reverse Phase Protein Array), a high-throughput technique of quantitated proteomic 
analysis, was performed as previously published (Tibes, 2006). The RPPA assay measures 
the change in protein levels (and phospho-protein levels) of hundred of proteins in a high-
throughput manner with little lysate needed. 293T cells were plated at 0.5 x 106 cells per 10 
cm plate. 24 hours post plating, 293T cells were transfected with either vector alone, PKCiota 
Wt, CA, or DN, and harvested 48 hours later as for a Western blot as above.  IGROV lysates 
(7 shControl and 7 shPKCiota) were prepared as for Western blot analysis (see above). 
Lysates were printed onto nitrocellulose-coated glass slides using an automated robotic 
arrayer (GeneTac). Probing these slides is similar to immunoblotting, where slides are 
subjected to a blocking step (for endogenous peroxidase and biotin protein activity). Primary 
antibody treatment was followed by washes and a secondary antibody incubation (biotinylated 
secondary antibody, either anti-mouse or anti-rabbit). The secondary antibody was followed by 
a biotinyl-tyramide deposition (causes amplification of the signal). The amplified signal was 
detected by a readout device (ImageQuant- Molecular Dynamics) and quantitated using an 
automated RPPA module (MicroVigene- VigeneTech). Analysis of the quantitated RPPA data 
was performed using Microsoft Excel.   
 
MEK/ PI3K Inhibition. 
MEK Inhibition. IGROV cells were plated at 0.5 x 106 cells per 10cm plate, and 24 hours later 
were serum starved for 18 hours (using alpha media plus 0.5 % FBS). Following serum 
starvation, the MEK inhibitor, U0126 (10 μM in DMSO) (Promega) was used in the presence of 
alpha complete media alone or supplemented with EGF (100 ng/mL) for 1, 12, and 24 hours.  
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Cells were then harvested and processed for Western blot analysis using antibodies against 
PKCiota, phospho-PKCiota, and cyclin E Results were quantitated by densitometric analysis 
(as above). 
 
PI3K Inhibition. 293T cells were plated at 0.5 x 106 cells per 10 cm plate, and were treated with 
PI3K inhibitors GDC-0941 (Selleck Chemicals) (0, 0.5, 1, 5, 10, and 20 μM) and PI-103 
(Selleck Chemicals) (0, 0.1, 0.5, 1, 1.5, 2.5, 5, and 10 μM) 24 hours post plating. Following 24 
hours of treatment with each PI3K inhibitor, cells were harvested as above and subjected to 
Western blot analysis using antibodies against phospho-PKCiota, PKCiota, and cyclin E. 
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CHAPTER 2: RESULTS 
 
Cyclin E and PKCiota Exhibit an in vivo and in vitro Correlation 
 PKCiota and cyclin E overexpression correlate in serous ovarian cancer patient 
samples, and this correlation results in decreased survival and a poor prognosis (Eder, 2005). 
In order to study the effect of PKCiota on cyclin E or vice versa, the correlation between these 
two oncogenic proteins in vitro needed to be established. To this end, a panel of nineteen 
ovarian cancer cell lines (see Table 1) were examined by Western blot analysis to PKCiota 
and cyclin E.  The PKCiota levels were dichotomized into high and low phospho-PKCiota (the 
active form of PKCiota) groups. In these two groups, cyclin E levels were quantitated by 
densitometric analysis and plotted as a function of PKCiota to examine the correlation of these 
two proteins in vitro. As a control for these analyses, we also examined the expression of 
cyclin E and PKCiota in nine randomly chosen tumor tissue samples (obtained from Dr. 
Isabelle Bedrosian) by Western blot analysis (Figure 1a). PKCiota and cyclin E (both full-
length and LMW-E) levels exhibited similar overexpression patterns (high PKCiota/ cyclin E in 
lanes 1,2, and 5; low in lanes 3, 6-9) consistent with similar findings in high grade serous 
epithelial ovarian cancer patient samples reported by Eder et al (Eder, 2005). p53 levels also 
appeared to be elevated in the high PKCiota/ high cyclin E samples, such as lanes 1, 2, 5, and 
6. However, elafin, the protein responsible for inhibition of the elastase-mediated generation of 
LMW-E, exhibited no correlative pattern, being only expressed in lane 5. We included the 
expression patterns of both p53 and elafin in this study to rule in/out the involvement of these 
proteins in the pathway between cyclin E and PKCiota. The results of the western blot analysis 
using the 19 different ovarian cancer cell lines described in Table 2 revealed that similar to the 
in vivo data, PKCiota levels had a similar expression pattern to that of cyclin E.  However, 
unlike the in vivo data, only the phospho-PKCiota rather than total PKCiota was correlated to 
cyclin E.  Total levels of PKCiota remained unchanged amongst cell lines examined, which 
could be due to the sensitivity of the PKCiota antibody. The following cell lines, FUOV, 
OVCAR3, IGROV, and OAW42 exhibited the highest levels of phospho-PKCiota and total 
cyclin E (full-length, LMW-E-Truncation T1, and LMW-E-Truncation T2), while 59M and 
OVCA420 had the reverse pattern, with low expression of both PKCiota and cyclin E. The 
level of expression of p53, p21, and CDK2 did not correlate to those of PKCiota and cyclin E in 
any of the cell lines. While protein levels of any given protein vary between cell lines, this lack 
of expression patterns could also be due to mutations within these genes. For example, 
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mutations in p53 could lead to p53 accumulation without subsequent activation of p21. We 
next separated cells into two groups of high and low phospho-PKCiota levels, with the cutoff 
value being the average densitometric value of all cell lines. When the levels of high/low 
phospho-PKCiota were compared to cyclin E, a significant correlation between these two 
proteins was noted (Figure 1c). Panel 1 of figure 1c displays the names of the cell lines in 
these two groups, while panel 2 exhibits the averages of the densitometry values of both 
phospho-PKCiota and cyclin E. In the high phospho-PKCiota group, full-length cyclin E (cyclin 
EL) levels are high, while in the low phospho-PKCiota group, cyclin EL levels are low. We 
limited our analysis between phospho-PKCiota and cyclin E to the EL and not the LMW-E 
forms of cyclin E. We believe that because LMW-E is derived from full length cyclin EL, and 
elafin was unaffected, we will likely notice the most significant change in cyclin EL that would 
correspond with further changes in the low forms of cyclin E. Cyclin EL levels as a function of 
phospho-PKCiota were plotted in a linear regression plot, and the correlation co-efficient was 
determined (by the Pearson method) (Figure 1d). A positive and significant correlation (p = 2.5 
x 10-5; r = 0.793) was established for the relationship between PKCiota and cyclin E. 
Therefore, while PKCiota and cyclin E levels correlate in vivo, phospho-PKCiota and cyclin EL 
protein levels correlate in vivo. These initial results raise the following questions: are these two 
important oncogenic proteins directly related in the same pathway, or is there something 
upstream of both of these factors driving the expression of cyclin E and the activity of 
PKCiota?  
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Figure 1: Correlation between phospho-PKCiota and Cyclin E in vitro  
(A) Nine ovarian cancer patient samples were analyzed by Western blot analysis. PKCiota, cyclin E 
(HE-12, which detects full-length (EL), LMW-E-T1 and LMW-E-T2), p53, and elafin antibodies were 
examined. Ponceau stain was used as a loading control. (B) Nineteen ovarian cancer cell lines of 
differing histological backgrounds were examined by Western blot analysis. Phospho-PKCiota, 
PKCiota, Cyclin E (HE-12), p53, p21, CDK2, and actin antibodies were examined. Actin was used 
as a loading control. (C) The protein expression levels of phospho-PKCiota and cyclin EL were 
analyzed by densitometry of the Western blot in (B). The cell lines were then dichotomized into a 
low phospho-PKCiota and a high phospho-PKCiota group, and plotted accordingly. The averages 
of the phospho-PKCiota and cyclin EL levels were plotted and revealed a potential correlation. (D) 
Cyclin EL levels as a function of phospho-PKCiota revealed a significant positive correlation (r = 
0.79; p = 2.5 x 10-5).  
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PKCiota Expression/Activity is Unaffected by Changes in Cyclin E Expression 
PKCiota overexpression correlates with LMW-E expression in serous ovarian cancer 
patient samples leading to a poor prognosis (Eder, 2005). Similarly, phospho-PKCiota levels 
correlate with total cyclin E expression levels in vitro (Figure 1). While a correlation was 
established between PKCiota and cyclin E, the connection between these oncogenic factors 
was not explored in a cause and effect relationship. To establish the effect of cyclin E (full-
length and LMW-E) on PKCiota levels and activity, stable cyclin E overexpressing clones were 
generated in SFHUC and MDA-2774 ovarian cancer cell lines. These two particular ovarian 
cancer cell lines were chosen due to their use in the characterization of LMW-E in ovarian 
cancer as previously published (Bedrosian, 2004; Bedrosian, 2007). However, these cell lines 
were not examined in the initial panel of 19 cell lines (Figure 1) because they were not as well 
characterized for protein expression as the Mills panel of ovarian cancer cell lines.  So, in 
addition to the SFHUCs and the MDA-2774 cell lines, we also examined the effect of cyclin E 
on PKCiota in a transient model using IGROV cells. IGROV cells, which have been 
characterized both by our laboratory as well as that of the Mills’ lab, were chosen due to their 
subtype. IGROV cells are serous epithelial ovarian cancer cells, which is the subtype that 
exhibited the initial correlation between PKCiota expression and LMW-E expression (Eder, 
2005). IGROV cells then were infected with Ad-cyclin EL and Ad-LMW-E followed by analysis 
of PKCiota/phospho-PKCiota by Western blot analysis.  
SFHUC and MDA-2774 cells were chosen due to their inability to process cyclin E into the 
LMW-E isoforms (Bedrosian, 2004; Bedrosian, 2007). Upon transfection with pcDNA3.1 vector 
alone, or cyclin EL, LMW-E-T1, or LMW-E-T2 clones were isolated by selection with G418. To 
generate the SFHUC cyclin E clones, multiple clones were picked and analyzed by Western 
blot analysis using a cyclin E antibody that detects all forms of cyclin E (Figure 2a,b). Clones 
3.1-3 and 3.1-5, transfected with empty vectors, were chosen as the control clones. EL-10 and 
EL-11 were chosen for their high full length cyclin E expression. LMW-E T1-4, T1-22, T2-4, 
and T2-10 were chosen as high LMW-E overexpressing clones. When the stably transfected 
clones from each cell line were subjected to western blot analysis with cyclin E and PKCiota 
the results revealed that PKCiota levels did not change upon stable cyclin E overexpression 
(Figure 3a). MDA-2774 stable cyclin E overexpressing cells exhibited similar pattern of 
expression to those of the SFHUC cyclin E clones. Both PKCiota and phospho-PKCiota levels 
were unaltered by stable overexpression of either cyclin EL or LMW-E. OVCAR-3, which 
expresses both cyclin E and LMW-E was used to compare the level of overexpression to 
endogenous levels of cyclin EL and LMW-E.  
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Since cyclin E levels are subject to cell cycle regulation and its levels can be altered if the 
cells are too confluent, MDA-2774 stable cyclin E overexpressing cells were also analyzed by 
Western blot at varying confluencies (Figure 3b). The results showed that while cyclin E, even 
exogenous cyclin E, was higher in the cells at 70% confluency compared to the cells 
harvested at 40% confluency, this increase in expression did not translate to any change in 
PKCiota or phospho-PKCiota levels. Thus, unlike cyclin E, PKCiota levels are not likely to be 
altered by changes in confluency.  
Since stable clones can have secondary oncogenic and/or signaling hits that could mask 
a potential direct and causal relationship between the transgene and endogenous protein 
being examined, it was important to also examine the relationship between cyclin E and 
PKCiota in a transient system.  For these studies, cyclin E overexpression was examined 
transiently in the serous ovarian cancer cell line, IGROV and OVCA420 ovarian cancer cells 
(which have low endogenous levels of PKCiota and cyclin E). Corresponding to the finding in 
stable SFHUC and MDA-2774 that cyclin E overexpression does not affect PKCiota levels or 
activity, IGROV cells infected transiently with cyclin EL or LMW-E did not exhibit changes in 
PKCiota levels/activity even at 48, 72, and 144 hours post infection (Figure 3c). Similarly, 
OVCA420 cells either transiently infected or transfected with cyclin E did not exhibit changes 
to the level or activity of endogenous PKCiota (Figure 3d). Collectively our results show that in 
four ovarian cancer cell lines under both transient and stable expression of cyclin E, no 
change to PKCiota protein levels or activity was observed. Thus, we conclude that cyclin E is 
likely not a regulator of PKCiota, either directly or in a feedback loop. Although cyclin E 
overexpression can not change the expression of PKCiota, a correlation still exists between 
these two oncogenic proteins. Thus, the question that still subsists, is PKCiota a regulator of 
cyclin E or are these proteins both regulated by an upstream effector molecule that controls 
the up-regulation of both? 
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Figure 2: Screening the Ovarian Cancer Cell Line, SFHUC, for Stable Cyclin E 
Overexpression  
(A) Western blot analysis of SFHUC clones generated by Dr. Isabelle Bedrosian. (B) SFHUC cells 
were transfected with vector alone (3.1), full-length cyclin E (EL) or LMW-E (LMW-E-T1 and LMW-
E-T2). Selection of clones by G418 was performed, and results were analyzed by Western blot 
analysis using cyclin E (HE-12) antibody. PKCiota antibody was also examined but revealed no 
change in levels upon exogenous cyclin E overexpression. Ponceau stain was used as a loading 
control.  Clones highlighted with red boxes were considered potential positive clones and were 
further analyzed for expression.  
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Figure 3: Exogenous Expression of Cyclin E does not Alter PKCiota Levels/ Activity 
(A) MDA2774 and SFHUC cells were transfected with vector alone (3.1), full-length cyclin E (EL) or 
LMW-E (LMW-E-T1 or LMW-E-T2). Stable clones were selected by G418 resistance and were 
subject to Western blot analysis using phospho-PKCiota, PKCiota, cyclin E (HE-12), and actin. 
Actin and Ponceau stain were used as loading controls.  Analysis revealed no change in PKCiota 
levels or activity (as determined using a phospho-PKCiota antibody) upon ectopic cyclin E 
overexpression. (B) MDA2774 stable cyclin E clones were examined by Western blot analysis 
under the same conditions of part (A) but at different confluencies. Confluency did not change the 
lack of effect of cyclin E overexpression of PKCiota. (C) IGROV cells were infected with Adeno-
virus expressing either LacZ (control), EL, LMW-E-T1, or LMW-E-T2. Transient expression of cyclin 
E (at 48, 72, and 144 hours post-infection) was examined by Western blot analysis as above. 
Transient ectopic expression of cyclin E did not alter PKCiota protein levels or activity. Vinculin was 
used as a loading control. (D) OVCA420 cells were infected with Adeno-virus expressing either 
LacZ (control), EL, LMW-E-T1, or LMW-E-T2 or were transfected with pcDNA3.1 vector, EL, LMW-
E-T1, or LMW-E-T2. Transient expression of cyclin E (at 72 hours post-infection/transfection) was 
examined by Western blot analysis as above. Again, transient ectopic expression of cyclin E did 
not alter PKCiota protein levels or activity. Actin was used as a loading control.   
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Cyclin E is Down-regulated by PKCiota Knockdown 
While PKCiota and cyclin E overexpression correlate both in vitro and in vivo, cyclin E 
overexpression fails to influence the levels of PKCiota (Figure 1-3). Thus, if these two proteins 
are in the same pathway, the next question is, does PKCiota expression modulate cyclin E’s 
expression?  More specifically, if PKCiota is down-regulated, does this translate to a decrease 
in cyclin E expression? To test the effect of PKCiota down-regulation on cyclin E levels, an 
ovarian cancer cell line was chosen as a model system based on high expression of both 
phospho-PKCiota and cyclin E. To choose a cell line with this criteria, we referred to our panel 
of 19 ovarian cancer cell lines presented in Table 1 and figure 1 and chose IGROV and 
OVCAR3 ovarian cancer cells based on their high levels of both phospho-PKCiota and cyclin 
E. In these two ovarian cancer cell lines, PKCiota was down-regulated by both stable shRNA 
and transient siRNA and the effect on cyclin E was examined by Western blot analysis to 
cyclin E.  
Once the appropriate cell lines were chosen for high expression of phospho-PKCiota and 
cyclin E, PKCiota was down-regulated by two mechanisms: stable silencing with shRNA to 
PKCiota (shPKCiota) and transient silencing with siRNA (siPKCiota). Stable silencing of 
PKCiota was achieved by transfection with 4 shRNA constructs to PKCiota (shPKCiota 4-8), 
each coding for a unique sequence within PKCiota. Upon examination of the 4 sequences with 
a Pubmed BLAST search, shPKCiota constructs 5 and 6 were determined to have greater 
than one hit and were thus not used in the selection of stable shPKCiota clones in IGROV and 
OVCAR3 cells (See Table 2). shPKCiota construct 7 (against exon 14) and construct 8 
(against exon 13) were used to generate stably-silenced shPKCiota clones. shControl is 
directed again GFP.  
 
Table 2: shRNA Sequences and Information 
shRNA 
Construct  
Against  
 
Sequence 
 
Exons 
 
Blast 
Hits 
3 GFP (-control) Not Determined  -   
5 PKCiota  CGGCATTCTTTGCCACAGGAACCAGTGAT 6,7 4 
6 PKCiota  CAACAGGCGTGCTCACTGTGCCATCTGCA 5,6 4 
7 PKCiota  TGACCAGAACACAGAGGATTATCTCTTCC 14 1 
8 PKCiota  CAGGAGATACAACCAGCACTTTCTGTGGT 13 1 
 
 Before stable shRNA clones were selected for in IGROV and OVCAR3 cell lines, the 
transient down-regulation of PKCiota by shRNA was examined by Western blot analysis with 
phospho-PKCiota and PKCiota (Figure 4). No significant change in PKCiota levels were 
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detected in IGROV, OVCAR3, or FUOV cell lysates 24, 48, or 72 hours post transfection. 
Selection for stable shPKCiota clones using Puromycin was still performed as the efficiency of 
transfection in these cells is very low, requiring the generation of pure clones. While 
shPKCiota constructs 4 and 5 were examined transiently, only shControl and shPKCiota 
constructs 7 and 8 were selected for generation of stable clones in IGROV and OVCAR3 cell 
lines.   
To generate the IGROV shPKCiota stable clones, the concentration of Puromycin to use 
in the selection of clones needed to be established in order to pick the most stringent 
conditions, to allow for best chance of selecting the most downregulated PKCiota clones. 
IGROV cells transfect with shControl, shPKCiota constructs 7, 8, or 7 and 8 combined (7/8), 
were exposed to 0.25, 0.5, or 1 μg/mL Puromycin (Figure S1a). 1 μg/mL Puromycin was 
determined to be the best concentration based on the limited number of clones that remained 
on the plate in comparison to the 0.25 and 0.5 μg/mL Puromycin plates, which still had a 
relatively high number of cells left on the plate one week post-selection. Single colonies were 
picked and cultured in the presence of Puromycin until enough cells were present to make 
lysates. 24 IGROV shControl clones were examined by Western blot analysis with antibodies 
directed against PKCiota and cyclin E (Figure S1b). While the PKCiota levels exhibited very 
little variability, the cyclin E levels varied considerably. This variability in the cyclin E levels was 
likely due to harvesting clones at different confluencies, which would be controlled for in future 
experiments with these cells. 96 shPKCiota construct 7 (24 per plate, plates A, B, C, and D) 
clones were examined (Figure S1c), as well as 24 shPKCiota construct 8 clones (Figure S1d), 
and 72 shPKCiota constructs 7/8 clones (24 per plate, plates A, B, and C) (Figure S1e). Of the 
almost 200 shPKCiota clones examined, over 50 clones displayed knockdown of PKCiota to 
nearly undetectable levels.  
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Figure 4: Transient Overexpression of shPKCiota 
Four shRNA constructs to PKCiota (P5, P6, P7, and P8) and shControl (C) were transfected into 
OVCAR3, FUOV, and IGROV ovarian cancer cell lines. Transient knock-down was examined over 
time (24, 48, and 72 hours) by Western blot analysis with antibodies against phospho-PKCiota, 
PKCiota, cyclin E, and actin (which was the loading control). No significant changes in PKCiota 
levels were detected.  
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 Over 50 IGROV shPKCiota clones were determined to be ‘potential positives.’ 
However, these clones had been cultured under slightly uncontrolled conditions, such as 
freshly made media made versus 2 weeks old media or harvested at 90% versus 40% 
confluency. Thus, in order to rule out the variability of the environmental conditions on cyclin E 
expression, potential positive clones were plated at the same density and harvest 48 hours 
post plating. Seven shControl clones, three clones for shPKCiota construct 7 (the most 
silenced clone per plate), one for shPKCiota construct 8, and three for shPKCiota constructs 
7/8 were chosen for analysis. These lysates were then analyzed by Western blot analysis 
using antibodies to PKCiota, phospho-PKCiota and cyclin E (Figure 5a). When PKCiota was 
stably silenced by shRNA, phospho-PKCiota, cyclin E, CDK4, and cyclin D1 levels decreased 
considerably. Cyclin D1 had already been shown to be regulated transcriptionally by PKCiota 
(Hellbert, 2000; Kampfer, 2001), thus cyclin D1 was used as a control for PKCiota knockdown. 
To quantitatively measure the effect of PKCiota knockdown on cyclin E expression (cyclin EL, 
LMW-E, and total cyclin E), densitometric analysis was performed on all lanes of Figure 5a 
(Figure 5b). The levels of cyclin E varied from clone to clone in the shControl as well as the 
shPKCiota lanes. However, overall, the average cyclin E level in the shPKCiota clones was 
lower than the average cyclin E level in the shControl clones, and this difference was 
statistically significant (p = 0.0021) (Figure 5e). Upon silencing PKCiota, full length (cyclin EL) 
as well as LMW-E decreased (Figure 5c). This led me to believe that cyclin E is a downstream 
mediator of PKCiota. If LMW-E levels varied without much effect on cyclin EL, one could 
conclude that the cyclin E cleavage machinery (either elastase, which cleaves cyclin E, or 
elafin, which inhibits elastase) was being targeted. Similarly, cyclin EL as a function of PKCiota 
expression exhibited a significant positive correlation (r = 0.803; p = 0.0005) (Figure 5d). 
Therefore, because cyclin EL seemed to be down-regulated at a level comparable to LMW-E 
(Figure 5a,b,c) and the levels of cyclin EL correlated with PKCiota expression (Figure 5d), we 
conclude that knockdown of PKCiota, in IGROV serous ovarian cancer cells, is able to induce 
a decrease in cyclin EL and LMW-E expression levels. 
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Figure 5: Analysis of Stable IGROV shPKCiota Clones Indicates Correlation between PKCiota 
and Cyclin E 
(A) IGROV stably silenced shControl and shPKCiota clones(constructs 7, 8, and 7/8) were 
subjected to Western blot analysis using phospho-PKCiota, PKCiota, cyclin E, CDK4, cyclin D1, 
and actin (as loading control). Cyclin E, CDK4, and cyclin D1 seem to decrease in shPKCiota 
clones as compared to shControl clones. (B) Densitometry of the PKCiota, cyclin EL (full-length), 
total cyclin E, or LMW-E to actin ratios were plotted for each individual clone. Averages of all 
shControl and shPKCiota densitometry data was plotted in (C). As PKCiota decreased, so did both 
cyclin EL and LMW-E. (D) Cyclin EL levels were plotted as a function of PKCiota. The result of the 
linear regression plot indicates a significant positive correlation (r = 0.803; p = 0.0005) between 
PKCiota and cyclin E. The dot-plot in (E) demonstrates that although there is a significant 
correlation, some overlap occurs between cyclin E levels in the shControl versus the shPKCiota 
clones.  
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To confirm the ability of PKCiota knockdown to down-regulate cyclin E, a shPKCiota 
reverted clone (shPKCiota clone 7B20) was utilized to examine the resulting change on cyclin 
E upon PKCiota re-expression. After only one passage (passage 2), the expression of 
PKCiota (and phospho-PKCiota) returned in IGROV clone 7B20 (Figure 6). In this reverted 
clone, cyclin E, CDK2, and CDK4 returned. However, no change in p27 or cyclin D1 was 
observed in the reverted clone. Clone shPKCiota 7/8A5 passage 2, which did not revert, was 
used as a control. Therefore we can conclude that cyclin E, CDK2, and CDK4 are likely 
regulated by PKCiota expression/activity in IGROV cells. The ability of PKCiota inhibition to 
cause a decrease in these vital drivers of the cell cycle could potentially be important when 
utilizing PKCiota inhibitors as targeted agents in ovarian cancer. 
The effect of PKCiota knockdown on cyclin E expression needed to be validated in 
another cell line. Initially we used different ovarian cancer cell lines for these experiments. 
OVCAR3, A2780CP, and SKOV3 cells, all of which have relatively high levels of PKCiota and 
cyclin E, were transfected with siRNA to PKCiota (Figure 7a- also see supplemental figure S2, 
S3). However, despite several attempts (see supplemental figures S2, S3) not one of the three 
cell lines exhibited consistent results. Where PKCiota was silenced by siRNA, cyclin E was not 
consistently downregulated, possibly due to a combination of low transfection efficiency 
coupled with the instability of siRNA oligos. We next examined transient PKCiota knockdown 
in 293T cells, which were chosen for siRNA analysis due to their extremely high transfection 
efficiencies. siRNA to PKCiota was transfected into 293T cells, in the presence or absence of 
EGF and insulin (two known regulators of PKCiota) (Figure 7b). When PKCiota was transiently 
knocked down in 293T cells, cyclin E levels corresponded to the decrease in PKCiota levels. 
The results in the 293T cells, reflected the results observed in the IGROV shPKCiota clones, 
that PKCiota knockdown led to a decrease in cyclin E levels (both full length and LMW-E). To 
further validate this result in 293T cells, a second siPKCiota oligo was obtained from Ambion 
(Ambion siPKCiota #311), the company from which the first siPKCiota oligo was obtained 
(Ambion siPKCiota #309), and transfected into these cells (Figure 7c). At 72 hours post-
transfection, both siPKCiota oligos resulted in PKCiota knockdown and subsequent cyclin E 
down-regulation compared to the siControl (Ambion-Scramble). Thus, 293T cells validated our 
results from IGROV cells showing that silencing of PKCiota corresponds with a decrease in 
cyclin EL and LMW-E levels.   
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Figure 6: Reversion of shPKCiota in IGROV Clone 7B20 
Western blot analysis was performed over several passages of clones using phospho-PKCiota, 
PKCiota, cyclin E/D1, CDK2/4, p27, and actin (loading control). Immortalized ovarian surface 
epithelium (IOSE29) were used as a control cell line. As shPKCiota clone 7B20 was passaged, 
PKCiota (and phospho-PKCiota) returned causing re-expression of cyclin E, CDK2, and CDK4. 
No reversion of cyclin D1 or p27 occurred.   
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Figure 7: Transient Knock-down of PKCiota in Various Cell Lines 
(A) Ovarian cancer cell lines: OVCAR3, A2780CP, and SKOV were all transfected with transient 
control (scramble) or PKCiota siRNA over 24, 48, and 72 hours. Western blot analysis using 
phospho-PKCiota, PKCiota, and cyclin E antibodies revealed that transient knock-down in these 
three cell lines would prove to be irregular and unrepeatable. Ponceau stain or actin were used as 
loading controls. (B) 293T cells were also transfected with transient control (scramble) or PKCiota 
siRNA for 72 hours. Western blot analysis using phospho-PKCiota and cyclin E antibodies 
indicated that transient PKCiota knockdown in 293T cells provided a highly reproducible model 
system for examination of the effect of PKCiota on cyclin E. Ponceau stain was used as a loading 
control. (C) Two distinct PKCiota siRNA oligos were used in conditions similar to (B) to determine 
the specificity of the effect of PKCiota knockdown on cyclin E.     
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Specifically, stable knockdown of PKCiota in IGROV cells and transient knockdown in 
OVCAR3 and 293T cells resulted in a decrease in cyclin EL and LMW-E levels. This 
connection between these two important oncogenic proteins raises several questions: does 
overexpression of PKCiota result in a corresponding increase in cyclin E levels and how is 
PKCiota regulating cyclin E? 
 
PKCiota Overexpression Corresponds with Increases in Cyclin Levels 
 Upon knockdown of PKCiota, either stably or transiently, cyclin EL and LMW-E levels 
decrease at the same ratio suggesting that the regulation of cyclin E by PKCiota is most likely 
through regulation of cyclin EL. Cyclin EL in turn modulates the changes in LMW-E without 
affecting the LMW-E-generating machinery. To examine the regulation of cyclin E by PKCiota, 
PKCiota was overexpressed in 293T and IGROV cells, and the effect on cyclin E levels were 
examined by Western blot analysis.  In order to examine the effect of PKCiota overexpression 
on cyclin E, first constitutively active (CA) and dominant negative (DN) mutant constructs were 
generated by site-directed mutagenesis to the PKCiota wild-type (Wt) construct as previously 
described (Jamieson, 1999; Regala, 2005). pCMV6-XL5-PKCiota cDNA, which was purchased 
from Origene, was subject to site-directed mutagenesis (Figure 8a). A mutation of PKCiota 
(A129E/A120E) results in a conformational change of PKCiota into its active or open 
conformation, thus creating a constitutively active (CA) PKCiota mutant (Jamieson, 1999). 
Another mutation of PKCiota (K122STOP/K113STOP) creates a truncated PKCiota, which 
only contains the PB1 domain, and acts as a dominant negative (DN) PKCiota (Regala, 2005). 
Because PKCiota was determined to have 9 additional amino acids at its N-terminus, the 
mutations are labeled differently depending on the time of their publication. After site-directed 
mutagenesis using the primers identified in Figure 8a, ten CA and ten DN constructs were sent 
for sequencing (Figure 8b). Of these 20 constructs, shown in Figure 8b to contain the PKCiota 
insert, three CA and three DN constructs were determined to contain the required mutations. 
Of the three mutated constructs, PKCiota CA clone 3a and PKCiota DN clone 3a were chosen 
for amplification to be used in further experimentation (Figure 8b and S4). Figure S4 shows the 
sequencing data that confirms the necessary mutation in PKCiota CA 3a and PKCiota DN 3a 
compared to the control PKCiota wildtype (Wt) sequence. In 293T cells, overexpression of 
PKCiota Wt and CA, but not PKCiota DN, resulted in an increase in cyclin E levels (Figure 8c). 
Particularly, the increase in cyclin EL was consistent with the hypothesis that PKCiota is 
regulating cyclin E through its expression rather than its processing by elastase/elafin. 
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Figure 8: Generation of PKCiota Wt, CA, and DN  
(A) PKCiota Wt (wildtype) in pCMV6-XL5 vector was subject to site-directed mutagenesis, using 
the indicated primers to make PKCiota CA (constitutively active) and PKCiota DN (dominant 
negative). Mutations necessary are indicated in the figure. (B) Upon site-directed mutagenesis, 
colonies were picked and sent for sequencing. The black circles indicate positive for mutations 
and red circles indicate that was the clone used in future experiments (CA3a and DN3a). (C) 
Transient transfection of these constructs into 293T cells indicate the ability to use these 
constructs in other experiments. Western blot analysis was performed using phospho-PKCiota, 
PKCiota, cyclin E, and actin (loading control). 
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Overexpression of PKCiota, in 293T cells, results in a concomitant increase in cyclin E 
levels. However, the level of PKCiota overexpression is much higher than physiologically 
relevant in 293T cells due to the extremely high transfection efficiency of these cells. To 
overcome this potential problem, PKCiota would need to be overexpression in another cell 
line, preferably an ovarian cancer cell line. IGROV cells were chosen due to the ability of 
PKCiota knockdown in these cells to lead to a decrease in cyclin E levels. Since IGROV cells 
do not transfect well, we co-transfected the different PKCiota vector with GFP and sorted the 
cells to increase the population of positively transfected cells in the sample population. For 
these experiments, IGROV cells were co-transfected with GFP and pcDNA3.1-PKCiota Wt or 
CA. The sorted cells were either harvested immediately for Western blot analysis or re-plated 
and selected with G418 (Figure 9b). The pcDNA3.1+ vector would need to be used instead of 
the pCMV6-XL5, because the latter vector does not contain a mammalian selection marker. 
PKCiota Wt, CA, and DN constructs were subcloned from pCMV6-XL5 to pcDNA3.1+ for the 
purpose of generation of stable clones (see Supplemental Figure S5 for details). 
  Cyclin E levels increased in 293T cells when transfected with PKCiota (either Wt or 
CA). For IGROV cells, they were co-transfected with the pcDNA3.1-PKCiota Wt and CA and 
GFP and sorted cells were subjected to G418 selection and single clones were picked and 
subjected to western blot analysis with an antibody against PKCiota (Figure 9c). The results 
revealed that the level of PKCiota in the ‘potential positive’ clones (lanes 3-9) was only 
modestly higher than the control GFP/pcDNA3.1+ vector clones (lanes 1 and 2), and no trend 
was observed in the levels of cyclin E whether or not PKCiota was overexpressed. However, 
in the GFP+/PKCiota sorted transient PKCiota-expressing cells, both PKCiota Wt (lane 3) and 
PKCiota CA (lane 4) resulted in an a subsequent increase in cyclin E (cyclin EL and LMW-E) 
expression, as well as an increase in cyclin D1, CDK2, and p53 levels and a decrease in p27 
levels (Figure 9d). The levels of cyclin E were quantitated by densitometric analysis (Figure 
9e). The increase in transient PKCiota expression resulted in a corresponding increase in full 
length and LMW-E expression. Thus, in IGROV and 293T cells, transient PKCiota expression 
resulted in an increase in overall cyclin E expression. Because increased cyclin EL levels 
resulted from increased PKCiota expression, this led to the hypothesis that cyclin E was being 
directly regulated by PKCiota rather than through changes in the cleavage machinery of cyclin 
E to generate LMW-E However, if cyclin E was being directly regulated by PKCiota, what is 
the mechanism for this regulation? Cyclin E is likely regulated transcriptionally by PKCiota, 
thus transcription would be the first mechanism of cyclin E regulation examined.  
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Figure 9: Overexpression of PKCiota in IGROV Cells. (A) IGROV ovarian cancer cells were 
transfected with shControl, shPKCiota (constructs 7 or 8), PKCiota (Wt-wildtype, Ca-constitutively 
active, of Dn-dominant negative), and GFP (negative control) and harvested at 24 and 48 hours 
post transfection for analysis by Western blot. Antibodies to phospho-PKCiota and cyclin E reveal 
that no changes in the activity of PKCiota (and therefore PKCiota levels) were observed. Ponceau 
stain was used as a loading control. (B) Schematic of cell sorting that occurred to overcome the 
lack of effect observed in (A). (C) Final result of the cell sorting/ selection with G418 clone isolation 
process that resulted in changes in PKCiota levels, but no change in cyclin E. Western blotting was 
performed as above. (D) Final result of the transient cell sorting that was run on Western blot as 
above immediately following sorting.  Antibodies to phospho-PKCiota, PKCiota, cyclin E, cyclin D1, 
CDK2, and p53 reveal that as PKCiota levels are increased, so are phospho-PKCiota , p53, CDK2, 
and the cyclins. The p27 antibody however indicated a decrease in p27 in response to PKCiota 
overexpression. This change in cyclin E in response to PKCiota was quantitated using 
densitometry (E). Actin was used as the loading control.  Site-directed mutagenesis of PKCiota Wt 
into PKCiota  Ca and DN. Subcloning PKCiota into a vector with G418 resistance (pcDNA3.1+) 
was necessary for this figure. See the next figure for generation of these necessary constructs.    
 
 
161
 
 
162
The Regulation of Cyclin EL by PKCiota is Not at the level of Transcription 
 PKCiota is able to up-regulate cyclin D1 protein levels, and this regulation is through a 
transcriptional increase in cyclin D1 (Hellbert, 2000; Mwanjewe, 2001). Therefore, because 
cyclin D1 and cyclin E are both upregulated in response to PKCiota, we hypothesized that the 
regulation of cyclin E by PKCiota could be transcriptional. To test the effect of PKCiota on 
cyclin E transcription, we used a cyclin E promoter-luciferase gene construct and compared 
the difference between shControl IGROVs and shPKCiota stably silenced IGROV cells for 
their ability to transcriptionally activate cyclin E.  
 Transcriptional regulation of cyclin E occurs in response to mitogenic factors and 
involves the transcription factor E2F1 (Ohtani, 1995; Botz, 1996). The regulation of cyclin E by 
E2F1 was determined by use of two cyclin E reporter constructs, one with the cyclin E 
promoter (-207 to +79; termed pE) and one with the cyclin E promoter with two mutations at 
E2F1 binding sites (termed pME) (Ohtani, 1995) (Figure 10a). To ensure that cyclin E 
transcriptional activity can be modulated by its own activator, we also included Ad-E2F1as a 
positive control for these studies (Figure 10b). In the control lane (no luciferase construct), no 
luciferase activity was observed. However, pE and to a lesser extent pME exhibited luciferase 
activity in IGROV cells. In the presence of Ad-E2F1, pE luciferase activity increased 6-fold 
while pME luciferase activity remained unaffected. Thus, the pE and pME constructs provide a 
feasible system for the investigation of transcriptional regulation of cyclin E by PKCiota.  Next 
we used IGROV cells stably expressing either shControl or shPKCiota to determine if 
downregulation of PKCiota modulates the transcriptional activity of cyclin E as measured by 
the pE (and pME) cyclin E luciferase reporter construct (Figure 10c). The results revealed that 
no difference in cyclin E transcription was observed between the IGROV shControl and 
shPKCiota cells. Thus, the regulation of cyclin E by PKCiota is likely through another 
mechanism rather than transcription. 
 To confirm the finding that cyclin E was not transcriptionally regulated by PKCiota, 
qRT-PCR was also used to measure cyclin E mRNA levels under both stable and transient 
knockdown of cyclin E in IGROV cells. While stable knockdown of PKCiota in IGROVs using 
shRNA to PKCiota has been documented (Figures 5 and 6), PKCiota would need to be 
transiently silenced in IGROV cells to determine the immediate effect on cyclin E transcription 
(Figure 10d). Upon the transient silencing of PKCiota with siRNA, mRNA was harvested at 24, 
48, 72, and 96 hours post transfection and subjected to qRT-PCR analysis of cyclin E 
transcription (see Figure 10e for a time table). While the PKCiota transcript decreased upon 
siPKCiota transfection, the cyclin E levels remained unchanged at all 4 time points (Figure 
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10f). To test the validity of the cyclin E primer, IGROV cells infected with Ad-Cyclin E-T1 
(IGROV-T1) were used as a control. No change was observed in cyclin E levels at 24, 48, 72, 
and 96 hours post siPKCiota transfection, thus validating the results of the cyclin E reporter 
gene study.  
 The cyclin E reporter gene assay (Figure 10 a-c) was performed using IGROV stable 
shPKCiota clones and resulted in no change in cyclin E transcription. To examine the cyclin E 
mRNA levels in the IGROV shPKCiota clones, qRT-PCR of cyclin E (and PKCiota as a 
control) was performed (Figure 10). While PKCiota mRNA levels were substantially decreased 
in the shPKCiota clones compared to the shControl clones (right panel), no pattern of cyclin E 
mRNA down-regulation was observed in these clones (left panel). The levels of cyclin E 
mRNA did vary from clone to clone, however, this was unlikely to be due to PKCiota stable 
knockdown due to the lack of a pattern among clones. Thus, based on the data observed 
using a cyclin E reported construct and qRT-PCR, we conclude that the regulation of cyclin E 
by PKCiota is non-transcriptional in IGROV cells. 
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Figure 10: Regulation of Cyclin E by PKCiota is Non-Transcriptional 
(A) Schematic representation of the pE and pME luciferase reporter constructs used to determine 
cyclin E promoter activity.  pE contains the cyclin E promoter sites -207 to +79. pME contains the 
same bases as pE, but with mutation at two putative E2F-binding sites (TGTCCCGC at position +7 
to TGTCATGC and changed TTCCGCGC at position -16 to TTCCGATC ). These promoter sites 
were published in : OHTANI, K., DEGREGORI, NEVINS, J. PNAS. Vol. 92, pp. 12146-12150, 
December 1995. (B) Luciferase Assay demonstrating the validity of these two constructs in IGROV 
cells. E2F adenovirus increased pE activity while not affecting pME activity. (C) Luciferase assay 
comparing cyclin E transcriptional upregulation in the shControl IGROV cells versus the shPKCiota 
stably silenced clones. No difference was detected between these two groups. (D) Western blot 
analysis was performed to confirm knockdown of PKCiota in siPKCiota samples. Cyclin E protein 
levels decrease upon silencing of PKCiota.  Actin was used as a loading control. (E) Timeline of 
qRT-PCR experiment in (F). Upon transient knockdown of PKCiota for 24, 48, 72, and 96 hours, 
RNA was harvested at each time point and used for analysis of cyclin E mRNA levels. (F) qRT-
PCR of IGROV samples listed in part (E). While PKCiota RNA expression levels decreased, cyclin 
E remained unchanged. IGROV infected with cyclin E-T1 (IGROV-T1) was used as a control for the 
cyclin E primers. GAPDH was used as a loading control, thus all samples were normalized to 
GAPDH of that sample. (G) qRT-PCR of IGROV stably knocked down PKCiota samples. Ad-T1 is 
positive control for the cyclin E promoter. 3A11 and 3A12 are shControl IGROV cell lines, while 
7A19, 8A18, and 7B8 are shPKCiota IGROV cell lines. Similar to part (F), PKCiota RNA expression 
levels decreased, while cyclin E remained unchanged. Expression levels were normalized as in 
part (F). 
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Cyclin E Stability is Regulated by PKCiota 
In addition to the transcriptional regulation of cyclin E, cyclin E is also regulated by 
degradation. As a dividing cell passes through S-phase, cyclin E levels decrease due to 
ubiquitin-mediated degradation. More specifically, cyclin E gets phosphorylated by either 
CDK2 of GSK3 at specific sites (at T62, S372, T380, and S384) and is then able to bind FBW7 
(F-box and WD-40 domain protein 7), which transports cyclin E to the SCF (Skp1-Cullin1-F-
box) ubiquitin ligase complex for degradation (Koepp, 2001; Moberg, 2001; Strohmaier, 2001; 
Welcker, 2003). Cyclin E levels decrease in response to knockdown of PKCiota, which here 
and based on our lack of transcriptional regulation, we hypothesize to be through increased 
degradation as opposed to decreased transcription. To examine the regulation of cyclin E 
stability by PKCiota, we overexpressed exogenous cyclin E (through adenovirus infection) in 
stably silenced IGROV shPKCiota cells and quantitatively measured the levels of cyclin E. 
Because cyclin E transcriptional regulation would then be under the CMV promoter instead of 
the cyclin E promoter, we can conclude that any changes in cyclin E levels are likely post-
translational (such as ubiquitin-mediated degradation). In order to determine if changes in 
cyclin E levels were a result of proteasomal degradation, MG132 (a proteasome inhibitor) was 
used to block degradation. If cyclin E is not degraded in the presence of MG132, even in 
response to PKCiota knockdown, then the regulation of cyclin E by PKCiota is likely through 
the degradation of cyclin E. 
To determine the effect of PKCiota knockdown on exogenous cyclin E expression, IGROV 
shPKCiota cells were infected with either Ad-LacZ, Ad-Cyclin EL, Ad-LMW-E-T1, or Ad-LMW-
E-T2 and the resulting levels if cyclin E were examined by Western blot analysis (Figure 11a). 
Although the two shControl and the two shPKCiota cell lines were infected simultaneously with 
Ad-cyclin at the same MOIs, the expression level of cyclin EL, LMW-E-T1, and LMW-E-T2 
were lower in the cells with stable knockdown of PKCiota compared to the control cells. The 
exogenous cyclin E was under the control of the CMV promoter and thus could not be 
regulated at the same transcriptional level as endogenous cyclin E (which was also decreased 
in the shPKCiota clones). The levels of endogenous cyclin E (Ad-LacZ) and exogenous cyclin 
E (Ad-cyclin EL, LMW-E-T1, and LMW-E-T2) were quantitated by densitometric analysis 
(Figure 11b). While the levels of cyclin E decrease in all conditions, only cyclin EL and LMW-
E-T2 were shown to be significant (p = 0.028 and p = 0.019, respectively). LMW-E-T1 was 
also decreased in the shPKCiota clones compared to the shControl clones. However, this 
decrease in LMW-E-T1 expression was not significant. The lack of significance of the LMW-E-
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T1 decrease could be due to the extremely large amount of LMW-E-T1 that was expressed. 
The levels of FBW-7 and the components of the SCF complex could lead to a potential limiting 
threshold effect in the degradation of cyclin E. While the decreased exogenous cyclin E protein 
levels in the shPKCiota clones compared to the shControl clones implies regulation via 
degradation, the direct effect of cyclin E degradation in response to PKCiota knockdown would 
need to be investigated further. 
While PKCiota knockdown results in a decrease in both endogenous and exogenous 
cyclin E, the direct effect of PKCiota knockdown on the proteasome needs to be addressed. 
To investigate the proteasomal regulation of cyclin E by PKCiota, the proteasome inhibitor, 
MG132, was used in the presence of both stable (IGROV cells) and transient (293T cells) 
PKCiota knockdown (Figure 11c). Silencing PKCiota was able to cause a decrease in cyclin E 
as seen in lane 3 (IGROV shPKCiota) and lane 4 (293T siPKCiota) compared to the controls, 
lanes 1 and 5 respectively. However, upon addition of 5 μM MG132, cyclin E failed to be 
degraded, implying PKCiota regulation of cyclin E is through regulation of proteasomal 
degradation. The total cyclin E and the PKCiota (control) levels of these lanes were 
quantitated by densitometric analysis (Figure 11d). In the IGROV stable PKCiota knockdown 
cells (left panel), addition of MG132 resulted in a partial return of cyclin E as compared to the 
293T cells (right panel), which exhibited a complete return of cyclin E in response to MG132. 
This could be easily explained by the stable versus transient nature of the two model systems. 
While the 293T cells have only functioned without PKCiota and as a result cyclin E for a matter 
of days, these cells are likely unable to select for cells that survive through upregulation of 
alternative pathways. Conversely, the stable IGROV shRNA cells have been passaged three 
times (at multiple days each) without PKCiota (and thus cyclin E) and have potentially been 
able to up-regulate PKCiota/cyclin E- independent survival pathways-through secondary 
oncogenic events. Because of the possible selection in IGROV stable shPKCiota clones, 
cyclin E could likely not be up-regulated at the same rate as the pre-shRNA cells, accounting 
for the lack of complete return of cyclin E levels in IGROV shPKCiota cells in response to 
MG132. Therefore, due to the ability of PKCiota knockdown to cause a decrease in exogenous 
cyclin E and the ability of MG132 to block cyclin E degradation, we conclude that regulation of 
cyclin E by PKCiota knockdown in both IGROV and 293T cells is post-translational, specifically 
this regulation is at the level of proteasomal degradation. Because cyclin E degradation is 
mediated by the F-box protein, FBW7, the effect of PKCiota knockdown on this protein needs 
to also be addressed.      
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Figure 11: PKCiota Knockdown Affects Cyclin E Stability 
(A) IGROV stably silenced shControl and shPKCiota clones were infected with Ad-LacZ (control), 
Ad-Cyclin EL, Ad-LMW-E-T1, and Ad-LMW-E-T2. shControl clones 1 (3A11) and 2 (3A12) and 
shPKCiota clones 1(7A19) and 2 (8A18) were infected for 48 hours with adenovirus, and lysates 
were subjected to Western blot analysis using phospho-PKCiota, PKCiota, cyclin E (HE-12), and 
vinculin (loading control).  When PKCiota levels decreased, so did exogenous cyclin EL, LMW-E-
T1, and LMW-E-T2. The levels of cyclin E and phospho-PKCiota (control) were quantitated by 
densitometric analysis (B). The decrease in cyclin EL and LMW-E-T2 were statistically significant 
between the average shControl and the average shPKCiota expression levels (p = 0.028 and p = 
0.019, respectively).  (C) In both IGROV stable shPKCiota cells and 293T transient siPKCiota cells, 
MG132 at least partially blocked degradation of cyclin E (full length and LMW-E). Western blot 
analysis was performed using phospho-PKCiota, PKCiota, cyclin E, p21 (control for MG132 
response), and actin (loading control).  Although all samples were run on the same gel, the 
exposure time for cyclin E and p21 Western blots were much longer in the 293T cells than the 
IGROV cells due to the innately low endogenous levels of these two proteins in 293T cells. With 
both stable (IGROVs) and transient (293Ts) PKCiota knockdown, addition of MG132 blocked the 
degradation of cyclin E, which was quantitated by densitometric analysis (D).  
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Because cyclin E protein levels decrease in response to PKCiota knockdown, we 
hypothesized that FBW7 expression would increase, which could account for the decrease in 
cyclin E. To determine the effect of PKCiota knockdown on FBW7 expression, IGROV cells 
transiently silenced with siRNA against PKCiota were examined for changes in FBW7 
expression (both total and individual isoforms) by qRT-PCR analysis. IGROV cells were 
transfected with either no siRNA, siControl (scramble), or siPKCiota for 48 hours and RNA 
was harvested for qRT-PCR analysis (Figure 12a and 12b). Positive (PKCiota) and negative 
(cyclin E and p53) controls (Figure 12a) as well as FBW7 α, β, and γ isoforms (Figure 12b) 
were examined. In response to PKCiota knockdown, PKCiota and FBW7 levels appeared to 
decrease while the negative controls (cyclin E and p53) remained unchanged. Thus, although 
we hypothesized that FBW7 levels would increase, we found that they actually decreased by 
48 hours post PKCiota knockdown. This decrease in FBW7 could be due to an initial increase 
in FBW7 levels resulting in a negative feedback loop. To test the levels of FBW7 expression 
as a function of time, we examined FBW7 (both isoforms and total) at 24, 48, 72, and 96 hours 
(Figure 12c and 12d). While FBW7 individual isoforms (Figure 12c) and total FBW7 (Figure 
12d) mRNA levels varied, no significant trend was observed. Thus, changes in FBW7 mRNA 
levels are likely not the cause of PKCiota knockdown-induced cyclin E degradation. However, 
because changes are not seen at the mRNA level, does not mean that there are not changes 
at the level of protein or localization that could be influencing the degradation of cyclin E in this 
circumstance. 
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Figure 12: PKCiota Knockdown Does Not Result in Increased FBW7 Expression 
(A,B) qRT-PCR was performed on IGROV cells with transiently silenced PKCiota (at 48 hours). No 
siRNA and siControl (scramble) were used as controls for the siPKCiota RNA sample. (A) Primers 
to PKCiota (positive control) and p53 and cyclin E (negative controls) were used to determine the 
ability to use these RNA samples for examination of FBW7 expression. (B) Primers to FBW7 alpha, 
beta, and gamma were used to examine the mRNA expression levels of these three transcripts at 
48 hours. FBW7 alpha, beta, and gamma all appeared to have decreased expression at 48 hours. 
(C) qRT-PCR of FBW7 alpha, beta, and gamma in siControl and siPKCiota in IGROV cells over a 
24 to 96 hour time frame. No trend in FBW7 alpha, beta, and gamma appeared. (D) qRT-PCR of 
FBW7-Total in siControl and siPKCiota in IGROV cells over a 24 to 96 hour time frame. No 
apparent or consistent trend in FBW7-Total was observed in response to PKCiota downregulation  
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RPPA Analysis of Ectopic PKCiota Reveals Potential Pathways for Cyclin E Regulation 
PKCiota regulates the stability of cyclin E, both full length and LMW-E. However, this 
regulation is not through the transcriptional regulation of FBW7. Thus, potential pathways that 
would affect both PKCiota and cyclin E would need to be identified. To identify several 
pathways simultaneously we used an RPPA (Reverse Phase Protein Array) assay with 293T 
cells transiently expressing PKCiota and IGROV stably silenced shRNA samples. In utilizing a 
protein expression-based array such as the RPPA assay we are able to examine hundreds of 
protein expression levels in a high-throughput manner (Tibes, 2006). RPPA analysis was 
performed on the IGROV shRNA clones (first panel: 7 control [rows 1-7] and 7 shPKCiota 
[rows 8-14]) as well as transiently expressed PKCiota wildtype (Wt), constitutively active (CA), 
and dominant negative (DN) in 293T cells (second panel) (Figure 13a-293T and S6a-IGROV). 
To validate the change in PKCiota protein levels in the two RPPA sets (293Ts and IGROVs), 
Western blot analysis was used (Figure 13b and S6b, respectively). Because of the increased 
passage of IGROV shRNA cells, cyclin E levels returned in the shPKCiota clones, rendering 
these clones as potentially useless (Figure S6b). However, transient expression of PKCiota 
both Wt and CA but not DN in 293T cells resulted in an increase in cyclin E (both cyclin EL 
and LMW-E levels) (Figure 13b). These 293T PKCiota-transfected cell lysates yielded 
promising hits in their RPPA analysis (Figure 13c,d). PKCiota overexpression resulted in a 
number of increased and decreased proteins within the PI3K pathway. In Figure 13c, the 
antibodies in bold print indicate a greater possibility of a valid hit. However, these antibodies 
would still need to be validated by Western blot analysis. Figure S6c shows the graphs of the 
potential increased and decreased protein levels in response to PKCiota overexpression in 
293T cells. The black titles indicate an increase in expression, while the red titles indicate a 
decrease in expression. Of note, MEK/phospho-MEK and the PI3K pathway returned several 
positive hits in the RPPA analysis of PKCiota-overexpressing 293T cells (Figure 13d). All 
proteins that are highlighted in green increased in response to PKCiota Wt and CA expression, 
while proteins highlighted in red decreased. As indicated by the affected proteins, translation 
(decreased S6 and increased GSK3) and apoptosis (decreased Caspase 9) should be 
inhibited, while anchorage-independent growth (increased cyclin E) and proliferation 
(increased c-myc, STAT3, and cyclin E) should be increased. Thus, MEK and PI3K pathways, 
which are known factors that influence or are influenced by PKCiota, will be examined in cyclin 
E regulation.    
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Figure 13: RPPA Analysis of 293T Cells with PKCiota Overexpression 
(A) Reverse Phase Protein Array (RPPA) heatmap for 293T samples analyzed. 293T samples 
transiently transfected with PKCiota wildtype (Wt), constitutively active (CA), or dominant negative 
(DN) were analyzed. (B) Western blot analysis depicting the 293T transiently transfected cells used 
in the RPPA assay in part (A). Antibodies against phospho-PKCiota, PKCiota and cyclin E were 
used, while actin was used as a loading control. (C) List of proteins whose expression levels either 
increased or decreased in the 293T-PKCiota Wt and CA samples but not the control or PKCiota 
DN samples. Bold letters indicate higher possibility of a true effect. (D) Schematic representation of 
the PI3K pathway. Green circles represent potential upregulated proteins (or phosphorylation 
events, see part (C) for details) in the PKCiota Wt and CA samples of the RPPA assay, while the 
red circles represent potential downregulated proteins.  
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Regulation of Cyclin E by PKCiota is MEK-Independent but PI3K-Dependent 
The RPPA assay of PKCiota overexpression in 293T cells revealed several potential 
factors that could provide the mechanism of cyclin E inhibition as highlighted in the pathway 
that RPPA proteins target (Figure 13d). One of the downstream targets identified in the RPPA 
screen was MEK. Of note, PKCiota has been shown to activate MEK1/2 through the:  PKCiota 
Æ Rac1 Æ Pak Æ MEK1/2 Æ ERK1/2 pathway (resulting in transformation) (Zhang, 2004; 
Regala, 2005; Regala, 2008; Justilien, 2009; Scotti, 2010). However, regulation of MEK has 
also been shown to be PKCiota-independent (Kampfer, 1998; Hellbert, 2000). Similarly, in 
IGROV cells, PKCiota knockdown did not reveal any relevant pattern of phospho-ERK 
expression (data not shown). However, Ras has been shown to regulate cyclin E degradation 
in an FBW7 and MEK-dependent, but PI3K independent manner in HELA and NIH3T3 cells 
with ectopic expression of cyclin E/CDK2, FBW7, RasV12, and MEK (Minella, 2005). To 
examine the effect of MEK on cyclin E expression, the MEK inhibitor, U0126, was used on 
IGROV cells, and the resulting levels of cyclin E were analyzed by Western blot analysis. 
Because MEK is likely to be downstream of PKCiota, cyclin E levels should decrease without 
further modulating PKCiota or phospho-PKCiota. To examine the effect of the MEK inhibitor, 
U0126, on cyclin E expression, IGROV parental cells were serum starved for 18 hours 
followed by addition of serum and U0126 in the presence or absence of EGF (Figure 14a). 
While cyclin E levels decreased in the presence of U0126, so did the levels of both total and 
phospho-PKCiota. Figure 14b gives the quantitative densitometric analysis of Figure 14a. 
Because the levels of PKCiota were altered in response to MEK inhibition, we were unable to 
conclude that PKCiota knockdown was MEK-dependent. One possible explanation is that 
inhibition of MEK could possibly be causing the decrease in cyclin E through the decrease in 
PKCiota. Also, because PKCiota knockdown resulted in no obvious pattern of phospho-ERK 
expression, we conclude that MEK is likely not the PKCiota effector molecule responsible for 
cyclin E regulation.   
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Figure 14: Inhibition of MEK Decreases both Cyclin E and PKCiota Protein Levels 
(A) IGROV cells were treated with the MEK inhibitor, U0126, for 1, 12, and 24 hours in the 
presence or absence of EGF. Western blot analysis was performed using antibodies against 
phospho-PKCiota, PKCiota, cyclin E, and actin (loading control). Both PKCiota and cyclin E levels 
were quantitated against actin levels using densitometric analysis (B). Expression levels of PKCiota 
and total cyclin E were normalized to the untreated control expression level of each group. Both 
PKCiota and total cyclin E levels decreased in response to U0126 regardless of the presence of 
EGF.   
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PKCiota is also downstream of PI3K-PDK1 (Chou, 1998; Akimoto, 1998; Standaert, 1999; 
Kanoh, 2003). It is possible that PI3K inhibition would result in a decrease in phospho-PKCiota 
levels, leading to a decrease in cyclin E expression. To examine the effect of PI3K inhibitors 
on cyclin E expression, the inhibitors GDC-0941 and PI-103 were used to treat 293T parental 
cells followed by Western blot analysis. The PI3K inhibitors, GDC-0941 and PI-103, were used 
at increasing doses to determine their effect on phospho-PKCiota compared to PKCiota 
(Figure 15a). While the active form of PKCiota (phospho-PKCiota) decreased in response to 
PI3K inhibitors, steady-state levels of PKCiota remained unaffected. Thus, PKCiota signaling 
is inhibited by the inhibition of PKCiota. To test the effect of PI3K inhibition on cyclin E levels, 
these two PI3K inhibitors were used to treat 293T cells based on the concentrations tested in 
Figure 15a (Figure 15b). Both PI3K inhibitors resulted in decreased phospho-PKCiota and 
cyclin E (cyclin EL and LMW-E) levels. This decrease in cyclin E was quantitated by 
densitometric analysis (Figure 15c). Both inhibitors resulted in considerable decreases in 
cyclin E expression. Thus, we conclude that inhibition of PI3K results in decreased phospho-
PKCiota leading to decreased cyclin E expression.  
Therefore, we have shown that PKCiota is upstream of cyclin E. More specifically, 
PKCiota knockdown results in decreased cyclin E stability as opposed to decreased 
transcriptional regulation. The regulation of cyclin E by PKCiota is downstream of PI3K (Figure 
16). Thus, PI3K or PKCiota inhibitors could clinically provide a feasible target for inhibition of 
several oncogenic pathways simultaneously. 
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Figure 15: Inhibition of PI3K Decreases Cyclin E Expression 
(A) 293T cells were exposed to PI3K inhibitors, GDC-0941 and PI-103, at increasing 
concentrations. Western blot analysis was used to examine changes in phospho-PKCiota and 
PKCiota levels. Ponceau stain was used as a loading control. (B) Based on the concentration of 
GDC-0941 and PI-103 from part (A), these two PI3K inhibitors were used on 293T cells and cyclin 
E expression was measured by Western blot analysis. Antibodies to phospho-AKT and AKT were 
used to validate the effectiveness of the GDC-0941 and PI-103. Actin was used as the loading 
control. The cyclin E (both cyclin EL and total cyclin E) levels were quantitated by densitometric 
analysis using the untreated counterpart as the control (C). Drug-treated sample values were 
normalized to the control untreated sample then normalized to actin levels. Error bars represent 
standard error.  
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CHAPTER 2: DISCUSSION 
 
 
 In this chapter, we demonstrated that PKCiota can regulate cyclin E expression, both 
the full length form (cyclin EL) and the low molecular weight isoforms (LMW-E), in several 
model systems through both overexpression and targeted knockdown of PKCiota. However, 
changes in cyclin E (both cyclin EL and LMW-E) in several cell lines under both transient and 
stable conditions were unable to alter the expression or activation of PKCiota. Thus, no 
feedback loop between cyclin E and PKCiota exists. PKCiota and cyclin E are both amplified 
and overexpressed in epithelial ovarian cancer and are designated as oncogenes based on 
their ability to drive ovarian cancer tumorigenesis (Bast, 2009). These two oncogenes had also 
previously been shown to correlate in human ovarian cancer, and a direct effect of PKCiota on 
both cyclin E and proliferation had been demonstrated in an in vivo drosophila eye model 
(Eder, 2005).  
While PKCiota is able to transcriptionally regulate cyclin D1 (Hellbert, 2000; Kampfer, 
2001), we have shown that cyclin E is regulated in a different manner by PKCiota than cyclin 
D1. We found that PKCiota regulates cyclin E stability instead of its synthesis. Of note, in 
1995, Minella et al found that cyclin E stability was regulated by Ras and was dependent on 
MEK (Minella, 2005). Using an RPPA assay, which measures protein expression, we identified 
MEK as being upregulated in response to PKCiota overexpression, even though the increase 
was moderate at best. Using a MEK-inhibitor (U0126), we did indeed decrease cyclin E levels. 
However, U0126-treatment also resulted in decreased phospho-PKCiota and total PKCiota 
levels, providing another role for MEK.  One new role for MEK, that my study has provided, is 
the possibility that it can modulate cyclin E’s protein levels directly. This seemed plausible, due 
to the findings of Minella et al that degradation of cyclin E occurred through MEK (Minella, 
2005). However, in the Minella study, the MEK inhibitor was only used with exogenous 
expression of cyclin E and CDK2 along with exogenous expression of RasV12, FBW7, MEK, 
or a combination of these proteins. Alternatively, based on the results from my study, it is 
possible that the effect of the MEK inhibitor on PKCiota lead to an indirect effect on cyclin E 
through a decrease in PKCiota protein levels. Either way, the effect of U0126 on cyclin E was 
nowhere near as pronounced as the effect that direct downregulation of PKCiota had on cyclin 
E levels.  Also, by examining phospho-ERK (which is phosphorylated in response to MEK) by 
Western blot analysis in IGROV PKCiota knockdown cells, no pattern in phospho-ERK 
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expression was identified. Collectively, these findings led us to conclude that regulation of 
cyclin E by PKCiota is likely not through MEK.  
In the publication by Minella et al, the PI3K inhibitor, LY294002 was used to 
demonstrate that cyclin E regulation by Ras was not in the PI3K pathway (Minella, 2005). 
Similarly, when we used the same approach and treated cells with LY294002, we found no 
effect on cyclin E levels as measured by Western blot analysis (data not shown). However, 
using two alternative PI3K inhibitors, GDC-0941 and PI-103, we found that only the phospho-
form of PKCiota changed (total PKCiota remained unchanged) in response to PI3K inhibition, 
but at higher concentrations, cyclin E levels also decreased. Thus, the PI3K pathway has 
implications in the regulation of cyclin E through PKCiota.  
The PI3K catalytic subunit gene, PIK3CA, is located on chromosome 3q26.3. This loci 
is important because, in addition to housing the PKCiota gene (PRKCI), this loci is also the site 
of the most frequently amplified genomic amplicon in ovarian cancer (Suzuki, 2000). While 
PKCiota is overexpressed in nearly 80% of epithelial ovarian cancer and mislocalized in 100% 
of serous epithelial ovarian cancer, the PI3K pathway is overexpressed in 70% of epithelial 
ovarian cancers (Bast, 2009; Eder, 2005; Bast, 2008). This activation of the PI3K pathway is 
not only through the genomic amplification of PIK3CA, but also through other mutations, 
including activating mutations within PIK3CA and inactivating mutations in PTEN, the tumor 
suppressor gene which inhibits PI3K activity (Bast, 2009). Interestingly, in xenograft mouse 
models, PI3K inhibitors are able to inhibit ovarian cancer proliferation, and these inhibitors are 
entering Phase I and II clinical trials (Hu, 2002; Raynaud, 2007). Thus, at least part of the 
potential mechanism of PI3K inhibitors in vivo could be through inhibition of PKCiota resulting 
in decreased cyclin E levels, and thus less uncontrolled tumor cell proliferation. In the next 
chapter, we will be discussing the vital role of cyclin E in PKCiota-induced transformation, 
which could also be part of the mechanism of PI3K inhibitor-induced growth arrest in mouse 
xenograft models. 
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Figure 16: PKCiota Regulation of Cyclin E through PI3K 
Schematic representation of the regulation of cyclin E by PI3K, possibly through mTOR and the 
phosphorylation of STAT3. PI-103 and GDC-0941 are PI3K inhibitors (PI-103 has off target affects 
on mTOR). Roscovitine is a CDK2-inhibitor.  
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As mentioned, the inhibition of PKCiota phosphorylation by the two PI3K inhibitors (in 
Figure 15) was at low concentrations, while the effect on cyclin E was not until the higher 
concentrations. In fact, with GDC-0941, only the highest used concentration of this drug (20 
μM) resulted in decreases in cyclin E levels. PI-103 however, exhibited a dose-dependent 
decrease in cyclin E levels starting at 1.5 μM and increasing until the final used concentration 
of 10 μM. PI-103, while it is a PI3K inhibitor, also inhibits mTOR at similar IC50 values to those 
of PI3K.  mTOR is also downstream of PI3K, and according to our RPPA assay with 
overexpressed PKCiota, mTOR levels are increased 3-fold in 293T cells overexpressing 
PKCiota wildtype (Wt) and constitutively active (CA) but not dominant negative (DN) mutant 
constructs (Figure 13d and 16). Furthermore, the MEK inhibitor used in Figure 14, U0126, has 
the ability to decrease mTOR signaling, which could potentially account for the changes in 
cyclin E levels see upon U0126 treatment (Fukazawa, 2000). Thus, mTOR could potentially be 
part of the mechanism of regulation of cyclin E by PI3K/PKCiota (Figure 16).  
STAT3 is another potential effector molecule linking PI3K, PKCiota, and cyclin E. 
STAT3, which is upregulated by both IL6 and mTOR (Zhou, 2007; Fujitani, 1994), was also 
identified in our RPPA screen as being upregulated by 2-fold in PKCiota Wt and CA-
overexpressing cells. Phospho-STAT3 (Ser727) was found to be increased by 3-fold in 
PKCiota Wt cells and nearly 6-fold in PKCiota CA cells. In addition to tyrosine phosphorylation 
at Tyr705 (by Src or TYK2), phosphorylation of Ser727 is also required for the transcriptional 
activation by STAT3 (Wen, 1995). Activation of STAT3 by PKCiota is nothing novel. Two 
recent studies have shown that PKCiota can cause STAT3 activation/ phosphorylation. (1) In 
human chondrocytes, PKCiota contributes to inflammatory joint disease through the pathway: 
IL1 Æ PKCiota Æ STAT3 phosphorylation (Litherland, 2010). (2) In prostate cancer cells, 
PKCiota caused IL6/STAT3 induction resulting in an autocrine response loop. Specifically, 
PKCiota knockdown by RNAi resulted in suppression of both STAT3 phosphorylation as well 
as IL6 expression (Ishiguro, 2009). Thus, it is highly possible that PKCiota could regulate 
cyclin E through a PI3K Æ PKCiota Æ mTOR/STAT3 Æ cyclin E pathway (Figure 16). 
In addition to STAT3 being downstream of PKCiota, STAT3 has also been 
demonstrated to be upstream of cyclin E regulation, providing the potential link between 
PKCiota and cyclin E. STAT3 has been shown to lead to the G1/S transition at least in part 
due to its regulation of cyclin E levels/ activity. As for cyclin E/CDK2 activity, when STAT3 is 
downregulated, it can result in decreased cyclin E activity through upregulation of the CKIs, 
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p21 and p27 (Fukada, 1998). In our study, upon PKCiota knockdown, we observed a 
decreased in p27 levels, which can result in decreased cyclin E activity. Several studies have 
shown cyclin E levels decrease in response to STAT3 inhibition. (1) Cyclin E levels decreased 
in response to mutant dominant negative STAT3 expression (STAT3D) (Odajima, 2000). (2) In 
another study, siRNA to STAT3 resulted in decreased cyclin E levels in pancreatic cancer cells 
(Bharadwaj, 2008). (3) Similarly, in HCT116 and SW480 cells, upon addition of anti-sense 
STAT3, CDKs 2/4/and 6, and cyclins D1 and E levels all decreased (Ma, 2003). In our own 
study, we found that upon PKCiota knockdown, CDKs 2 and 4 as well as cyclins D1 and E 
decreased (Figures 5 and 6). While we did not examine the effect of STAT3 knockdown on 
cyclin E levels, the literature would suggest that decreased STAT3 phosphorylation by 
PKCiota knockdown could be the reason for decreased cyclin E levels. Thus, inhibition of 
STAT3 by PKCiota knockdown could potentially account for several of the effects we observed 
on the cell cycle regulators, including the effect we observed in the decrease of cyclin E levels.  
 Therefore, in this chapter, we have demonstrated that PI3K, PKCiota, and cyclin E, 
most likely through mTOR/ STAT3 activation, provide a novel ovarian cancer pathway to be 
targeted therapeutically. In serous epithelial ovarian cancer, because PKCiota is always 
mislocalized or overexpressed (Eder, 2005), ovarian cancer patients with this cancer subtype 
would be most likely to benefit from PKCiota inhibition. For non-serous epithelial ovarian 
cancer, screening these patients based on amplification of chromosome 3q26.3, the loci for 
the genes that encode PI3K and PKCiota, would be a means for identifying the subpopulation 
of patients with non-serous epithelial ovarian cancer who would be most likely to benefit from 
PI3K or PKCiota-targeted therapies via this novel cancer pathway.  
 
 
182
 
 
 
 
 
 
 
 
CHAPTER 3: 
 
 
The Functional Relevance of the PKCiota/ Cyclin E Pathway  
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CHAPTER 3: INTRODUCTION 
 
Ovarian cancer is the leading cause of cancer-related death among the gynecologic 
malignancies (CF&F, 2010). While little progress has been made in the way of targeted 
therapeutics for ovarian cancer treatment, several potential targets have been identified, 
including cyclin E and PKCiota, which are both genomically amplified and overexpressed in 
ovarian cancer (Courjal, 1996, Marone, 1998; Eder, 2005; Bast, 2009). Because we have 
shown that PKCiota regulates cyclin E levels (Chapter 2), we examined which important 
functions of PKCiota require cyclin E. Also, because cyclin E is an essential regulator of the 
cell cycle, we examined the effect of PKCiota on the cell cycle. Identification of the PKCiota-
cyclin E functions, allows for stratification of ovarian cancer patients into those who would be 
most likely to benefit from PKCiota-targeted therapies and those who would not.   
PKCiota, an atypical member of the protein kinase C (PKC) family of serine/threonine 
kinases, is a bona fide oncogene in ovarian cancer (Zhang, 2006). PKCiota is involved in 
many diverse functions, such as proliferation, migration, transformation, and establishment 
and maintenance of apical-basal polarity (Weichert, 2003; Noda, 2001; Coghlan, 2000; Eder, 
2005). The mechanism by which PKCiota overexpression is able to disrupt epithelial cell 
polarity is through upregulation of cyclin E, which in turn leads to increased proliferation (Eder, 
2005). PKCiota and cyclin E expression correlate in high grade serous epithelial tumors, which 
exhibit a poor prognosis (Eder, 2005). Thus, it seems feasible that the other functions of 
PKCiota could potentially require cyclin E.   
Cyclin E, through binding to its catalytic binding partner CDK2, is essential for the G1 
to S-phase transition (Ohtsubo, 1993; Ohtsubo, 1995; Resnitzky, 1994). Improper regulation of 
cyclin E can result in increased proliferation and transformation, which can lead to increased 
tumorigenesis (Resnitzky, 1994; Fang, 1996; Kang, 1996). In ovarian cancer, cyclin E is 
genomically amplified and overexpressed (Courjal, 1996; Marone, 1998) and can be cleaved 
post-translationally into hyperactive low molecular weight isoforms (LMW-E) (Bedrosian, 
2004). LMW-E can lead to increased tumorigenesis through increased proliferation, increased 
cyclin E-dependent CDK2 kinase activity, resistance to p21/p27, and induction of genomic 
instability (Bedrosian, 2004; Wingate, 2005; Porter, 2001; Akli, 2004; Corin, 2006; Wingate, 
2003; Bagheri-Yarmand, 2010; Bagheri-Yarmand, 2010). However, PKCiota knockdown 
results in decreased cyclin E stability (both full length cyclin E and LMW-E) (Chapter 2). 
In this chapter, we examined the functional relationship between PKCiota and cyclin E 
in serous epithelial ovarian cancer. We found that PKCiota knockdown results in a decrease 
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number of proliferating cells through a G1 arrest as opposed to increased cell death. In 3D-
matrigel, downregulation of PKCiota in IGROV serous ovarian cancer cells resulted in a return 
to an apical-basal polarized-like acinus structure, complete with upregulation of E-cadherin 
and alpha 6 integrin. However, this result was likely cyclin E-independent, due to the inability 
of endogenous cyclin E reversion to rescue the phenotype. We found that decreases in cyclin 
E and cyclin E-associated kinase activity were both necessary and sufficient in causing a 
PKCiota-knockdown-mediated decrease in anchorage-independent growth. Lastly, we found 
that PKCiota knockdown-induced decreased migration was independent of cyclin E. 
Summarized, either PKCiota-or cyclin E- targeted therapies could provide a means of 
inhibiting anchorage-independent growth in serous epithelial ovarian tumors. 
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CHAPTER 3: METHODS 
Methods are in the order of appearance in this chapter. 
 
Tissue Culture/ Generation of Stable Clones. See Chapter 2 
 
MTT Assay. 
Using a 96-well plate (tissue culture-treated, flat-bottomed plate- Costar 3595), 5,000 cells/200 
µl of cell suspension was added to each well (Day 1). After 24hrs post plating (Day 1), cells 
were treated with drug (either ATM-aurothiomalate, ATG-aurothioglucose, or Oncrasin-1) at 
varying concentrations. This drug plus induction was incubated at 37°C for 3 days (until Day 
5). At day 5, the cells were immediately harvested by addition of 50µL of 2.5mg/mL MTT 
reagent (Sigma M-5655- Methylthiazolyldiphenyl-tetrazolium bromide) in serum-free media per 
well. The plates were then sealed in foil and incubated at 37°C for 4 hours. Post-incubation, 
these 96-well plates were then aspirated, and 100μL solubilization solution (0.04N HCL, 
1%SDS, in isopropyl alcohol) was added to each well. Plates were then lightly agitated at 
room temperature for 2-3 hours. After solubilization occurred, these plates were read at 590nm 
by the Perkin Elmer- Wallac- Victor3 1420 multilabel counter. Results were analyzed using 
Microsoft Excel. 
 
Western Blot Analysis. See Chapter 2 
Primary Antibodies. For a complete list of antibodies used, see Chapter 2, plus this antibody: 
E-cadherin (BD Transduction Labs 1:250 in Blotto)   
 
Growth Curves/ Doubling Time Analysis. 
All cell lines analyzed, see results for details, were plated in triplicate at 25,000 cells per well 
(6-well plates-Costar) on day 0. Cell numbers were counted every 48 hours for eight days 
using a Coulter counter. Cell numbers were averaged and analyzed in Microsoft Excel. 
Doubling times were determined using the results of the growth curves according to the 
formula DB = (0.301 x ∆T)/ (Log10 [N/No]).  
 
FACS Cell Cycle Analysis. 
Cells were plated in duplicate at 0.5 x 106 cells per plate on day 1. At day 2, fresh media was 
added. At day 3, cells were trypsinized and washed with cold PBS two times. Cell pellet was 
resuspended in 1.5 mL cold PBS by vortexing while PBS was added drop wise. 3.5 mL of ice 
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cold 200 proof EtOH was then added drop wise. Cells were then fixed overnight at 4oC. The 
PBS:EtOH solution was removed and fixed cells were washed with cold PBS twice. Cell pellet 
was then resuspended to an approximate concentration 1 x 106 cells/ mL in PPR (40 mL 
PBTB; 400 µL 1 mg/mL PI- propidium iodide; 80 μLof 10 mg/mL RNAase A). PBTB (0.5% 
Tween 20 and 0.5% BSA in PBS). Cell:PPR mixture was wrapped in foil and incubated at 
37oC for 1 hour before being analyzed by a flow cytometer (BD Facscalibur) in the MD 
Anderson core facility. Readouts were analyzed by Microsoft Excel.  
 
Apoptosis Analysis. 
SubG1 Population. SubG1 population was determined by use of FACS samples- above. When 
the cell cycle distribution was determined by flow cytometry, the subG1 fraction was noted and 
analyzed using Microsoft Excel. 
TUNEL Assay. All samples were prepared/ fixed as with the FACS analysis- see above. The 
percent TUNEL positive cells were established using a TUNEL assay kit (APO-BRDU Kit- BD 
Pharmingen) as per the manufacturer’s instruction. Positive and negative controls were 
provided in the kit. Percent positive TUNEL cells were determined using a flow cytometer (BD 
Facscalibur) in the MD Anderson core facility. Readouts were analyzed by Microsoft Excel.    
 
3D Culture- Plating Cells in Matrigel.  
Growth Factor Reduced (GFR) Matrigel (BD Biosciences Cat # 356231) was thawed on ice for 
one hour and plated evenly at 40 μL per chamber on 8-chamber slides (Nunc) being careful 
not to cause air bubbles. Slides were then incubated at 37oC for 15 minutes to allow for 
polymerization. Pre-trypsinized cells were rinsed one time with fresh media before being 
plated at 2500 cells per chamber in 400 μL of media and 2% matrigel. Media used was Alpha 
Complete Media (HyQ MEM alpha-modification cell culture medium (HyClone) which was 
supplemented with 10% fetal bovine serum (FBS), 10 mM HEPES, non-essential amino acids, 
2 mM L-glutamine, sodium pyruvate, hydrocortisone, and 10μg/mL Cipro). Media (plus 2% 
matrigel) was changed every 4 days for 14 days.    
 
3D Culture- Staining/ Confocal Microscopy. 
All solutions were filter sterilized before use in staining.  
Fixation: Media (with 2% matrigel) was aspirated from chamber slides. Residual matrigel/cells 
were rinsed with cold sterile PBS three times (5 minutes each wash) and fixed with 4% 
paraformaldehyde (4% PFA in PBS- freshly prepared) for ten minutes at room temperature. 
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Slides were then washed with cold sterile PBS three times (5 minutes each).   
Permeabilization:  Methanol (100%) was then added to the slides for 10 minutes. PBS 
containing 0.5% Triton X-100 was added to the slides for 10 minutes at room temperature. 
Slides were then washed with cold sterile PBS three times (5 minutes each). 
Blocking Solution:  Add blocking solution (3% bovine serum albumin- BSA and 1% horse 
serum in PBS) and incubate 1 to 2 hours at room temperature. Slides were then washed with 
cold sterile PBS three times (5 minutes each). 
Primary Antibody: Primary antibody (1:1000 to 1:5000 in blocking buffer) was added to the 
slides and incubated overnight at 4oC. To prevent contamination, slides were wrapped in 
parafilm before 4oC incubation. Slides were then washed with cold sterile PBS three times (5 
minutes each). Primary Antibodies Used: Primary antibodies used were PKCiota (BD 
Transduction Laboratories- 610176), cyclin E (HE-12, Santa Cruz Biotechnology), Phospho-
PKCiota (Abcam: Phospho T555 + T563) 
Secondary Antibody: Fluorescent conjugated secondary antibody (1:2000- Alexa-conjugated; 
Molecular Probes) was added to the slides and incubated at room temperature in the dark for 
1 hour. Slides were then washed with cold sterile PBS three times (5 minutes each). Slides 
were then stained with DAPI (4’,6-diamidino-2-phenylindole) at 0.5 ng/mL (5 μL in 2 mL of 
PBS) for 15 minutes in the dark at room temperature. Slides were then washed with cold 
sterile PBS three times (5 minutes each). The chambers were then removed from the slides 
and a cover slip was mounted with mounting solution (Dako). After the cover slip was allowed 
to dry (approximately 15 minutes) slides were sealed with nail hardener and placed in the cold 
room until able to be read. Confocal microscopy was performed using the Olympus DSU 
spinning disc confocal fluorescent microscope.  
 
Soft Agar Colony Formation.  
Base Agar. Make 2.4% Noble agar (Difco) in autoclaved water. Heat to melt agar in the 
microwave. Combine pre-warmed (37oC) complete media with 2.4% Noble agar at an 80:20 
ratio. Immediately add 1 mL/ per plate (35mm plates- gridded). Allow to cool while preparing 
the top agar and cells. 
Top Agar. Combine 5.8 mL pre-warmed completely media with 1mL 2.4% Noble agar (from 
above) and 1 mL of 1 x 105 cells/mL. Immediately add 1mL of the cells: agar mixture on top of 
the base agar plates. Incubate at 37oC/ 6.5% CO2 for 14 days.  
Analysis. Count gridded cells completely both horizontally and vertically. Analyzed cell counts 
using Microsoft Excel. 
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Infection with Ad-Cyclin E. See Chapter 2. 
 
Wound Heal Assay.  
In 6-well plates, cells were cultured to 90% confluency. Cells were the serum starved 
overnight. Using a black marker, a reference line was drawn on the bottom of each well. Using 
a sterile p200 pipet tip, 3 scratches were made perpendicular to the reference line. Cells were 
then rinsed and 1.5 mL fresh complete media was added. Pictures were taken at 10X zoom on 
an inverted microscope at 0 hours and then every 6-12 hours depending on the experiment. 
Fresh media was added before each picture. The same scratch was measured for each 
condition. Pictures were printed and measured with a ruler. The distance of wound closure at 
each time point was documented and total numbers were analyzed using Microsoft Excel. 
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CHAPTER 3: RESULTS 
 
PKCiota Alters Proliferation through Cyclin E and Changes in Cell Cycle Distribution 
PKCiota has been implicated in the proliferation of ovarian cancer (Weichert, 2003). In 
a drosophila in vivo model, overexpression of PKCiota resulted in increased proliferation as 
determined by BrdU incorporation, most likely due to a subsequent increase in the cell cycle 
protein, cyclin E. Also, in tissue microarrays, PKCiota exhibited a significant positive 
correlation with cyclin E (p = 0.01) and proliferation as determined by Ki67 levels (p = 0.02) 
(Eder, 2005).  
In Chapter 2, we demonstrated that knockdown of PKCiota caused a decrease in cyclin 
E protein levels. Because PKCiota is involved in cyclin E regulation, we expect proliferation to 
decrease in response to PKCiota inhibition in ovarian cancer cells. To test the need for cyclin 
E inhibition as the mechanism of decreased proliferation by inhibition of PKCiota, we used the 
PKCiota inhibitors, aurothiomalate (ATM), aurothioglucose (ATG), and oncrasin, in IGROV and 
OVCAR3 cells. IGROV cells were chosen because stable knockdown of PKCiota resulted in 
decreased cyclin E levels (Chapter 2: Figure 7 and 8). Likewise, OVCAR3 cells were chosen 
because stable knockdown of PKCiota did not result in alterations of cyclin E levels (Chapter 
2: Figure 9c). The PKCiota inhibitors, ATG and ATM, did not alter the rate of proliferation in the 
OVCAR3 cells (Figures 1a and 1b, respectively). This result was not surprising, given the 
inability of PKCiota knockdown to change cyclin E levels. In OVCAR3 cells, ATG and ATM did 
not alter the expression of phospho-PKCiota, PKCiota, or cyclin E (Figure 1c and 1d). While 
PKCiota inhibition in OVCAR3 cells did not alter the proliferation rate, in IGROV cells, both 
ATM and the Ras/PKCiota inhibitor oncrasin (Guo, 2008; Guo, 2009) were able to decrease 
proliferation (Figure 1e and 1f). However, phospho-PKCiota and cyclin E levels did not 
decrease in response to these two inhibitors (Figure 1g). Thus, PKCiota inhibition results in a 
decrease in proliferation in IGROV cells but not OVCAR3 cells. This decrease in proliferation 
in IGROV cells is seen without detectable changes in phospho-PKCiota or cyclin E. The lack 
of changes in protein levels in IGROV cells treated with ATM and oncrasin can be explained 
by the ability of the proliferating cells to upregulate either alternative pathways or alter 
regulation within the PKCiota/cyclin E pathway, in response to PKCiota inhibition. This effect 
was observed in IGROV cells previously, when PKCiota was stably silenced, after several 
passages, PKCiota remained silenced but cyclin E protein returned (Chapter 2; Figure 18b). 
Therefore, inhibition of PKCiota by small molecule inhibitors in IGROV cells resulted in a 
decrease in proliferation. However, as with any small molecule inhibitors, non-specific events 
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can occur. To rule out the possibility of the decrease in proliferation being non-specific, we 
would need to examine the direct effect of PKCiota knockdown on proliferation. 
PKCiota inhibition by ATM and oncrasin resulted in a decrease in proliferation as 
determined by MTT assay. In order to exclude the possibility of non-specific targets mediating 
this effect on IGROV cell proliferation, we need to specifically target PKCiota and examine the 
effect on proliferation. To investigate the role of PKCiota in proliferation, we stably silenced 
PKCiota using shRNA and subjected these cells to growth curves in order to measure 
changes in doubling times. Also, to rule out the possibility of cell death being the cause of a 
decrease in cell number, TUNEL and FACS (subG1) analysis were performed to determine 
the percentage of apoptotic cells. In IGROV cells, when PKCiota was stably silenced, over 
time the number of cells declined compared to the control (Figure 2a-all clones and 2b-
averages of clones). In fact, after eight days, the number of cells decreased from 3 x 106 cells 
to 2 x 106, a 33% decrease upon PKCiota knockdown. This change in the rate of growth 
corresponded with a significant increase in doubling time (p = 0.043) (Figure 2c). Because the 
number of cells could be skewed by an apoptotic effect, the possibility of PKCiota knockdown-
induced apoptosis needed to be excluded. No change was observed in the percentage of 
apoptotic cells when PKCiota was silenced (Figure 2f). Using both TUNEL and subG1 FACS 
analysis, no change was observed in the number of apoptotic cells in the shPKCiota clones 
compared to the shControl clones. Thus PKCiota is able to decrease proliferation in IGROV 
cells independent of cell death. This raises the question, do changes in PKCiota alter cell cycle 
distribution? 
When PKCiota is stably silenced in IGROV cells, the proliferation rate decreases 
unaided by cell death. In chapter 2, we saw that the cell cycle proteins, CDK2/4 and cyclins 
D1/E decreased and p27 increased in response to PKCiota knockdown (Chapter 2; Figures 
7a, 8). Given these two points, we hypothesized that changes in cell cycle proteins as a result 
of PKCiota knockdown would translate to a change in cell cycle distribution. To test this 
hypothesis, we used FACS analysis with PI staining to determine the percentage of cells 
(IGROV shPKCiota versus shControl clones) in the different phases of the cell cycle. Upon 
PKCiota knockdown, the percentage of cells present in the G1 phase increases with a 
corresponding decrease in the S-phase fraction (Figures 2d and 2e). The G2-phase fraction 
remains unaffected. Thus, PKCiota knockdown results in an apparent G1 arrest, which could 
account for the decrease in the proliferation rate. While proliferation in 2D cultures is an 
important first step, the need for more in vivo- like studies is essential for physiological 
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relevance. Thus, the effect of PKCiota knockdown in 3D cultures is vital, especially given 
PKCiota’s vital role in establishment and maintenance of apical-basal polarity.           
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Figure 1: PKCiota Inhibition by Small Molecule 
Compounds  
OVCAR3 cells did not respond to the PKCiota inhibitors (A) 
aurothioglucose –ATG or (B) aurothiomalate –ATM as 
determined by an MTT Proliferation Assay. Similarly, as 
analyzed by Western blot analysis, no change in phospho-
PKCiota, PKCiota, or cyclin E protein levels occurred in 
response to ATG (C) and ATM (D) treatment for 48 hours. 
Actin was used as a loading control. In IGROV cells, ATM 
(E), and the K-Ras/PKCiota inhibitor, Oncrasin (F), 
decreased proliferation according to the MTT Proliferation 
Assay. (G) The levels of phospho-PKCiota remained 
unchanged at IC50 values according to (E) and (F), while 
cyclin E levels slightly increased as measured by Western 
blot analysis. Actin was use
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d as a loading control.  
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Figure 2: PKCiota Knockdown Leads to Decreased Proliferation Through Alterations in the Cell Cycle 
(A) Growth curves showing IGROV shControl clones (3A11, 3A12) and shPKCiota clones (7A19, 
7B8, 7B9, 7D8, and 8A18). (B) Growth curves with the averages of the IGROV shControl and 
shPKCiota clones from (A). * p = 0.01.  (C) Averages of the doubling times of the IGROV shControl 
and shPKCiota clones from part (A). p = 0.043. (D) FACS cell cycle analysis of IGROV shControl 
and shPKCiota clones. Changes in the phases of the cell cycle were measured and graphed with 
standard deviation (E). The G1 fraction increased, the S fraction decreased, and the G2 phase 
remained unchanged. (F) Apoptosis in the IGROV transient siRNA of PKCiota (versus control) was 
measured by both quantitation of the SubG1 fraction (by FACS) as well as TUNEL analysis. BD 
Biosciences ‘positive control’ cells were used as the positive control.    
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In 3D Matrigel PKCiota Expression is Indicative of a More Aggressive Phenotype  
PKCiota, a component of the PKCiota/PAR-6/PAR-3 polarity complex, is mislocalized or 
overexpressed in serous epithelial ovarian cancer (Eder, 2005). We hypothesized that 
PKCiota knockdown could revert the tumor cells in 3D matrigel (in vivo-like culture) to a pre-
tumorigenic like structure. To test this hypothesis, we examined cell lines with different 
PKCiota expression levels in both 2D and 3D culture conditions. Then, we used IGROV 
serous epithelial cells with stably silenced PKCiota to examine the role of PKCiota in the 
structure/ size of 3D acini. Using cells with low (HeyA8; 59M) or high (OVCAR3; IGROV) 
PKCiota/ cyclin E levels as determined by Western blot analysis in Chapter 2 (Chapter 2; 
Figure 1b and 1c), we plated these cells in 3D matrigel to examine the resulting phenotype 
(Figure 3a). In 3D matrigel, ovarian cancer cells with low PKCiota/cyclin E levels formed either 
a blanket layer of cells on top of the matrigel (HeyA8) or very small/ spherical acini (59M) 
versus the cells with high PKCiota/ cyclin E levels (OVCAR3 and IGROV), which formed large 
asymmetric acini, possibly indicative of a more tumorigenic phenotype. Quantitation analysis 
of the acini revealed that the averages of the diameter of the acini were significantly larger in 
the OVCAR3 and IGROV cell lines than the 59M cell line (p = 0.0007 and p = 1.8 x 10-11, 
respectively) (Figure 3b). Similarly, the percent of asymmetric acini was significantly higher for 
the OVCAR3 and IGROV cell lines than the 59M cells (p = 0.00006 and p = 0.004, 
respectively). However, the number of acini was not significantly different between these cell 
lines. This lack of difference in the number of acini is likely due to the large, clumped, globular 
structures that are observed in the OVCAR3 and IGROV cell lines, making these structures 
difficult to quantitate. However, in 2D culture conditions the low PKCiota/ cyclin E cells grew 
with a more spread blanket-like phenotype compared to the high PKCiota/ cyclin E cells, which 
grew in tight clusters. The expression levels did not seem to change between the 2D and 3D 
conditions as determined by Western blot analysis (Figure 3c). Thus, we conclude that high 
expression levels of PKCiota/ cyclin E could potentially be an indicator of larger, asymmetric 
3D acini. However, all cell lines are heterogeneous and no two are identical, thus protein 
manipulation would need to be performed in a single cell line to validate the effect of PKCiota 
on the aggressive phenotype in 3D culture.   
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Figure 3:  Differential Expression of PKCiota / Cyclin E in 3D Matrigel  
(A) Cell lines with low PKCiota/ cyclin E expression (HEYA8 and 59M) versus those with high 
PKCiota/ cyclin E (OVCAR3 and IGROV) were plated and photographed over time in 2D versus 3D 
matrigel culture. Images are 4X on left panels (2D) and 10X on the right (3D). (B) Quantitation and 
statistical analysis of the size (diameter), average number of acini per section, and percent 
asymmetry of the acini from part (A). The HeyA8 cell line does not form acini. (C) Expression of 
PKCiota and cyclin E were examined in these two conditions in all four cell lines by Western blot 
analysis with antibodies against PKCiota and cyclin E; actin was used as a loading control.   
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 While PKCiota levels seem to correlate with a more aggressive 3D culture phenotype 
(a greater number of acini, that are larger and asymmetric in morphology), we needed to know 
if this correlation could be directly linked to PKCiota. To address this question, we used 
IGROV PKCiota stably silenced clones or the PKCiota inhibitor, ATM to examine the resulting 
acini morphology in 3D matrigel. When PKCiota was stably silenced in IGROV cells, the size 
and morphology of the acini appeared more normal-like, exhibiting apical-basal-like polarity 
with a cleared lumen (Figure 4a and 5a). In the shPKCiota clones, the acini were significantly 
smaller (p = 0.00003) and were more symmetrical (p = 0.002) than the shControl clones at 
Day 15. However, while the number of acini structures appeared to be lower, these results 
were not significant (p = 0.08). The use of the PKCiota inhibitor, ATM (100 μM) resulted in a 
significant decrease in the number of acini in the shControl clones (IC50= 100 μM) versus the 
shPKCiota clones (80% inhibition at 100 μM), which show resistance to ATM (p = 0.03) 
(Figure 4b). While ATM did not cause a significant decrease in the size or asymmetry of the 
acini in the shControl or shPKCiota clones, significant decreases at each ATM concentration 
were observed between the shControl and shPKCiota clones. Therefore, only the number of 
acini (not the size or symmetry) was affected by ATM-treatment, and this effect was increased 
in the shControl clones as opposed to the shPKCiota clones, which no longer overexpress 
PKCiota. This affect validates the find that ATM, through PKCiota inhibition, leads to a 30% 
greater decrease in the number of acini in a 3D matrigel system. In order to exclude the 
possibility that the phenotype observed in Figure 4a,b was simply clonal variation, we clonally 
isolated IGROV parental cells into 24 isolates and cultured these cells in 2D (Figure 4d) and 
3D (Figure 4c) conditions. In 3D conditions (Figure 4c), several clones (i.e. 5, 6, 7, and 13) 
appeared either smaller or polarized-like, but this phenotype did not correspond to the 
PKCiota/cyclin E levels as determined by Western blot analysis (Figure 4d), which also varied 
extensively. The average diameter was significantly smaller in the shPKCiota clone 1 than all 
the shControl isolates (p < 0.005 when compared to any individual shControl isolate). 
However, shPKCiota clones 2 and 3 did not differ significantly in size. Also according to the 
quantitation, the number of colonies does not differ between the shControl and shPKCiota 
clones, but the average of the percent asymmetry of the shPKCiota is significantly smaller 
than the average percent asymmetry of the shControl clones (p = 0.04). Thus, the decrease in 
the tumorigenic-like phenotype in 3D matrigel in the IGROV shPKCiota clones when compared 
to the shControl clones could potentially be due to clonal variation. Thus, another 3D approach 
would need to be utilized to determine the role of PKCiota in a 3D system.  Similarly, different 
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markers of polarity would need to be examined in both 2D and 3D culture conditions in several 
IGROV shPKCiota clones, instead of only two.  
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Figure 4: PKCiota Knockdown Results in Decreased Number / Size of 3D Matrigel Acini  
(A) Two IGROV shControl and 2 shPKCiota clones were plated in matrigel and imaged at days 4, 8, 12, and 
15. Images are at 10X zoom. Diameter (size), average number of acini per section (n), and the percent 
asymmetric acini for Day 15 were quantitated and plotted. n (shControl) = 66 and n (shPKCiota) = 36. *p = 
0.00003 and ** p= 0.002.(B) In IGROV cells from part (A), increasing concentrations of the PKCiota 
inhibitor, aurothiomalate (ATM) were used over a period of 2 weeks. Images are at 4X zoom. Dead cells 
(dirty looking matrigel) occurred at the highest concentration, mainly in the shControl clones. Acini size, 
number, and symmetry were quantitated and plotted at 0, 1, 10, and 100 micromolar concentrations of 
ATM. Significance for each plot was indicated to the right of its respective graph. If no p-value was 
indicated, the result for that graph was not statistically significant. N-values for 0 ATM, Control= 90, 
PKCiota= 76; 1 ATM, Control= 90; PKCiota= 72; 10 ATM, Control= 72, PKCiota= 65; 100 ATM, Control= 
47, PKCiota= 50. (C) Clonal isolates of IGROV parental cells were plated in matrigel and imaged after 2 
weeks. IGROV shPKCiota cells were used as a control. Acini were measured (diameter) and counted 
(total number and asymmetric number) and quantitated accordingly. * p-value is less than 0.005 for all 24 
shControl isolates compared to the shPKCiota clone 1. shPKCiota clones 2 and 3 were not statistically 
significant. ** p-value is 0.04 comparing the average percent asymmetry of the shControl isolates to the 
average of the shPKCiota clones. (D) Western blot analysis of clonal isolates from part (C). Antibodies 
against phospho-PKCiota and cyclin E were examined. Ponceau stain was used as a loading control.  
Linear Regression of total cyclin E levels as a function of phospho-PKCiota levels was plotted, correlation 
coefficient (r) = 0.87, p = 1 x 10-6. (E)  Acini diameter from part (C) was plotted as a function of phospho-
PKCiota levels (panel 1) and cyclin E levels (panel 2) from part (D) densitometry. For phospho-PKCiota 
levels, r = 0.35, p = 0.09; for cyclin E, also = 0.35, p = 0.09. 
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In 3D culture, knockdown of PKCiota induced a return to normal-like acini, as indicated 
by a cleared lumen and restored apical-basal polarity. However, the possibility of this effect 
being clonal variation could not be excluded. Thus, we needed to next examine the 
downstream polarity effects in several IGROV shPKCiota clones. The hypothesis is that in 3D 
matrigel, PKCiota knockdown can cause a reversion to a polarized state through re-expression 
of polarity proteins, such as E-cadherin. To test this hypothesis, we examined several polarity 
markers, such as E-cadherin, alpha 6 integrin (a basal marker), and gm130 (an apical marker), 
in IGROV shPKCiota clones in 3D culture using immunofluorescence (IF) and in 2D using 
Western blot analysis. IGROV shPKCiota clones cultured in 3D matrigel exhibited a decrease 
in cyclin E levels (Figure 5a). This observation was consistent with previous finding that 
PKCiota knockdown resulted in decreased cyclin E levels in 2D culture conditions (Chapter 2). 
In these stable IGROV shPKCiota clones, expression levels of E-cadherin and alpha 6 integrin 
increased coupled with a cleared internal lumen (Figure 5b), indicating the possibility of 
PKCiota knockdown resulting in a reversion to polarity through E-cadherin. However, while 
PKCiota knockdown may result in changes in polarity, this result is independent of cyclin E. In 
IGROV cells that have been passaged multiple rounds, cyclin E levels can revert to a pre-
PKCiota-silenced state (Figures 5c and 5d). However, this reversion of cyclin E expression did 
not alter E-cadherin levels. While E-cadherin was more highly expressed in shPKCiota clones, 
more of a correlation than a direct effect can be concluded due to the high expression of E-
cadherin in shControl clone 3A3. Similarly, IGROV shPKCiota clone 7B20 (Figures 5c and 5d) 
reverted to upregulation of  PKCiota levels, and this reversal, even over several passages did 
not seem to decrease the levels of E-cadherin, indicative of a potential clonal variation effect. 
Also, in IGROV cells that have not reverted to re-express cyclin E or PKCiota, E-cadherin 
levels also fluctuate between clones (Figure 5e). In OVCAR3 cells, which are resistant to 
PKCiota inhibition, the PKCiota expression pattern is similar to that of IGROV cells, with 
PKCiota being mislocalized to the basal-lateral membrane (Figure 5g). In OVCAR3 cells, like 
IGROV cells, E-cadherin levels fluctuate in clones independent of PKCiota knockdown (Figure 
5f). In Chapter 2, in the RPPA analysis of the IGROV shRNA clones, E-cadherin levels 
changed. However, in the 293T cells transiently transfected with PKCiota Wt, CA, or DN, no 
change in E-cadherin was observed (Chapter 2; Figure 18 and data not shown). Thus, we 
conclude that the changes in E-cadherin expression and possibly the altered polarity in the 
IGROV shPKCiota clones is likely due to clonal variation. This raises the question, does 
PKCiota knockdown truly result in a decrease in the tumorigenic phenotype, and if so, is this 
through cyclin E?    
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Figure 5: PKCiota Knockdown Results in Increased E-
Cadherin and Alpha-6 Integrin and Decreased Cyclin E 
(A) IGROV shControl and shPKCiota clones were plated in 
matrigel for 2 weeks and stained with PKCiota or cyclin E 
antibodies. Images were visualized using confocal microscopy 
under identical conditions. PKCiota is mislocalized to the basal 
membrane. Cyclin E is predominantly nuclear. Both are 
downregulated in the shPKCiota clones. DAPI is used to stain the 
nuclei of cells. (B) In IGROV shPKCiota clones, alpha 6 integrin 
and E-cadherin were both upregulated compared to the shControl 
clones. Acini were visualized as in part (A). Plus, quantitation; 
shControl n= 154, shPKCiota n= 172 acini. P-values are indicated 
by *’s. (C) Western blot analysis was used to examine the levels 
of E-cadherin in the IGROV shControl and shPKCiota clones. 
Anti-PKCiota was used to determine status of PKCiota 
knockdown. Cyclin E and actin (loading control) antibodies were 
also examined. (D) Western blot analysis of 4 clones from (C) 
over several passages. Antibodies to E-cadherin, phospho-
PKCiota, and cyclin E were examined. Ponceau stain was used 
as the loading control. (E) Western blot analysis of several shPKCiota clones over 3 passages. 
Antibodies to E-cadherin, PKCiota, and cyclin E were examined. Ponceau stain was used as the loading 
control.  (F) OVCAR3 cells with stably silenced PKCiota do not exhibit changes in cyclin E or E-cadherin 
levels as determined by Western blot analysis with indicated antibodies. Ponceau stain was the loading 
control. (G) Confocal microscopy shows that in 3D matrigel after 2 weeks, in OVCAR3 cells cyclin E is 
predominantly nuclear, and PKCiota/ phospho-PKCiota are mislocalized to the basal membrane of the 
acinus structure. GM130 was used as an apical marker, and DAPI was used to stain nuclei.  
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PKCiota Alters Anchorage-Independent Growth by Way of Cyclin E 
 Because the matrigel assay exhibited so much variability, and matrigel is not the 
proper assay to measure anchorage-independent growth, we turned our focus to soft-agar, 
which is commonly used in transformation assays as an indicator of a cells ability to grow 
independently of an extracellular matrix (such as matrigel). Cyclin E and PKCiota individually 
have been implicated in the transformation stage of tumorigenesis through alterations in 
anchorage independent growth (Fang, 1996; Kang, 1996; Coghlan, 2000; Murray, 2004). In 
chapter 2, we found that PKCiota regulates cyclin E levels. Therefore, we hypothesized that 
the effect of PKCiota on anchorage-independent growth could be through cyclin E.  To 
examine the effect of PKCiota on anchorage-independent growth, we first used soft agar 
colony formation to compare cell lines with various levels of PKCiota/ cyclin E expression in 
the presence or absence of PKCiota inhibition. Next, we used IGROV shPKCiota clones to 
examine the effect on soft agar colony formation. When PKCiota resulted in a decrease in the 
number of soft agar colonies, we re-introduced cyclin E (EL and LMW-E) using adenovirus to 
examine the possibility of cyclin E’s ability to revert the shPKCiota phenotype. In a previous 
publication, Regala et al had shown that NSCLC cell lines with higher PKCiota expression 
resulted in fewer soft agar colonies in response to the PKCiota inhibitor, ATM, than those cell 
lines which exhibited low levels of PKCiota (Regala, 2008). In seven ovarian cancer cell lines 
and 293T cells, we examined the effect of PKCiota expression on response to PKCiota 
inhibition with ATM and ATG (Figure 6a). Cell lines with high PKCiota/ cyclin E levels as 
determined in Chapter 2; Figure 1 (OAW42, Hoc1, IGROV, 293T) or with low PKCiota/ cyclin E 
levels (Hoc7, EF027, A2780CP, SKOV) did not differ in their response to PKCiota in soft agar. 
Similarly, half of the high and half of the low PKCiota expressing cell lines did not even grow in 
soft agar, thus no pattern was established based on PKCiota expression alone. Upon 
examination of phospho-PKCiota levels compared to the response to ATM in soft agar, the 
higher phospho-PKCiota levels seemed to respond worse to ATM than those with lower 
phospho-PKCiota expression, an opposite effect of the Regala study in NSCLC (Figure 6b and 
6c). In order of highest PKCiota expression OAW42 > IGROV > Hoc7 > SKOV3, the highest 
expresser of phospho-PKCiota (OAW42) responded the least to ATM when compared to the 
lowest expresser of phospho-PKCiota (SKOV3).  However, this study only consisted of four 
cell lines, so results are not substantial. To examine a direct effect of PKCiota on soft agar 
colony formation, we used IGROV cells, which respond to ATM, but have high levels of 
PKCiota and cyclin E, and we stably silenced PKCiota to determine the effect on soft agar 
colony formation (Figure 6d-f). IGROV shPKCiota clones exhibited stable knockdown of 
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PKCiota resulting in low levels of PKCiota (Figure 6d and Chapter 2). These clones were 
grown in soft agar for 14 days, and soft agar colonies were quantitated (Figure 6e and 6f). 
Figure 6f shows all clones tested in order to rule out the possibility of clonal variation. 
However, Figure 6e shows clones used in future experiments (shPKCiota clone 1 = clone 
7A19, and clone 2 = 8A18). When PKCiota was silenced, fewer soft agar colonies were 
present. Specifically, silencing PKCiota resulted in a 2-fold (IGROV shPKCiota clone 7B9) up 
to an 8-fold decrease in the number of soft agar colonies (p < 0.0005 for all shControl versus 
shPKCiota comparisons). Thus, PKCiota was determined to be necessary for soft agar 
colonies formation, indicative of anchorage-independent growth, in IGROV serous epithelial 
ovarian cancer cells. However, this leaves the question, is the role of PKCiota in anchorage 
independent growth through its regulation of cyclin E?  
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Figure 6: Altered PKCiota Expression Results in Changes in Anchorage-Independent Growth  
(A) Soft agar colony formation was decreased in all 7 cell lines examined in response to the 
PKCiota inhibitor ATM, but not ATG. Concentrations of ATM and ATG were based on IC50 values in 
a  previous publication  (Stallings-Mann 2006). Examination of 2 high PKCiota/ cyclin E (IGROV 
and OAW42) versus 2 low PKCiota/ cyclin E (SKOV3 and HOC7) cell lines by soft agar colony 
formation in response to ATM (B) and by Western blot analysis (C). Actin was used as a loading 
control. (D) Western blot analysis showing PKCiota knockdown in IGROV shControl versus 
shPKCiota clones. Anti-phospho-PKCiota, PKCiota, and cyclin E antibodies were used, and actin 
was used as a loading control. (E) Bar graph demonstrating a decrease in soft agar colony 
formation in IGROV shPKCiota clones. These clones were used in future experiments. * p = 2.7 x 
10-7; ** p = 4.4 x 10-5 (F) Bar graph showing the decrease in soft agar colonies in all IGROV 
shPKCiota clones. *** p < 0.0005 for all individual comparisons. 
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Because cyclin E and PKCiota have both been implicated in anchorage-independent 
growth, a hallmark of cancer, we hypothesized that cyclin E was required for PKCiota-induced 
anchorage-independent growth. To test this hypothesis, we used IGROV shPKCiota clones 
from Figure 6d,e and re-introduced cyclin E by use of adenovirus. Because cyclin E is 
regulated at the level of protein stability by PKCiota (Chapter 2; Figure 16), cyclin E levels are 
slightly lower in the shPKCiota clones compared to the shControl clones. However, because 
adenovirus infection results in such a high level of expression, the effect on cyclin E levels was 
not considered to be a variable. When cyclin E (EL or LMW-E) was re-expressed in shPKCiota 
clones, the number of the soft agar colonies increased to pre-PKCiota knockdown values from 
an averages of 75 colonies per plate (in shPKCiota untreated and LacZ control) up to 150 
colonies (a 2-fold increase), which was similar to the shControl numbers (Figure 7a and 7b). In 
shPKCiota clones with re-expressed cyclin E, especially LMW-E, the number (2-fold) (Figure 
7b) and size (Figure 7a, panels 2 and 3) of the colonies increased, possibly due to the 
increase in cyclin E-associated CDK2 activity. While the number of shPKCiota colonies versus 
the number of shControl colonies were a 2-fold decrease (which was reverted upon re-
expression of cyclin E, the change in diameter was not as pronounced as the change in colony 
numbers (Figure 7a; panel 2) However, in shControl clones with re-expressed cyclin E, the 
number did not change as appreciably (less than 25%), but the colonies were overall larger in 
size (Figure 7a and 7b). More specifically, in both the shControl and shPKCiota conditions, the 
cyclin EL-overexpressing colonies were significantly larger than the LacZ-control colonies 
(pshControl = 0.02 and pshPKCiota = 5.5 x 10-5). Similarly, when compared to the LacZ control 
colonies, the LMW-E-T1 and LMW-E-T2- overexpressing colonies were larger in diameter 
(LMW-E-T1, pshControl = 0.00004 and pshPKCiota = 5.3 x 10-5; and LMW-E-T2, pshControl = 0.0009 
and pshPKCiota = 5.7 x 10-6) (Figure 7a, panel 3). Interestingly, the LMW-E-T1 (but not LMW-E-
T2)-overexpressing colonies were significantly larger than the cyclin EL-overexpressing 
colonies in both the shControl (p = 0.02) and the shPKCiota (p = 0.004) cells (Figure 7a, panel 
3). As indicated in figure 7b, the cyclin EL and LMW-E-T2-overexpressing cells exhibited a 
larger increase in colony number compared to the LMW-E-T1-expressing cells, while in Figure 
7a (panel 3), the LMW-E-T1-expressing cells exhibited large colony diameter, implying cyclin 
EL and LMW-E-T2 may cause more colonies, while LMW-E-T1 leads to larger colonies. 
Overall, in regard to the number of colonies, a potential threshold effect, where overexpression 
of cyclin E could potentially be limited by the concentration of CDK2 present in the cells, is 
possibly not allowing greater soft agar colony formation in the shControl clones (Figure 7b). 
Quantitative analysis of the soft agar colony formation seen in part 7a is represented in Figure 
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7b. The reversion of the shPKCiota phenotype by re-introduction of cyclin E (EL, LMW-E-T1, 
and LMW-E-T2) was shown to be statistically significant (p = 0.046, 0.03, and 0.007, 
respectively). Western blot analysis of the 2D cultures of the cells used in this experiment are 
represented in Figure 7c, and indicate that cyclin EL and LMW-E adenovirus infection was 
successful for this experiment. Thus, we conclude that the role of PKCiota in anchorage-
independent growth is through its regulation of cyclin E. However, we wanted to know if a 
decrease in cyclin E is necessary or sufficient to decrease the anchorage independent growth.   
To more specifically examine the role of cyclin E in anchorage-independent growth, in 
IGROV cells, we needed to see the effect of decreased cyclin E in IGROV cells. Because 
cyclin E-CDK2 activity was shown to be necessary for cells to grow in suspension (Fang, 
1996), we used a CDK2 inhibitor, Roscovitine, in IGROV shControl and shPKCiota clones and 
quantitated the number of soft agar colonies (Figure 7d). CDK2 inhibition was able to decrease 
the number of soft agar colonies formed. The shPKCiota clones, which have decreased cyclin 
E-CDK2 levels, are not as sensitive to Roscovitine as the shControl clones, which is expected 
due to lower levels of cyclin E and CDK2 (Chapter 2; Figure 8) in the shPKCiota clones. Thus, 
decrease in cyclin E levels/ activity is necessary and sufficient in decreasing the amount of 
anchorage-independent growth in IGROV serous epithelial ovarian cancer cells. This raised 
the question, is cyclin E necessary for other PKCiota functions, such as migration?  
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 Figure 7: Exogenous Cyclin E Expression Reverted the PKCiota Knockdown Phenotype in 
Anchorage-Independent Growth 
(A) Panel 1: Soft agar colonies. IGROV shControl and shPKCiota stable clones were infected with 
Ad-LacZ, Ad-Cyclin EL, Ad-LMW-E-T1 or –T2 and were plated in soft agar for only 10 days before 
being imaged. Images are at 10X zoom. Panel 2: Colony diameter was quantitated using 4 
sections from each condition. The averages were normalized to the shPKCiota LacZ average. 
Statistical analysis was performed on all conditions, but only LacZ, shControl versus shPKCiota 
was significant (p = 0.001). n= LacZ-(shControl= 29, shPKCiota= 20); Cyc. EL (shC= 72, shP= 57); 
LMW-E-T1 (shC= 54, shP=37); LMW-E-T2 (shC= 64), shP=68). Panel 3: Colony diameter was 
quantitated as above, and the averages were normalized to the LacZ average for each group 
(shControl versus shPKCiota). Statistical analysis was performed, and significant differences are 
presented above.  (B) Bar graph showing the cell numbers from part (A) were quantitated and 
statistical analysis on several experiments was performed. pEL = 0.046, pT1 = 0.03, and pT2 = 0.007. 
Exogenous cyclin E expression caused a reversion of the PKCiota knockdown phenotype on 
anchorage independent growth.  (C) Western blot analysis confirming the infection of the IGROV 
stable shRNA clones with Ad-cyclin E. Phospho-PKCiota and PKCiota antibodies were used to 
confirm stable knockdown of PKCiota. Vinculin was used as a loading control.  (D) Graph of 
IGROV shControl and shPKCiota soft agar colonies upon exposure to increased concentrations of 
the CDK inhibitor, Roscovitine. Roscovitine decreased soft agar colony formation in all shRNA cell 
lines, but to a greater extent in shControl cells.  
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The Role of PKCiota in Migration is Cyclin E-Independent 
 PKCiota plays a very important role in migration through its binding to Par-6 at the 
membrane ruffles of the leading edge of migrating cells (Noda, 2001). We have identified 
cyclin E as being necessary for PKCiota-induced anchorage independent growth. Therefore, 
we hypothesize that cyclin E is necessary for PKCiota-induced cell migration. To test this 
hypothesis, we used a wound healing/ scratch assay comparing IGROV shControl and 
shPKCiota clones in the presence or absence of ad-cyclin E expression. If cyclin E was 
necessary for PKCiota-induced migration, re-expression of cyclin E should be able to revert 
the shPKCiota phenotype to resemble that of the shControl phenotype. However, by 36 hours 
after the initial scratch, the shControl wounds had closed, while the shPKCiota wounds, 
regardless of cyclin E re-expression, remained open, indicating a deficiency in the rate of 
migration (Figure 8a). In the quantitation of these findings, we observed that the shControl-
cyclin E clones resembled the shControl alone, and the shPKCiota-cyclin E clones resembled 
the shPKCiota alone clones (Figure 8b). The wound was 50% closed 24 hours sooner with the 
shControl cells than the shPKCiota cells (24 versus 48 hours to 50% closed), which was not 
altered upon re-expression of cyclin E. Thus, cyclin E was unable to revert the shPKCiota 
phenotype in migration, implying that the role of PKCiota in migration is cyclin E independent.  
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Figure 8: Exogenous Cyclin E Expression Can Not Revert the PKCiota Knockdown Phenotype 
in Migration  
(A) Wound Healing (scratch) assay with IGROV shControl and shPKCiota clones. Clones have 
been infected with Ad-LacZ, Ad-Cyclin EL, Ad-LMW-E-T1 or –T2 for 48 hours. While several clones 
of each were examined, only one clone of each is represented here. shPKCiota clones exhibited 
delayed wound healing, and exogenous cyclin E expression did not revert this phenotype. (B) 
Graph representing the quantitation of part (A). Solid lines represent shControl clones, while dotted 
lines represent shPKCiota clones. shControl clones exhibit a closed wound by 48 hours, while 
shPKCiota clones exhibit delayed migration.  
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Thus, in this chapter, we have shown that PKCiota can affect cell growth through 
alterations in the cell cycle distribution as opposed to changes in cell death. While PKCiota 
knockdown in 3D matrigel resulted in a return to a smaller more polarized acinus state, the 
possibility of this effect being through clonal variation was not ruled out. However, in soft agar, 
cyclin E was shown to be both necessary and sufficient for PKCiota-mediated anchorage-
independent growth. Examination of the role of cyclin E in PKCiota-mediated migration 
revealed that although cyclin E was necessary for anchorage-independent growth, cyclin E 
was dispensable for PKCiota-mediated migration.  
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CHAPTER 3: DISCUSSION 
 In this chapter, we demonstrated that while cyclin E is necessary and sufficient for 
some of the functions of PKCiota, others are cyclin E-independent. Similarly, we found that 
cyclin E-CDK2 activity is required for the cyclin E-dependent functions of PKCiota. Because 
the genes that encode for PKCiota and cyclin E are both amplified (Eder, 2005; Zhang, 2006; 
and Courjal, 1996; Marone, 1998, respectively) and overexpressed in epithelial ovarian 
cancer, these two oncogenic proteins provide one pathway to potentially be targeted in the 
treatment of ovarian cancer. In chapter 2, we demonstrated that PKCiota knockdown can 
cause a decrease in cyclin E levels, and this decrease is through degradation rather than lack 
of expression of cyclin E. Thus, it is possible that targeting PKCiota for treatment of ovarian 
cancer could result in a decrease in cyclin E, even in the rare circumstance that cyclin E 
protein levels are high due to genomic amplification. 
 PKCiota has been found to be involved in several diverse cellular functions, such as 
establishment and maintenance of epithelial cell polarity, migration, protein trafficking, 
proliferation, transformation, invasion, differentiation, and survival (see Chapter 1). In a 
drosophila epithelial tissue model, Eder et al found that cyclin E was required for the 
establishment and maintenance of apical-basal polarity in epithelial cells (Eder, 2005). More 
specifically, cyclin E-associated kinase activity was required for polarity, because ectopic 
expression of the drosophila ortholog to p27, which inhibits cyclin E-associated kinase activity, 
reverted the non-polarized phenotype that resulted from overexpression of constitutively active 
PKCiota. Thus, this begged the question, if cyclin E was necessary for a disruption in polarity 
by PKCiota overexpression, which is a characteristic of serous epithelial ovarian cancer, what 
other functions of PKCiota require cyclin E-associated kinase activity?  
 In IGROV serous epithelial cells, PKCiota knockdown resulted in a decrease in cyclin E 
levels (and a decrease in other cell cycle proteins, such as CDK2/4 and cyclin D1) (Chapter 2). 
Because so many drivers of the cell cycle were decreased in response to stable PKCiota 
knockdown, we wanted to examine the effect of PKCiota knockdown on the rate of 
proliferation and cell cycle distribution. In IGROV cells, PKCiota inhibition with the PKCiota 
inhibitor aurothiomalate (ATM) resulted in a dose-dependent decrease in cell proliferation (IC50 
= 45 μM) (Figure 1e). Interestingly, in OVCAR3 cells, which did not result in a decrease in 
cyclin E upon stable PKCiota knockdown (Chapter 2; Supplemental Figure S2), did not result 
in decreased proliferation in response to ATM (IC50 > 800 μM) (Figure 1b). Thus, cyclin E is 
implicated as the downstream regulator of proliferation by PKCiota.  
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 In our study, we used the MTT assay, which measures proliferation, to determine the 
effect of PKCiota inhibition on proliferation. However, the decrease in proliferation in response 
to PKCiota inhibition could be due to either a lack of proliferation (induction of a quiescent 
state) or an increase in cell death. We found that PKCiota knockdown resulted in an increase 
in the fraction of cells in the G1-phase of the cell cycle and a corresponding decrease in the S-
phase fraction (Figure 2d,e). Because cell death could also cause a decrease in the number of 
proliferating cells, we examined the effect of PKCiota knockdown on apoptosis. We observed 
no change in the percentage of apoptotic cells between stable PKCiota knockdown and the 
control shRNA clones (Figure 2f). Thus, the decrease in proliferation observed by PKCiota 
knockdown was likely due to an apparent G1-arrest of these cells, as opposed to cell death. 
The change in the G1 fraction in response to PKCiota knockdown could be through 
downregulation of cyclin E. When cyclin E-CDK2 is inhibited, cells arrest in G1 (Tsai, 1993). 
Similarly, because proliferation did not change in the OVCAR3 cells, which do not 
downregulate cyclin E upon stable PKCiota knockdown, this led us to infer that the change in 
proliferation in IGROV cells is though a decrease in cyclin E levels resulting in a G1 arrest 
leading to a decrease in proliferation.  
 PKCiota also plays a role in polarity. As stated, in a drosophila epithelial tissue model, 
cyclin E activity was necessary to disrupt polarity in normal epithelium by way of exogenous 
constitutively active PKCiota overexpression (Eder, 2005). We attempted the opposite 
experiment. In IGROV serous epithelial ovarian cancer cells, which exhibited overexpressed 
and mislocalized PKCiota, we stably silenced PKCiota with RNAi in an attempt to restore 
polarity (Figures 4a and 5a,b). At first glance, PKCiota knockdown resulted in a restoration of 
apical-basal polarity, complete with a cleared lumen and increased expression of E-cadherin 
and alpha 6 integrin (a basal membrane marker) (Figure 5a,d). However, upon further 
investigation, we found that this effect could be due clonal variation in the IGROV shControl 
and shPKCiota clones that occurred in nearly 50% of the shControl clones (based on acini 
size) and 15% (based on percent asymmetry). However, it should be noted that these clones 
were not examined by confocal microscopy for the presence of a hollow lumen or staining for 
polarity markers, such as alpha 6 integrin or GM-130. While the effect of PKCiota knockdown 
on a reversion of a tumorigenic phenotype is highly likely, the best method to test this 
hypothesis would be through an inducible knockdown or Tet-off system. At the beginning of 
these experiments with IGROV cells, we did not realize that clonal variation would play such a 
significant role, but in retrospect, if repeated, one of these two systems would be utilized. 
 
 
217
Thus, we directed our attention to the role of PKCiota on anchorage-independent growth and 
migration, some of the earlier events in the tumorigenic process. 
 Both Cyclin E and PKCiota individually have been demonstrated in anchorage-
independent growth and transformation, one of the initial events in tumorigenesis (Fang, 1996; 
Kang, 1996; Coghlan, 2000; Murray, 2004). More specifically, Ras, which is infamous for its 
role in transformation, requires both cyclin E and PKCiota in order to transform normal non-
tumorigenic cells into invasive tumorigenic cells, which are anchorage-independent (Kang, 
1996; Murray, 2004 respectively). Thus, we hypothesized that with PKCiota and cyclin E 
having seemingly overlapping roles in transformation, PKCiota requires cyclin E for 
transformation. Using the PKCiota inhibitor ATM in IGROV cells, we found that PKCiota 
inhibition resulted in a reduced number of soft agar colonies formed (Figure 6b). More 
specifically, we used IGROV cells with stable PKCiota knockdown, and found that when 
PKCiota was absent, the number of soft agar colonies decreased significantly (Figure 6e). 
Exogenous cyclin E expression was able to revert the PKCiota knockdown phenotype, 
indicating that PKCiota’s role in anchorage-independent growth was through cyclin E (Figure 
6f). We also found that CDK2 inhibition could also result in a decrease in soft agar colonies, 
thus cyclin E though its binding to its catalytic partner, CDK2, was responsible for anchorage-
independent growth in IGROV cells. This role of PKCiota through cyclin E has implications in 
cancer therapy. If inhibition of PKCiota could decrease cyclin E-induced transformation, one 
could infer that tumor volume would also be decreased.  
In Chapter 2, we found that PKCiota is regulating cyclin E via the PI3K pathway, and 
use of the PI3K inhibitor GDC-0941 reduced the levels of phospho-PKCiota and cyclin E. In 
IGROV xenograft models, use of this PI3K inhibitor reduced the tumor growth (Raynaud, 
2009). Thus, the reduction in tumorigenic growth of IGROV xenografts could potentially be 
though inhibition of the PKCiota/ cyclin E pathway. See Chapter 2 discussion for details about 
PI3K inhibition and the potential effects on the PKCiota/ cyclin E pathway.  
 Ras through PI3K leads to several aspects of transformation, including reorganization 
of the cytoskeleton (Rodriguez-Viciana, 1994). Similarly, PKCiota was demonstrated to be 
necessary for Ras/PI3K- induced transformation by disassembly of actin fibers (Uberall, 1999). 
While cyclin E was not addresses directly in this paper, the same year, cyclin E 
overexpression was found to rescue the inhibition of Ras/Rho as measured by cytoskeleton 
re-arrangement (Ghosh, 1999). Thus, cyclin E and PKCiota both have been implicated in 
cytoskeletal re-arrangement. Therefore, it is possible that Ras induces transformation through 
the PI3KÆ PKCiotaÆ cyclin EÆ cytoskeletal rearrangementÆ transformation pathway.  
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Lastly, because PKCiota plays an important role in migration, we attempted to 
establish cyclin E as a downstream regulator of PKCiota-induced migration. However, in 
IGROV cells, we found that PKCiota knockdown resulted in decreased migration, but 
expression of cyclin E, unlike with anchorage-independent growth, was unable to restore the 
phenotype. Thus, it is highly unlikely that cyclin E is involved in the migration function of 
PKCiota. Because PKCiota is co-localized with PAR-6 and Rac1 at the leading edge of 
migrating cells (Noda, 2001), the effect of PKCiota on migration is probably a more direct 
phosphorylation effect, as opposed to through signal transduction, as is the case with cyclin E 
and anchorage-independent growth.   
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CHAPTER 4: 
 
 
Discussion/ Future Directions  
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PKCiota as a Potential Therapeutic Target in Ovarian Cancer 
One in 72 women in the U.S. today will be diagnosed with ovarian cancer in their 
lifetime (NCI-SEER, 2011). This means that at some point in our lives, we all will likely know 
someone whose life is upset by this disease. However, also according to the NCI, the mortality 
rate due to ovarian cancer has not changed (less than 2%) since 1975. This lack of 
improvement in the diagnosis and treatment of ovarian cancer, demonstrates the current need 
for greater knowledge and understanding of ovarian cancer including in depth insight into the 
cancer pathways that drive ovarian cancer tumorigenesis.  
Several oncogenes have been identified in ovarian cancer. Some oncogenes are more 
specific to ovarian cancer, such as Rab25, which is the most overexpressed oncogene (80-
89%) in epithelial ovarian cancer, but serves as a tumor suppressor in other cancer types (i.e. 
breast and intestinal cancer) (Cheng, 2004; Cheng, 2006; Cheng, 2010; Nam, 2010). Other 
ovarian cancer oncogenes are the usual suspects in cancer initiation and procession, such as: 
Ras, PI3K, Myc, EGF, ErbB2, and AKT to name a few (Bast, 2009). A particular oncogene, 
PKCiota was first identified as an oncogene in lung cancer (NSCLC: non-small cell lung 
cancer) (Regala, 2005), but since 2005 has been designated as a bona fide oncogene in other 
cancer types, such as ovarian cancer and pancreatic cancer (Zhang, 2006 and Scotti, 2010 
respectively). PRKCI (the gene that encodes for PKCiota) is the only gene in the PKC family of 
serine/threonine kinases that is designated as an oncogene in ovarian cancer (Zhang, 2006). 
While ten family members exist in the PKC family of kinases, PKCiota and PKCzeta, which 
often display overlapping functions, are the two members of the atypical branch of the PKC 
family. This distinction as ‘atypical’ is due to their lack of regulation by Ca2+, DAG, or phorbol 
esters, which regulate the other 8 PKC family members (Nishizuka, 1995). While PKCiota and 
PKCzeta have overlapping roles, only PRKCI due to either genomic amplification, 
overexpression, or protein mislocalization, has been designated as an oncogene in ovarian 
cancer. PKCiota activity is regulated through protein:protein interaction via a PB1 domain, 
providing a potential motif for drug design for the inhibition of PKCiota (Hirano, 2004). Also, 
understanding which PKCiota-binding partners exhibit which tumorigenic function is vital to the 
use of PKCiota as a therapeutic target. 
PKCiota displays several diverse tumorigenic functions, such as cellular/tumor growth, 
proliferation, protein/lipid trafficking, glucose metabolism, transformation and anchorage-
independent growth, survival, chemoresistance, migration, and invasion (Chapter 1). Because 
PKCiota is involved in so many steps of the tumorigenic process, PKCiota inhibition could 
potentially be useful in the clinic for ovarian cancer treatment regardless of tumor stage. In 
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fact, a small molecule inhibitor of the PKCiota PB1 domain is currently in Phase I clinical trials 
for the treatment of pancreatic cancer and NSCLC (Mayo Clinic). If this PKCiota inhibitor 
(ATM: aurothiomalate) proves to be successful in the treatment of these other types of cancer, 
ovarian cancer is likely the next type of cancer to be involved in clinical trials due to PKCiota’s 
designation as an oncogene in ovarian cancer.  
 Based on the role of PKCiota in ovarian cancer, I speculate that epithelial ovarian 
cancer patients will benefit tremendously from the use of ATM in the treatment of ovarian 
cancer. According to the NCI, more than half (62%) of the patients that are first diagnosed with 
ovarian cancer are already in the late stage: the cancer has already metastasized from the 
ovary to a distant site, making five year survival only 27.6% (NCI-SEER, 2011). While ovarian 
cancer is first “cured” by chemotherapeutic agents, the cancer often times will return, 
distributed throughout the peritoneum or peritoneal cavity, and is likely chemo-resistant. 
PKCiota overexpression causes a tumor to potentially develop chemoresistance. While 
PKCiota’s function specifically in ovarian cancer chemoresistance has not been explored, 
PKCiota has already been implicated in chemoresistance in other tumor types, including lung 
cancer and leukemia (Jin, 2005; Jamieson, 1999; Lu, 2001).  Similarly, PKCiota has been 
implicated in cell survival, though upregulation of NFκB, resulting in transcriptional 
upregulation of genes involved in the anti-apoptotic response (Chapter 1). Because PKCiota 
inhibition could result in a decrease in cell survival due to a lack of induction of anti-apoptotic 
genes, PKCiota inhibition in ovarian cancer could potentially cause these tumors to be 
sensitized to pro-apoptotic inducers, such as chemotherapy. Thus, due to the role of PKCiota 
in cell survival and chemoresistance, PKCiota appears to be a likely therapeutic target in an 
ovarian cancer model. 
Similarly, PKCiota has been shown to be involved in migration and invasion (Chapter 
1). These two steps in metastasis obviously occur in metastatic ovarian cancer. However, it is 
likely that if ovarian cancer is first diagnosed at a later stage, PKCiota inhibition could 
potentially at that point be too little too late. However, it seems reasonable to speculate that 
PKCiota inhibition could result in inhibition of future migration and invasion. 
Another important role of PKCiota in tumorigenesis is in tumor growth. In two different 
NSCLC xenograft models (with A549 and A427 lung cancer cells), PKCiota inhibitors ATM and 
ATG (aurothioglucose, a compound similar in function to ATM) resulted in a 4-fold decrease in 
tumor volume in both cases (Stallings-Mann, 2006; Regala, 2008). However, these two lung 
cancer models were chosen based on their high levels of PKCiota expression/ activity. Thus, 
for ATM or ATG inhibition of ovarian cancer to be most successful, a comparable pre-
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screening method needs to be employed in ovarian cancer similar to that in the lung cancer 
model. We found that PKCiota inhibition (by ATM and PKCiota RNAi to more specifically target 
PKCiota) in IGROV (a serous epithelial ovarian cancer cell line) resulted in a dose-dependent 
decrease in anchorage-independent growth (Chapter 3; Figure 1). In the lung cancer model, 
when lung cancer cell lines exhibited a decrease in anchorage-independent growth with the 
soft agar colony formation assay, these same cell lines when used in mouse xenograft models 
and were treated with the gold compounds (ATM/ATG) also resulted in a decrease in tumor 
volume. For example, with the H460 lung cancer cell line, that did not respond to ATM in vitro 
(number of soft agar colonies were not affected by treatment with ATM), when H460 cells were 
used in mouse xenografts, the resulting tumors did not decrease in volume in response to 
PKCiota inhibition (Regala, 2008). The ability of ATM to inhibit soft agar colony formation 
significantly correlated with the overexpression levels of PKCiota. Thus, it seems feasible that 
in ovarian cancer cells, prescreening of patient biopsies (by IHC or Western blot analysis to 
determine PKCiota protein levels) could be advantageous in determining a patient’s potential 
response to PKCiota inhibitors. However, we have found in two epithelial ovarian cancer cell 
lines, both of which exhibit the highest levels of PKCiota and phospho-PKCiota out of 20 
ovarian cancer cell lines (Chapter 2; Figure 1), upon treatment with ATM, the effect of this drug 
on proliferation was quite distinctive. While both cell lines should respond to ATM-treatment 
due to their high levels of PKCiota/phospho-PKCiota, only the IGROV cells exhibited a dose-
dependent decrease in proliferation (IC50 = 40 micromolar as measured by MTT), while the 
OVCAR-3 cell line, even treated with up to 800 micromolar ATM, never reached an IC50 value 
(Chapter 3; Figure 1). Upon further examination, we found that knockdown of PKCiota resulted 
in a significant decrease in cyclin E levels in IGROV cells (Chapter 2; Figure 5) but not in 
OVCAR-3 cells (Supplemental Material). Thus, cyclin E is likely essential for ATM-
responsiveness in regard to proliferation, making determination of PKCiota levels in ovarian 
cancer cells not on its own sufficient to determine a cell lines ability to respond to ATM, which 
was the case for lung cancer cell lines. A further method of addressing this issue would be to 
directly inhibit cyclin E-CDK2 activity in OVCAR-3 cells to see if direct inhibition of cyclin E-
associated kinase activity could decrease the rate of proliferation in these cells. Perhaps one 
of the most important means of determining how critical cyclin E is in PKCiota-driven 
tumorigenesis, would be to examine both IGROV and OVCAR-3 in mouse xenograft models to 
determine the effect of PKCiota inhibition (ATM) on tumor growth. If the IGROV xenograft 
model respondes to ATM, but the OVCAR-3 xenograft model does not respond, one could 
hypothesize that this difference in effects could be due to cyclin E inhibition in the IGROV 
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mouse model, which could be tested by the use of a CDK2-inhibitor. If PKCiota is manifesting 
its effect through cyclin E, as I speculate is the case, the idea of combination treatment of both 
PKCiota and CDK inhibitors should be explored. While PKCiota inhibition would result in a 
decrease in cyclin E levels, other pathways could become compensatory leading to 
upregulation of cyclin E and hence the use of concurrent CDK inhibition alongside PKCiota 
inhibition is justified. Because we already know that in IGROV cells, inhibition of PKCiota 
results in a decrease of both cyclin E levels and proliferation, the IGROV cell line would make 
an excellent model system for studying the use of combination therapy of dual PKCiota and 
cyclin E-associated kinase activity inhibition on survival analysis (in vitro). If the use of both 
PKCiota and CDK inhibitors results in synergistic cell death, the use of these two inhibitors in 
vivo is warranted. However, in order for these inhibitors to move into clinical trials, they would 
also need to be used in combination with the standard of chemotherapy, which at MD 
Anderson Cancer Center is paclitaxel combined with a platinum-based drug (i.e. carboplatin or 
cisplatin). In vivo studies would need to be performed to optimize for the best order of 
treatment, chemotherapy versus targeted inhibition of PKCiota/cyclin E. The use of both 
PKCiota and cyclin E-associated kinase activity inhibitors could potentially sensitize the tumor-
bearing mice to the effects of paclitaxel/carboplatin, allowing lower, less toxic concentrations of 
the chemotherapeutics to be needed to decrease overall tumor burden.  
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Mechanism of PKCiota-Induced Tumorigenesis 
PKCiota and cyclin E expression correlate in serous epithelial ovarian cancer patient 
samples, and in non-serous epithelial ovarian cancer, overexpression of both cyclin E and 
PKCiota resulted in a poor prognosis (Eder, 2005). These two oncogenes in ovarian cancer 
have individually been implicated in transformation and anchorage-independent growth and 
are both required for Ras-induced transformation (Haas, 1997; Murray, 2004), thus leading us 
to the hypothesis that cyclin E could potentially be downstream of PKCiota in the 
transformation process. We began by showing that PKCiota (phospho-PKCiota) and cyclin E 
levels also significantly correlate in ovarian cancer cell lines (Chapter 2; Figure 1). Establishing 
this correlation was important to be able to study this relationship in an in vitro model. In order 
to establish the direction of regulation cyclin E Æ PKCiota versus PKCiota Æ cyclin E, we 
overexpressed cyclin E (full length or LMW-E) stably in two cell lines and transiently in a single 
cell line and found that no cyclin E isoform was capable of altering PKCiota protein levels or 
activity (autophosphorylation of PKCiota) (Chapter 2; Figure 3). Thus, not only did this rule out 
the cyclin E Æ PKCiota pathway, but this excluded the possibility of any type of positive 
feedback loop.  
To examine the regulation of cyclin E by PKCiota, we stably knocked down PKCiota 
and examined the effect on cyclin E (Chapter 2; Figures 5 and 6- in Figure 7 PKCiota was 
knocked down transiently) and conversely, we overexpressed PKCiota to examine cyclin E 
protein levels (Chapter 2; Figures 8 and 9). Using these methods, we were able to establish 
the ability of PKCiota to regulate cyclin E protein levels in several cell lines. Thus, we 
established PKCiota as the upstream regulator in the PKCiota/cyclin E relationship. We next 
wanted to address the question of which functions of PKCiota would require cyclin E to be 
accomplished. 
 Because both PKCiota and cyclin E are implicated in transformation and PKCiota is 
able to regulate cyclin E, we next hypothesized that PKCiota’s role in transformation was 
through its regulation of cyclin E. Using rescue/ reversion experiments, we were able to 
determine that cyclin E was require for PKCiota-induced transformation (Chapter 3; Figures 6 
and 7). Thus, the PKCiota Æ cyclin E Æ transformation pathway provides a novel cancer 
pathway to potentially be targeted therapeutically. To further validate the role of cyclin E in 
transformation in the IGROV cell line, we used Roscovitine, a small molecule competitive 
inhibitor of CDK2 (the catalytic binding partner of cyclin E), and we found that CDK2-inhibition 
resulted in a dose-dependent decrease in the number of soft agar colonies (Chapter 3; Figure 
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7). Thus, cyclin E-associated kinase activity is necessary to accomplish PKCiota’s effects on 
transformation.  
However, we found that cyclin E was only involved in certain functions of PKCiota. For 
example, PKCiota is involved in migration through its interaction with PAR-6 and Rac1 at the 
membrane ruffles found at the leading edge of migrating cells (Noda, 2001; Xu, 2006). To 
examine the role of cyclin E in PKCiota-induced migration, we stably knocked down PKCiota 
and rescued with exogenous cyclin E (Chapter 3; Figure 8). However, unlike the result of this 
same experiment but with transformation as the readout instead of migration, we found that 
PKCiota’s role in migration is cyclin E-independent. It seems likely that the role of PKCiota in 
migration is quite direct, with PKCiota and other migration proteins being localized at the 
leading edge, while the role of PKCiota in transformation is through a more extensive signal 
transduction cascade.  
Because PKCiota exhibits both cyclin E-dependent and cyclin E-independent functions, 
one could speculate that PKCiota as a therapeutic target would encompass more aspects of 
tumorigenesis than cyclin E-CDK2 inhibitors. However, cyclin E is also involved in many 
aspects of tumorigenesis that are not downstream of PKCiota. For example, PKCiota has 
never been linked to genomic instability, while cyclin E (both full length and LMW-E) has been 
implicated in centrosome amplification and genomic instability, which is central in tumor 
formation (Spruck, 1999; Bagheri-Yarmand, 2010; Bagheri-Yarmand, 2010). Because LMW-E 
exhibits a significant effect on the induction of genomic instability over the full length form (Akli, 
2004; Nanos-Webb 2011 in revision), screening methods are still necessary to determine 
which targeted therapies to use. For example, in ovarian cancer, PKCiota can be 
overexpressed and cyclin E can be cleaved into LMW-E forms. As stated, these two 
phenotypes often correlate in epithelial ovarian tumors of serous histology and in non-serous 
epithelial tumors, these two prognostic factors together result in a poor prognosis (Eder, 2005), 
thus the potential for dual targets through inhibition of both PKCiota and cyclin E exists. 
Further studies would need to be done to determine the effect, whether synergistic, additive, or 
antagonistic, on combination treatments of PKCiota and cyclin E inhibitors on cell death. Also, 
order of inhibition would need to be established.  
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 Screening methods for patients with high PKCiota/cyclin E expressing ovarian tumors 
 As mentioned above, PKCiota and cyclin E are not always linked in their effects on 
tumorigenesis. Thus, IHC screening for both proteins (PKCiota and cyclin E) needs to be 
performed on tumor tissue samples from the biopsies to determine if inhibitors to these 
proteins would be effective. With PKCiota, either overexpression or mislocalization to the 
cytoplasm would likely be sufficient to warrant use of PKCiota inhibitors in these patients, and 
with cyclin E, either overexpression or the presence of cytoplasmic cyclin E (LMW-E localizes 
to the cytoplasm (Delk 2009)) would likely be a good indicator of potential use of CDK2-
inhibitors in these patients. While IHC is effective in identifying protein overexpression with 
specific proteins, genomic amplification can also occur in ovarian cancer in the case of both 
PRKCI and CCNE1 (cyclin E), and genomic amplification of both of these genes individually is 
sufficient to result in poor prognosis (Eder, 2005; Zhang, 2006; Courjal, 1996; Marone, 1998). 
Thus, an alternative method of identifying ovarian cancer patients for potential sensitivity to 
PKCiota and/or cyclin E inhibition could be through the examination of the gene copy number 
of these two genes. PRKCI (3q26) is amplified in 44% of epithelial ovarian cancer patient 
samples, while CCNE1 (19q12) is amplified in 12-36% (Bast 2009). However, amplification of 
these genes correlated with poor survival, thus identification of these ovarian cancer patients 
that exhibit amplification at these loci could be beneficial in determining their response to 
targeted inhibition of the protein products of these genes.  
 As mentioned above, many ovarian cancer patients initially benefit from use of 
chemotherapy but then later develop metastases that are chemo-resistant. This chemo-
resistant cancer is what is the actual cause of death for many ovarian cancer patients. I had 
mentioned above that PKCiota is involved in chemoresistance, and whether this effect is 
through cyclin E is yet to be determined. However, in a PKCiota-independent fashion, CCNE1 
amplification is involved in chemoresistance. In fact, Etemadmoghadam et al, using a high-
resolution oligonucleotide microarray to measure gene copy number in 118 ovarian cancer 
tumor samples, found that CCNE1 amplification was the largest predictor of chemoresistance 
in serous ovarian cancer (Etemadmoghadam, 2009). Thus, both CCNE1 and PRKCI genomic 
amplification should be examined in patient samples to determine the course of action for the 
treatment of specific deregulated genes.  
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 The next generation of ovarian cancer treatment 
 With so many biomarkers of various tumor types and so many inhibitors of these 
molecules, I believe the next generation of cancer therapy will be tailored to each patient. With 
arrays available today that can determine gene copy number, mRNA expression, or even 
protein or phospho-protein levels it seems feasible that a patient biopsy could be performed, 
and their samples could be arrayed to determine the course of treatment. While PKCiota 
(PRKCI) and cyclin E (CCNE1) would be amplified or overexpressed in a tumor, it may be that 
other tumor-promoting pathways could also be overexpressed. Thus, personalized targeted 
treatments could potentially be custom made for each individual patient. However, knowledge 
of the commonly deregulated genes in ovarian cancer needs to be better established, but the 
increased levels of PKCiota and cyclin E provide a piece of that puzzle. For example, because 
gene amplification of CCNE1 leads to chemo-resistant tumors (Etemadmoghadam 2009), 
knowledge of CCNE1 levels would allow an oncologist to examine these patients more 
frequently after they have undergone their treatment, and cyclin E-CDK2 inhibitors could 
potentially be included in their treatment regimen. Thus, an in-depth understanding of the 
genes/pathways commonly involved in ovarian tumorigenesis coupled to identifying an 
affordable array technique to classify these pathways in individual patients is what I believe to 
be the next generation of ovarian cancer treatment.  
We have contributed to this cancer pathways analysis by identifying several protein 
expression levels that are up or down regulated upon exogenous PKCiota expression 
(Chapter 2, Figure 13 and Supplemental Figure S6) using the reverse phase protein array 
(RPPA) assay as described in Chapter 2, which identifies changes in protein levels. Many of 
these proteins are involved in the PI3K pathway (Chapter 2, Figure 13). One of the proteins in 
the PI3K pathway that could potentially link the PKCiota/cyclin E pathway is STAT3 (see 
Chapter 2: Discussion for details). However, others have yet to be linked at all with PI3K. 
While the RPPA analysis resulted in an excellent starting or reference point, further analysis 
would need to be performed in order to validate these findings, including transient silencing of 
endogenous PKCiota and Western blot analysis. Also, in order to determine the mechanism of 
regulation, I would do qRT-PCR analysis.  
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Potential gaps/questions raised by this dissertation project 
 As with any research project, while this project answered many questions in regard to 
the regulation of cyclin E by PKCiota, many gaps are present that would potentially be 
experimentally addressed. For example, all experiments in this dissertation project were 
performed in vitro. I believe one of the most important questions would be if IGROV (ATM-
sensitive) and OVCAR3 (ATM-insensitive) cell lines (see Chapter 3; Figure 1) were injected 
into nude mice, would these cell lines exhibit similar effects in vivo? For example, in vivo would 
inhibition of PKCiota in IGROV xenografts result in a decrease in cyclin E levels/activity and 
would this be the reason for ATM-sensitivity (assuming that these cells would also be ATM-
sensitive in vivo)? Also, would the OVCAR3 cell line still be ATM-insensitive in vivo? If 
OVCAR3 cells did become sensitive to ATM in vivo would it follow the same cyclin E-
dependent mechanism, and if so, why was this mechanism present in vivo and not in vitro in 
this cell line?  
 Along the same line of thinking, another important question would be if overexpression 
of PKCiota (for example in a PKCiota-transgenic or inducible-PKCiota in vivo mouse model) 
would be sufficient to induce cyclin E activity and cause tumor formation? Using these PKCiota 
transgenic mice, one could examine the downstream effects in the tumor versus the normal 
tissue over a period of time to see if genomic instability is induced. Also, using this mouse 
model, we could examine the effect of PKCiota overexpression on LMW-E generation, this 
could help us better understand if the generation of LMW-E is simply due to the increase in 
cyclin E in already transformed cells versus cells that would likely not have the cyclin E 
cleavage machinery (i.e. elastase) already established. We have shown that overexpression of 
cyclin E can cause an increase in elastase levels creating a feedback loop (Nanos-Webb 2011 
in revision), but is this increase enough to generate the LMW-E isoforms in the PKCiota 
transgenic model? Similarly, if these low forms of cyclin E are generated, is this sufficient to 
induce centrosome amplification and genomic instability? I think the most important question 
that one could ask, using these PKCiota transgenic mice, would be if these mice do exhibit 
tumor formation, would cyclin E-CDK2 inhibitors be sufficient to decrease the tumor volume? 
Addressing this question would help us determine if PKCiota is manifesting its effect on 
tumorigenesis solely through increases in cyclin E (and LMW-E).  
 Other questions that could arise due to this dissertation project are: what is the exact 
mechanism of PKCiota’s regulation of cyclin E. We have shown that cyclin E stability is 
regulated by PKCiota (Chapter 2; Figure 11). However, we did not see any changes in FBW7 
mRNA expression (Chapter 2; Figure 12). We assume that because we used MG132 to block 
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the proteasome (Chapter 2; Figure 11), that the regulation of cyclin E by PKCiota is 
proteasomal. In order to completely rule out FBW7 as the mechanism for this increased 
degradation, we would need to examine FBW7 protein levels or localization. However, 
limitations in the commercially-available anti-FBW7 antibodies have made this difficult to 
examine, but recently some antibodies, while weak, have emerged and FBW7 overexpression 
could now potentially be examined. Another possibility would be to examine the localization of 
FBW7 in response to alteration in PKCiota levels using immunofluorescence.  
 Other effector molecules in the PKCiota/cyclin E pathway are yet to be validated. While 
the RPPA analysis of PKCiota-overexpressing 293T cells resulted in a slew of PI3K pathway 
proteins being altered, whether these factors are all in the PKCiota/cyclin E pathway is 
unknown (Chapter 2; Figure 13). Many of the proteins in the PI3K pathway have never been 
shown to affect cyclin E levels, thus an siRNA array of the PI3K family member would be 
useful in determining exactly which PI3K pathway proteins are involved in the PKCiota/cyclin E 
pathway. By using an siRNA array, we would be able to individually examine which genes in 
the PI3K pathway, if not expressed, would lead to decreases in the levels of cyclin E. This 
would allow us to further understand exactly which genes within the PI3K pathway are 
responsible for the regulation of cyclin E. These genes could then be validated by either 
knocking down or overexpressing them and determining the result on cyclin E regulation. 
Based on the proteins involved, we would examine the effect of these proteins on mRNA 
expression and protein stability. 
 Another gap that exists in this dissertation is cyclin E’s involvement with other PKCiota 
functions. While we were able to show that cyclin E was necessary for PKCiota-driven 
proliferation (Chapter 3; Figure 2) and transformation (Chapter 3; Figure 7), but cyclin E was 
not involved in PKCiota-driven migration (Chapter 3; Figure 8), many other functions of 
PKCiota exist in which cyclin E’s role downstream of PKCiota has not been addressed such 
as: (1) tumor growth, (2) glucose metabolism, (3) survival and chemoresistance, and (4) 
invasion. It seems quite feasible that many of these functions of PKCiota may also require 
cyclin E. For example, current research suggests that (1) LMW-E plays a fundamental role in 
the promotion of tumorigenesis as determined by a cyclin E transgenic mouse model (Akli 
2007; Akli, 2011), (2) recent data in our lab shows that cyclin E (full length as well as LMW-E) 
binds to ACLY, which is involved in glucose metabolism (Szymanski, dissertation in progress 
Keyomarsi lab), (3) CCNE1 was recently identified as one of the key markers of 
chemoresistance in ovarian cancer (Etemadmoghadam 2009), and (4) LMW-E plays a vital 
role in invasion (Duong, dissertation in progress Keyomarsi lab). Thus, the role of cyclin E in 
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these functions of PKCiota is completely feasible, and research could be performed to link 
these functions of PKCiota to cyclin E.  Much like we examined the role of cyclin E in PKCiota-
induced transformation and migration, the experiments to determine the role of cyclin E in 
these other cellular function could be performed by knockdown of PKCiota followed by 
exogenous addition of cyclin E (EL or LMW-E) with different readouts. Instead of measuring 
soft agar colony formation or migration, we will examine the effect of cyclin E on the ability to 
revert the effects of PKCiota knockdown on tumor formation, glucose transport/uptake, 
chemoresistance, and invasion.  
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Supplemental Figure S1. 
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Figure S1: Selection of Stable IGROV shRNA Clones 
(A) shControl or shPKCiota (constructs 7, 8, or 7/8) were transfected into IGROV cells, and stable 
pools were generated using increasing concentrations of Puromycin (0.25, 0.5, and 1 μg/mL). 
Western blot analysis using PKCiota and cyclin E (HE-12) antibodies was performed. Ponceau was 
used as a loading control. Stable clones of shControl (B), shPKCiota construct 7 (C), 8 (D), and 7 
and 8 (E) were also examined by Western blot analysis. Each blot contained a parental control (C) 
and/or a stable shControl control (clone 3A14). Either Ponceau stain or actin were used as loading 
controls. Several clones were determined to be ‘potential positives’ and were examined further.    
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Supplemental Figure S2 and S3. 
To validate the effect of PKCiota knockdown on cyclin E in another cell line, we used 
OVCAR3 cells based on the initial findings that cyclin E and PKCiota are highly overexpressed 
in these cells (Figures 1 and Table 1). OVCAR3 shPKCiota clones were generated similarly to 
the IGROV shPKCiota clones. However, OVCAR3 cells were more sensitive to Puromycin 
than IGROV cells (IGROV- Figure S1a; OVCAR3- Figure S2a). In OVCAR3 cells, 0.1 μg/mL 
Puromycin was determined to be the optimal concentration to obtain single shPKCiota clones. 
Similar to the IGROV cells, the stable pools of OVCAR3 cells with shPKCiota 7, 8, or 7/8 
appeared to have decreased cyclin E levels compared to the shControl clones. OVCAR3 
shPKCiota clones were picked and analyzed by Western blot analysis using antibodies against 
PKCiota and cyclin E (Figure S2b). Several OVCAR3 shPKCiota ‘potential positive’ clones 
were identified and of these, several were chosen. 5 shControl clones and 9 shPKCiota clones 
were re-grown and analyzed at comparable confluencies (Figure S2c). Unlike IGROV 
shPKCiota clones, the OVCAR3 shPKCiota clones did not exhibit changes in the level of cyclin 
E (either cyclin E or LMW-E). Thus, an unknown factor between IGROV and OVCAR3 cells is 
involved in PKCiota-mediated cyclin E regulation. Another possible explanation for the 
difference between regulation of cyclin E by PKCiota in these two cell lines could be in the 
ability of OVCAR3 cells to revert. 
Several IGROV shPKCiota clones reverted after only one or two passages post 
transfection. Because cyclin E is essential for cell growth, many of these clones were able to 
up-regulate cyclin E in a PKCiota-independent manner. This selection for cyclin E-expressing 
cells could be due to the inability of the cells with down-regulated cyclin E to proliferate. To test 
this theory, OVCAR3 cells would be transiently transfected with siRNA to PKCiota and the 
results would be measured over a period of 24-72 hours post transfection to prevent possible 
selection for cyclin E-expressing cells. OVCAR3 cells transfected with siRNA (siPKCiota) over 
increasing time (Figure S3a) and increasing amount of siPKCiota (Figure S3b) were analyzed 
by Western blot analysis with antibodies directed against PKCiota and cyclin E. In both 
conditions (increasing time and increasing siRNA), the levels of cyclin E (both cyclin EL and 
LMW-E) decrease. Examining increasing amounts of siRNA to PKCiota over increasing time 
resulted in mixed results (Figure S3c). The level of cyclin E did not correlate with the level of 
PKCiota knockdown in this experiment. Examination of OVCAR3 cells at differing confluencies 
revealed that these cells vary too greatly to examine down-stream effects on cyclin E 
expression quantitatively (Figure S3d). Thus, OVCAR3 cells were not used in experiments 
from this point forward where cyclin E was measured as the downstream effect.   
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Figure S2: Selection of Stable OVCAR3 shRNA Clones 
(A) OVCAR3 ovarian cancer cells were transfected with shControl (construct 3) or shPKCiota 
(constructs 7, 8, or 7/8). Stable pools were generated by selection with Puromycin (0.05 or 0.1 
μg/mL). Western blot analysis was performed using antibodies: PKCiota and cyclin E. Ponceau 
stain was used as a loading control. (B) Upon selection, individual clones were selected, and 
subjected to Western blot analysis as above. Clones 3-- are shControl, while 7--,8--, or 7/8-- are 
shPKCiota. A,B, or C following 3, 7, 8, or 7/8 designates a different plate. The number following  A, 
B, or C designates the clone number on that plate. (C) Positive clones with stable PKCiota knock-
down were then subjected to Western blot analysis as above. No correlation between PKCiota and 
cyclin E was observed in OVCAR3 ovarian cancer cells.    
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Figure S3: Transient Knock-down of PKCiota in OVCAR3 Cells 
(A) Transient siRNA (either control- scrambled or PKCiota) was delivered over 24, 48, and 72 
hours. Western analysis was performed using PKCiota, cyclin E, and actin (loading control) 
antibodies. Upon silencing of PKCiota, both full length cyclin E and LMW-E decreased. (B) Similar 
results were observed upon increasing amounts of PKCiota siRNA at 72 hours. Western blot 
analysis was similar to above. (C) When parts (A) and (B) were repeated, cyclin E levels did not 
correlate with PKCiota knock-down as before. Western blot analysis was similar to above plus 
phospho-PKCiota antibody. (D) Examination of PKCiota and Cyclin E protein levels over different 
cell confluencies revealed that PKCiota and cyclin E levels change substantially, perhaps 
accounting for the differences between (A), (B), and (C).   
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Supplemental Figure S4. 
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PKCiota CA Clone 3a
A Æ E    GCA Æ GAA
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PKCiota DN Clone 3a
K Æ STOP   AAA Æ TAA
 
 
Figure S4: Sequence Results for Generation of PKCiota CA and DN Constructs. 
 The sequencing data for colonies CA3a and DN3a as well as a control (Wt) are pictured here. This 
confirms site-directed mutagenesis of Figure 8. 
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Supplemental Figure S5. 
Before selection of IGROV cells transfected with PKCiota could be performed, the pCMV-
XL5-PKCiota Wt, CA, and DN constricts would need to be subcloned into the pcDNA3.1+ 
vector (Figure S5a). The pCMV6-XL5-PKCiota Wt, CA, and DN constructs could be cut with 
the restriction enzyme, NotI. The PKCiota inserts and the cut pcDNA3.1 vector would be gel 
purified (Figure S5b) and ligated at a 1:3 (vector to insert ratio). The colonies that transformed 
into bacteria were sent for sequencing. In the first round of sequencing, all inserts were in the 
reverse orientation (data not shown). However, the second round of sequencing revealed 2 to 
4 clones in the positive orientation (Figure S5c- white arrows; Figure S5d- sequencing data). 
Constructs circled in red (Wt-14C; CA-15B; and DN-16B) were oriented properly (Figure S5d), 
and were used in further experimentation.  
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Figure S5: Subcloning of the PKCiota Gene into the pcDNA3.1+ Vector  
(A) Schematic of the steps involved in subcloning of pCMV6-XL5 PKCiota Wt (wildtype), CA 
(constitutively active), and DN (dominant negative) into pcDNA3.1(+)-PKCiota Wt, CA, and DN. 
pCMV6-XL5-PKCiota was cut at NotI sites, the insert was gel purified, and then ligated at a 1:3 
(pcDNA3.1+ vector: PKCiota insert) ratio and sent out for sequencing. (B) The vector (pcDNA3.1+) 
and inserts (PKCiota Wt, CA, and DN) were run on a 1% agarose gel and purified for ligation. 
pcDNA3.1(+)-PKCiota Wt, CA, and DN colonies were sent for sequencing (D) and analyzed by gel 
electrophoresis (C). In (C), the arrow indicates that the clone was in the correct orientation and 
contained the necessary mutation. The red circle indicates this clone was chosen for DNA 
amplification for future experiments. “MW” is the molecular weight ladder, and “U” indicates uncut 
pcDNA3.1+ vector control. (D) The sequences for clones 15B (positive pcDNA3.1(+)-PKCiota CA) 
and 16B (positive pcDNA3.1(+)-PKCiota DN).  
 Supplemental Figure S6. 
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293T ca PKCiota
30hr
293T dn PKCiota
30hr
BAX
0
0.05
0.1
0.15
0.2
0.25
0.3
293T Mock
Transf 30hr
293T wt PKCiota
30hr
293T ca PKCiota
30hr
293T dn PKCiota
30hr
BID
0
0.05
0.1
0.15
0.2
0.25
0.3
0.35
0.4
293T Mock
Transf 30hr
293T wt PKCiota
30hr
293T ca PKCiota
30hr
293T dn PKCiota
30hr
BID (Alternate Ab)
0
0.1
0.2
0.3
0.4
0.5
0.6
293T Mock Transf
30hr
293T wt PKCiota
30hr
293T ca PKCiota
30hr
293T dn PKCiota
30hr
BRCA1
0
0.5
1
1.5
2
2.5
293T Mock Transf
30hr
293T wt PKCiota
30hr
293T ca PKCiota
30hr
293T dn PKCiota
30hr
cJUN_pS73
0
0.2
0.4
0.6
0.8
1
1.2
293T Mock Transf
30hr
293T wt PKCiota
30hr
293T ca PKCiota
30hr
293T dn PKCiota
30hr
cMyc
0
0.01
0.02
0.03
0.04
0.05
0.06
0.07
0.08
0.09
0.1
293T Mock
Transf 30hr
293T wt PKCiota
30hr
293T ca PKCiota
30hr
293T dn PKCiota
30hr
cMyc_pT58
0
2
4
6
8
10
12
14
16
293T Mock Transf
30hr
293T wt PKCiota
30hr
293T ca PKCiota
30hr
293T dn PKCiota
30hr
Cyclin B1
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
293T Mock Transf
30hr
293T wt PKCiota
30hr
293T ca PKCiota
30hr
293T dn PKCiota
30hr
Cyclin E1
0
0.5
1
1.5
2
2.5
3
3.5
4
293T Mock Transf
30hr
293T wt PKCiota
30hr
293T ca PKCiota
30hr
293T dn PKCiota
30hr
FOXO3a_pS318
0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
5
293T Mock Transf
30hr
293T wt PKCiota
30hr
293T ca PKCiota
30hr
293T dn PKCiota
30hr
FOXO3a_pS318 (Alt. Ab)
0
0.5
1
1.5
2
2.5
293T Mock Transf
30hr
293T wt PKCiota
30hr
293T ca PKCiota
30hr
293T dn PKCiota
30hr
GSK_pS9
0
1
2
3
4
5
6
293T Mock Transf
30hr
293T wt PKCiota
30hr
293T ca PKCiota
30hr
293T dn PKCiota
30hr
GSK3a_B
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GSK3a_b (Alt Ab)
IRS1_pS307
mTOR
MAPK_pT202
MEK1
MEK1 (Alt Ab)
MEK1/2_pS217
MSH2
mTOR_pS2448
p53
p70S6K
p70S6K_pS371
p70S6K_pT389
PDK1_pS241
PLK1
Rb
Rb_pS807
STAT3
STAT3_pS727
STAT5
0
1
2
3
4
5
6
7
8
293T Mock Transf
30hr
293T wt PKCiota
30hr
293T ca PKCiota
30hr
293T dn PKCiota
30hr
0
0.5
1
1.5
2
2.5
3
3.5
293T Mock Transf
30hr
293T wt PKCiota
30hr
293T ca PKCiota
30hr
293T dn PKCiota
30hr
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
293T Mock Transf
30hr
293T wt PKCiota
30hr
293T ca PKCiota
30hr
293T dn PKCiota
30hr
0
0.5
1
1.5
2
2.5
293T Mock Transf
30hr
293T wt PKCiota
30hr
293T ca PKCiota
30hr
293T dn PKCiota
30hr
0
1
2
3
4
5
6
7
8
293T Mock Transf
30hr
293T wt PKCiota
30hr
293T ca PKCiota
30hr
293T dn PKCiota
30hr
0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
5
293T Mock Transf
30hr
293T wt PKCiota
30hr
293T ca PKCiota
30hr
293T dn PKCiota
30hr
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
293T Mock Transf
30hr
293T wt PKCiota
30hr
293T ca PKCiota
30hr
293T dn PKCiota
30hr
0
0.05
0.1
0.15
0.2
0.25
0.3
0.35
0.4
0.45
293T Mock
Transf 30hr
293T wt PKCiota
30hr
293T ca PKCiota
30hr
293T dn PKCiota
30hr
0
0.01
0.02
0.03
0.04
0.05
0.06
0.07
0.08
293T Mock
Transf 30hr
293T wt PKCiota
30hr
293T ca PKCiota
30hr
293T dn PKCiota
30hr
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
293T Mock Transf
30hr
293T wt PKCiota
30hr
293T ca PKCiota
30hr
293T dn PKCiota
30hr
0
1
2
3
4
5
6
7
8
9
293T Mock Transf
30hr
293T wt PKCiota
30hr
293T ca PKCiota
30hr
293T dn PKCiota
30hr
0
0.05
0.1
0.15
0.2
0.25
0.3
0.35
0.4
0.45
0.5
293T Mock
Transf 30hr
293T wt PKCiota
30hr
293T ca PKCiota
30hr
293T dn PKCiota
30hr
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
293T Mock Transf
30hr
293T wt PKCiota
30hr
293T ca PKCiota
30hr
293T dn PKCiota
30hr
0
1
2
3
4
5
6
293T Mock Transf
30hr
293T wt PKCiota
30hr
293T ca PKCiota
30hr
293T dn PKCiota
30hr
0
0.02
0.04
0.06
0.08
0.1
0.12
0.14
0.16
0.18
293T Mock
Transf 30hr
293T wt PKCiota
30hr
293T ca PKCiota
30hr
293T dn PKCiota
30hr
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
293T Mock Transf
30hr
293T wt PKCiota
30hr
293T ca PKCiota
30hr
293T dn PKCiota
30hr
0
0.5
1
1.5
2
2.5
3
3.5
4
293T Mock Transf
30hr
293T wt PKCiota
30hr
293T ca PKCiota
30hr
293T dn PKCiota
30hr
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
293T Mock Transf
30hr
293T wt PKCiota
30hr
293T ca PKCiota
30hr
293T dn PKCiota
30hr
0
0.2
0.4
0.6
0.8
1
1.2
1.4
293T Mock Transf
30hr
293T wt PKCiota
30hr
293T ca PKCiota
30hr
293T dn PKCiota
30hr
0
0.05
0.1
0.15
0.2
0.25
0.3
0.35
0.4
293T Mock
Transf 30hr
293T wt PKCiota
30hr
293T ca PKCiota
30hr
293T dn PKCiota
30hr  
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Annexin
0
0.02
0.04
0.06
0.08
0.1
0.12
293T Mock
Transf 30hr
293T wt PKCiota
30hr
293T ca PKCiota
30hr
293T dn PKCiota
30hr
0
0.02
0.04
0.06
0.08
0.1
0.12
0.14
293T Mock
Transf 30hr
293T wt PKCiota
30hr
293T ca PKCiota
30hr
293T dn PKCiota
30hr
Casein Kinase
0
0.005
0.01
0.015
0.02
0.025
0.03
0.035
0.04
293T Mock
Transf 30hr
293T wt PKCiota
30hr
293T ca PKCiota
30hr
293T dn PKCiota
30hr
Caspase 3.Active
0
0.005
0.01
0.015
0.02
0.025
293T Mock
Transf 30hr
293T wt PKCiota
30hr
293T ca PKCiota
30hr
293T dn PKCiota
30hr
Caspase 9
0
0.005
0.01
0.015
0.02
0.025
0.03
293T Mock
Transf 30hr
293T wt PKCiota
30hr
293T ca PKCiota
30hr
293T dn PKCiota
30hr
CD11a
0
0.2
0.4
0.6
0.8
1
1.2
293T Mock Transf
30hr
293T wt PKCiota
30hr
293T ca PKCiota
30hr
293T dn PKCiota
30hr
IGFBP2
0
0.01
0.02
0.03
0.04
0.05
0.06
0.07
293T Mock
Transf 30hr
293T wt PKCiota
30hr
293T ca PKCiota
30hr
293T dn PKCiota
30hr
PAI.1
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
293T Mock Transf
30hr
293T wt PKCiota
30hr
293T ca PKCiota
30hr
293T dn PKCiota
30hr
PI3Kp110
0
0.2
0.4
0.6
0.8
1
1.2
1.4
293T Mock Transf
30hr
293T wt PKCiota
30hr
293T ca PKCiota
30hr
293T dn PKCiota
30hr
S6
0
0.05
0.1
0.15
0.2
0.25
0.3
0.35
0.4
0.45
293T Mock
Transf 30hr
293T wt PKCiota
30hr
293T ca PKCiota
30hr
293T dn PKCiota
30hr
S6 (Alt Ab)
0
0.02
0.04
0.06
0.08
0.1
0.12
0.14
293T Mock
Transf 30hr
293T wt PKCiota
30hr
293T ca PKCiota
30hr
293T dn PKCiota
30hr
S6_pS235
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
293T Mock Transf
30hr
293T wt PKCiota
30hr
293T ca PKCiota
30hr
293T dn PKCiota
30hr
S6_pS240
0
1
2
3
4
5
6
7
8
9
10
293T Mock Transf
30hr
293T wt PKCiota
30hr
293T ca PKCiota
30hr
293T dn PKCiota
30hr
Telomerase
0
0.2
0.4
0.6
0.8
1
1.2
1.4
293T Mock Transf
30hr
293T wt PKCiota
30hr
293T ca PKCiota
30hr
293T dn PKCiota
30hr
TSC2
TSC2_pT1462
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
293T Mock Transf
30hr
293T wt PKCiota
30hr
293T ca PKCiota
30hr
293T dn PKCiota
30hr
Telomerase (Alt Ab)
0
0.05
0.1
0.15
0.2
0.25
0.3
0.35
0.4
0.45
0.5
293T Mock
Transf 30hr
293T wt PKCiota
30hr
293T ca PKCiota
30hr
293T dn PKCiota
30hr
0
0.05
0.1
0.15
0.2
0.25
293T Mock
Transf 30hr
293T wt PKCiota
30hr
293T ca PKCiota
30hr
293T dn PKCiota
30hr
ATRIP
COX2
PAI.1 (Alt Ab)
Decrease Expression
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
293T Mock Transf
30hr
293T wt PKCiota
30hr
293T ca PKCiota
30hr
293T dn PKCiota
30hr
0
0.002
0.004
0.006
0.008
0.01
0.012
0.014
293T Mock
Transf 30hr
293T wt PKCiota
30hr
293T ca PKCiota
30hr
293T dn PKCiota
30hr  
 
 
Figure S6: RPPA Analysis of IGROV Cells with PKCiota Knockdown 
(A) Reverse Phase Protein Array (RPPA) heatmap for IGROV samples analyzed. IGROV 
shControl (first 7 samples) and shPKCiota (next 7 samples) were compared. (B) Western blot 
analysis depicting the IGROV shRNA stable clones used in the RPPA assay (first 14 lanes in (A)). 
Antibodies against PKCiota and cyclin E were used, while Ponceau stain was used as a loading 
control. (C) Graphs of proteins from the chart in (Figure 13c) whose expression levels either 
increased (black letters in title) versus decreased (red letters in title) in response to PKCiota 
overexpression. ‘Alt Ab’ or alternate antibody after a title indicates that two antibodies against this 
particular protein were examined. 
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